<SEC-DOCUMENT>0001824293-22-000004.txt : 20220214
<SEC-HEADER>0001824293-22-000004.hdr.sgml : 20220214
<ACCEPTANCE-DATETIME>20220214161528
ACCESSION NUMBER:		0001824293-22-000004
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		68
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220214
DATE AS OF CHANGE:		20220214

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vallon Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001824293
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				824369909
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40034
		FILM NUMBER:		22632136

	BUSINESS ADDRESS:	
		STREET 1:		TWO LOGAN SQUARE
		STREET 2:		100 N. 18TH STREET, SUITE 300
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
		BUSINESS PHONE:		(267) 207-3606

	MAIL ADDRESS:	
		STREET 1:		TWO LOGAN SQUARE
		STREET 2:		100 N. 18TH STREET, SUITE 300
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ck0001824293-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:b31decee-d9de-40ed-b802-73f93418660f,g:197f3557-28e9-444a-8b20-482cd1ad7630,d:8c772b1568214a7294558171471dfda5--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ck0001824293="http://www.vallon-pharma.com/20211231" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ck0001824293-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV80L2ZyYWc6YjA5NWRmYjQ0YWYyNGVkNzllMGM1NTY1ZDg4ZGY4M2QvdGFibGU6YTNiNjY5OGI1NjU5NDhkZmJjZjhlNjNjZjY5MWJhNzIvdGFibGVyYW5nZTphM2I2Njk4YjU2NTk0OGRmYmNmOGU2M2NmNjkxYmE3Ml8yMS0xLTEtMS0yMTAwMg_e3feac2a-30eb-4940-9213-adf9b948eb91">0001824293</ix:nonNumeric><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV80L2ZyYWc6YjA5NWRmYjQ0YWYyNGVkNzllMGM1NTY1ZDg4ZGY4M2QvdGFibGU6YTNiNjY5OGI1NjU5NDhkZmJjZjhlNjNjZjY5MWJhNzIvdGFibGVyYW5nZTphM2I2Njk4YjU2NTk0OGRmYmNmOGU2M2NmNjkxYmE3Ml8zMC0xLTEtMS0yMTAwMg_3e1d2124-4eb5-402c-aa4c-1ea258967cad">false</ix:nonNumeric><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV80L2ZyYWc6YjA5NWRmYjQ0YWYyNGVkNzllMGM1NTY1ZDg4ZGY4M2QvdGFibGU6YTNiNjY5OGI1NjU5NDhkZmJjZjhlNjNjZjY5MWJhNzIvdGFibGVyYW5nZTphM2I2Njk4YjU2NTk0OGRmYmNmOGU2M2NmNjkxYmE3Ml8zMS0xLTEtMS0yMTAwMg_955ccd41-8b73-4589-874f-35137e031e59">2021</ix:nonNumeric><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV80L2ZyYWc6YjA5NWRmYjQ0YWYyNGVkNzllMGM1NTY1ZDg4ZGY4M2QvdGFibGU6YTNiNjY5OGI1NjU5NDhkZmJjZjhlNjNjZjY5MWJhNzIvdGFibGVyYW5nZTphM2I2Njk4YjU2NTk0OGRmYmNmOGU2M2NmNjkxYmE3Ml8zMi0xLTEtMS0yMTAwMg_8cfd916b-ef6d-4feb-b8b0-7dc72aa82729">12-31</ix:nonNumeric><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV80L2ZyYWc6YjA5NWRmYjQ0YWYyNGVkNzllMGM1NTY1ZDg4ZGY4M2QvdGFibGU6YTNiNjY5OGI1NjU5NDhkZmJjZjhlNjNjZjY5MWJhNzIvdGFibGVyYW5nZTphM2I2Njk4YjU2NTk0OGRmYmNmOGU2M2NmNjkxYmE3Ml8zMy0xLTEtMS0yMTAwMg_d83206c8-346b-4476-b650-3ce555272a94">FY</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i9318b4034bf247a7bf81e79df11bc14e_D20210212-20210212" decimals="3" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMTkzL2ZyYWc6YzgxMTM0ZTkyZjE4NGZiN2ExYWZjYmQ1ZGMyZmY3MmQvdGFibGU6MTViMjViM2Y3NTQ5NDQ3Y2I5OTg2MmUzN2ZkNjFhNTIvdGFibGVyYW5nZToxNWIyNWIzZjc1NDk0NDdjYjk5ODYyZTM3ZmQ2MWE1Ml8xLTEtMS0xLTI3NjU4_38d57c4c-05bd-4fb0-bd80-03562eff751d">0.025</ix:nonFraction><ix:nonNumeric contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzItMi0xLTEtMjcwNjk_d0fa8a87-0583-4dbe-aa44-438729a21dce">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzItNC0xLTEtMjcxMDQ_1d91015f-66ad-42d5-87ce-9f403c36c69c">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzQtMi0xLTEtMjcwNzY_4d9aad60-57b0-43cc-9c32-3717c31c5311">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzQtNC0xLTEtMjcxMTE_878bb0e5-bbd6-48e9-9988-7643436d0dee">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzUtMi0xLTEtMjcwNzY_0cbe9984-707d-4160-b526-ea4fa4370ae5">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzUtNC0xLTEtMjcxMTE_15864d26-3ad3-4b32-a575-a615f5f41fef">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="if77c3753756e4eb8b7f0d6919514e0d1_D20200501-20200531" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjAvZnJhZzo0NGYyNDgzZmE3NGI0MWY2OWRlOGU2ZTVhNzZlOWM2Zi90ZXh0cmVnaW9uOjQ0ZjI0ODNmYTc0YjQxZjY5ZGU4ZTZlNWE3NmU5YzZmXzU2OA_a031568f-8be9-4dd8-8877-34662d6a2613">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="if6d11153da3c4046926d1df8862e08df_I20210212" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90ZXh0cmVnaW9uOmYzODY5MGU0NWM0ODQ1ZjZiMmEzOGNjMTRiZGU0NzkyXzE2NDkyNjc0NDQzMDI_d0b1e4ec-bc6a-4c22-8fd2-7d9f5a4cd028">P5Y0M0D</ix:nonNumeric><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODcvZnJhZzowZDU0N2Q5Y2RkMjI0ZGI0YTM5YmUyNGM0Y2U4YzFlNi90ZXh0cmVnaW9uOjBkNTQ3ZDljZGQyMjRkYjRhMzliZTI0YzRjZThjMWU2XzIyNjM_78fa8817-af6f-44a3-ac14-32aa0ae3785c" escape="true">SUBSEQUENT EVENTS[TBD]</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ck0001824293-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65072bfeaf3a4457ad6a97aa44ce8820_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="iabb727de2d49441ba5658b9b5a183b63_I20220211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="id84cb895052844b483a1ef69b0f12655_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7361a85c9d0470a8ca351dad193b452_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa705715f28d4b5eacce471c76e4867b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a303ff40d68410ea858ad97833960cc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38e2e0b664e044f1ab6f20ebf44f6f59_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23ee9c62820d4f39a904524cfe778f00_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd9521358ab247c2b64d4cbe8a945e84_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60aca420575a440fa652609aad540150_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6476323fed784d85832b674bde1f5d2b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5b0ac7b11494351935046ce5bf1cc8e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia70712498a0f4941ab0ea3722b2be30f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffdd767329aa4cd59029b7fd066b141d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i270b8e6dd74f41e4a133ae1c6754d770_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia203ce9d16f8445c984d50be01b6c4af_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ede8e54df1449d8b82bb4b005ed5a86_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92ca8836910146858994d27a6356eec0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i033d2a786a29471796dbfe50eb424da2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5e826ed29c14a57ab4a163d538e1c37_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2716e8a4ca0545f8bbce622e4d52158f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i550459c5b5124776a49bbd935630fdc7_D20210111-20210111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-11</xbrli:startDate><xbrli:endDate>2021-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia17353f6bf834b99aeb72bb19eed6773_D20210212-20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5daddf114f0241b4a966bccf6d899e1c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic638fa8850574f0f85cdf96878a4008b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9318b4034bf247a7bf81e79df11bc14e_D20210212-20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ie118df7159634a91976e521f2425da1c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icff8b71b9c8244dcb12cc9ac5efd5b53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia10c21fff10b48d78e5b10b6645fdc7f_I20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idef5c95d6a30458ebd4eb95332917688_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1531f974668b4107b1b1a1654cd76006_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f49d0df94644a32ab3d051a753eeb16_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1944122310504f56b217249a0d49b19a_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if77c3753756e4eb8b7f0d6919514e0d1_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ff8206d11c1434cb0abe54052617449_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9d5b9a898334b7cb7f34285a2ddd313_D20210111-20210111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-11</xbrli:startDate><xbrli:endDate>2021-01-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfa130da617a43abb627558cf21129fe_I20210111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3844e69fe7884e4db36fb500c88c1e90_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f45c53a2fd14b19a55e65c0b6f087be_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic698111b087341fab1ee0949330016d5_I20211106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ck0001824293:RendonVVallonIncEtAlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>ck0001824293:claim</xbrli:measure></xbrli:unit><xbrli:context id="i9f824c725f73426d90c2105cddf2d5ca_I20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6d11153da3c4046926d1df8862e08df_I20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f7f365dc72f44f98ddaa19c2a6fe7c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i233cc24405d641289d6ab6f271edbce0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0508ecc21bf1424db461226872bd262c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dc2bc5f633b4fe997a55197c7618e72_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01c972ebfcea4e9f9fb0d25b4590b552_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:A2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i414ab16442df41e0a789424f9dcdbb64_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic219cdbb38f64f029ff62ec56ce54f18_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic19d630a0cfb4614bc03d9687c1b1adf_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25bc9e21732d46a495fab6ec37e81bd6_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia48dc025b4ca46bfbb1119e73f604f09_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefc0efe048504719968099425a5fc1f0_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2042fe817e6b415d99dcd18a2761b5b7_D20181001-20181001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:A2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7543349bff1e4b3d8106535d9eae2358_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d5a202b2ddb4a648aebf40b599e2cf3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f9b7fb9cf6a4e3a91f85fc43dab1e80_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">ck0001824293:StateTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ffe46279ad1467fbb2755ef0532a308_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">ck0001824293:LocalTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1b89a713dfe46188f25b2cff340c80d_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:MediceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b1123c092e44fef8394165e79c1a211_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55442e45b4004aa1ab3f8d35b70ac615_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i8c772b1568214a7294558171471dfda5_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV8yOTU1_2d00d47c-8f24-4d4c-ae1e-1842c4f144d2">10-K</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">________________________________</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Mark&#160;One)</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6MTMwYjU4NDVjZGQ4NGY0NTg3N2ViYmQwNWM3ZDVmNjgvdGFibGVyYW5nZToxMzBiNTg0NWNkZDg0ZjQ1ODc3ZWJiZDA1YzdkNWY2OF8wLTAtMS0xLTIxMDAy_9fc7d40f-8a1e-4b04-9649-fa82afedd4eb">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal&#160;year ended <ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV8xOTQ_89484c0f-4678-4cfb-bdf1-75b571ab7a8f"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV8xOTQ_b1099096-8dc7-4a2b-a3f9-220efcc2e693">December 31</ix:nonNumeric>, 2021</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6MDMxZjYyZmM1MTliNDk1NzhhOTE0M2E0NmQzN2YyNmIvdGFibGVyYW5nZTowMzFmNjJmYzUxOWI0OTU3OGE5MTQzYTQ2ZDM3ZjI2Yl8wLTAtMS0xLTIxMDAy_6831a1ed-77bd-468b-bb57-4be6c1ab27f4">&#168;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV8yOTU2_d0f3ace2-5e1f-4a32-a7fd-71fcc6ba30f6">001-40034</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV8yOTU4_df472f03-c43a-4cf5-a4ff-85a1de64699c">VALLON PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6ZTYwZGIwZWI5MTkwNGI5MjkzODA5ODAzN2E1NjFkOGYvdGFibGVyYW5nZTplNjBkYjBlYjkxOTA0YjkyOTM4MDk4MDM3YTU2MWQ4Zl8wLTEtMS0xLTIxMDAy_e2102b58-12e2-49b1-967a-8ee29c923791">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6ZTYwZGIwZWI5MTkwNGI5MjkzODA5ODAzN2E1NjFkOGYvdGFibGVyYW5nZTplNjBkYjBlYjkxOTA0YjkyOTM4MDk4MDM3YTU2MWQ4Zl8wLTMtMS0xLTIxMDAy_26887ad0-33f0-4367-8b2d-4b46e19c43f3">82-4369909</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(State or other jurisdiction of<br/>incorporation and organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(I.R.S. Employer Identification No.)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6NzBkZTgxYzMzNWJmNDdjNzg2MTc0MjM0ZTNkOTFjODkvdGFibGVyYW5nZTo3MGRlODFjMzM1YmY0N2M3ODYxNzQyMzRlM2Q5MWM4OV8wLTAtMS0xLTIxMDAyL3RleHRyZWdpb246NDU3NTgwNDI5OTRiNDg0YTgwODA5ZDBhOTFhZTJkMzdfNQ_2cf877a8-f5cd-4622-b8c5-1e81f52c4bd0">100 N. 18th Street</ix:nonNumeric>, <ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6NzBkZTgxYzMzNWJmNDdjNzg2MTc0MjM0ZTNkOTFjODkvdGFibGVyYW5nZTo3MGRlODFjMzM1YmY0N2M3ODYxNzQyMzRlM2Q5MWM4OV8wLTAtMS0xLTIxMDAyL3RleHRyZWdpb246NDU3NTgwNDI5OTRiNDg0YTgwODA5ZDBhOTFhZTJkMzdfOQ_dbfbcf95-6453-498e-9d01-a32d6d90692c">Suite 300</ix:nonNumeric>, <ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6NzBkZTgxYzMzNWJmNDdjNzg2MTc0MjM0ZTNkOTFjODkvdGFibGVyYW5nZTo3MGRlODFjMzM1YmY0N2M3ODYxNzQyMzRlM2Q5MWM4OV8wLTAtMS0xLTIxMDAyL3RleHRyZWdpb246NDU3NTgwNDI5OTRiNDg0YTgwODA5ZDBhOTFhZTJkMzdfMTM_d6ec9dec-cf50-4afd-8b6f-570091296296">Philadelphia</ix:nonNumeric>, <ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6NzBkZTgxYzMzNWJmNDdjNzg2MTc0MjM0ZTNkOTFjODkvdGFibGVyYW5nZTo3MGRlODFjMzM1YmY0N2M3ODYxNzQyMzRlM2Q5MWM4OV8wLTAtMS0xLTIxMDAyL3RleHRyZWdpb246NDU3NTgwNDI5OTRiNDg0YTgwODA5ZDBhOTFhZTJkMzdfMTc_ac817c59-a8f6-4fdf-adb0-57a8d1f9f7fb">PA</ix:nonNumeric>&#160;&#160;<ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6NzBkZTgxYzMzNWJmNDdjNzg2MTc0MjM0ZTNkOTFjODkvdGFibGVyYW5nZTo3MGRlODFjMzM1YmY0N2M3ODYxNzQyMzRlM2Q5MWM4OV8wLTAtMS0xLTIxMDAyL3RleHRyZWdpb246NDU3NTgwNDI5OTRiNDg0YTgwODA5ZDBhOTFhZTJkMzdfMjE_020da308-e644-4aff-9bca-74dfc674b69c">19103</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6NzBkZTgxYzMzNWJmNDdjNzg2MTc0MjM0ZTNkOTFjODkvdGFibGVyYW5nZTo3MGRlODFjMzM1YmY0N2M3ODYxNzQyMzRlM2Q5MWM4OV8wLTEtMS0xLTIxMDAyL3RleHRyZWdpb246MTA5YjJlNGI2ZmE0NGIyN2JlYTllYjhhZWEyOTI0Y2VfNg_213a9cc6-27f0-4c4d-9eaf-cc2b5651193f">267</ix:nonNumeric>) <ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6NzBkZTgxYzMzNWJmNDdjNzg2MTc0MjM0ZTNkOTFjODkvdGFibGVyYW5nZTo3MGRlODFjMzM1YmY0N2M3ODYxNzQyMzRlM2Q5MWM4OV8wLTEtMS0xLTIxMDAyL3RleHRyZWdpb246MTA5YjJlNGI2ZmE0NGIyN2JlYTllYjhhZWEyOTI0Y2VfMTA_e58d46c1-0d73-4add-b0b0-18b75468a75f">607-8255</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:40.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.337%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6MjQ3MmMwZTY3MDAyNDBmMmEzMmRhM2JlZjIwYzM2YzMvdGFibGVyYW5nZToyNDcyYzBlNjcwMDI0MGYyYTMyZGEzYmVmMjBjMzZjM18xLTAtMS0xLTIxMDAy_1516e01a-71f3-4c16-b33e-9ad8ac58ab2c">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6MjQ3MmMwZTY3MDAyNDBmMmEzMmRhM2JlZjIwYzM2YzMvdGFibGVyYW5nZToyNDcyYzBlNjcwMDI0MGYyYTMyZGEzYmVmMjBjMzZjM18xLTItMS0xLTIxMDAy_65949821-445f-4f26-99a2-8251abbebe26">VLON</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6MjQ3MmMwZTY3MDAyNDBmMmEzMmRhM2JlZjIwYzM2YzMvdGFibGVyYW5nZToyNDcyYzBlNjcwMDI0MGYyYTMyZGEzYmVmMjBjMzZjM18xLTQtMS0xLTIxMDAyL3RleHRyZWdpb246MWNmNTExNTFmMzMyNDE2YTkzNmZmZWE0NmQ4ZWUzMDhfNA_8ac821fc-2a2e-4983-8668-37d5a5151896">NASDAQ</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. &#160;&#160;&#160;Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV81NDk3NTU4MTQyNTkz_d363aeed-73e7-47cc-9dcf-1c45552cfe12">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. &#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV81NDk3NTU4MTQyNTk1_b563fb89-34e7-4534-9b86-c1c9ade72f1c">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;&#160;<ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV8yOTU5_d476e12c-7e20-4c63-9396-ce37f639287a">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).  &#160;<ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV8yOTU3_a95a9c32-a515-4806-9fe1-6c6cb40f740b">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.317%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6YjllN2Y1ZmNiYjUyNGEwN2I3MjJhZTA1ZWYzMWIyMmYvdGFibGVyYW5nZTpiOWU3ZjVmY2JiNTI0YTA3YjcyMmFlMDVlZjMxYjIyZl8xLTAtMS0xLTIxMDAy_31a5c49a-732c-4e78-bdf0-a07f56a53389">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6YjllN2Y1ZmNiYjUyNGEwN2I3MjJhZTA1ZWYzMWIyMmYvdGFibGVyYW5nZTpiOWU3ZjVmY2JiNTI0YTA3YjcyMmFlMDVlZjMxYjIyZl8xLTMtMS0xLTIxMDAy_b2e0200f-73d7-43e2-9d13-fe3a58146799">x</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6YjllN2Y1ZmNiYjUyNGEwN2I3MjJhZTA1ZWYzMWIyMmYvdGFibGVyYW5nZTpiOWU3ZjVmY2JiNTI0YTA3YjcyMmFlMDVlZjMxYjIyZl8yLTMtMS0xLTIxMDAy_25ce9dca-dbc4-461e-b897-fbdd9ab09e35">x</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV8yOTYw_b8cd682d-3714-48a4-8d18-057bc5e32f19">&#168;</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV8xNjQ5MjY3NDQ1Njky_f4753500-6b4f-4372-93e1-0525db67ac16">&#168;</ix:nonNumeric>  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV8yOTYx_ab0dc4e8-6d0d-4860-bee5-70a3bb932b09">&#168;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter), the aggregate market value of the registrant&#8217;s common stock held by non-affiliates was approximately $<ix:nonFraction unitRef="usd" contextRef="i65072bfeaf3a4457ad6a97aa44ce8820_I20210630" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV81NDk3NTU4MTQyNTk3_3bab5dec-c5fe-4680-af24-1c451a6e9205">22.9</ix:nonFraction>&#160;million based on the last reported sale price of the registrant&#8217;s common stock on the Nasdaq Capital Market on June 30, 2021.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 11, 2022, <ix:nonFraction unitRef="shares" contextRef="iabb727de2d49441ba5658b9b5a183b63_I20220211" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV81NDk3NTU4MTQyNjEz_c64c8063-9c21-4531-aa0d-1087fb23ced9">6,812,836</ix:nonFraction> shares of the Registrant&#8217;s Common Stock were outstanding. </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt"><span><br/></span></div></div></div><div id="i8c772b1568214a7294558171471dfda5_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VALLON PHARMACEUTICALS, INC.</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page&#160;No.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_10">NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_873">RISK FACTOR SUMMARY</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_868">MARKET, INDUSTRY AND OTHER DATA</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-top:8pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_13">PART&#160;I&#160;</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_13">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_13">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_13">TEM</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_13">&#160;1.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">BUSINESS</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_16">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_19">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_19">TEM</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_19">&#160;1A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">RISK FACTORS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_19">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_22">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_22">TEM </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_22">1B.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">UNRESOLVED STAFF COMMENTS</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_22">36</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_25">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_25">TEM</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_25">&#160;2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">PROPERTIES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_25">36</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_28">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_28">TEM</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_28">&#160;3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">LEGAL PROCEEDINGS</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_28">36</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_31">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_31">TEM</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_31">&#160;4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">MINE SAFETY DISCLOSURES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_31">36</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_34">PART II</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_34">37</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ITEM<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_37">&#160;5.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_37">M</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_37">A</a>RKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUE PURCHASES OF EQUITY SECURITIES</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_37">37</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_40">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_40">TEM</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_40">&#160;6.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">[RESERVED]</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_40">37</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_43">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_43">TEM</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_43">&#160;7.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_43">M</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_43">A</a>NAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_43">37</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_88">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_88">TEM</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_88">&#160;7A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_88">Q</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_88">U</a>ANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_88">44</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_91">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_91">TEM</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_91">8.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_91">F</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_91">I</a>NANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_91">44</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_94">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_94">TEM</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_94">&#160;9.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_94">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_94">H</a>ANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_94">44</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ITEM<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_97">&#160;9A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_97">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_97">O</a>NTROLS AND PROCEDURES</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_97">44</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_100">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_100">TEM</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_100">&#160;9B.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_100">O</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_100">T</a>HER INFORMATION</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_100">46</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_1200">ITEM 9C.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_1200">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_1200">46</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_103">PART III</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_103">47</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ITEM<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_106">&#160;10.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_106">47</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ITEM<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_109">&#160;11.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_109">E</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_109">X</a>ECUTIVE COMPENSATION</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_109">53</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ITEM<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_112">&#160;12.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_112">S</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_112">E</a>CURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_112">57</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ITEM<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_115">&#160;13.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_115">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_115">E</a>RTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_115">59</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ITEM<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_118">&#160;14.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_118">P</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_118">R</a>INCIPAL ACCOUNTANT FEES AND SERVICES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_118">62</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_121">PART IV</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_121">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ITEM<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_124">&#160;15.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_124">E</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_124">X</a>HIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_124">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_1208">ITEM 16.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_1208">FORM 10-K SUMMARY</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_1208">65</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_130">S</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_130">I</a>GNATURE PAGE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_130">66</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span><br/></span></div></div></div><div id="i8c772b1568214a7294558171471dfda5_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K (this Annual Report) contains forward-looking statements that are based on management&#8217;s beliefs and assumptions and on information currently available to management. Some of the statements in the sections captioned &#8220;Item 1. Business,&#8221; &#8220;Item 1A. Risk Factors,&#8221; &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and elsewhere in this Annual Report contain forward-looking statements. In some cases, you can identify forward-looking statements by the following words: &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements contained in this Annual Report include, but are not limited to, statements about:&#160;</span></div><div style="margin-bottom:9pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the likelihood of our clinical trials and non-clinical studies demonstrating safety and efficacy of our product candidates, and other positive results;</span></div><div style="margin-bottom:9pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of initiation of our future clinical trials, and the reporting of data from our completed, current and future preclinical and clinical trials;</span></div><div style="margin-bottom:9pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the market opportunity for our product candidates;</span></div><div style="margin-bottom:9pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and sales strategy;</span></div><div style="margin-bottom:9pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competing therapies that are or may become available;</span></div><div style="margin-bottom:9pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates of the number of patients in the United States who suffer from ADHD or narcolepsy and the number of patients that will enroll in our clinical trials;</span></div><div style="margin-bottom:9pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the beneficial characteristics, safety and efficacy of our product candidates;</span></div><div style="margin-bottom:9pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing or likelihood of regulatory filings and approval for our product candidates;</span></div><div style="margin-bottom:9pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain regulatory approval of our product candidates;</span></div><div style="margin-bottom:9pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to the further development and manufacturing of our product candidates, including ADMIR;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the expected potential benefits of strategic collaborations with third parties, including MEDICE Arzneimittel P&#252;tter GmbH &amp; Co. KG (Medice), who is affiliated with one of our principal stockholders, SALMON Pharma GmbH (Salmon Pharma), and represented by one member of our board of directors, and our ability to attract collaborators with development, regulatory and commercialization expertise;</span></div><div style="margin-bottom:9pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">existing regulations and regulatory developments in the United States, the European Union, and other geographic territories;</span></div><div style="margin-bottom:9pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available;</span></div><div style="margin-bottom:9pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials;</span></div><div style="margin-bottom:9pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to hire additional personnel, and our ability to attract and retain such personnel;</span></div><div style="margin-bottom:9pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-bottom:9pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance;</span></div><div style="margin-bottom:9pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sufficiency of our existing capital resources to fund our future operating expenses and capital expenditure requirements;</span></div><div style="margin-bottom:9pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impacts of the COVID-19 pandemic on our operations;</span></div><div style="margin-bottom:9pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our anticipated use of our existing resources and the proceeds from this offering; and</span></div><div style="margin-bottom:9pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain the listing of our common stock on The Nasdaq Capital Market.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, we have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. You should refer to the &#8220;Risk Factors&#8221; section of this Annual Report for a discussion of other important factors that may cause actual results to differ materially from those expressed or implied by the forward-looking statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward- looking statements as predictions of future events. If the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this Annual Report represent our views as of the date of this Annual Report. We anticipate that subsequent events and developments will cause our views to change, however, except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein until after we distribute this Annual Report, whether as a result of any new information, future events or otherwise. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report includes trademarks and registered trademarks of Vallon Pharmaceuticals, Inc. Products or service names of other companies mentioned in this Annual Report may be trademarks or registered trademarks of their respective owners.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this Annual Report, unless the context requires otherwise, the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Vallon Pharmaceuticals, Inc.</span></div><div id="i8c772b1568214a7294558171471dfda5_873"></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTOR SUMMARY</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the principal risks described below in Part I, Item 1A &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. We believe that the risks described in the &#8220;Risk Factors&#8221; section are material to investors, but other factors not presently known to us or that we currently believe are immaterial may also adversely affect us. The following summary should not be considered an exhaustive summary of the material risks facing us, and it should be read in conjunction with the &#8220;Risk Factors&#8221; section and the other information contained in this Annual Report on Form 10-K.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Business and Industry</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We anticipate future losses and negative cash flow, and it is uncertain if or when we will become profitable.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are a clinical-stage company with no approved products and a lack of operating history, which makes it difficult to assess our future viability.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As a result of our limited operating history, we may not be able to correctly estimate our future revenues, operating expenses, need for investment capital, or stability of operations, which could lead to cash shortfalls.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We do not currently have any drug products for sale, and only one clinical stage product under development, ADAIR. Our prospects currently depend largely on the success of ADAIR, which is still in clinical development, and we may not be able to generate revenues from ADAIR.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If serious adverse or unacceptable side effects are identified during the development of ADAIR or any potential future products, such as ADMIR, we may need to abandon or limit our development of some of such products.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If ADAIR does not achieve broad market acceptance, the revenues that we generate from its sales will be limited.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we obtain approval to commercialize ADAIR, or any other future product, such as ADMIR, outside of the U.S., a variety of risks associated with international operations could materially adversely affect our business.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the government or third-party payors fail to provide adequate coverage and payment rates for ADAIR or any future products, such as ADMIR, we may develop, license or acquire, if any, our revenue and prospects for profitability will be limited.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to establish sales, marketing, and distribution capabilities or to enter into agreements with third parties to market and sell ADAIR or any other future product, such as ADMIR, we may not be successful in commercializing ADAIR or any other future product if and when they are approved.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Relating to Finances and Capital Requirements</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not so available, may require us to delay, limit, reduce or cease our operations.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will continue to incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Regulatory Matters</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not receive regulatory approval for ADAIR or any future product, such as ADMIR, or its or their approvals may be delayed, which would have a material adverse effect on our business and financial condition.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if ADAIR or any other proposed product that we develop, such as ADMIR, receives marketing approval, we will continue to face extensive regulatory requirements and the product may still face future development and regulatory difficulties.&#160;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The abuse, misuse or off-label use of our products may harm our image in the marketplace, result in injuries that lead to product liability suits or result in costly investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly to our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Intellectual Property</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have filed multiple patent applications and have two issued patents by the U.S. Patent and Trademark Office (U.S. PTO) and one issued patent by the European Patent Office. These or any other patent applications may not result in issued patents, and as a result we may have limited protection of our proprietary technology in the marketplace.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because it is difficult and costly to protect our proprietary rights, we may not be able to ensure their protection.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Securities Markets and Our Common Stock</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we cannot continue to satisfy the listing requirements of The Nasdaq Capital Market and other rules, including the director independence requirements, our securities may be delisted, which could negatively impact the price of our securities and stockholders&#8217; ability to sell them.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our stock may be subject to substantial price and volume fluctuations due to a number of factors, many of which are beyond our control and may prevent our stockholders from reselling our common stock at a profit.</span></div><div id="i8c772b1568214a7294558171471dfda5_868"></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MARKET, INDUSTRY AND OTHER DATA</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains estimates, projections and other information concerning our industry, our business and the markets for our drug candidates, including data regarding the estimated size of such markets and the incidence of certain medical conditions. We obtained the industry, market and similar data set forth in this report from our internal estimates and research and from independent industry publications, governmental publications, reports by market research firms or other independent sources that we believe to be reliable sources. In some cases, we do not expressly refer to the sources from which this data is derived. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our internal data and estimates are based upon information obtained from trade and business organizations and other contacts in the industry in which we operate, and our management&#8217;s understanding of industry conditions. While we believe our internal research is reliable, it has not been verified by an independent source. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. We are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">responsible for all of the disclosure contained in this report, and we believe these industry publications and third-party research, surveys and studies are reliable. While we are not aware of any misstatements regarding any third-party information presented in this report, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties, and are subject to change based on various factors, including those discussed under the section entitled &#8220;Risk Factors&#8221; in this report, and elsewhere in this report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span><br/></span></div></div></div><div id="i8c772b1568214a7294558171471dfda5_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I</span></div><div id="i8c772b1568214a7294558171471dfda5_16"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;BUSINESS </span></div><div style="margin-bottom:9pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company primarily focused on the development and commercialization of proprietary biopharmaceutical products. We are developing novel medications for central nervous system (CNS) disorders with a focus on abuse-deterrent medications. Our lead investigational product candidate, ADAIR, is a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine (the main active ingredient in Adderall&#174;) for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. According to the US Department of Health and Human Services&#8217; 2018 National Survey on Drug Use and Health, over five million adolescents and adults misuse prescription stimulant medications on an annual basis. The misuse and abuse of prescription stimulants has substantial medical risk, including risk of irregular heartbeat, heart attack, seizures, hallucinations, hostile behavior and stroke, as well as increased risk of addiction. ADAIR is designed to deter attempts to crush and snort and to provide barriers to injection while still providing the expected therapeutic benefit when taken orally.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing ADAIR for registration with the U.S. Food and Drug Administration (FDA) through the Section 505(b)(2) regulatory pathway, which is expected to obviate the need for large Phase 2 and Phase 3 efficacy and safety studies. In July 2018, our Investigational New Drug (IND) application for ADAIR was approved by the FDA. We have completed three Phase 1 trials of ADAIR including a proof-of-concept intranasal human abuse potential study. We have also completed a 13-week preclinical toxicology study on the final formulation of ADAIR that showed no safety findings of concern. We are currently conducting the SEAL study, a pivotal intranasal abuse study, and have completed its patient enrollment and treatment phases. The SEAL study enrolled 55 subjects who successfully passed the qualification phase with a total of 53 completing the study. We expect to report top-line results of  the SEAL study in the first quarter of 2022. Additionally, we continue to conduct preclinical studies and manufacturing work and evaluate the potential for any additional studies to support the submission of a New Drug Application (NDA) for ADAIR to the FDA. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, we entered into a license agreement (the Medice License Agreement) with Medice, which grants Medice an exclusive license to develop, use, manufacture, market and sell ADAIR throughout Europe. Under the Medice License Agreement, Medice paid us a $0.1 million upfront payment and will pay milestone payments of up to $6.3 million in aggregate upon achieving certain regulatory and sales milestones. We are also entitled to low-double digit tiered royalties on net sales of ADAIR.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to ADAIR, we completed formulation development work and selected the final formulation of our second product candidate, ADMIR, an abuse deterrent formulation of methylphenidate (Ritalin&#174;), for the treatment of ADHD. We also plan to utilize the Section 505(b)(2) regulatory pathway for registration of ADMIR.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we plan to use our abuse deterrent platform technology to develop other products that have potential for abuse in their current forms and will continue business development activities and seek partnering, licensing, merger and acquisition opportunities or other transactions to further develop our pipeline and drug-development capabilities.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global COVID-19 pandemic continues to present uncertainty and unforeseeable new risks to our operations and business plan. We have closely monitored recent COVID-19 developments, including states&#8217; lifting COVID-19 safety measures, drops in vaccination rates, and the spread of various coronavirus strains such as the Delta and Omicron variants. In light of these developments, the full impact of the COVID-19 pandemic on our business, operations and clinical development plans remains uncertain and will vary depending on the pandemic&#8217;s future impact on our clinical trial enrollment, clinical trial sites, clinical research organizations (CROs), third-party manufacturers, and other third parties with whom we do business, as well as any legal or regulatory consequences resulting therefrom. To the extent possible, we are conducting business as usual, with necessary or advisable modifications to employee travel and with most of our employees and consultants working remotely. We will continue to actively monitor the COVID-19 situation and may take further actions that alter our operations, including those that may be required by federal, state or local authorities, or that we determine are in the best interests of our employees and other third parties with whom we do business.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reverse Split</span></div><div style="margin-bottom:9pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we filed a certificate of amendment to our amended and restated certificate of incorporation with the Secretary of State of the State of Delaware, which effected a one-for-40 reverse stock split (the reverse split) of our issued and outstanding shares of common stock. As a result of the reverse split, every 40 shares of common stock issued and outstanding were reclassified into one share of common stock. No fractional shares were issued in connection with the reverse split and any fractional shares were rounded up to the nearest whole share.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All share and per share amounts contained in this Annual Report on Form 10-K give retroactive effect to the reverse split.</span></div><div style="margin-bottom:9pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medice License Agreement</span></div><div style="margin-bottom:9pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;6, 2020, we entered into a license agreement with Medice, who is affiliated with one of our principal stockholders, Salmon Pharma, and represented by one member of our board of directors, which grants Medice an exclusive license, with the right to grant sublicenses, to develop, use, manufacture, market and sell ADAIR throughout Europe. Medice currently markets several ADHD products in Europe and is the ADHD market leader in Europe based on branded prescription market share. Medice is responsible for obtaining regulatory approval of ADAIR in the licensed territory. Under the license agreement, Medice paid us a minimal upfront payment and will pay milestone payments of up to $6.3&#160;million in the aggregate upon first obtaining regulatory approval to market and sell ADAIR in any country, territory or region in the licensed territory and upon achieving certain annual net sales thresholds. For the term of the license agreement, Medice will also pay tiered royalties on annual net sales of ADAIR at rates between 10% and 20%. The initial term of the license agreement will expire five&#160;years after the date on which Medice first obtains regulatory approval in any country, territory or region in the licensed territory. Medice has the option to extend the term of the license agreement for additional periods of five&#160;years each. Medice has the right to terminate the license agreement at any time upon twelve&#160;months&#8217; prior written notice to us. We have the right to terminate the license agreement immediately upon notice if Medice challenges the validity, enforceability or patentability of any patent right comprising the licensed intellectual property. Either party may terminate the license agreement if the other party materially breaches its obligations under the license agreement, provided that the terminating party gives the breaching party notice of the breach and a specified opportunity to cure the breach, or upon the other party&#8217;s bankruptcy.</span></div><div style="margin-bottom:9pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:9pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to pursue, maintain and defend patent rights developed internally and to protect the technology, inventions and improvements that are commercially important to the development of our business. We currently have two issued U.S. patents directed to specific ADAIR formulations (i.e., composition of matter) and one pending patent application for ADAIR that is under examination with the U.S. PTO. The U.S. patents will expire in 2037. We have one issued European patent which expires in 2038. Our international PCT application has entered national phase is under examination in several foreign countries and territories, including Australia, Brazil, Canada, China, and Japan. We also rely on know-how relating to our proprietary technology and product candidates and continuing innovation to develop, strengthen and maintain our proprietary position. We also plan to rely on data exclusivity, market exclusivity and patent term extensions when available.</span></div><div style="margin-bottom:9pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees</span></div><div style="margin-bottom:9pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 4, 2022, we had three full-time employee and had engaged six consultants. We have no collective bargaining agreements with our employees and none are represented by labor unions. We consider our current relations with our employees to be good.</span></div><div style="margin-bottom:9pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Facilities</span></div><div style="margin-bottom:9pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive offices are located at 100 N. 18th Street, Suite 300, Philadelphia, PA 19103. We believe that our facilities are adequate to meet our current needs. Should we be required to obtain additional space in the future, we believe we can obtain the required facilities at competitive rates. </span></div><div style="margin-bottom:9pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any legal proceedings.</span></div><div style="margin-bottom:9pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-bottom:9pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated under the laws of the State of Delaware in January 2018, and completed our organization, formation and initial capitalization activities effective in June&#160;2018. Our telephone number is 267-607-8255, and our email address is info@vallon-pharma.com. Our website address is https://www.vallon-pharma.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, proxy and information statements and amendments to those reports filed or furnished pursuant to Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act), are available through the &#8220;Investors&#8221; portion of our website after we file such material with the SEC. The information contained on, or that can be accessed through, our website is not part of this Annual Report and is not incorporated by reference. We have included our website address herein solely as an inactive textual reference. Our filings with the SEC may be accessed through the SEC&#8217;s Interactive Data Electronic Applications system at https://www.sec.gov.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act of 1933, as amended (the&#160;Securities Act), as modified by the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). Emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. Therefore, we may not be subject to the same new or revised accounting standards as other public companies that are not &#8220;emerging growth companies.&#8221; For as long as we continue to be an emerging growth company, we also intend to take advantage of certain other exemptions from various reporting requirements that are applicable to other public companies including, but not limited to, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, exemptions from the requirements of holding a nonbinding advisory stockholder vote on executive compensation and any golden parachute payments not previously approved, exemption from the requirement of auditor attestation in the assessment of our internal control over financial reporting and exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements (auditor discussion and analysis). We will remain an emerging growth company until the earliest of (i)&#160;the end of the fiscal year in which the market value of our common stock that is held by non-affiliates exceeds $700&#160;million as of the end of the second fiscal quarter, (ii)&#160;the end of the fiscal year in which we have total annual gross revenues of $1.07&#160;billion or more during such fiscal year, (iii)&#160;the date on which we issue more than $1&#160;billion in non-convertible debt in a three-year period, or (iv)&#160;the end of the fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement filed under the Securities Act.</span></div><div id="i8c772b1568214a7294558171471dfda5_19"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should consider carefully the following risks described below, together with the other information contained in this Annual Report and in our other public filings, in evaluating our business. If any of the following risks actually occurs, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock would likely decline.</span></div><div style="margin-bottom:9pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Relating to Our Business and Industry</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We anticipate future losses and negative cash flow, and it is uncertain if or when we will become profitable.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate any significant revenues until we successfully complete development of our first product, including obtaining all required regulatory approvals, and we are able to successfully commercialize the product through sales and licensing. As of the date of this report, our product candidates are still in development and have not been approved by the FDA.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not yet demonstrated our ability to generate revenue, and we may never be able to produce revenues or operate on a profitable basis. We have incurred losses since our inception (January&#160;11, 2018) and expect to experience operating losses and negative cash flow for the foreseeable future. ADAIR or any other future product, such as ADMIR, may never be approved or become commercially viable. Even if we and any collaborators are able to commercialize our technology, which may include licensing, we may never recover our research and development expenses.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a clinical-stage company with no approved products and a lack of operating history, which makes it difficult to assess our future viability.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated on January&#160;11, 2018, and our operations to date have been limited to organizing and staffing our company, acquiring rights to ADAIR, preparing and filing an IND application for ADAIR, conducting four Phase&#160;I studies and working on the commercial formulation and manufacturing of ADAIR. We have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical area. For example, to execute our business plan, we will need to successfully:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain adequate financing on terms that are acceptable to us;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">execute product development activities;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain required regulatory approvals for the development and commercialization of ADAIR or any other future product, such as ADMIR;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, leverage, and expand our intellectual property portfolio;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">build and maintain robust sales, distribution, and marketing capabilities, either on our own or in collaboration with strategic partners;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">gain market acceptance for ADAIR or any other future product, such as ADMIR;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop and maintain any strategic relationships we elect to enter into; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage our spending as costs and expenses increase due to clinical trials, regulatory approvals, and commercialization.&#160;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unsuccessful in accomplishing these objectives, we may not be able to develop ADAIR or any other future product, such as ADMIR, raise capital, expand our business, or continue our operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, our lack of operating history makes it difficult to evaluate our business and prospects. Our prospects must be considered in light of the risks, uncertainties, expenses, and difficulties frequently encountered by companies in their early stages of development, particularly companies in the biopharmaceutical industry. As a young business, we may encounter unforeseen expenses, difficulties, complications, delays, and other known and unknown factors. We will need to expand our capabilities to support commercial activities. We may not be successful in adding such capabilities. The historical information in this report may not be indicative of our future financial condition and future performance. We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, stockholders should not rely upon our past results of as an indication of future operating performance.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a result of our limited operating history, we may not be able to correctly estimate our future revenues, operating expenses, need for investment capital, or stability of operations, which could lead to cash shortfalls.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a limited operating history from which to evaluate our business. As a result, our historical financial data is of limited value in estimating future operating expenses. In addition, although we are a clinical-stage company, we have not yet completed all of the non-clinical safety studies for ADAIR or other pivotal clinical trials. We also have not obtained regulatory approvals for any of our products, manufactured a commercial scale product, arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful product commercialization. Therefore, our budgeted operating expense levels are based in part on our expectations concerning the FDA approval process and expenses related to development of other product candidates. Failing to reach our short-term developmental milestones within anticipated timelines due to delays caused by the COVID-19 outbreak, serious adverse or unacceptable side effects caused by our product candidates, or other events, many of which may be beyond our control, may cause our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not currently have any drug products for sale, and only one clinical stage product under development, ADAIR. Our prospects currently depend largely on the success of ADAIR, which is still in clinical development, and we may not be able to generate revenues from ADAIR.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any prescription drug products that have been approved by the FDA, or any similar regulatory authority. Our business success depends on our ability to obtain regulatory approval for and successfully commercialize our only product currently under development, ADAIR, which will require substantial investment, access to sufficient commercial manufacturing capacity, and significant marketing efforts before we can generate any revenue from sales of ADAIR, if it is ever approved for commercialization.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have only one other prescription drug candidate in early development today and so our business prospects currently depend primarily on the successful development, regulatory approval, and commercialization of ADAIR, which may never occur. Even though ADAIR is in the clinical development stage, it has an uncertain chance of successfully completing clinical development and gaining regulatory approval. Any significant delays in obtaining approval for and commercializing ADAIR will have a substantial adverse impact on our business and financial condition.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if approved, we may be unable to successfully commercialize ADAIR and we may never generate meaningful revenues. Our ability to generate revenues from ADAIR will depend on our ability to:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire, train, deploy, and support our sales force, including any contract sales force engaged;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">create market demand for ADAIR through our own marketing and sales activities, and any other promotional arrangements we may later establish;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain sufficient quantities of ADAIR from our third-party manufacturers as required to meet commercial demand at launch and thereafter;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish and maintain agreements with wholesalers, distributors and group purchasing organizations on commercially reasonable terms; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain patent protection and regulatory exclusivity for ADAIR.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if the market for ADAIR develops less rapidly than we anticipate, we may not have the ability to shift our resources to the development of alternative products.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If serious adverse or unacceptable side effects are identified during the development of ADAIR or any potential future products, such as ADMIR, we may need to abandon or limit our development of such products.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If ADAIR or potential future products, such as ADMIR, are associated with undesirable side effects in preclinical studies or clinical trials or have characteristics that are unexpected, we may need to abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe, or more acceptable from a risk-benefit perspective. In our industry, many compounds that initially showed promise in early stage testing have later been found to cause side effects that prevented further development of the compound. In the event that our clinical trials reveal a high and unacceptable severity and prevalence of side effects, our trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development or deny approval of ADAIR or potential future products for any or all targeted indications. The FDA could also issue a letter requesting additional data or information prior to making a final decision regarding whether or not to approve a product. The number of requests for additional data or information issued by the FDA in recent&#160;years has increased, and resulted in substantial delays in the approval of several new drugs. Undesirable side effects caused by ADAIR or potential future products could also result in the inclusion of unfavorable information in our product labeling, denial of regulatory approval by the FDA, or other regulatory authorities for any or all targeted indications, and in turn prevent us from commercializing and generating revenues from the sale of ADAIR or potential future products. Drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial and could result in potential product liability claims.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if one or more of our current or potential future products, including ADAIR or ADMIR, receive marketing approval and we or others later identify undesirable side effects caused by this product, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of unfavorable labeling statements, specific warnings, or a contraindication;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may suspend or withdraw their approval of the product, or require it to be removed from the market;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to change the way the product is administered, conduct additional clinical trials, or change the labeling of the product; or</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of ADAIR or potential future products, such as ADMIR, or could substantially increase our commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenues from its sale.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If ADAIR does not achieve broad market acceptance, the revenues that we generate from its sales will be limited.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of ADAIR, if approved by the FDA, will depend upon its acceptance by the medical community, our ability to ensure that the drug is included in hospital formularies, and coverage and reimbursement for ADAIR by third-party payors, including government payors. The degree of market acceptance of ADAIR or any other product we may license or acquire will depend on a number of factors, including, but not necessarily limited to:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and safety as demonstrated in clinical trials;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of market introduction of such proposed product as well as competitive products;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical indications for which the drug is approved;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance by physicians and patients of the drug as a safe and effective treatment;&#160;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety of such proposed product seen in a broader patient group, including its use outside the approved indications;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability, cost, and potential advantages of alternative treatments, including less expensive generic drugs;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of adequate reimbursement and pricing by third-party payors and government authorities;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the relative convenience and ease of administration of the proposed product for clinical practices;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product labeling or product insert required by the FDA or regulatory authority in other countries;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval, availability, market acceptance, and reimbursement for a companion diagnostic, if any;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of adverse side effects;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our sales and marketing efforts;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations or warnings contained in the product&#8217;s FDA-approved labeling;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the standard of care for the targeted indications for ADAIR or any future product, such as ADMIR, which could reduce the marketing impact of any superiority claims that we could make following FDA approval; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential advantages over, and availability of, alternative treatments.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any proposed product that we develop does not provide a treatment regimen that is as beneficial as, or is not perceived as being as beneficial as, the current standard of care or otherwise does not provide patient benefit, that proposed product, if approved for commercial sale by the FDA or other regulatory authorities, likely will not achieve market acceptance. Our ability to effectively promote and sell ADAIR and any other product we may license or acquire will also depend on pricing and cost effectiveness, including our ability to produce a product at a competitive price and achieve acceptance of the product onto hospital formularies, as well as our ability to obtain sufficient third-party coverage or reimbursement. Since many hospitals are members of group purchasing organizations, which leverage the purchasing power of a group of entities to obtain discounts based on the collective buying power of the group, our ability to attract customers will also depend on our ability to effectively promote ADAIR or any other future product to group purchasing organizations. We will also need to demonstrate acceptable evidence of safety and efficacy, as well as relative convenience and ease of administration. Market acceptance could be further limited depending on the prevalence and severity of any expected or unexpected adverse side effects associated with ADAIR or any other future product, such as ADMIR. If ADAIR or any other future product are approved but do not achieve an adequate level of acceptance by physicians, health care payors, and patients, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, our efforts to educate the medical community and third-party payors on the benefits of ADAIR or any other future product may require significant resources and may never be successful.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we obtain approval to commercialize ADAIR, or any other future product, such as ADMIR, outside of the U.S., a variety of risks associated with international operations could materially adversely affect our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If ADAIR, or any other future product, such as ADMIR, is approved for commercialization outside the U.S., such as pursuant to the license agreement with Medice, who is affiliated with one of our principal stockholders, Salmon Pharma, and represented by one member of our board of directors, we will likely enter into agreements with third parties to market such product outside the U.S. We expect that we will be subject to additional risks related to entering into or maintaining international business relationships, including:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different regulatory requirements for drug approvals in foreign countries;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing U.S. and foreign drug import and export rules, particularly regarding controlled substances and scheduled products, such as ADAIR;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced protection for intellectual property rights in foreign countries;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers, and regulatory requirements;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different reimbursement systems;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign taxes, including withholding of payroll taxes;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential liability resulting from development work conducted by these distributors; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenues from ADAIR or any other future product, such as ADMIR. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the government or third-party payors fail to provide adequate coverage and payment rates for ADAIR or any future products, such as ADMIR, we may develop, license or acquire, if any, our revenue and prospects for profitability will be limited.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both domestic and foreign markets, our sales of any future products, such as ADMIR, will depend in part upon the availability of coverage and reimbursement from third-party payors. Such third-party payors include government health programs such as Medicare, Medicaid, managed care providers, private health insurers and other organizations. Accordingly, ADAIR or any other future product that we may develop, in-license or acquire, if approved, will face competition from other therapies and drugs for these limited payor financial resources. We may need to conduct post-marketing studies in order to demonstrate the cost-effectiveness of any future products to the satisfaction of insurers, hospitals, other target customers and their third-party payors. Such studies might require us to commit a significant amount of management time and financial and other resources. Any of our future products might not ultimately be considered cost-effective. Adequate third-party coverage and reimbursement might not be available to enable us to maintain price levels sufficient to realize an appropriate return on investment in product development.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish sales, marketing, and distribution capabilities or to enter into agreements with third parties to market and sell ADAIR or any other future product, such as ADMIR, we may not be successful in commercializing ADAIR or any other future product if and when they are approved</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the license agreement with Medice, we currently do not have a marketing or sales organization for the marketing, sales and distribution of biopharmaceutical products. In order to commercialize any product that receives marketing approval, we would need to build marketing, sales, distribution, managerial, and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. In the event of successful development and regulatory approval of ADAIR or another future product, such as ADMIR, we expect to build a targeted specialist sales force to market or co-promote the product. There are risks involved with establishing our own sales, marketing, and distribution capabilities. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may inhibit our efforts to commercialize our products, if any, on our own include, but are not necessarily limited to:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to recruit, train, and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the lack of complementary or other products to be offered by sales personnel, which may put us at a competitive disadvantage from the perspective of sales efficiency relative to companies with more extensive product lines; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an alternative to establishing our own sales force, we may choose to partner with third parties that have well-established direct sales forces to sell, market, and distribute our products.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on a limited number of suppliers and manufacturers for ADAIR and expect to continue to do so for any future product that we may develop, including ADMIR, and for commercialization of our products. This reliance on a limited number of third parties increases the risk that we will not have sufficient quantities of ADAIR or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of biopharmaceutical products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls and the use of specialized processing equipment. We </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have entered into an agreement to complete pre-commercial manufacturing development activities with one contract manufacturer and expect to contract with them for the commercial manufacture of ADAIR. However, we have not yet negotiated and signed a commercial supply agreement. The inability of a third-party manufacturer to successfully manufacture ADAIR may materially harm our business and financial condition, and frustrate future development and any commercialization efforts for this product.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any of our own manufacturing facilities or personnel. We rely, and expect to continue to rely, on third parties for the manufacture of ADAIR or any other future product, such as ADMIR, for clinical testing, as well as for commercial manufacture if any of ADAIR or any other future product receive marketing approval. This reliance on third parties increases the risk that we will not have sufficient quantities of ADAIR or any other future product or such quantities at an acceptable cost or quality, which could delay, prevent, or impair our development or commercialization efforts.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also expect to rely on third-party manufacturers or third-party collaborators for the manufacture of commercial supply of any product for which our collaborators or we obtain marketing approval. We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including, but not necessarily limited to:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reliance on the third party for regulatory compliance and quality assurance;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possible breach of the manufacturing agreement by the third party;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing delays if our third-party manufacturers give greater priority to the supply of other products over ADAIR or any other future product, such as ADMIR, or otherwise do not satisfactorily perform according to the terms of the agreement between us;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our contract manufacturers must comply with strictly enforced federal, state, and foreign regulations, including current Good Manufacturing Practice (cGMP) requirements enforced by the FDA through its facilities inspection program. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturers for compliance with cGMP regulations for manufacture of ADAIR or any other future product, such as ADMIR. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations or similar regulatory requirements outside the U.S. could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, suspension of production, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. Any manufacturing defect or error discovered after products have been produced and distributed could result in even more significant consequences, including costly recall procedures, re-stocking costs, damage to our reputation, and potential for product liability claims.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADAIR and any products that we may develop may compete with other products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant supply or a second source for bulk drug substance. If our current contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers. We may incur added costs and delays in identifying and qualifying any replacement manufacturers. The DEA restricts the importation of a controlled substance finished drug product when the same substance is commercially available in the United States, which could reduce the number of potential alternative manufacturers for ADAIR.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and anticipated future dependence upon others for the manufacture of ADAIR or any other future products, such as ADMIR, may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of ADAIR or any other future product, such as ADMIR, or commercialization of any of our products, producing additional losses and depriving us of potential product revenue.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public health crises such as pandemics or similar outbreaks could materially and adversely affect our preclinical and clinical trials, business, financial condition and results of operations.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March&#160;2020, the World Health Organization declared COVID-19 a global pandemic and the United States declared a national emergency with respect to COVID-19. The COVID-19 pandemic continues to affect the U.S. and global economies and may affect our operations and certain other third parties on which we rely, including by causing disruptions in the supply of our product candidates and the conduct of future clinical trials. Moreover, the COVID-19 pandemic may adversely affect the operations of the FDA and other health authorities, resulting in delays of reviews and approvals with respect to our product candidates. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce our ability to access capital, which could negatively impact our short-term and long-term liquidity. In addition, the loss of any of our employees as a result of COVID-19, or another pandemic, may adversely affect our operations. The ultimate impact of the COVID-19 pandemic is highly uncertain, and we do not yet know the full extent of potential delays or impacts that COVID-19 may have on our business, financing or clinical trial activities.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some examples of potential disruptions that may result from the COVID-19 pandemic, include, but are not limited to:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in enrolling patients in our clinical trials;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in initiating or expanding clinical trials, including delays or difficulties with clinical site initiation and recruiting clinical site investigators and clinical site staff;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19 or other health conditions or being forced to quarantine;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of key clinical trial activities, such as clinical trial site data monitoring and efficacy, safety and translational data collection, processing and analyses, due to limitations on travel imposed or recommended by federal, state or local governments, employers and others or interruption of clinical trial subject visits, which may impact the collection and integrity of subject data and clinical study endpoints;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or disruptions in preclinical experiments and IND-enabling studies due to restrictions of on-site staff and unforeseen circumstances at CROs and vendors, including any delays caused by the COVID-19 pandemic;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption or delays in the operations of the FDA and comparable foreign regulatory agencies;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on employee or other resources that would otherwise be focused on the conduct of our clinical trials and pre-clinical work, including because of sickness of employees or their families, the desire of employees to avoid travel or contact with large groups of people, an increased reliance on working from home, school closures or mass transit disruptions or the refusal of employees to comply with COVID-19 vaccine mandates;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to accept data from clinical trials in affected geographies outside the United States.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 global pandemic remains a public health threat and its ultimate impact on our business and the global economy is uncertain. The extent to which the pandemic may affect our clinical trials, business, financial condition and results of operations will depend on future developments, which are highly uncertain and cannot be predicted at this time, such as the ultimate geographic spread of the disease, the duration of the pandemic, travel restrictions, actions to contain the pandemic or treat its impact, such as social distancing and quarantines or lock-downs in the United States, and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, and the ongoing worldwide vaccine rollout and implementation of vaccine mandates. Future developments in these and other areas present material uncertainty and risk with respect to our clinical trials, business, financial condition and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future growth may depend on our ability to identify and acquire or in-license products and if we do not successfully identify and acquire or in-license related product candidates and products or integrate them into our operations, we may have limited growth opportunities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An important part of our business strategy is to continue to develop a pipeline of product candidates and products by acquiring or in-licensing products, businesses or technologies that we believe are a strategic fit with our business. Future in-licenses or acquisitions, however, may entail numerous operational and financial risks, including:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exposure to unknown liabilities;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption of our business and diversion of our management&#8217;s time and attention to develop acquired products or technologies;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty or inability to secure financing to fund development activities for such acquired or in-licensed technologies in the current economic environment;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">higher than expected acquisition and integration costs;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased amortization expenses;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to retain key employees of any acquired businesses.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. In particular, we may compete with larger biopharmaceutical companies and other competitors in our efforts to establish new collaborations and in-licensing opportunities. These competitors likely will have access to greater financial resources than us and may have greater expertise in identifying and evaluating new opportunities. Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expanding our product offerings may not be profitable.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may choose to develop new products to offer. We are currently developing an abuse deterrent formulation of Ritalin, ADMIR, another commonly prescribed product for the treatment of ADHD. Developing new products involves inherent risks, including our inability to estimate demand for the new offerings, competition from more established market participants, and a lack of market understanding. In addition, expanding into new geographic areas and/or expanding product offerings will be challenging and may require integrating new employees into our culture as well as assessing the demand in the applicable market.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular proposed product or indication, and fail to capitalize on a different proposed product or indication that may have been more profitable or for which there would have been a greater likelihood of success.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on research programs and proposed products that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other proposed products, or for other indications, that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and proposed products for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular proposed product, we may relinquish valuable rights to that proposed product through collaboration, licensing, or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such proposed product.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to effectively manage our growth, our business and reputation, results of operations, and financial condition may be adversely affected.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience a rapid growth in operations, which may place significant demands on our management team and our operational and financial infrastructure. As we continue to grow, we must effectively identify, integrate, develop and motivate new employees, and maintain the beneficial aspects of our corporate culture. To attract top talent, we believe we will have to offer attractive compensation packages. The risks of over-hiring or overcompensating and the challenges of integrating a rapidly growing employee base may impact profitability.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if we do not effectively manage our growth, the quality of our services could suffer, which could adversely affect our business and reputation, results of operations, and financial condition. If operational, technology, and infrastructure improvements are not implemented successfully, our ability to manage our growth will be impaired and we may have to make significant additional expenditures to address these issues. To effectively manage our growth, we will need to continue to improve our operational, financial, and management controls and our reporting systems and procedures. This will require that we refine our information technology systems to maintain effective online services and enhance information and communication systems to ensure that our employees effectively communicate with each other and our growing base of customers. These system enhancements and improvements will require significant incremental and ongoing capital expenditures and allocation of valuable management and employee resources. If we fail to implement these improvements and maintenance programs effectively, our ability to manage our expected growth and comply with the rules and regulations that are applicable to publicly reporting companies will be impaired and we may incur additional expenses.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to manage our business effectively if we are unable to attract and retain key personnel.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our key employees currently include Mr. David Baker, our President and Chief Executive Officer, Ms. Leanne Kelly, our Chief Financial Officer and Ms.&#160;Penny Toren, our Senior Vice President, Regulatory Affairs &amp; Program Management, who is responsible for regulatory affairs, and consulting arrangements with individuals such as our Chief Medical Officer, Dr.&#160;Timothy Whitaker, who is responsible for overseeing clinical development of our product candidates. Our future growth and success depend on our ability to recruit, retain, manage, and motivate our employees and key consultants. The loss of the services of our Chief Executive Officer, or any of our key employees or the inability to hire or retain experienced management personnel could adversely affect our ability to execute our business plan and harm our operating results. Although we have employment agreements in place with management, these agreements are terminable at will with minimal notice.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the specialized scientific and managerial nature of our business, we rely heavily on our ability to attract and retain qualified scientific and technical consultants. We may not be able to attract or retain qualified management and commercial, scientific, and clinical personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical, and other businesses. In addition, the loss of one or more of our senior executive officers or key consultants could be detrimental to us if we cannot recruit suitable replacements in a timely manner.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently carry &#8220;key person&#8221; insurance on the lives of members of senior management. The competition for qualified personnel in the biopharmaceutical field is intense.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to attract and retain necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our directors, consultants and advisors are not obligated to commit their time and attention exclusively to our business and therefore they may encounter conflicts of interest with respect to the allocation of time and business opportunities between our operations and those of other businesses.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our directors are not obligated to commit their time and attention exclusively to our business and, accordingly, they may encounter conflicts of interest in allocating their own time, or any business opportunities which they may encounter, between our operations and those of other businesses.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, our full-time employees consist of David Baker, our President and Chief Executive Officer, Leanne Kelly, our Chief Financial Officer, and Penny Toren, our Senior Vice President, Regulatory Affairs. Our key consultants consist of Dr.&#160;Timothy Whitaker, our Chief Medical Officer, as well as consultants for bookkeeping, pre-clinical and formulation development, chemistry manufacturing and controls (CMC), and clinical operations. Currently, consulting arrangements with individuals, such as Dr.&#160;Whitaker, only require them to devote an average of approximately 10 to 20 hours per week to our business. In addition, our consultants and advisors may have other clients or projects that grow in scope or they may acquire new clients and projects that require more of their time that may come at our expense. We also currently rely on consultants for clinical </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations, statistical support, and preclinical development. If the execution of our business plan demands more time than is currently committed by any of our officers, directors, consultants or advisors, they will be under no obligation to commit such additional time, and their failure to do so may adversely affect our ability to carry on our business and successfully execute our business plan.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, all of our officers and directors, in the course of their other business activities, may become aware of investments, business opportunities, or information which may be appropriate for presentation to us as well as to other entities to which they owe a fiduciary duty. They may also in the future become affiliated with entities that are engaged in business or other activities similar to those we intend to conduct. As a result, they may have conflicts of interest in determining to which entity particular opportunities or information should be presented. If, as a result of such conflict, we are deprived of investment, business or information, the execution of our business plan and our ability to effectively compete in the marketplace may be adversely affected.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we have established, comply with federal and state health-care fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us under the Federal Physician Payments Sunshine Act and similar state laws. In particular, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing, making or contributing to the making of a false claim for reimbursement to federal, state or private payors, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. The precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our market is subject to intense competition. If we are unable to compete effectively, ADAIR or any other proposed product that we develop may be rendered noncompetitive or obsolete.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of existing treatments for ADHD currently on the market, all of which are marketed by pharmaceutical companies that are far larger and more experienced than we are. Patients and doctors are often unwilling to change medications, and this factor will make it difficult for ADAIR or any other proposed product to penetrate the market. Further, our industry is highly competitive and subject to rapid and significant technological change. Our potential competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and research institutions. All of these competitors currently engage in, have engaged in or may engage in the future in the development, manufacturing, marketing and commercialization of new pharmaceuticals, some of which may compete with ADAIR or other proposed product we may have in the future. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. These companies may have products in development that are superior to ADAIR or any other future product, such as ADMIR. Key competitive factors affecting the commercial success of ADAIR and any other proposed product that we may develop in the future are likely to be efficacy, time of onset, safety and tolerability profile, reliability, convenience of dosing, price, and reimbursement.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our potential competitors have substantially greater financial, technical, and human resources than we do and significantly greater experience in the discovery and development of drug candidates, obtaining FDA and other regulatory approvals of products, and the commercialization of those products. Established competitors may invest heavily to quickly discover and develop novel compounds that could make ADAIR or other proposed product we may develop obsolete. Other companies may be developing abuse deterrent formulations of ADHD treatments that may be approved and marketed before ADAIR, limiting the commercial potential of ADAIR. Accordingly, our competitors may be more successful than us in obtaining FDA and other marketing approvals, or more favorable language in the prescription information, for their drugs, and achieving widespread market acceptance. Our competitors&#8217; drugs may be more effective, or more effectively marketed and sold, than any drug we may commercialize and may render ADAIR or any other proposed product that we develop obsolete or non-competitive before we can recover the expenses of developing and commercializing the product. We anticipate that we will face intense and increasing competition as new drugs enter the market and advanced technologies become available. Finally, the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development of new treatment methods for the diseases we are targeting could render ADAIR or any other proposed product that we develop non-competitive or obsolete.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for ADAIR or other proposed product we may license or acquire and may have to limit their commercialization.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of ADAIR and any other proposed product we may license or acquire in clinical trials and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing, or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, or a breach of warranties. Product liability claims might be brought against us by consumers, health care providers, or others using, administering, or selling our products. If we cannot successfully defend ourselves against these claims, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination of clinical trial sites or entire trial programs;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for any proposed product or products that we may develop;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiation of investigations by regulators;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of our business reputation;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of related litigation;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to patients or other claimants;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenues; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced resources of our management to pursue our business strategy.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will obtain limited product liability insurance coverage for any and all of our clinical trials. However, our insurance coverage may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. When needed, we intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for ADAIR or any other future product in development, such as ADMIR, but we may be unable to obtain commercially reasonable product liability insurance for any product approved for marketing. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to fall and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those used by third-party CROs, manufacturers, or other contractors or consultants, may fail or suffer security breaches.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems and those of our future CROs, manufacturers, and other contractors and consultants are vulnerable to damage from computer viruses and unauthorized access. Although to our knowledge we have not experienced any such material system failure or security breach to date, if such an event were to occur, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information (such as individually identifiable health information), we could incur significant liabilities and the further development and commercialization of ADAIR or any other future product, including ADMIR, could be delayed.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medice may not successfully develop or commercialize ADAIR in Europe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;6, 2020, Vallon entered into a license agreement with Medice, who is affiliated with one of our principal stockholders, Salmon Pharma, and represented by one member of our board of directors, which grants Medice an exclusive license, with the right to grant sublicenses, to develop, use, manufacture, market and sell ADAIR throughout Europe. Medice may be unsuccessful with the development program for ADAIR as required to gain regulatory approval in European countries. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirements for approval by European regulatory agencies may be deemed too onerous and expensive to continue the development of ADAIR in Europe. Even if Medice is successful in gaining approval of ADAIR in European countries, it may be unsuccessful in gaining favorable reimbursement of ADAIR by national payors of prescription medications in Europe. Medice may not generate sufficient sales of ADAIR in Europe to support continued commercialization. All of the commercial risks for ADAIR in the United States may also apply to Europe. In addition, Medice may not devote adequate marketing and sales efforts to generate meaningful sales of ADAIR in Europe. The ADHD market in Europe is substantially smaller than in the United States, estimated to be approximately $700&#160;million annually as compared to $9&#160;billion in the United States. Dextroamphetamine products as a class capture much lower market share in Europe as compared to the United States. If European regulatory authorities reject the approval of ADAIR in Europe, this may reflect poorly on ADAIR and diminish sales growth or overall sales in the United States.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increased scrutiny of our environmental, social or governance responsibilities have and will likely continue to result in additional costs and risks and may adversely impact our reputation, employee retention and willingness of customers and suppliers to do business with us.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is an increasing focus from certain customers, consumers, employees and other stakeholders concerning environmental, social and governance (ESG) matters, including corporate citizenship and sustainability. Additionally, public interest and legislative pressure related to public companies&#8217; ESG practices continues to grow. If our ESG practices fail to meet regulatory requirements or stakeholders&#8217; evolving expectations and standards for responsible corporate citizenship in areas including environmental stewardship, support for local communities, Board of Director and employee diversity, human capital management, employee health and safety practices, corporate governance and transparency and employing ESG strategies in our operations, our brand, reputation and employee retention may be negatively impacted, and customers and suppliers may be unwilling to do business with us.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to adopt ESG standards or practices as quickly as stakeholders desire, fail, or be perceived to fail, in our achievement of such initiatives or goals, or fail in fully and accurately reporting our progress on such initiatives and goals, our reputation, business, financial performance and growth may be adversely impacted. In addition, we could be criticized for the scope of such initiatives or goals or perceived as not acting responsibly in connection with these matters. Our business could be negatively impacted by such matters. Any such matters, or related corporate citizenship and sustainability matters, could have a material adverse effect on our business.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks Relating to Finances and Capital Requirements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not so available, may require us to delay, limit, reduce or cease our operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have consumed substantial amounts of cash since our inception. As of December 31, 2021, we had an accumulated deficit of $21.9&#160;million and our net loss was $9.3 million for the year ended December 31, 2021. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. Our business will require additional capital for implementation of our long-term business plan and product development and commercialization.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. As we require additional funds, we may seek to fund our operations through the sale of additional equity securities, debt financing and/or strategic collaboration agreements. We cannot be sure that additional financing from any of these sources will be available when needed or that, if available, the additional financing will be obtained on favorable terms.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, timing, scope, and costs of our clinical trials, including the ability to timely enroll patients in our potential future clinical trials;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing, and cost of regulatory approvals by the FDA and comparable regulatory authorities, including the potential that the FDA or comparable regulatory authorities may require that we perform more studies than those that we currently expect;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and characteristics of ADAIR or any other future product, such as ADMIR, that we may in-license and develop;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize ADAIR or any other future product, such as ADMIR;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount of sales and other revenues from ADAIR or any other future product, such as ADMIR, that we may commercialize, if any, including the selling prices for such potential product and the availability of adequate third-party reimbursement;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">selling and marketing costs associated with our potential products, including the cost and timing of expanding our marketing and sales capabilities;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of any potential future collaborations, licensing or other arrangements that we may establish;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cash requirements of any future acquisitions and/or the development of other products;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of operating as a public company;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of completion of commercial-scale, outsourced manufacturing activities;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and cost necessary to respond to technological and market developments;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any disputes which may occur between us and Arcturus, employees, collaborators or other prospective business partners; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of filing, prosecuting, defending, and enforcing any patent claims and other intellectual property rights.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds by selling shares of our common stock or other equity-linked securities, the ownership interest of our current stockholders will be diluted. We may seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or products or to grant licenses on terms that may not be acceptable to us. If we raise additional funds through debt financing, we may have to grant a security interest on our assets to the future lenders, our debt service costs may be substantial, and the lenders may have a preferential position in connection with any future bankruptcy or liquidation involving the company.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to raise additional capital when needed, we may be required to curtail the development of our technology or materially curtail or reduce our operations. We could be forced to sell or dispose of our rights or assets. Any inability to raise adequate funds on commercially reasonable terms could have a material adverse effect on our business, results of operations, and financial condition, including the possibility that a lack of funds could cause our business to fail and our company to dissolve and liquidate with little or no return to investors.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will continue to incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we incur significant legal, accounting, and other expenses under the Securities Exchange Act of 1934, as amended (Exchange Act), the Sarbanes-Oxley Act, and other applicable securities rules and regulations. In addition, we are subject to the requirements of The Nasdaq Capital Market.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These rules impose various requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and appropriate corporate governance practices. Our management and other personnel have devoted and will continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. For example, these rules and regulations make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. In addition, the listing requirements of The Nasdaq Capital Market require that we satisfy certain corporate governance requirements relating to director independence, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel need to devote a substantial amount of time to ensure that we comply with all of these requirements. As a result, it may be difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sarbanes-Oxley Act of 2002 requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. As a result, we are required to periodically perform an evaluation of our internal controls over financial reporting to allow management to report on the effectiveness of those controls, as required by Section&#160;404 of the Sarbanes-Oxley Act. Additionally, our independent auditors may be required to perform a similar evaluation and report on the effectiveness of our internal controls over financial reporting. These efforts to comply with Section&#160;404 and related regulations have required, and continue to require, the commitment of significant financial and managerial resources. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we anticipate maintaining the integrity of our internal controls over financial reporting and all other aspects of Section&#160;404, we cannot be certain that a material weakness will not be identified when we test the effectiveness of our control systems in the future. If a material weakness is identified, we could be subject to sanctions or investigations by the U.S. Securities and Exchange Commission (the SEC), or other regulatory authorities, which would require additional financial and management resources, costly litigation or a loss of public confidence in our internal controls, which could have an adverse effect on the market price of our stock. See the risk factor entitled &#8220;Financial reporting obligations of being a public company in the United States require well defined disclosure and financial controls and procedures that we did not have as a private company and that are expensive and time-consuming requiring our management to devote substantial time to compliance matters.&#8221; in this report for more information on our internal controls over financial reporting.&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an &#8220;emerging growth company&#8221; and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our securities less attractive to investors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. Emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. As an emerging growth company, we are not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, we have reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and we are exempt from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Additionally, as an emerging growth company, we have elected to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As such, our financial statements may not be comparable to companies that comply with public company effective dates. We cannot predict if investors will find our stock less attractive because we may rely on these provisions. If some investors find our stock less attractive as a result, there may be a less active trading market for our shares and our stock price may be more volatile.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. We have elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, will not adopt the new or revised standard until the time private companies are required to adopt the new or revised standard. This may make comparison of our financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accountant standards used.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After we become a reporting company under the Exchange Act, we will remain an emerging growth company until the earliest of (i)&#160;the end of the fiscal year in which the market value of our common stock that is held by non-affiliates exceeds $700&#160;million as of the end of the second fiscal quarter, (ii)&#160;the end of the fiscal year in which we have total annual gross revenues of $1.07&#160;billion or more during such fiscal year, (iii)&#160;the date on which we issue more than $1&#160;billion in non-convertible debt in a three-year period, or (iv)&#160;the end of the fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement filed under the Securities Act.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss (NOL) carryforwards may be limited.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had NOL carryforwards available to reduce future taxable income, if any, for federal and state income tax purposes of $20.1&#160;million and $20.4 million, respectively. The federal net operating loss carryforwards do not expire. If not utilized, the state and local losses begin to expire in the year ending December 31, 2038. Our ability to utilize NOL carryforward amounts to reduce taxable income in future&#160;years may be limited for various reasons, including if future taxable income is insufficient to recognize the full benefit of such NOL carryforward amounts prior to their expiration. Additionally, our ability to fully utilize these U.S. tax assets can also be adversely affected by &#8220;ownership changes&#8221; within the meaning of Section&#160;382 of the Internal Revenue Code of 1986, as amended (the Code), in a three-year period. Any ownership change is generally defined as a greater than 50% increase in equity ownership by &#8220;5% stockholders,&#8221; as that term is defined for purposes of Section&#160;382 of the Code in any three-year period. Further, we may experience an ownership change in the future as a result of further shifts in our stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change NOL carryforwards to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOL carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws and regulations or in our operations may impact our effective tax rate and may adversely affect our business, financial condition and operating results.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in tax laws in any jurisdiction in which we operate, or adverse outcomes from any tax audits that we may be subject to in any such jurisdictions, could result in an unfavorable change in our effective tax rate in the future, which could adversely affect our business, financial condition, and operating results.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The report of our independent registered public accounting firm included a &#8220;going concern&#8221; explanatory paragraph.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The report of our independent registered public accounting firm on our financial statements as of and for the year ended December&#160;31, 2021 included an explanatory paragraph indicating that there is substantial doubt about our ability to continue as a going concern. We have financed our working capital requirements to date by raising capital through private placements of shares of our common stock, issuing of short-term and convertible notes, and the proceeds from our initial public offering (IPO) completed in February 2021. If we are unable to raise sufficient capital as and when needed, our business, financial condition and results of operations will be materially and adversely affected, and we will need to significantly modify our operational plans to continue as a going concern. If we are unable to continue as a going concern, we may have to liquidate our assets, and the values we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements. The inclusion of a going concern explanatory paragraph by our independent registered public accounting firm, our lack of cash resources and our potential inability to continue as a going concern may materially adversely affect our share price and our ability to raise new capital, enter into critical contractual relations with third parties and otherwise execute our development strategy.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Relating to Regulatory Matters</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not receive regulatory approval for ADAIR or any future product, such as ADMIR, or its or their approvals may be delayed, which would have a material adverse effect on our business and financial condition.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADAIR and any other future product, such as ADMIR, as well as the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by the European Medicines Agency, and similar regulatory authorities outside the U.S. Failure to obtain marketing approval for ADAIR or any future product will prevent us from commercializing such products. We have not received approval to market ADAIR from regulatory authorities in any jurisdiction. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party contract research organizations and regulatory consultants to assist us in this process. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the proposed product&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. ADAIR or any future product may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. If ADAIR or any future product receives marketing approval, the accompanying label may limit the approved use of our drug, which could limit sales of the product. We may never succeed in convincing regulatory agencies to allow us to promote the abuse deterrent properties of ADAIR, even if we are successful in demonstrating these characteristics in studies. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many&#160;years if approval is granted at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the proposed product involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical studies and/or clinical trials. In addition, varying interpretations of the data obtained from preclinical studies and/or clinical testing could delay, limit, or prevent marketing approval of a proposed product. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays in obtaining approval or if we fail to obtain approval of our proposed product or any future product, the commercial prospects for our proposed product may be harmed and our ability to generate revenue will be materially impaired.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if we obtain approval, regulatory authorities may approve our proposed product or any future product for fewer or more limited indications than we request, may not approve the price we intend to charge for our product, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a proposed product with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product. Any of these scenarios could compromise the commercial prospects for our proposed product or any future product.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in response to the global pandemic of COVID-19, on March&#160;10, 2020 the FDA announced its intention to postpone most foreign inspections of manufacturing facilities and products, and subsequently, on March&#160;18, 2020, the FDA announced its intention to temporarily postpone routine surveillance inspections of domestic manufacturing facilities. The FDA reiterated its stance to Congress on June&#160;2, 2020 stating, &#8220;only inspections deemed mission-critical will be considered on a case-by-case basis as this outbreak continues to unfold.&#8221; On August 20, 2020, and subsequently updated on January 29, 2021, the FDA&#8217;s Guidance for Industry against stated, &#8220;foreign pre-approval and for-cause inspection assignments that are not deemed mission-critical remain temporarily postponed, while those deemed mission-critical will still be considered for inspection on a case-by-case basis.&#8221;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. If the FDA becomes unable to continue its current level of performance, we could experience delays and setbacks for our product candidates, including ADAIR and ADMIR, and for any approvals we may seek which could adversely affect our business.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if ADAIR or any other proposed product that we develop, such as ADMIR, receives marketing approval, we will continue to face extensive regulatory requirements and the product may still face future development and regulatory difficulties.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADAIR and any other proposed product we may develop, such as ADMIR, or license or acquire, will also be subject to ongoing requirements and review of the FDA and other regulatory authorities. These requirements include labeling, packaging, storage, advertising, promotion, record-keeping and submission of safety and other post-market information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and recordkeeping of the drug.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we do not market ADAIR or any other future product for only their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the FDCA, relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state health care fraud and abuse laws, false claims acts, as well as state consumer protection laws.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, later discovery of previously unknown adverse events or other problems with ADAIR or any other future product, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on such products, operations, manufacturers, or manufacturing processes;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the labeling or marketing of a product;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on product distribution or use;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements to conduct post-marketing studies or clinical trials;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning letters;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of the products from the market;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recall of products;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, restitution, or disgorgement of profits;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or withdrawal of marketing or regulatory approvals;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension of any ongoing clinical trials;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to permit the import or export of ADAIR or any other future product, such as ADMIR;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure; or</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP and other regulations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our proposed product. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The abuse, misuse or off-label use of our products may harm our image in the marketplace, result in injuries that lead to product liability suits or result in costly investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly to our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The products we market will be approved by the FDA for specific treatments. We will train our marketing and direct sales force to not promote our products for uses outside of the FDA-approved indications for use, known as &#8220;off-label uses.&#8221; We cannot, however, prevent a physician from using our products off-label, when in the physician&#8217;s independent professional medical judgement, he or she deems it appropriate. There may be increased risk of injury to patients if physicians attempt to use our products off-label. Furthermore, the use of our products for indications other than those approved by the FDA or approved by any foreign regulatory body may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and patients. In addition, although ADAIR is very difficult to manipulate into a form that can be snorted, it is not impossible to do so, as was shown by a third-party drug laboratory, hired by us in preparation for human abuse studies, that was able to develop a time-consuming and laborious process to convert ADAIR into a form that could be insufflated. In addition, although ADAIR is difficult to solubilize into a form that can be injected, sophisticated drug abusers may be able to develop methods to manipulate ADAIR into a form that can be injected. We cannot assure stockholders that users of ADAIR or such other products we may develop in the future will not manipulate our products with the intention of abusing our products. Such abuse of our products may harm our image in the marketplace and damage our reputation.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or any foreign regulatory body determines that our promotional materials or training constitute promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil fine or criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our business activities to constitute promotion of an off-label use, which could result in significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs, and the curtailment of our operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, physicians may misuse our products if they are not adequately trained, potentially leading to injury and an increased risk of product liability. If our products are misused or used with improper technique, we may become subject to costly litigation by our customers or their patients. As described elsewhere, product liability claims could divert management&#8217;s attention from our core business, be expensive to defend and result in sizeable damage awards against us that may not be covered by insurance.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current and future relationships with customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security, and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens, and diminished profits and future earnings.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, which may constrain the business or financial arrangements and relationships through which we sell, market, and distribute any product for which we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obtain marketing approval. In addition, we may be subject to transparency laws and patient privacy regulation by U.S. federal and state governments and by governments in foreign jurisdictions in which we conduct our business. The applicable federal, state, and foreign healthcare laws and regulations that may affect our ability to operate include, but are not necessarily limited to:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs, such as Medicare and Medicaid;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws and civil monetary penalty laws, including the federal False Claims Act, which impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH) and their respective implementing regulations, which impose obligations on covered healthcare providers, health plans, and healthcare clearinghouses, as well as their business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Open Payments program, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare&#160;&amp; Medicaid Services (CMS) information related to &#8220;payments or other transfers of value&#8221; made to physicians, which is defined to include doctors, dentists, optometrists, podiatrists and chiropractors, and teaching hospitals and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by the physicians and their immediate family members. Data collection began on August&#160;1, 2013 with requirements for manufacturers to submit reports to CMS by March&#160;31, 2014 and 90&#160;days after the end each subsequent calendar year. Disclosure of such information was made by CMS on a publicly available website beginning in September&#160;2014; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thereby complicating compliance efforts.&#160;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, which could have a material adverse effect on our business. If any of the physicians or other healthcare providers or entities with whom we expect to do business, including our collaborators, is found not to be in compliance with applicable laws, it may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also materially affect our business.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory approval for any approved product is limited by the FDA to those specific indications and conditions for which clinical safety and efficacy have been demonstrated.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approval is limited to those specific diseases and indications for which a product is deemed to be safe and effective by the FDA. In addition to the FDA approval required for new formulations, any new indication for an approved product also requires FDA approval. If we are not able to obtain FDA approval for any desired future indications for ADAIR or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any other future product, such as ADMIR, our ability to effectively market and sell ADAIR or any other future product may be reduced, and our business may be adversely affected.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While physicians may choose to prescribe drugs for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical studies and approved by the regulatory authorities, our ability to promote the products is limited to those indications that are specifically approved by the FDA. These &#8220;off-label&#8221; uses are common across medical specialties and may constitute an appropriate treatment for some patients in varied circumstances. Regulatory authorities in the United States generally do not regulate the behavior of physicians in their choice of treatments. Regulatory authorities do, however, restrict communications by pharmaceutical companies on the subject of off-label use. If our promotional activities fail to comply with these regulations or guidelines, we may be subject to warnings from, or enforcement action by, these authorities. In addition, our failure to follow FDA rules and guidelines relating to promotion and advertising may cause the FDA to send a Warning Letter to the Company (which becomes public) alleging violations of the FDCA and subjecting the Company to other potential enforcement such as to suspend or withdraw an approved product from the market, require a recall or institute fines, or could diminish our reputation and result in disgorgement of money, operating restrictions, injunctions, or criminal prosecution, any of which could harm our business.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public concern regarding the safety of drug products such as ADAIR could delay or limit our ability to obtain regulatory approval, result in the inclusion of unfavorable information in our labeling, or require us to undertake other activities that may entail additional costs.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of widely publicized events concerning the safety risk of certain drug products, the FDA, members of Congress, the Government Accountability Office, medical professionals and the general public have raised concerns about potential drug safety issues. These events have resulted in the withdrawal of drug products, revisions to drug labeling that further limit use of the drug products and the establishment of risk management programs. The Food and Drug Administration Amendments Act of 2007 (FDAAA) grants significant expanded authority to the FDA, much of which is aimed at improving the safety of drug products before and after approval. In particular, this law authorizes the FDA to, among other things, require post-approval studies and clinical trials, mandate changes to drug labeling to reflect new safety information and require risk evaluation and mitigation strategies for certain drugs, including certain currently approved drugs. It also significantly expands the federal government&#8217;s clinical trial registry and results databank, which we expect will result in significantly increased government oversight of clinical trials. Under the FDAAA, companies that violate these and other provisions of this law are subject to substantial civil monetary penalties, among other regulatory, civil and criminal penalties. The increased attention to drug safety issues may result in a more cautious approach by the FDA in its review of data from our preclinical studies and clinical trials. Data from preclinical studies and clinical trials may receive greater scrutiny, particularly with respect to safety, which may make the FDA or other regulatory authorities more likely to require additional preclinical studies and/or clinical trials. If the FDA requires us to conduct additional preclinical studies or clinical trials prior to approving ADAIR, our ability to obtain approval of this proposed product will be delayed. If the FDA requires us to provide additional preclinical studies and/or clinical data following the approval of ADAIR, the indications for which this proposed product is approved may be limited or there may be specific warnings or limitations on dosing, and our efforts to commercialize ADAIR may be otherwise adversely impacted.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to continue existing clinical trials, or initiate new clinical trials, for our proposed product if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the U.S. Some of our competitors have ongoing clinical trials for proposed products that treat the same indications as our proposed product, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; proposed products. Available therapies for the indications we are pursuing can also affect enrollment in our clinical trials. Patient enrollment is affected by other factors including, but not necessarily limited to:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the severity of the disease under investigation;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the eligibility criteria for the study in question;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perceived risks and benefits of the proposed product under study;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efforts to facilitate timely enrollment in clinical trials;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient referral practices of physicians;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to monitor patients adequately during and after treatment; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of other approved drugs to treat the same condition, thereby creating competition for our clinical trial enrollment and reducing the incentive for prospective patients to participate in our trials.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for ADAIR or any future product, such as ADMIR, which would cause the value of our company to decline and limit our ability to obtain additional financing.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize ADAIR or any other proposed product that we develop and affect the prices we may set.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval for ADAIR or any other proposed product that we develop, restrict or regulate post-approval activities and affect our ability to profitably sell ADAIR or any other proposed product for which we obtain marketing approval.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory proposals have been made to expand post-approval requirements, restrict sales and promotional activities for pharmaceutical products, and regulate pricing. We are not sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our proposed product, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize ADAIR and for any future product, such as ADMIR, and may affect the prices we may set.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system, including cost-containment measures that may reduce or limit coverage and reimbursement for newly approved drugs and affect our ability to profitably sell ADAIR and for any future product, such as ADMIR, for which we obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs, restrict or regulate post-approval activities and improve the quality of healthcare.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sales prices for drugs. In addition, this legislation authorized Medicare Part&#160;D prescription drug plans to limit the number of drugs that will be covered in any therapeutic class. As a result of this legislation and the expansion of federal coverage of drug products, we expect that there will be additional pressure to contain and reduce costs. These cost reduction initiatives and other provisions of this legislation could decrease the coverage and price that we receive for any approved products and could seriously harm our business. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates, and any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private payors.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in March&#160;2010, the Affordable Care Act, was enacted in the United States. Among the provisions of the Affordable Care Act of importance to ADAIR and for any future product, the Affordable Care Act: establishes an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; extends manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; expands eligibility criteria for Medicaid programs; expands the entities eligible for discounts under the Public Health program; increases the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; creates a new Medicare Part&#160;D coverage gap discount program; establishes a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research; and establishes a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, we are unsure of the full impact that the Affordable Care Act will have on our business. There have been judicial and political challenges to certain aspects of the Affordable Care Act. For example, since January&#160;2017, President Trump has signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements of the Affordable Care Act. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Affordable Care Act. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the Affordable Care Act have been signed into law. The Tax Cuts and Jobs Act of 2017 (Tax Act) included a provision repealing, effective January&#160;1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On January&#160;22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain Affordable Care Act-mandated fees, including the so-called &#8220;Cadillac&#8221; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share. The Bipartisan Budget Act of 2018 (the BBA) among other things, amends the Affordable Care Act, effective January&#160;1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole,&#8221; by increasing from 50&#160;percent to 70&#160;percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part&#160;D. In July&#160;2018, CMS published a final rule permitting further collections and payments to and from certain Affordable Care Act qualified health plans and health insurance issuers under the Affordable Care Act risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On December&#160;14, 2018, a U.S. District Court Judge in the Northern District of Texas (Texas District Court Judge) ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. While the Texas District Court Judge, as well as the Trump Administration and CMS, have stated that the ruling will have no immediate effect, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the ACA will impact the ACA and our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. The Coronavirus Aid, Relief, and Economic Security Act, which was signed into law on March&#160;27, 2020, designed to provide financial support and resources to individuals and businesses affected by the COVID-19 pandemic, suspended these reductions from May&#160;1, 2020 through December&#160;31, 2020, and extended the sequester by one year, through 2030. In addition, on January&#160;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the federal level, the Trump administration&#8217;s budget proposal for fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part&#160;D plans to negotiate the price of certain drugs under Medicare Part&#160;B, to allow some states to negotiate drug prices under Medicaid and to eliminate cost sharing for generic drugs for low-income patients. Additionally, the Trump administration released a &#8220;Blueprint&#8221; to lower drug prices through proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. The U.S. Department of Health and Human Services has begun the process of soliciting feedback on some of these measures and, at the same time, is implementing others under its existing authority. Although some of these, and other, proposals will require authorization through additional legislation to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for ADAIR and for any future product, such as ADMIR, if approved, or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the Affordable Care Act, these new laws and other healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize ADAIR and for any future product, such as ADMIR, if approved.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely, and expect to continue to rely, on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials or complying with applicable regulatory requirements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party contract research organizations and clinical research organizations to conduct our clinical trials for ADAIR and for any future product, such as ADMIR. We expect to continue to rely on third parties, such as contract research organizations, clinical research organizations, clinical data management organizations, medical institutions and clinical investigators, to conduct all of our clinical trials. The agreements with these third parties might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, that could delay our product development activities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials are conducted in accordance with the general investigational plan and protocols for the trial and in accordance with good laboratory practice, as appropriate. Moreover, the FDA requires us to comply with standards, commonly referred to as good clinical practices (GCPs) for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Regulatory authorities enforce these requirements through periodic inspections of trial sponsors, clinical investigators, and trial sites. If we or any of our clinical research organizations fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure investors that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The third parties with whom we have contracted to help perform our clinical trials may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our proposed product and will not be able to, or may be delayed in our efforts to, successfully commercialize our proposed product.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with these third-party contract research organizations or clinical research organizations terminates, we may not be able to enter into arrangements with alternative contract research organizations or clinical research organizations or to do so on commercially reasonable terms. Switching or adding additional contract research organizations or clinical research organizations involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new contract research organization or clinical research organization commences work. As a result, delays could occur, which could compromise our ability to meet our desired development timelines. Though we carefully manage our relationships with our contract research organizations or clinical research organizations, there can be no assurance that we will not encounter similar challenges or delays in the future.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on clinical data and results obtained by third parties that could ultimately prove to be inaccurate or unreliable.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our strategy to mitigate development risk, we seek to develop proposed products with validated mechanisms of action, and we utilize biomarkers to assess potential clinical efficacy early in the development process. This strategy necessarily relies upon clinical data and other results obtained by third parties that may ultimately prove to be inaccurate or unreliable. Further, such clinical data and results may be based on products or proposed products that are significantly different from ADAIR or any future product, such as ADMIR. If the third-party data and results we rely upon prove to be inaccurate, unreliable or not applicable to ADAIR or any future product, we could make inaccurate assumptions and conclusions about our proposed product and our research and development efforts could be compromised.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health, and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous materials and wastes. Our operations involve </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. Although we believe that the safety procedures for handling and disposing of these materials comply with the standards prescribed by these laws and regulations, we cannot eliminate the risk of accidental contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA does not conclude that ADAIR is sufficiently bioequivalent, or demonstrate comparable bioavailability to its reference listed drug (RLD), or if the FDA otherwise does not conclude that ADAIR satisfies the requirements of Section&#160;505(b)(2) of the FDCA, approval pathway, the approval pathway for this proposed product will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and the FDA may not approve this proposed product.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key element of our strategy is to seek FDA approval for ADAIR through Section&#160;505(b)(2) approval pathway. Section&#160;505(b)(2) of the FDCA permits the filing of an NDA that contains full safety and efficacy reports but where at least some of the information required for approval comes from studies not conducted by or for the applicant. Such information could include the FDA&#8217;s findings of safety and efficacy in the approval of a similar drug, and for which the applicant has not obtained a right of reference and/or published literature. Such reliance is typically predicated on a showing of bioequivalence or comparable bioavailability to an approved drug.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA does not allow us to pursue the Section&#160;505(b)(2) approval pathway for ADAIR, or if we cannot demonstrate bioequivalence or comparable bioavailability of ADAIR to an approved product, we may need to conduct additional clinical trials, provide additional data and information, and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required to obtain FDA approval for ADAIR would increase. Moreover, our inability to pursue the Section&#160;505(b)(2) approval pathway could result in new competitive products reaching the market sooner than ADAIR, which could have a material adverse effect on our competitive position and our business prospects. Even if we are allowed to pursue the Section&#160;505(b)(2) approval pathway, we cannot assure investors that ADAIR will receive the requisite approval for commercialization on a timely basis, if at all.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, notwithstanding the approval of a number of products by the FDA under the Section&#160;505(b)(2) approval pathway over the last few&#160;years, pharmaceutical companies and others have objected to the FDA&#8217;s interpretation of Section&#160;505(b)(2). If the FDA&#8217;s interpretation of Section&#160;505(b)(2) is successfully challenged, the FDA may change its policies and practices with respect to the Section&#160;505(b)(2) approval pathway, which could delay or even prevent the FDA from approving any NDA that we submit under Section&#160;505(b)(2).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if ADAIR is approved under Section&#160;505(b)(2), the approval may be subject to limitations on the indicated uses for which the product may be marketed or to other conditions of approval, or may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product, including additional clinical trials.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ADAIR contains a controlled substance, the manufacture, use, sale, importation, exportation, and distribution of which are subject to regulation by state, federal, and foreign law enforcement and other regulatory agencies.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADAIR contains, and any future product, such as ADMIR, if any, may contain, controlled substances which are subject to state, federal, and foreign laws and other regulations regarding their manufacturing, use, sale, importation, exportation, and distribution. ADAIR&#8217;s active ingredient, dextroamphetamine, is classified as a controlled substance under the CSA, and regulations of the DEA. A number of states also independently regulate these drugs as controlled substances. Controlled substances are classified by the DEA as Schedule&#160;I, II, III, IV, or V substances, with Schedule&#160;I substances considered to present the highest risk of substance abuse and Schedule&#160;V substances the lowest risk. The active ingredient in ADAIR, dextroamphetamine, is listed by the DEA as a Schedule&#160;II controlled substance under the CSA. For our current proposed </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product, and any potential future product, such as ADMIR, containing a controlled substance, we and our suppliers, manufacturers, contractors, customers, and distributors are required to obtain and maintain applicable registrations from state, federal, and foreign law enforcement and regulatory agencies and comply with their laws and regulations regarding the manufacturing, use, sale, importation, exportation, and distribution of controlled substances. An example of such practice is that all Schedule&#160;II drug prescriptions must be signed by a physician, physically presented to a pharmacist and may not be refilled without a new prescription. Furthermore, the amount of Schedule&#160;II substances that can be obtained for clinical trials and commercial distribution is limited by the CSA and DEA regulations. We may not be able to obtain sufficient quantities of these controlled substances in order to complete our clinical trials or meet commercial demand, even if ADAIR is approved for marketing.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, controlled substances are subject to regulations governing manufacturing, labeling, packaging, testing, dispensing, production and procurement quotas, recordkeeping, reporting, handling, shipment, and disposal. These regulations increase the personnel needs and the expense associated with development and commercialization of proposed products that include controlled substances. The DEA and some states conduct periodic inspections of registered establishments that handle controlled substances.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to obtain and maintain required registrations or to comply with any applicable regulations, including quotas imposed by the DEA, could delay or preclude us from developing and commercializing our proposed product that contains a controlled substance and subject us to enforcement action. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to revoke those registrations. In some circumstances, violations could lead to criminal proceedings. Because of their restrictive nature, these regulations could limit commercialization of our proposed product containing controlled substances.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we, our drug products or the manufacturing facilities for our drug products fail to comply with applicable regulatory requirements, a regulatory agency may:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue warning letters or untitled letters;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek an injunction or impose civil or criminal penalties or monetary fines;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or withdraw marketing approval;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to approve pending applications or supplements to applications;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or impose restrictions on operations, including costly new manufacturing requirements;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize or detain products, refuse to permit the import or export of products or request that we initiate a product recall; or</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to allow us to enter into supply contracts, including government contracts.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA may not approve product labeling for ADAIR that would permit us to market and promote our product in the United States by describing its abuse-deterrent features.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested resources conducting Laboratory Manipulation and Extraction Studies (Category 1), and may spend substantial additional resources conducting Pharmacokinetic Studies (Category 2) and Clinical Abuse Potential Studies (Category 3) to support ADAIR&#8217;s abuse-deterrence characteristics, and we believe such studies are consistent with the April&#160;2015 final FDA guidance on opioid medications (the 2015 FDA Guidance), as no guidance exists on stimulants. However, we have not yet received regulatory approval to market ADAIR and additional data may emerge that could change the FDA&#8217;s position on the proposed product label, and there can be no assurance that ADAIR or our other current or any future product, such as ADMIR, will receive FDA-approved product labeling that describes abuse-deterrent features of such product given the current absence of specific FDA guidance on development of abuse-deterrent amphetamines. Our failure to achieve FDA approval of product labeling containing information on abuse-deterrence characteristics of ADAIR will prevent or substantially limit our promotion of the abuse-deterrent features of ADAIR. This type of limitation would make it difficult for us to differentiate ADAIR from other amphetamine-containing products, may cause us to lower the price of our product to the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">extent that there are competing products with abuse-deterrent claims on their product labels and as a result, our product would be less competitive in the market. The FDA closely regulates promotional materials and other promotional activities, even if the FDA initially approves product labeling that includes a description of the abuse- deterrent characteristics of ADAIR and therefore the FDA may object to our marketing claims and product advertising campaigns. This could lead to the issuance of warning letters or untitled letters, suspension or withdrawal of our product from the market, recalls, fines, disgorgement of money, operating restrictions, injunctions, and civil or criminal prosecution. Any of these consequences would harm the commercial success of ADAIR or any other future product.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if any other proposed products are approved for marketing with certain abuse-deterrence claims, the 2015 FDA Guidance may not apply to such proposed product, as the said guidance is not binding law and may be superseded or modified at any time. Also, if the FDA determines that our post-marketing data do not demonstrate that the abuse-deterrent properties result in reduction of abuse, or demonstrate a shift to routes of abuse that present a greater risk, the FDA may find that product labeling revisions are needed, and may require the removal of our abuse-deterrence claims. Although ADAIR is very difficult to manipulate into a form that can be snorted, it is not impossible to do so, as was shown by a third-party drug laboratory, hired by us in preparation for human abuse studies, that was able to develop a time-consuming and laborious process to convert ADAIR into a form that could be insufflated. In addition, although ADAIR is difficult to solubilize into a form that can be injected, sophisticated drug abusers may be able to develop methods to manipulate ADAIR into a form that can be injected.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, in October 2020, an FDA advisory committee reviewed another abuse deterrent stimulant which relied on different delivery technology and a different active molecule than ADAIR. The advisory committee recommended against the approval of the other product, voting that the benefits did not outweigh the risks. In particular, the advisory committee determined that the other product had not established that it could deter the risk of intranasal abuse based on the results of its human abuse liability study because it failed the study&#8217;s primary endpoint. Further the advisory committee voted that the safety of the other product had not been adequately characterized because of safety concerns with two inactive ingredients contained in the other product. ADAIR does not contain either of these inactive ingredients. Nevertheless, we may not be able to conduct a successful pivotal human abuse trial and an FDA advisory committee could vote that the benefits of ADAIR or ADMIR do not outweigh the risks.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to comply with the requirements of the Drug Supply Chain Security Act, which outlines critical steps required to build an electronic, interoperable system to identify and trace certain prescription drugs as they are distributed in the United States.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to comply with the requirements of the Drug Supply Chain Security Act, including those related to product tracing, verification, and authorized trading partners. Signed into law in 2013, the Drug Supply Chain Security Act, amended the FDCA, and is being implemented over a 10-year period. The law&#8217;s requirements include the ability to quarantine and promptly investigate a suspect product, such as a potentially counterfeit, diverted or stolen product, to determine if it is illegitimate, and notify our trading partners and the FDA of any illegitimate product. Such compliance may be time consuming and expensive to implement. Also, in the event that we fail to comply with these requirements, we may face regulatory actions that could affect our ability to commercialize ADAIR.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if ADAIR or any other future product, such as ADMIR, we may develop receives marketing approval, there could be adverse effects not discovered during development.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if any of our proposed products receive marketing approval, we or others may later identify undesirable side-effects caused by the product or problems with our third-party manufacturers or manufacturing processes, and in either event a number of potentially significant negative consequences could result, including:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may suspend or withdraw their approval of the product;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, such as warnings or contraindications or distribution and use restrictions;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require us to issue specific communications to healthcare professionals, such as &#8220;Dear Doctor&#8221; letters;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may issue negative publicity regarding the affected product, including safety communications;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to change the way the product is administered, conduct additional clinical trials or restrict the distribution or use of the product;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product and could substantially increase commercialization costs or even force us to cease operations.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products may cause or contribute to adverse medical events that we are required to report to the FDA and if we fail to do so, we would be subject to sanctions that would materially harm our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-marketing safety data collection and adverse event reporting (ADR) are critical elements of FDA&#8217;s oversight of drugs and therapeutic biologics available to the American public. The testing that helps to establish the safety of products, such as drugs and therapeutic biologics, is typically conducted on small groups before FDA approves the products for sale. Some problems can remain unknown, only to be discovered when a product is used by a large number of people. An adverse event is any unanticipated experience or side effect associated with the use of a drug or therapeutic biologic in humans, whether or not it is considered related to the product. An adverse event could occur:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">with use in professional practice;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">from overdose whether accidental or intentional;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">from abuse;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">from withdrawal; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">due to lack of expected effectiveness.&#160;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During inspections, FDA investigators will review a company&#8217;s post-marketing adverse event information to ensure compliance with federal laws and regulations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products are subject to ADR which require that we report to the FDA events related to our products. The timing of our obligation to report under the ADR regulations is triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA could take action, including warning letters, untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device clearances or approvals, seizure of our products, or delay in clearance or approval of future products.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products may in the future be subject to product recalls. A recall of our products, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with our products, could have a significant adverse impact on u</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and similar foreign governmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies or defects in their design or manufacture. A government-mandated or voluntary recall could occur as a result of an unacceptable risk to health, contaminated product, manufacturing errors, or labeling defects or other deficiencies and issues. Recalls of any of our products would divert managerial and financial resources and have an adverse effect on our reputation, results of operations and financial condition, which could impair our ability to produce our products in a cost-effective and timely manner in order to meet our customers&#8217; demands. We may also be subject to liability claims, be required to bear other costs, or take other actions that may have a negative impact on our future sales and our ability to generate profits.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in regulatory requirements and guidance or unanticipated events during our clinical trials may occur, which may result in necessary changes to clinical trial protocols, which could result in increased costs to us, delay our development timeline or reduce the likelihood of successful completion of our clinical trials.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in regulatory requirements and guidance or unanticipated events during our clinical trials may occur, as a result of which we may need to amend clinical trial protocols. Amendments may require us to resubmit our clinical trial protocols to IRBs for review and approval, which may impact the cost, timing or successful completion of a clinical trial. If we experience delays in completion of, or if we terminate, any of our clinical trials, the commercial prospects for our proposed product would be harmed and our ability to generate product revenue would be delayed, possibly materially.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation designate specific courts as the exclusive forum for certain litigation that may be initiated by the Company&#8217;s stockholders, which could limit its stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to our amended and restated certificate of incorporation, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for any state law claims for (1)&#160;any derivative action or proceeding brought on our behalf; (2)&#160;any action asserting a claim of or based on a breach of a fiduciary duty owed by any director, officer or other employee of ours to us or our stockholders; (3)&#160;any action asserting a claim pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation; or (4)&#160;any action asserting a claim governed by the internal affairs doctrine (Delaware Forum Provisio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">n</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our amended and restated certificate of incorporation further provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act (Federal Forum Provision). In addition, our amended and restated certificate of incorporation provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to the Delaware Forum Provision and the Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize that the Delaware Forum Provision in our amended and restated certificate of incorporation may impose additional litigation costs on stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware. Additionally, the forum selection clauses in our amended and restated certificate of incorporation may limit our stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers and employees, even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court ruled in March&#160;2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court are &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the United States District Court may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Relating to Intellectual Property&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have filed multiple patent applications and have two issued patents by the U.S. PTO and one issued patent by the European Patent Office. These or any other patent applications may not result in issued patents, and as a result we may have limited protection of our proprietary technology in the marketplace.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have had two patents granted and one additional patent application directed to ADAIR for ADHD and narcolepsy filed in the United States, have had one patent granted in Europe, and we are seeking patent protection for ADAIR internationally in several foreign countries and territories, including Australia, Brazil, Canada, China, and Japan. The U.S. patents will expire in 2037 and the European patent will expire in 2038. It is impossible to predict whether or how our PCT application will result in any issued patent. Even if the pending application issues, it may issue with claims significantly narrower than those we currently seek.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and biopharmaceutical companies is generally uncertain because it involves complex legal and factual considerations. The standards applied by the U.S. PTO and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology and biopharmaceutical patents. Consequently, a patent may not issue from our pending patent applications. Therefore, we do not know the degree of future protection that we will have on any proprietary product or technology that we have or may develop.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection in the United States and other countries with respect to ADAIR or any other future product, such as ADMIR, that we may license or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquire and the methods we use to manufacture them, as well as successfully defending these patents and trade secrets against third-party challenges. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our proposed products. We will only be able to protect our technologies from unauthorized use by third parties to the extent that valid and enforceable patents or trade secrets cover them.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. If our licensors or we fail to obtain or maintain patent protection or trade secret protection for ADAIR or any other future product, such as ADMIR, we may license or acquire, third parties could use our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and achieve profitability. Moreover, should we enter into other collaborations we may be required to consult with or cede control to collaborators regarding the prosecution, maintenance, and enforcement of our patents. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has in recent&#160;years been the subject of much litigation. In addition, no consistent policy regarding the breadth of claims allowed in biopharmaceutical or biotechnology patents has emerged to date in the United States. The patent situation outside the U.S. is even more uncertain. The laws of foreign countries may not protect our rights to the same extent as the laws of the U.S. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until eighteen (18) months after a first filing, or in some cases at all. Therefore, we cannot know with certainty whether we or our licensors were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or whether we were the first to file for patent protection of such inventions. In the event that a third party has also filed a U.S. patent application relating to our proposed products or a similar invention, we may have to participate in interference proceedings declared by the U.S.&#160;PTO to determine priority of invention in the United States. The costs of these proceedings could be substantial, and it is possible that our efforts would be unsuccessful, resulting in a material adverse effect on our U.S. patent position. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On September&#160;16, 2011, the Leahy-Smith America Invents Act (the Leahy-Smith Act) was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The U.S. PTO recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective on March&#160;16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the U.S. PTO, or become involved in opposition, derivation, reexamination,&#160;inter parties&#160;review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, patent office trial, proceeding or litigation could reduce the scope of, render unenforceable, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent does not foreclose challenges to its inventorship, scope, validity or enforceability. Therefore, our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing, and regulatory review of new proposed products, patents protecting such proposed products might expire before or shortly after such proposed products are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because it is difficult and costly to protect our proprietary rights, we may not be able to ensure their protection.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain, because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our licensors might not have been the first to make the inventions covered by each of our pending patent applications and issued patents;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our licensors might not have been the first to file patent applications for these inventions;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate ADAIR or any future product, such as ADMIR;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that none of the pending patent applications licensed to us will result in issued patents;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents covering ADAIR or any future product, such as ADMIR, may not provide a basis for market exclusivity for active products, may not provide us with any competitive advantages, or may be challenged by third parties;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable; or</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patents of others may have an adverse effect on our business.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our issued patents or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated, rendered unenforceable, or interpreted narrowly.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in any litigation would harm our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to develop, manufacture, market and sell ADAIR or any other future product, such as ADMIR, that we may license or acquire depends upon our ability to avoid infringing the proprietary rights of third parties. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the general fields of ADHD and cover the use of numerous compounds and formulations in our targeted markets. Because of the uncertainty inherent in any patent or other litigation involving proprietary rights, we and our licensors may not be successful in defending intellectual property claims by third parties, which could have a material adverse effect on our results of operations. Regardless of the outcome of any litigation, defending the litigation may be expensive, time-consuming and distracting to management. In addition, because patent applications can take many&#160;years to issue, there may be currently pending applications, unknown to us, which may later result in issued patents that ADAIR may infringe. There could also be existing patents of which we are not aware that ADAIR may inadvertently infringe</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and biopharmaceutical industries generally. If a third party claims that we infringe on their patents or misappropriated their technology, we could face a number of issues, including:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">infringement and other intellectual property claims, which, with or without merit, can be expensive and time consuming to litigate and can divert management&#8217;s attention from our core business;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial damages for past infringement which we may have to pay if a court decides that our product infringes on a competitor&#8217;s patent;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a court prohibiting us from selling or licensing our product unless the patent holder licenses the patent to us, which it would not be required to do;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if a license is available from a patent holder, we may have to pay substantial royalties or grant cross licenses to our patents; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">redesigning our processes so they do not infringe, which may not be possible or could require substantial funds and time.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third party may hold intellectual property, including patent rights that are important or necessary to the development and commercialization of ADAIR or any other future product, such as ADMIR. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize ADAIR or any other future product. If we are unable to obtain a license from these third parties, or unable to obtain a license, on commercially reasonable terms, our business could be harmed.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in our intellectual property licenses and funding arrangements with third parties, we could lose rights that are important to our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may become party to licenses that are important for product development and commercialization. If we fail to comply with our obligations under current or future license and funding agreements, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market any product or utilize any technology that is covered by these agreements or may face other penalties under the agreements. Such an occurrence could materially and adversely affect the value of a proposed product being developed under any such agreement or could restrict our drug discovery activities. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biotechnology and biopharmaceutical industry, we employ individuals who were previously employed at other biotechnology or biopharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patent protection for ADAIR or any future product, such as ADMIR, we also rely on trade secrets, including unpatented know-how, technology, and other proprietary information, to maintain our competitive position, particularly where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We limit disclosure of such trade secrets where possible, but we also seek to protect these trade secrets, in part, by </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">entering into non-disclosure and confidentiality agreements with parties who do have access to them, such as our employees, our licensors, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors, and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and may unintentionally or willfully disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets. Moreover, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Securities Markets and Our Common Stock</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active, liquid and orderly market for our common stock may not be maintained.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to our February 2021 IPO, there had been no public market for our common stock. Our common stock only recently began trading on The Nasdaq Capital Market, but we can provide no assurance that we will be able to develop and sustain an active trading market for our common stock. Even if an active trading market is developed, it may not be sustained. The lack of an active market may impair stockholders&#8217; ability to sell their shares at the time they wish to sell them or at a price that they consider reasonable. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other businesses or technologies using our shares as consideration, which, in turn, could materially adversely affect our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot continue to satisfy the listing requirements of The Nasdaq Capital Market and other rules, including the director independence requirements, our securities may be delisted, which could negatively impact the price of our securities and stockholders&#8217; ability to sell them.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although common stock is listed on The Nasdaq Capital Market, we may be unable to continue to satisfy the listing requirements and rules, including the director independence requirements and certain financial metrics for our stockholders&#8217; equity and market value of listed securities or net income from continuing operations. If we are unable to satisfy The Nasdaq Capital Market criteria for maintaining our listing, our securities could be subject to delisting. If The Nasdaq Capital Market delists our securities, we could face significant consequences, including:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a limited availability for market quotations for our securities;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced liquidity with respect to our securities;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a determination that our common stock is a &#8220;penny stock,&#8221; which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in reduced trading;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">activity in the secondary trading market for our common stock;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limited amount of news and analyst coverage; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decreased ability to issue additional securities or obtain additional financing in the future.&#160;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we would no longer be subject to The Nasdaq Capital Market rules, including rules requiring us to have a certain number of independent directors and to meet other corporate governance standards.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock may be subject to substantial price and volume fluctuations due to a number of factors, many of which are beyond our control and may prevent our stockholders from reselling our common stock at a profit.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market prices for securities of biotechnology and biopharmaceutical companies have historically been highly volatile, and the market has from time-to-time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. In particular, the trading prices for pharmaceutical, biopharmaceutical and biotechnology companies have been highly volatile as a result of the COVID-19 pandemic.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock is likely to be highly volatile and may fluctuate substantially due to many factors, including:</span></div><div style="margin-top:8pt;padding-left:37.4pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">results from, and any delays in, our clinical trials for our product candidates, including ADAIR and ADMIR, or any other future clinical development programs, including any delays related to the COVID-19 pandemic;</span></div><div style="margin-top:8pt;padding-left:37.4pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">announcements concerning the progress of our efforts to obtain regulatory approval for and commercialize ADAIR or any future product, including ADMIR, including any requests we receive from the FDA for additional studies or data that result in delays in obtaining regulatory approval or launching such proposed product, if approved;</span></div><div style="margin-top:8pt;padding-left:37.4pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">market conditions in the biopharmaceutical and biotechnology sectors or the economy as a whole;</span></div><div style="margin-top:8pt;padding-left:37.4pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">price and volume fluctuations in the overall stock market;</span></div><div style="margin-top:8pt;padding-left:37.4pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">the failure of ADAIR or any future product, such as ADMIR, if approved, to achieve commercial success;</span></div><div style="margin-top:8pt;padding-left:37.4pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">announcements of the introduction of new products by us or our competitors;</span></div><div style="margin-top:8pt;padding-left:37.4pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">developments concerning product development results or intellectual property rights of others;</span></div><div style="margin-top:8pt;padding-left:37.4pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">litigation or public concern about the safety of our potential products;</span></div><div style="margin-top:8pt;padding-left:37.4pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">actual fluctuations in our quarterly operating results, and concerns by investors that such fluctuations may occur in the future;</span></div><div style="margin-top:8pt;padding-left:37.4pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">deviations in our operating results from the estimates of securities analysts or other analyst comments;</span></div><div style="margin-top:8pt;padding-left:37.4pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">additions or departures of key personnel;</span></div><div style="margin-top:8pt;padding-left:37.4pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">health care reform legislation, including measures directed at controlling the pricing of biopharmaceutical products, and third-party coverage and reimbursement policies;</span></div><div style="margin-top:8pt;padding-left:37.4pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">developments concerning current or future strategic collaborations; and</span></div><div style="margin-top:8pt;padding-left:37.4pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">discussion of us or our stock price by the financial and scientific press and in online investor communities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they adversely change their recommendations or publish negative reports regarding our business or our common stock, a liquid trading market, if any, for our common stock may not develop, and if it does, our share price and trading volume could decline.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts may publish about us, our business, our market or our competitors. We do not have any control over these analysts and analysts may not provide favorable coverage, or any coverage at all. If any of the analysts that do cover us make an adverse recommendation regarding our stock, or provide more favorable relative recommendations about our competitors, our stock price would likely decline. If any analyst who may cover us were to cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our share price or trading volume to decline.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not intend to declare cash dividends on our common stock in the foreseeable future, stockholders must rely on appreciation of the value of our common stock for any return on their investment.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends in the foreseeable future.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our significant stockholders may exert a substantial influence on actions requiring a stockholder vote, potentially in a manner that you do not support.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 31, 2022, our executive officers, directors, beneficial owners of 5% of more of our capital stock and their respective affiliates will, in the aggregate, beneficially own approximately 54.4% of our outstanding common stock, including Medice, through its affiliated entity, Salmon Pharma, and Arcturus Therapeutics, Ltd. (Arcturus), our largest stockholders, assuming no exercise of the underwriters&#8217; option to purchase additional shares. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Salmon Pharma, Arcturus or any member of our board or management acquires additional shares of common stock in the aftermarket or in privately negotiated transactions, this would increase their control. Factors that would be considered in making such additional purchases would include consideration of the current trading price of our common stock.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salmon Pharma and Arcturus&#8217;s large ownership stake may allow it to exert a substantial influence on actions requiring a stockholder vote, potentially in a manner that stockholders&#8217; do not support, including amendments to our amended and restated certificate of incorporation, election of our board of directors, removal of any of our directors, adoption of measures that could delay or prevent a change in control or impede a merger, takeover, or other business combination involving us, and approval of other major corporate transactions. In addition, Salmon Pharma and Arcturus&#8217;s stock ownership may discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of us, which in turn could reduce our stock price or prevent our stockholders from realizing a premium over our stock price. Accordingly, our stockholders other than Salmon Pharma and Arcturus may be unable to influence management and exercise control over our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our charter documents and Delaware law may inhibit a takeover that stockholders consider favorable.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of our amended and restated certificate of incorporation and our amended and restated bylaws and applicable provisions of Delaware law may delay or discourage transactions involving an actual or potential change in control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests. The provisions in our amended and restated certificate of incorporation and amended and restated bylaws:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit who may call stockholder meetings;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">do not provide for cumulative voting rights;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that all vacancies may be filled only by the affirmative vote of a majority of directors then in office, even if less than a quorum;</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that the Court of Chancery of the State of Delaware will be the exclusive forum for certain legal claims; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that the federal district courts of the United States of American will be the exclusive forum for legal claims under the Securities Act.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, once we become a publicly traded corporation, Section&#160;203 of the Delaware General Corporation Law may limit our ability to engage in any business combination with a person who beneficially owns 15% or more of our outstanding voting stock unless certain conditions are satisfied. This restriction lasts for a period of three&#160;years following the share acquisition. These provisions may have the effect of entrenching our management team and may deprive stockholders&#8217; of the opportunity to sell their shares to potential acquirers at a premium over prevailing prices. This potential inability to obtain a control premium could reduce the price of our common stock. See Exhibit 4.5 &#8220;Description of Capital Stock&#8221; for additional information.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial reporting obligations of being a public company in the United States require well defined disclosure and financial controls and procedures that are expensive and time-consuming requiring our management to devote substantial time to compliance matters.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a publicly traded company, we incur significant legal, accounting and other expenses that we did not incur as a privately held company prior to the completion of our IPO in February 2021. These reporting obligations associated with being a public company in the United States require significant expenditures and place significant demands on our management and other personnel, including costs resulting from our reporting obligations under the Exchange Act and the rules and regulations regarding corporate governance practices, including those under the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, as amended, and the listing requirements of The Nasdaq Capital Market. These rules require the establishment and maintenance of effective disclosure and financial controls and procedures, internal control over financial reporting and changes in corporate governance practices, among many other complex rules that are often difficult to implement, monitor and maintain compliance with. Moreover, despite recent reforms made possible by the JOBS Act, the reporting requirements, rules, and regulations may make some activities more time-consuming and costly, particularly after we are no longer an &#8220;emerging growth company.&#8221; In addition, we expect these rules and regulations to make it more difficult and more expensive for us to maintain director and officer liability insurance. Our management and other personnel need to devote a substantial amount of time to ensure that we comply with all of these requirements and to keep pace with new regulations, otherwise we may fall out of compliance and risk becoming subject to litigation or being delisted, among other potential problems.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with the rules under the Sarbanes-Oxley Act related to accounting controls and procedures in the future, or, if we discover additional material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult. Section&#160;404 of the Sarbanes-Oxley Act requires annual management assessments of the effectiveness of our internal control over financial reporting after a transition period ending with our second annual report on Form 10-K filed under Section&#160;13(a) of the Exchange Act. If we fail to comply with the rules under the Sarbanes-Oxley Act related to disclosure controls and procedures in the future, or, if in the future we discover additional material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult.</span></div><div id="i8c772b1568214a7294558171471dfda5_22"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i8c772b1568214a7294558171471dfda5_25"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;PROPERTIES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive offices are located at 100 N. 18th Street, Suite 300, Philadelphia, PA 19103. We believe that our facilities are adequate to meet our current needs. Should we be required to obtain additional space in the future, we believe we can obtain the required facilities at competitive rates. </span></div><div id="i8c772b1568214a7294558171471dfda5_28"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings. </span></div><div id="i8c772b1568214a7294558171471dfda5_31"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i8c772b1568214a7294558171471dfda5_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div id="i8c772b1568214a7294558171471dfda5_37"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on The Nasdaq Capital Market under the symbol &#8220;VLON&#8221;. As of February 4, 2022, there were 7 holders of record of our common stock. As of such date, there were 6,812,836 shares of our common stock outstanding. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part III, Item 12. &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters&#8221; for information relating to our equity compensation plans.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Convertible Note Financing</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2021, we entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, our Chief Executive Officer, pursuant to which we issued convertible promissory notes (the 2021 Convertible Notes) for cash proceeds of $350,000. The 2021 Convertible Notes bear an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September 30, 2021. The 2021 Convertible Notes were convertible into shares of our capital stock offered to investors in any subsequent equity financing after the date of their issuance in which we issued any of our equity securities (a Qualified Financing), and were convertible at a twenty percent (20%) discount to the price per share offered in such Qualified Financing. Such Qualified Financing included the IPO of our common stock, consummated on February 12, 2021; therefore, the 2021 Convertible Notes converted into an aggregate of 54,906 shares of our common stock immediately prior to the closing of the IPO, as agreed upon among the parties thereto.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based in part upon the representations of Salmon Pharma and David Baker, the offering and sale of the 2021 Convertible Notes and the shares of our common stock issued upon conversion thereof were exempt from registration under Section 4(a)(2) of the Securities Act. The sales of our common stock issued upon conversion of the 2021 Convertible Notes will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration requirements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Proceeds from Registered Securities</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2021, our Registration Statement on Form S-1 (File No. 333-249636) relating to the IPO of our common stock was declared effective by the SEC. Pursuant to such Registration Statement, we sold an aggregate of 2,250,000 shares of our common stock at a price of $8.00 per share for aggregate cash proceeds of approximately $15.5 million, which amount is net of $1.6 million in underwriter&#8217;s discounts, commissions and expenses, and $0.9 million of other expenses incurred in connection with the offering.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no material change in the expected use of the net proceeds from our IPO, as described in our final prospectus filed with the SEC on February 11, 2021 pursuant to Rule 424(b) under the Securities Act.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities By the Issuer and Affiliated Purchasers</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neither we nor any affiliated purchaser or anyone acting on our behalf or on behalf of an affiliated purchaser made any purchases of shares of our common stock during the year ended December 31, 2021.</span></div><div id="i8c772b1568214a7294558171471dfda5_40"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;[Reserved]</span></div><div style="margin-top:10pt"><span><br/></span></div><div id="i8c772b1568214a7294558171471dfda5_43"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes beginning on page F-1 of this Annual Report. Some of the information contained in this </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the section entitled &#8220;Item 1A. Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements&#8221; of this Annual Report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></div><div id="i8c772b1568214a7294558171471dfda5_46"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company primarily focused on the development and commercialization of proprietary biopharmaceutical products. We are developing novel medications for central nervous system (CNS) disorders with a focus on abuse-deterrent medications. Our lead investigational product candidate, ADAIR, is a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine (the main active ingredient in Adderall&#174;) for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. According to the US Department of Health and Human Services&#8217; 2018 National Survey on Drug Use and Health, over 5 million adolescents and adults misuse prescription stimulant medications on an annual basis. The misuse and abuse of prescription stimulants has substantial medical risk, including risk of irregular heartbeat, heart attack, seizures, hallucinations, hostile behavior and stroke, as well as increased risk of addiction. ADAIR is designed to deter attempts to crush and snort and to provide barriers to injection while still providing the expected therapeutic benefit when taken orally.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing ADAIR for registration with the U.S. Food and Drug Administration (the FDA) through the Section 505(b)(2) regulatory pathway, which is expected to obviate the need for large Phase 2 and Phase 3 efficacy and safety studies. In July 2018, our Investigational New Drug (IND) application for ADAIR was approved by the FDA. We have completed three Phase 1 trials of ADAIR including a proof-of-concept intranasal human abuse potential study. In the second quarter of 2021, we completed a 13-week preclinical toxicology study on the final formulation of ADAIR that showed no safety findings of concern. We are currently conducting the SEAL study, a pivotal intranasal abuse study, and have recently completed its patient enrollment and treatment phases. The SEAL study enrolled 55 subjects who successfully passed the qualification phase with a total of 53 completing the study. We expect to report top-line results of  the SEAL study in the first quarter of 2022. Additionally, we continue to conduct preclinical studies and manufacturing work and continue to evaluate the potential for any additional studies to support the submission of a New Drug Application (NDA) for ADAIR to the FDA. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, we entered into the Medice License Agreement, which grants Medice an exclusive license to develop, use, manufacture, market and sell ADAIR throughout Europe. Under the license agreement, Medice paid us a $0.1 million upfront payment and will pay milestone payments of up to $6.3 million in aggregate upon achieving certain regulatory and sales milestones. We are also entitled to low-double digit tiered royalties on net sales of ADAIR.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to ADAIR, we completed formulation development work and selected the final formulation of our second product candidate, ADMIR, an abuse deterrent formulation of methylphenidate (Ritalin&#174;), for the treatment of ADHD. We also plan to utilize the Section 505(b)(2) regulatory pathway for registration of ADMIR.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we plan to use our abuse deterrent platform technology to develop other products that have potential for abuse in their current forms and will continue business development activities and seek partnering, licensing, merger and acquisition opportunities or other transactions to further develop our pipeline and drug-development capabilities.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global COVID-19 pandemic continues to present uncertainty and unforeseeable new risks to our operations and business plan. We have closely monitored recent COVID-19 developments, including states&#8217; lifting COVID-19 safety measures, drops in vaccination rates, and the spread of various coronavirus strains such as the Delta and Omicron variants. In light of these developments, the full impact of the COVID-19 pandemic on our business, operations and clinical development plans remains uncertain and will vary depending on the pandemic&#8217;s future impact on our clinical trial enrollment, clinical trial sites, clinical research organizations (CROs), third-party manufacturers, and other third parties with whom we do business, as well as any legal or regulatory consequences resulting therefrom. To the extent possible, we are conducting business as usual, with necessary or advisable modifications to employee travel and with most of our employees and consultants working remotely. We will continue to actively monitor the COVID-19 situation and may take further actions that alter our operations, including those that may be required by federal, state or local authorities, or that we determine are in the best interests of our employees and other third parties with whom we do business.</span></div><div id="i8c772b1568214a7294558171471dfda5_58"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial statements are prepared in accordance with accounting principles generally accepted in the United States (GAAP). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail in the notes to our financial statements, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of debt securities that are designated as available-for-sale. Marketable debt securities are recorded at fair value and unrealized holding gains or losses are reported as a component of accumulated other comprehensive income (loss). The amortization of discounts and premiums on marketable securities is included in interest expense, net on the statements of operations and comprehensive loss. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains or losses resulting from the sale of these securities are determined based on the specific identification of the securities sold. An impairment charge is recognized when the decline in the fair value of a debt security below the amortized cost basis is determined to be other-than-temporary. We consider various factors in determining whether to recognize an impairment charge, including the duration and severity of any decline in fair value below the amortized cost basis, any adverse changes in the financial condition of the issuers and our intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenue in accordance with Financial Accounting Standards Board Accounting Standards Codification (ASC) Topic 606,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard applies to all contracts with customers with the exception of contracts that are within the scope of other standards, such as leases, insurance and financial instruments. Under ASC Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to be entitled in exchange for those goods or services.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform the following five steps to recognize revenue under ASC Topic 606: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only recognize revenue when it is probable that we will collect the consideration to which we are entitled in exchange for the goods or services that will be transferred to the customer.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, our revenues have been generated by a single license agreement (the Medice License Agreement) with Medice (Note 13). &#160;The Medice License Agreement included an exclusive license to develop, use, manufacture, market and sell ADAIR&#160;throughout&#160;Europe, a non-refundable up-front payment, regulatory and sales milestones and royalty payments.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASC Topic 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. We account for forfeitures as incurred. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of option shares issued under the employee stock purchase plan requires the input of subjective assumptions, including the estimated fair value of our common stock, the expected life of the option, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in our Black-Scholes option-pricing model represent management's best estimates and involve a number of variables, uncertainties and assumptions and the application of management's judgment, as they are inherently subjective. If any assumptions change, our stock-based compensation expense could be materially different in the future.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assumptions used in our Black-Scholes option-pricing model are estimated as follows:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Due to the lack of sufficient company-specific historical data, the expected term of employee options is determined using the "simplified" method, as prescribed in SEC&#8217;s Staff Accounting Bulletin (SAB) No. 107, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option. The expected term of nonemployee options is equal to the contractual term. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The expected volatility is based on historical volatilities of similar entities within our industry which were commensurate with the expected term assumption as described in SAB No. 107. </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-Free Interest Rat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.  The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term. </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Dividends</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The expected dividend yield is 0% because we have not historically paid, and do not expect for the foreseeable future to pay, a dividend on our common stock.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for leases in accordance with Accounting Standards Update (ASU) 2016-02,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and ASU 2018-10,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 842, Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and ASU 2018-11,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842): Targeted Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, both of which clarify and enhance the certain amendments made in ASU 2016-02. The ASUs increase transparency and comparability among entities by recognizing for all leases lease assets and lease liabilities on the balance sheet and disclosing key information about lease arrangements. We entered into one lease for manufacturing equipment for ADAIR which we determined was a finance lease.</span></div><div id="i8c772b1568214a7294558171471dfda5_61"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenues from product sales. All of our revenue to date has been derived from the Medice License Agreement. We do not expect to generate significant product revenue until we obtain approval and commercialize ADAIR. Under the terms of the Medice License Agreement, we received  $0.1 million in licensing revenues in connection with the initial signing of the license agreement in the first quarter of 2020.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include personnel costs associated with research and development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. We accrue for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses have consisted primarily of in-process research and development expenses, costs incurred in preparing for and conducting the development program for ADAIR, working on commercial manufacturing of ADAIR and developing formulations for ADMIR. Research and development costs are expensed as incurred. These expenses include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee -related expenses, such as salaries, bonuses and benefits, consultant-related expenses such as consultant fees and bonuses, stock-based compensation, overhead related expenses and travel related expenses for our research and development personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with contract research organizations (CROs), as well as consultants that support the implementation of our clinical and non-clinical studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing and packaging costs in connection with conducting clinical trials and for stability and other studies required to support the NDA filing as well as manufacturing drug product for commercial launch;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">formulation, research and development expenses related to ADMIR; and other products we may choose to develop; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs for sponsored research.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically use our employee, consultant and infrastructure resources across our research and development programs. Although we track certain outsourced development costs by product candidate, we do not allocate personnel costs or other internal costs to specific product candidates.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to incur research and development expenses for the foreseeable future as we expect to continue the development of ADAIR and our other product candidates. At this time, due to the inherently unpredictable nature of preclinical and clinical development and the early stage of our other product candidates, we are unable to estimate with any certainty the costs we will incur and the timelines we will require in our continued development efforts.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of compensation and consulting related expenses for executives and other administrative personnel, professional fees and other corporate expenses, including legal and accounting fees, travel expenses, facilities-related expenses, and consulting services relating to our formation and corporate matters.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase in the future as we support our continued research and development activities and operate as a public company. These increases will likely include increased costs related to the hiring of personnel, including compensation and employee-related expenses, including stock-based compensation, and fees to outside consultants, lawyers and accountants, among other expenses. Additionally, we anticipate increased costs associated with being a public company, including expenses related to services associated with maintaining compliance with The Nasdaq Capital Market and SEC requirements, directors and officers insurance, increased legal and accounting costs and investor relations costs. In addition, if ADAIR obtains regulatory approval for marketing, we expect that we would incur expenses associated with building a commercialization team if we have not sold or licensed the rights to commercialize ADAIR to a third party in territories not under the license agreement with Medice.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income consists of income recognized as a result of the extinguishment of the promissory note issued to us under the Paycheck Protection Program (PPP) as a result of the forgiveness of the note. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revaluation of Derivative Instruments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a Convertible Promissory Note Purchase Agreement pursuant to which we issued $350,000 in convertible promissory notes (the 2021 Convertible Notes). The 2021 Convertible Notes automatically converted into 54,906 shares of our common stock concurrently with the closing of the IPO. We identified the mandatory conversion into shares our common stock as a redemption feature, which requires bifurcation from the 2021 Convertible Notes and treated it as a derivative liability under ASC 815 as the redemption feature was not clearly and closely related to the debt. We evaluated the fair value of the derivative liability at issuance. Upon the conversion of the 2021 Convertible Notes to common stock at the closing of the IPO, the embedded derivative liability was remeasured and removed from the balance sheet.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense, net</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net, consists of interest earned on our cash, cash equivalents and marketable securities held with institutional banks, the amortization of discounts and premiums on marketable securities and interest expense on our finance lease of equipment utilized in the commercial scale manufacturing of ADAIR.</span></div><div id="i8c772b1568214a7294558171471dfda5_76"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider the applicability and impact of all ASUs. ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on the financial statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, we adopted ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending the existing guidance.  The adoption of this standard did not have a material impact on our financial statements.&#160;</span></div><div id="i8c772b1568214a7294558171471dfda5_82"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOBS Act</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) the Securities Act, as modified by the JOBS Act. Emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. Therefore, we may not be subject to the same new or revised accounting standards as other public companies that are not &#8220;emerging growth companies.&#8221; For as long as we continue to be an emerging growth company, we also intend to take advantage of certain other exemptions from various reporting requirements that are applicable to other public companies including, but not limited to, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, exemptions from the requirements of holding a nonbinding advisory stockholder vote on executive compensation and any golden parachute payments not previously approved, exemption from the requirement of auditor attestation in the assessment of our internal control over financial reporting and exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements (auditor discussion and analysis). After we become a reporting company under the Exchange Act, we will remain an emerging growth company until the earliest of (i)&#160;the end of the fiscal year in which the market value of our common stock that is held by non-affiliates exceeds $700&#160;million as of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the end of the second fiscal quarter, (ii)&#160;the end of the fiscal year in which we have total annual gross revenues of $1.07&#160;billion or more during such fiscal year, (iii)&#160;the date on which we issue more than $1&#160;billion in non-convertible debt in a three-year period or (iv)&#160;the end of the fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement filed under the Securities Act.</span></div><div id="i8c772b1568214a7294558171471dfda5_64"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December&#160;31, 2021 and 2020</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our results of operations for the year ended December 31, 2021 compared to the year ended December 31, 2020 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenue &#8211; from related party</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,888&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,259)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,788)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(89)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,303)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,822)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Revenue &#8211; From Related Party</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing revenues were $0.1 million for the year ended December&#160;31, 2020 as a result of the upfront payment received under the terms of the Medice License Agreement. No licensing revenues were recognized during the year ended December&#160;31, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $5.2 million and $3.7 million for the years ended December&#160;31, 2021 and 2020, respectively. The $1.5 million increase in research and development expenses was primarily due to increases of $1.5 million in expenses related to the registration development program of ADAIR and $0.1 million in consulting fees, offset by a decrease of&#160;$0.1 million in expenses related to the formulation work for ADMIR.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $4.1 million and $1.2 million for the years ended December&#160;31, 2021 and 2020, respectively. The $2.9 million increase was primarily related to increased costs for directors and officers insurance of $1.3 million, personnel expense, including non-cash stock compensation, of $1.0 million, and public company expenses of $0.5 million.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we issued a promissory note under the PPP totaling $61,000. As of December 31, 2020, we had utilized the entire proceeds from such note for payroll costs (greater than 75%), costs related to health care benefits and rent payments. In January 2021, we were notified that the note along with accumulated interest had been forgiven. As a result, we recorded income from the extinguishment of the obligation in accordance with ASC 405-20-40-1.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revaluation of Derivative Liability</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, pursuant to ASC 815, we revalued the embedded derivative liability associated with the 2021 Convertible Notes, resulting in an $89,000 decrease in the fair value of the derivative liability associated with the 2021 Convertible Notes.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense, net</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net, was $16,000 and $34,000 for the years ended December&#160;31, 2021 and 2020, respectively. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span><br/></span></div><div id="i8c772b1568214a7294558171471dfda5_67"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred losses and expect to continue to incur losses for the foreseeable future. We incurred net losses of $9.3 million and $4.8 million for the years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, we had an accumulated deficit of $21.9 million.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our working capital requirements to date through the issuance of common stock, convertible notes, short-term promissory notes, and a PPP promissory note. As of December&#160;31, 2021, we had $3.7 million in cash and cash equivalents. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,312)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,706)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,842)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,593&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,712)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021 and 2020, $8.3 million and $3.7 million were used in operating activities, respectively. The $4.6 million increase was primarily due to a $4.5 million increase in our net loss, a $0.5 million increase in non-cash stock compensation expense, as well as increases in accrued and prepaid expenses of $0.1 million, offset by a $0.3 million decrease in accounts payable. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $3.8 million for the year ended December&#160;31, 2021, which was related to the purchase of marketable securities. Net cash used in investing activities was $2,000 for the year ended December&#160;31, 2020, which was related to the purchase of computer equipment.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $4,000 during the year ended December&#160;31, 2020, which was related to proceeds received from a PPP note of $61,000, offset by payments related to our finance lease of $65,000. Net cash provided by financing activities was $15.8 million for the year ended December&#160;31, 2021 and was primarily related to the net proceeds from our IPO and 2021 Convertible Notes financings.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Convertible Note Financing</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, our Chief Executive Officer, pursuant to which we issued convertible promissory notes (the 2021 Convertible Notes) for cash proceeds of $350,000. The 2021 Convertible Notes bear an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September 30, 2021. The 2021 Convertible Notes were convertible into shares of our capital stock offered to investors in any subsequent equity financing after the date of their issuance in which we issued any of our equity securities (a Qualified Financing) and were convertible at a twenty percent discount to the price per share offered in such Qualified Financing. Such Qualified Financing included the IPO of our common stock, consummated on February 12, 2021; therefore, the 2021 Convertible Notes converted into an aggregate of 54,906 shares of our common stock immediately prior to the closing of the IPO, as agreed upon among the parties thereto.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although it is difficult to predict future liquidity requirements, we expect that our existing cash and cash equivalents will provide funding for our ongoing business activities into the third quarter of 2022. We will require substantial additional financing  to fund our research and development activities. No assurance can be given that any such financing will be available when needed or that our research and development efforts will be successful. If the we are not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund our future operating requirements, we may be forced </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Ta</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">b</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">le of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to reduce or discontinue our operations entirely. Therefore, there is substantial doubt about our ability to continue as a going concern. We expect to continue to incur significant and increasing operating losses at least for the foreseeable future. We do not expect to generate product revenue unless and until we successfully complete development, obtain regulatory approval for, and successfully commercialize ADAIR, or any other future products, including ADMIR. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of planned clinical trials and our expenditures on other research and development activities. We anticipate that our expenses will increase substantially as we:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct clinical trials and non-clinical studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scale up manufacturing capabilities with third-party contract manufacturer(s);</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct ongoing stability studies of ADAIR;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to identify, acquire, develop and commercialize additional products, such as ADMIR;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">integrate acquired technologies into a comprehensive regulatory and product development strategy;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire scientific, clinical, quality control and administrative personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add operational, financial and management information systems and personnel, including personnel to support our drug development efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approvals for any products that successfully complete clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ultimately establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any drug candidates for which we may obtain regulatory approval, including through the license agreement with Medice; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operate as a public company.</span></div><div id="i8c772b1568214a7294558171471dfda5_70"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Other Commitments</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into contracts in the normal course of business with third-party contract organizations for clinical trials, preclinical studies, manufacturing and other services and products for operating purposes. These contracts generally provide for termination following a certain period after notice and therefore we believe that our non-cancelable obligations under these agreements are not material.</span></div><div id="i8c772b1568214a7294558171471dfda5_79"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not entered into any off-balance sheet arrangements.</span></div><div id="i8c772b1568214a7294558171471dfda5_88"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable to a smaller reporting company.</span></div><div id="i8c772b1568214a7294558171471dfda5_91"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements required pursuant to this item are incorporated by reference herein from the applicable information included in Item 15 of this annual report and are presented beginning on page F-1.</span></div><div id="i8c772b1568214a7294558171471dfda5_94"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i8c772b1568214a7294558171471dfda5_97"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ensure that such information is accumulated and communicated to a company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Executive Officer (our principal executive officer) and our Chief Financial Officer (our principal financial officer) evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a 15(e) and 15d 15(e) under the Exchange Act, as of the end of the period covered by this report. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2021.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance of the reliability of financial reporting and of the preparation of financial statements for external reporting purposes, in accordance with U.S. generally accepted accounting principles.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal control over financial reporting includes policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect transactions and disposition of assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with the authorization of its management and directors; and (3) provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on its financial statements.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of the effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures included in such controls may deteriorate.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2021. In making this assessment, management used the criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework (2013). These criteria are in the areas of control environment, risk assessment, control activities, information and communication, and monitoring. Management&#8217;s assessment included documentation, evaluating and testing the design and operating effectiveness of its internal controls over financial reporting.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on management&#8217;s processes and assessment, as described above, management has concluded that, as of December 31, 2021, our internal control over financial reporting was effective.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remediation of Material Weakness in Internal Control Over Financial Reporting</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The closing of our IPO occurred on February 12, 2021. As a newly public company under the Exchange Act, we were not required to evaluate the effectiveness of our internal controls over financial reporting until the end of the fiscal year after we file our Annual Report on Form 10-K for the year ended December 31, 2020. Although our management did not conduct an evaluation of our internal control over financial reporting, in connection with the audit of our financial statements for the years ended December 31, 2020, 2019 and 2018, we became aware of material weaknesses in our internal controls over financial reporting for those periods. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. The material weaknesses related to a lack of segregation of duties in the financial reporting process due to the small size of our accounting and finance department, lack of sufficient documentation of various accounting processes, and the design over controls related to recording certain transactions. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have remediated the material weaknesses by hiring additional accounting and finance staff, and implementing new controls, processes and technologies to formalize internal controls frameworks and procedures. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Attestation Report of the Registered Public Accounting Firm</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report does not include an attestation report of our registered public accounting firm due to an exemption provided by the JOBS Act for &#8220;emerging growth companies.&#8221;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have taken actions and remediated the material weaknesses relating to our internal controls over financial reporting as described above. Except as otherwise disclosed herein, there have been no changes in our internal control over financial reporting during the quarter ended December 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i8c772b1568214a7294558171471dfda5_100"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9B.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i8c772b1568214a7294558171471dfda5_1200"></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9C.&#160;&#160;&#160;&#160;DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="i8c772b1568214a7294558171471dfda5_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;III</span></div><div id="i8c772b1568214a7294558171471dfda5_106"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE MANAGEMENT</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information about our directors, director nominees, our executive officers, and a key consultant.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.587%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Age</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Position</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Officers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David Baker</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President, Chief Executive Officer and Director</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leanne Kelly</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Financial and Accounting Officer)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Penny S. Toren</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President, Regulatory Affairs &amp; Program Management</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Employee Directors and Director Nominee</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ofir Levi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director, Chairman of the Board</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Joseph Payne</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Richard Ammer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marella Thorell</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Key Consultant</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Timothy Whitaker, M.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Medical Officer</span></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Member of the audit committee.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Member of the compensation committee.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Member of the nominating and corporate governance committee.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Officers</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">David Baker</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;has served as our President and Chief Executive Officer since January&#160;15, 2019, and as a member of the board of directors from that time until August&#160;23, 2019, and upon the consummation of the IPO of our common stock on February 12, 2021, he was again appointed as a director. Prior to being appointed our President and Chief Executive Officer, he served as a consultant to our company since January&#160;15, 2018. He previously served as the Interim Chief Executive Officer and Chief Commercial Officer of Alcobra Ltd (now known as Arcturus), where he oversaw the development of ADAIR. Prior to joining Alcobra Ltd., he worked at Shire Pharmaceuticals for 10&#160;years, including as Vice President of Commercial Strategy and New Business in the Neuroscience Business Unit. In that role, Mr.&#160;Baker led the commercial assessment of neuroscience licensing opportunities, managed commercial efforts on pipeline CNS products, and led the long-term strategic planning process. Previously, he served as Global General Manager for Shire&#8217;s Vyvanse&#174; where he led the launch of Vyvanse and led global expansion efforts including successful establishment of a partnership in Japan and launches in Canada and Brazil. Prior to that, Mr.&#160;Baker served as Vice President of Marketing for all of Shire&#8217;s ADHD products. From 1990 through 2004, Mr.&#160;Baker worked at Merck &amp; Co., where he held positions of increasing responsibility in marketing, sales, market research, and business development. In addition to his knowledge and experience with CNS medications, Mr.&#160;Baker&#8217;s expertise includes therapeutics for osteoporosis, migraine, and hyperlipidemia. He has been directly involved with the marketing of five medications with annual sales in excess of $1&#160;billion each. Mr.&#160;Baker graduated Magna Cum Laude with a bachelor&#8217;s degree in Economics and Computer Science from Duke University. He earned a Master of Business Administration in Marketing from Duke&#8217;s Fuqua School of Business. Mr.&#160;Baker also serves on the board of directors of Benchworks, Inc., a private healthcare advertising agency.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Mr.&#160;Baker&#8217;s extensive experience in the biopharmaceuticals industry and his in-depth understanding of our business, strategy and management team qualifies him to serve on our board of directors.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leanne M. Kelly </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as our Chief Financial Officer since May 2021. She brings over 20 years of experience leading private and publicly traded companies across life science, technology and e-Commerce sectors with a foundation in public accounting. Prior to joining Vallon, she most recently served as the Controller and Executive Director, Global Financial Reporting at OptiNose, Inc, a $50 million revenue specialty pharmaceutical company. Over the course of her career, she has held Senior Vice President of Finance, Controller and Chief Financial Officer positions in private and public companies such as </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Flower Orthopedics, Iroko Pharmaceuticals, LLC, and Genaera Corporation. Ms. Kelly began her career as an auditor with KPMG LLP. While serving in those roles, Ms. Kelly's work included multi-million dollar financings, M&amp;A diligence and support. She also has experience in financial oversight, internal and external financial reporting, forecasting, and financial analysis, as well as investor and public relations. Ms. Kelly received her Bachelor of Science degree in Business Economics with a concentration in Accounting from Lehigh University, and is a licensed CPA (inactive status) in the state of Pennsylvania.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Penny S. Toren</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;has served as our Senior Vice President, Regulatory Affairs, since April&#160;2018. She brings over 25&#160;years of Regulatory and Clinical Development experience in the pharmaceutical industry from Glaxo SmithKline, AstraZeneca, Cephalon, and Teva. At Vallon, Ms.&#160;Toren heads the Regulatory Affairs &amp; Program Management function, providing regulatory strategies to optimize the most efficient and effective outcomes for Vallon&#8217;s drug products as well as ensuring full compliance with FDA and DEA regulations for products in development through post approval. From 2003 until April&#160;2018, Ms.&#160;Toren developed the Global Regulatory Policy &amp; Intelligence function for Teva&#8217;s Specialty, Generic, &amp; Biosimilar portfolio. In this role, Ms.&#160;Toren participated in several FDA, PhRMA, and BIO cross company working groups to address regulatory policy for abuse deterrent products. Prior to that, Ms.&#160;Toren led the successful registration of Fentora&#174;, negotiated approval of the first RiskMap for opioids, and was a driver of the initial development of the Fentora&#174; and Actiq&#174; REMS programs. Ms.&#160;Toren earned her bachelor&#8217;s degree in Chemistry and Biology from Florida Atlantic University, an MS in Biostatistics and Epidemiology from New York Medical College.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Executive Directors</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ofir Levi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;has served as a member of our board of directors since inception and has served as the Chairman of the board of directors since our inception. He is an accomplished biotech entrepreneur with over 16&#160;years of experience establishing, managing and investing in early to late stage life science companies. He was a research consultant for Adamas Health Care Fund from its inception in 2014 until January&#160;2020 where he led a research team that conducts deep scientific analysis of publicly traded pharmaceutical and biotechnology companies. Prior to his engagement with Adamas Health Care Fund, Dr.&#160;Levi was the founder and CEO at Bioassociate Ltd., an expertise-based consulting, research and analysis company focused on the pharmaceutical, biotechnology and life science sectors. Until 2011, Dr.&#160;Levi was the CEO of Radmor Biocap LLC, a company that invested and managed seed and early stage companies, pharmaceutical development, clinical diagnostics and medical devices. Led by Dr.&#160;Levi, Radmor signed several license agreements with leading universities around the world for novel technologies, and established companies developing these technologies. Dr.&#160;Levi completed his Ph.D. studies in Prof.&#160;Daniel Michaelson&#8217;s neurobiology lab at Tel-Aviv University. During the four&#160;years of his Ph.D. studies, he led a research group in both in-house research and several international collaborations. Dr.&#160;Levi&#8217;s PhD thesis focused on neurogenesis processes in Alzheimer&#8217;s Disease.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Dr.&#160;Levi&#8217;s extensive experience as an investor and entrepreneur in the biopharmaceuticals industry and his in-depth understanding of our business, strategy and management team qualifies him to serve on our board of directors.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joseph Payne</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;joined our board of directors on June&#160;22, 2018 in connection with the Asset Purchase Agreement, as the designated director nominee of Arcturus pursuant to the terms of the 2018 Voting Agreement (as hereinafter defined), which agreement terminated upon the filing of the&#160;registration statement&#160;in connection with the IPO of our common stock. He also serves on the board of directors of Arcturus since November&#160;2017. Mr.&#160;Payne previously served as President and Chief Executive Officer of Arcturus and on its board of directors from March&#160;2013 to February&#160;2018. Prior to joining Arcturus, Mr.&#160;Payne served as Senior Manager of Nitto Denko Corporation, a life sciences research company, from June&#160;2009 until February&#160;2013. Mr.&#160;Payne&#8217;s background includes over 20&#160;years of drug discovery experience at Arcturus, Nitto Denko Corporation, Kalypsys Inc., Merck Research Labs, Bristol-Myers Squibb Co. and DuPont Pharmaceuticals Co. Mr.&#160;Payne received a bachelor&#8217;s degree in Chemistry, magna cum laude from Brigham Young University, a Master of Science in Synthetic Organic Chemistry from the University of Calgary and an Executive Training Certificate from MIT Sloan School of Management.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Mr.&#160;Payne&#8217;s extensive experience in the biopharmaceuticals industry and as a chief executive officer of a biopharmaceutical company qualifies him to serve on our board of directors.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Richard Ammer, M.D., Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> joined our board of directors in July 2019 in connection with the July 2019 private placement. Since 2003, Dr.&#160;Ammer served as general manager and since 2012 as managing owner of MEDICE Arzneimittel P&#252;tter GmbH &amp; Co. KG, a family-owned mid-sized pharmaceutical enterprise, where he is responsible for search and development, medical and regulatory affairs, manufacturing, market access and international marketing and distribution. Since 2008, Dr.&#160;Ammer has served as a board member and Vice President of the German Pharmaceutical Association with a focus on research and development. Dr.&#160;Ammer graduated with a degree in medicine from Technical University, Munich, and internship at Harvard Medical School, Boston. Dr.&#160;Ammer pursued his clinical and scientific education in internal medicine at Massachusetts General Hospital in Boston from 1996 until 2000, the German Heart Center from 2000 until 2001, and the University Hospital in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Muenster 2001, where he has been responsible for patients undergoing cardiac and renal care. He also established a nation-wide network of excellence and competence on cardiac arrhythmias, sponsored by the federal ministry of science (BMBF), for which he served as its general manager from 2002 to 2004. His research on atrial fibrillation, for which he obtained his PhD in 2000 from Technical University, Munich, was awarded by the European Society in Cardiology with the Young Investigator Award in Basic Science in 2001. Dr.&#160;Ammer also studied business administration and economics at University St. Gallen from 1992 until 1996, and at Harvard Extension School from 1996 until 1998 and obtained a PhD in 2005 from University St. Gallen. Since 2001, Dr.&#160;Ammer has also served as lecturer at University St. Gallen, Switzerland.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Dr.&#160;Ammer&#8217;s extensive experience in the biopharmaceuticals industry and as a chief executive officer of a biopharmaceutical company qualifies him to serve on our board of directors.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marella Thorell</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;has served as a director and as the chairperson of our audit committee since February 12, 2021. Ms. Thorell has more than 30 years of accomplishments in finance and operations having successfully led multiple M&amp;A, licensing, and fundraising transactions. She currently serves as the Chief Accounting Officer of Centessa Pharmaceuticals plc (Nasdaq: CNTA) and previously served as Head of Finance. Prior to that, Ms. Thorell was the Chief Financial Officer of Palladio Biosciences, leading their finance operations and capital strategy and execution. Before joining Palladio, she served in various capacities at Realm Therapeutics, PLC, (Nasdaq: RLM), including Chief Financial Officer, Chief Operating Officer and Executive Director. In this role, she led accounting and financial reporting operations and helped transition Realm&#8217;s focus to drug development following a strategic overhaul. She was also responsible for divesting domestic and international operating businesses and in-licensing and out-licensing assets. Earlier in her career Ms. Thorell worked for Campbell Soup Company (NYSE: CPB) in finance and operational roles of increasing responsibility and at Ernst &amp; Young, LLP where she earned a C.P.A. Ms. Thorell also serves on the Board of Essa Pharm (Nasdaq: EPIX) and on the Board of Living Beyond Breast Cancer (lbbc.org). Ms. Thorell earned a B.S. in Business from Lehigh University, magna cum laude.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Ms. Thorell&#8217;s extensive experience and education in finance and accounting in the biopharmaceuticals industry qualifies her to serve on our board of directors.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Consultant</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Timothy Whitaker, M.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;is a part-time consultant that has served as our Chief Medical Officer since April&#160;2018. He brings over 20&#160;years of experience in the pharmaceutical industry and nearly a decade in academic medicine. His pharmaceutical industry experience involves extensive leadership and management of many global clinical development programs, achieving numerous global regulatory approvals. The majority of this work has been in neuroscience and includes leading the development and approval of multiple ADHD medications. Most recently, Dr.&#160;Whitaker served as the Chief Medical Officer at Alder Biopharmaceuticals leading a positive Phase&#160;III study in the development of a CGRP antagonist for migraine. Prior to that, Dr.&#160;Whitaker worked at Shire for more than 10&#160;years, most recently as VP and Neuroscience Therapeutic Area Head, Global Clinical Development. Prior to Shire, Dr.&#160;Whitaker served as a Senior Director&#8201;&#8212;&#8201;Neuroscience at Wyeth Research with a focus on sleep disorders and life cycle management for Effexor&#174;. Prior to joining industry, Dr.&#160;Whitaker held a variety of clinical and teaching positions at the University of Vermont (UVM) College of Medicine and the Medical Center Hospital of Vermont, including Associate Professor of Psychiatry, Director of the Inpatient Services, Executive Committee of the Vermont Regional Sleep Disorders Center, and Director of the Psychopharmacology Clinic. He earned his bachelor&#8217;s degree from Duke University, and his medical degree from Wake Forest University School of Medicine. He completed a residency training program in psychiatry and a fellowship in clinical psychopharmacology at UVM/Medical Center Hospital of Vermont in Burlington.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Family Relationships</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no family relationship between any director, executive officer or person nominated to become a director or executive officer.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Composition of Our Board of Directors</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws provide that the number of directors on our board shall be determined from time to time by resolution of the Board or our stockholders, and the current size of our Board is five members.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated bylaws also provide that our directors may be removed from office with or without cause by vote of the holders of a majority of the shares of stock entitled to vote in the election of directors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and future executive officers and significant employees serve at the discretion of our board of directors. Our board of directors may also choose to form certain committees, such as a compensation and an audit committee.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors is divided into three classes with staggered three-year terms. At each annual meeting of stockholders, the directors whose terms then expire will be subject to re-election to serve until the third annual meeting following re-election. As a result, only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Our directors are divided among the three classes as follows:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Class&#160;I directors are David Baker and Ofir Levi, and their term expires at the annual meeting of stockholders to be held in 2022;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Class&#160;II directors are Richard Ammer and Marella Thorell, and their term expires at the annual meeting of stockholders to be held in 2022; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Class&#160;III directors are Joseph Payne, and his term expires at the annual meeting of stockholders to be held in 2023.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the Class I directors, their terms were originally scheduled to expire at last year&#8217;s annual meeting. Because we did not hold an annual meeting of stockholders in 2021, the Class I directors will continue to serve as directors through this year&#8217;s annual meeting, whereby both Class I and Class II directors will be subject to re-election. Upon re-election, each Class I director will serve a term expiring at our annual meeting of stockholders in 2024, while each Class II director will serve the full three-year term. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws provide that only our board of directors can fill vacancies on the board, including due to increases in the size of the board. Any additional directorships resulting from an increase in the authorized number of directors would be placed among the three classes so that, as nearly as possible, each class consists of one-third of the authorized number of directors.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classification of our board of directors may have the effect of delaying or preventing changes in our control or management. See Exhibit 4.5 &#8220;Description of Capital Stock&#8201;&#8212;&#8201;Anti-Takeover Effects of our Certificate of Incorporation and Bylaws and Delaware Law.&#8221;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Independence</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the listing requirements of The Nasdaq Capital Market, independent directors must comprise a majority of a listed company&#8217;s board of directors within twelve months from the date of listing. In addition, subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating and governance committees must be independent within twelve months from the date of listing. Audit committee members must also satisfy additional independence criteria, including those set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended (the Exchange Act), and compensation committee members must also satisfy the independence criteria set forth in Rule 10C-1 under the Exchange Act. A director will only qualify as an &#8220;independent director&#8221; if, in the opinion of that company&#8217;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule 10A-3 under the Exchange Act, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board committee: (1) accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries, other than compensation for board service; or (2) be an affiliated person of the listed company or any of its subsidiaries. In order to be considered independent for purposes of Rule 10C-1, the board of directors must consider, for each member of a compensation committee of a listed company, all factors specifically relevant to determining whether a director has a relationship to such company which is material to that director&#8217;s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to: the source of compensation of the director, including any consulting advisory or other compensatory fee paid by such company to the director, and whether the director is affiliated with the company or any of its subsidiaries or affiliates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has determined that all members of the board of directors and our director nominees, except Richard Ammer and David Baker, are independent directors, including for purposes of the rules of The Nasdaq Capital Market and the SEC. In making such independence determination, our board of directors considered the relationships that each non-employee director has with us and all other facts and circumstances that our board of directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each non-employee director. The composition and functioning of our board of directors and each of our committees comply with all applicable requirements of The Nasdaq Capital Market and the rules and regulations of the SEC.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Oversight of Risk</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the key functions of our board of directors is informed oversight of our risk management process. In particular our board of directors is responsible for monitoring and assessing strategic risk exposure. Our executive officers are responsible for the day-to-day management of the material risks we face. Our board of directors administers its oversight function directly as a whole. Our board of directors also administers its oversight through various standing committees, which address risks inherent in their respective areas of oversight. For example, our audit committee is responsible for overseeing the management of risks associated with financial reporting, accounting and auditing matters; our compensation committee oversees the management of risks associated with our compensation policies and programs; and our nominating and corporate governance committee oversees the management of risks associated with director independence, conflicts of interest, composition and organization of our board of directors and director succession planning.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Committees</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors established an audit committee, a compensation committee and a nominating and corporate governance committee and may establish other committees to facilitate the management of our business. Members serve on these committees until their resignation or until otherwise determined by our board of directors. Our board of directors and its committees set meeting schedules throughout the year and can also hold special meetings and act by written consent from time to time, as appropriate.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors expects to delegate various responsibilities and authority to committees as generally described below. The committees regularly report on their activities and actions to the full board of directors. Each member of each committee of our board of directors qualifies as an independent director in accordance with the listing standards of The Nasdaq Capital Market. Each committee of our board of directors has a written charter that was approved by our board of directors.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Copies of each charter are posted on our website at www.vallon-pharma.com under the Investor Relations section. Information contained on our website is not incorporated by reference into this Annual Report.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Audit Committee</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The members of our audit committee are Ofir Levi, Joseph Payne and Marella Thorell, who is the chair of the audit committee.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit committee assists our board of directors with its oversight of the integrity of our financial statements; our compliance with legal and regulatory requirements; the qualifications, independence and performance of the independent registered public accounting firm; the design and implementation of our financial risk assessment and risk management. Among other things, our audit committee is responsible for reviewing and discussing with our management the adequacy and effectiveness of our disclosure controls and procedures. Our audit committee also discusses with our management and independent registered public accounting firm the annual audit plan and scope of audit activities, scope and timing of the annual audit of our financial statements, and the results of the audit, quarterly reviews of our financial statements and, as appropriate, initiates inquiries into certain aspects of our financial affairs.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit committee is responsible for establishing and overseeing procedures for the receipt, retention and treatment of any complaints regarding accounting, internal accounting controls or auditing matters, as well as for the confidential and anonymous submissions by our employees of concerns regarding questionable accounting or auditing matters. In addition, our audit committee has direct responsibility for the appointment, compensation, retention and oversight of the work of our independent registered public accounting firm. Our audit committee has sole authority to approve the hiring and discharging of our independent registered public accounting firm, all audit engagement terms and fees and all permissible non-audit engagements with the independent auditor. Our audit committee reviews and oversees all related person transactions in accordance with our policies and procedures.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each member of our audit committee is independent under the rules and regulations of the SEC and the listing standards of The Nasdaq Capital Market applicable to audit committee members. Our board of directors has determined that Marella Thorell qualifies as an audit committee financial expert within the meaning of SEC regulations and meets the financial sophistication requirements of The Nasdaq Capital Market listing standards. In making this determination, our board has considered Ms. Thorell&#8217;s prior experience, business acumen and independence. Both our independent registered public accounting firm and management periodically meets privately with our audit committee.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the composition and functioning of our audit committee complies with all applicable requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, and all applicable SEC and The Nasdaq Capital Market rules and regulations. We intend to comply with future requirements to the extent they become applicable to us.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Committee</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The members of our compensation committee are Marella Thorell and Joseph Payne, who is the chair of the compensation committee.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each member of our compensation committee is independent under the rules and regulations of the SEC and the listing standards of The Nasdaq Capital Market applicable to compensation committee members. Our compensation committee assists our board of directors with its oversight of the forms and amount of compensation for our executive officers (including officers reporting under Section&#160;16 of the Exchange Act), the administration of our equity and non-equity incentive plans for employees and other service providers and certain other matters related to our compensation programs. Our compensation committee, among other responsibilities, evaluates the performance of our chief executive officer and, in consultation with him, evaluates the performance of our other executive officers (including officers reporting under Section&#160;16 of the Exchange Act).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nominating and Corporate Governance Committee</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The members of our nominating and corporate governance committee are Joseph Payne and Ofir&#160;Levi, who is the chair of the nominating and corporate governance committee.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each member of our nominating and governance committee is independent under the rules and regulations of the SEC and the listing standards of The Nasdaq Capital Market, applicable to nominating and governance committee members. Our nominating and corporate governance committee assists our board of directors with its oversight of and identification of individuals qualified to become members of our board of directors, consistent with criteria approved by our board of directors, and selects, or recommends that our board of directors selects, director nominees; develops and recommends to our board of directors a set of corporate governance guidelines and oversees the evaluation of our board of directors.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Communicating with Our Board of Directors</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You may communicate with our board of directors as a group, or to specific directors, by writing to the Chairman of our board of directors at our offices located at 100 N. 18th Street, Suite 300, Philadelphia, PA 19103, or board@vallon-pharma.com, who will then forward all such correspondence to the Chairman. The Chairman will review all such correspondence and regularly forward to our full board of directors such correspondence and copies of all correspondence that, in the opinion of the Chairman, deals with the functions of our board of directors or committees thereof or that he otherwise determines requires their attention. Directors may at any time review a log of all correspondence we receive that is addressed to members of our board of directors and request copies of any such correspondence. Concerns relating to accounting, internal controls, or auditing matters may be communicated in this manner. These concerns will be immediately brought to the attention of our board of directors and handled in accordance with procedures established by our board of directors. Notwithstanding the foregoing, the non-management directors have requested that the Chairman not forward to them advertisements, solicitations for periodicals or other subscriptions, and other similar communications.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Committee Interlocks and Insider Participation</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our current or former executive officers serve as a member of the compensation committee. None of our officers serve, or have served during the last completed fiscal year, on the board of directors or compensation committee, or other committee serving an equivalent function, of any other entity that has one or more of its executive officers serving as a member of our board of directors or our compensation committee. For a description of transactions between us and members of our compensation committee and affiliates of such members, see the section entitled &#8220;Certain Relationships and Related Party Transactions.&#8221;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Business Conduct and Ethics</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted a Code of Business Conduct and Ethics that applies to all directors, officers and employees. Our Code of Business Conduct and Ethics is available on our website at&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">https://www.vallon-pharma.com/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A copy of our code of ethics will also be provided to any person without charge, upon written request sent to us at our offices located at 100 N. 18th Street, Suite 300, Philadelphia, PA 19103.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="i8c772b1568214a7294558171471dfda5_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;11.&#160;&#160;&#160;EXECUTIVE COMPENSATION&#160;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Compensation Table</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an emerging growth company, we are required to disclose the compensation earned by or paid to our named executive officers for the last two completed fiscal years.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.509%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name and Principal Position</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Salary ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Option</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Awards ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-Equity Incentive Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">All Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Compensation</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David Baker</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">391,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">259,136&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">812,689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">President and Chief Executive Officer </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">330,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">206,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">669,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leanne M. Kelly</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">177,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">259,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">498,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chief Financial Officer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Penny S. Toren</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">256,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">359,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Vice President, Regulatory Affairs &amp; Program Management</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">235,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">358,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the aggregate grant date fair value of stock options granted during the fiscal year calculated in accordance with FASB ASC Topic 718. These amounts do not necessarily correspond to the actual value that may be realized by the executive in connection with the option awards.The assumptions made in valuing the option awards reported in this column are described in our audited financial statements (Note B. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies - [3] Stock-based compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note F, Equity incentive plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The amounts in this column represent performance bonuses earned by the named executive officers in the year shown based upon the achievement of pre-established performance objectives. See "&#8212; Non-Equity Incentive Plan Compensation" below.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The amounts reflect matching contributions to the named executive officers&#8217; accounts under our SIMPLE IRA plan. </span></div><div style="margin-bottom:9pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Elements of Compensation</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Base Salaries</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of April 1, 2021, Mr. Baker&#8217;s annual salary was increased to $400,000. Effective as of March 1, 2021, Ms. Toren&#8217;s annual salary was increased to $251,450. Ms. Kelly&#8217;s base salary, which was negotiated in connection with her appointment as Chief Financial Officer on May 10, 2021, was set at $275,000.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Equity Incentive Plan Compensation</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our named executive officers is eligible to receive an annual performance bonus based on the achievement of corporate and personal objectives as determined by our board of directors or compensation committee. Each executive officer is assigned a target bonus expressed as a percentage of base salary. For 2021, the target bonus opportunities for Mr. Baker, Ms. Kelly (prorated to her May 10, 2021 start date) and Ms. Toren, expressed as a percentage of base salary, were 50%, 35% and 20%, respectively. Actual performance bonus payments depend on the extent to which we achieve pre-established corporate objectives for the year, along with an overall assessment of each officer&#8217;s personal performance, as determined by our board of directors or compensation committee. For 2021, the corporate objectives, consisted primarily of: (i) IPO completion; (ii) execution of the SEAL study; (iii) determination of ADMIR ; (iv) execution of key non-clinical studies; and (v) manufacture of ADAIR. In the first quarter of 2022, our compensation committee assessed our level of achievement of these objectives. Based on this assessment, our compensation committee determined that our performance relative to the corporate objectives warranted a payout of 75% of the target bonus opportunity, subject to adjustments for personal performance. Actual bonus amounts paid with respect to 2021 are reflected in the "Non-Equity Incentive Plan Compensation" column of the Summary Compensation Table above.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, pursuant to her employment agreement, Ms. Toren is entitled to receive a one-time performance bonus of $130,000 related to the development and commercialization of ADAIR, which will vest in installments on the following dates: (i)&#160;$25,000 on the date the FDA completes its 30-day review period of our IND application for ADAIR , which occurred in July&#160;2018 (ii)&#160;$25,000 on the date that we successfully complete the human abuse liability study for ADAIR , (iii)&#160;$30,000 on the date that we submit an NDA filing for ADAIR , and (iv)&#160;$50,000 on the later of the date when the FDA approves the NDA and the date we engage in exclusive collaboration for commercialization of the product.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Option Awards Granted During 2021</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 14, 2021, each of Mr. Baker and Ms. Toren was granted a non-qualified stock option to purchase 100,000 and 25,000 shares of our common stock, respectively, with an exercise price of $3.66 per share, which was equal to the closing price of our common stock on the date of grant. Subject to the executive's continued employment on each applicable vesting date, 25% of the shares underlying these options vest on May 14, 2022, with the remainder vesting in equal quarterly installments thereafter through May 14, 2025. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on May 14, 2021, in conjunction with the commencement of her employment with the Company, Ms. Kelly was granted non-qualified options to purchase 100,000 shares of our common stock, with an exercise price of $3.66 per share, which was equal to the closing price of our common stock on the date of grant. Subject to Ms. Kelly's continued employment on each applicable vesting date, 70,000 shares underlying these options will vest as follows: (i) 17,500 shares on May 14, 2022, and (ii) the remainder vesting in equal quarterly installments thereafter through May 14, 2025. An additional 30,000 shares underlying these options will vest, if at all, following the achievement of certain performance conditions related to regulatory submissions to the FDA for ADAIR, subject to Ms. Kelly&#8217;s continued employment.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qualified Retirement Plan</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer our employees, including our named executive officers, retirement and certain other benefits, including participation in the tax-qualified SIMPLE IRA retirement plan sponsored by the Company in the same manner as all of our other employees. Pursuant to the SIMPLE IRA program, employees are eligible to contribute to an individual SIMPLE IRA account on a tax-deferred basis. If an employee participates in the SIMPLE IRA plan, we make a matching contribution to the employee&#8217;s SIMPLE IRA account in an amount up to 3% of the employee&#8217;s base salary (subject to applicable IRS compensation limits). In 2021, Mr.&#160;Baker, Ms. Kelly and Ms.&#160;Toren contributed to the SIMPLE IRA and received a related matching contribution. Participants are fully vested in both their own contribution and the matching contributions at all times.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not maintain any deferred compensation, pension, or profit-sharing plans.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into an employment agreement with each of our named executive officers. The employment agreements provide that the executive will receive a base salary and be eligible to receive an annual cash bonus contingent upon the attainment of certain company milestones and/or individual objectives. Pursuant to the employment agreements, each executive's base salary and target bonus will be reviewed periodically by our compensation committee or board of directors. The employment agreements also provide for certain termination benefits, which are described below in the section entitled "Potential Payments Upon a Termination or Change in Control</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our named executive officers are also entitled to participate in all of our retirement and group welfare plans available to our senior level executives as a group or our employees generally, subject to the terms and conditions applicable to such plans. Further, each such executive's employment agreement contains restrictive covenants relating to non-disclosure of confidential information, mutual non-disparagement, assignment of inventions, non-competition and non-solicitation provisions.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Potential Payments Upon a Termination or Change in Control</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">David Baker</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to his employment agreement with us, if Mr. Baker&#8217;s employment were terminated by us without cause or terminated by Mr. Baker for good reason, in either case not in connection with a change in control, then Mr. Baker is entitled to the following severance benefits:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> continued base salary for a period of 12 months, plus a pro-rated bonus for the year of termination, based on actual performance results for the entire year, and provided he was employed for at least six months during that year; and </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subsidized premiums for COBRA continuation coverage for a period of 12 months (or such earlier date that he obtains alternative coverage).</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to his employment agreement with us, if Mr. Baker&#8217;s employment were terminated by us without cause or terminated by Mr. Baker for good reason,in either case withing the one-year period following a change in control, then Mr. Baker would be entitled to the following severance benefits:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued base salary for a period of 18 months, plus a lump sum payment equal to 150% of his target bonus, without proration, for the fiscal year of termination; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subsidized premiums for COBRA continuation coverage for a period of 18 months (or such earlier date that he obtains alternative coverage); and </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">accelerated vesting of all outstanding stock-based awards held by the executive as of the date of termination, with any performance awards deemed satisfied at the &#8220;target&#8221; performance level, and any stock options remaining outstanding for their full term.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leanne M. Kelly</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to her employment agreement with us, if Ms. Kelly&#8217;s employment were terminated by us without cause or terminated by Ms. Kelly for good reason, in either case not in connection with a change in control, then Ms. Kelly would be entitled to the following severance benefits:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued base salary for a period of nine months, plus a pro-rated bonus for the year of termination, based on actual performance results for the entire year, and provided she was employed for at least six months during that year; and </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subsidized premiums for COBRA continuation coverage for a period of nine months (or such earlier date that she obtains alternative coverage). </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to her employment agreement with us, if Ms.Kelly&#8217;s employment were terminated by us without cause or terminated by Ms. Kelly for good reason, in ether case within the one-year period following a change in control transaction, then Ms. Kelly would be entitled to the following severance benefits:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued base salary for a period of 12 months, plus a lump sum payment equal to 100% of her target bonus, without proration, for the fiscal year of termination; </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subsidized premiums for COBRA continuation coverage for a period of 12 months (or such earlier date that she obtains alternative coverage); and </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">accelerated vesting of all outstanding stock-based awards held by the executive as of the date of termination, with any performance awards deemed satisfied at the &#8220;target&#8221; performance level, and any stock options remaining outstanding for their full term.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Penny S. Toren</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to her employment agreement with us, if Ms. Toren&#8217;s employment were terminated by us without cause or terminated by Ms. Toren for good reason, then Ms. Toren would be entitled to the following severance benefits:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued base salary for a period equal to two&#160;months, plus an additional one month for every whole year of service performance by Ms.&#160;Toren for the Company and its affiliates, up to a maximum of six&#160;months. </span></div><div style="margin-bottom:9pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding Equity Awards at Fiscal Year-End</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Awards</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding stock option awards as of December 31, 2021 held by our named executive officers, on an award-by-award basis, setting forth the total number of shares underlying each stock option award that are (i) </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exercisable, but not yet exercised, (ii) unexercisable and not yet exercised, and (iii) total aggregate amount underlying each award.</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of securities underlying unexercised, but vested stock options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of securities underlying unexercised, but unvested stock options (time based) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of securities underlying unexercised, but unvested stock options (performance based) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total securities underlying the stock options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Option exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Option expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David Baker</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,875&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,875&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10/1/2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chief Executive Officer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2/5/2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/22/2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/14/2031</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leanne Kelly</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/14/2031</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chief Financial Officer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Penny Toren</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10/1/2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SVP, Regulatory Affairs and Project Management</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10/11/2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/22/2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/14/2031</span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">All stock option awards were granted under our 2018 Equity Incentive Plan.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The stock option award will vest upon satisfaction of certain performance milestones.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The stock option award is fully vested.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The stock options award will vest 25% on the first anniversary of the vesting start date (May 14, 2021) and 6.25% (1/16th of such shares) for each subsequent full quarter that the executive remains employed with us.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">70% of the stock option award will vest 25% on the first anniversary of the vesting start date (May 14, 2021) and 6.25% (1/16th of such shares) for each subsequent full quarter that the executive remains employed with us. The remaining 30% of the stock option award will vest upon the satisfaction of certain performance milestones.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The stock option award vests as to one-sixth of the underlying shares of common stock upon the date of grant, then upon satisfaction of certain performance milestones.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The stock option award vests as to one-third of the underlying shares of common stock on each of October 11, 2020, October 11, 2021 and October 11, 2022.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Awards</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not granted any stock awards to any of our named executive officers.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Compensation and Compensation Table</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our director compensation program is designed to enhance our ability to attract and retain highly qualified directors and to align their interests with the long-term interests of our shareholders. The program generally includes a cash component, which is designed to compensate non-employee directors for their service on our board of directors and an equity component, which is designed to align the interests of non-employee directors and shareholders. Directors who are employees of the Company receive no additional compensation for their service on our board of directors.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation committee annually reviews compensation paid to our non-employee directors and makes recommendations for adjustments, as appropriate, to the full board of directors. As part of this annual review, the committee considers the significant time commitment and skill level required by each non-employee director in serving on our board of directors and its various committees. The compensation committee seeks to maintain a market competitive director compensation program and benchmarks our director compensation program against those maintained by our peer group.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2021, each of our non-employee directors was eligible to receive an annual retainer of $25,000, and the chair of the audit committee was eligible to receive an additional retainer of $10,000. The annual retainer was payable in cash, or at the election of a director, in the form of an equivalent amount of stock options. In addition, each non-employee director serving in 2021 received an initial stock option grant to purchase 15,000 shares, which generally vests in quarterly or monthly installments over two years.  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the board of directors, upon recommendation of the compensation committee, increased the annual retainer for each non-employee director to $30,000, increased the annual retainer for the chair of the audit committee to $15,000, and provided an annual retainer for the chair of the compensation committee of $10,000 and for the chair of the nominating and governance committee of $5,000. Going forward, non-employee directors who are first appointed or elected to the board will receive an initial stock option grant to purchase 15,000 shares, which generally will vest in quarterly installments over two years.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information on compensation paid to our non-employee directors in 2021:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fees Earned<br/>or Paid in<br/>Cash (US$)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Option Awards ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)(7)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Richard Ammer</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(3)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ofir Levi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Joseph Payne</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(5)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marella Thorell</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the aggregate grant date fair value of stock options granted during the fiscal year calculated in accordance with FASB ASC Topic 718. These amounts do not necessarily correspond to the actual value that may be realized by the executive in connection with the option awards.The assumptions made in valuing the option awards reported in this column are described in our audited financial statements (Note B. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies - [3] Stock-based compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note F, Equity incentive plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Options to purchase 15,000 shares of common stock were granted on May 14, 2021 and vest monthly over a 24-month period.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Options to purchase 10,204 shares of common stock were granted on May 14, 2021 of which 25% vested immediately and an additional 25% vested on each of June 30, 2021, September 30, 2021 and December 31, 2021.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Options to purchase 30,000 shares of common stock were granted on May 14, 2021 which vest monthly over a 24-month period. An additional 15,000 options to purchase common stock were grantedon May 14, 2021 of which 25% vested immediately and an additional 25% vested on each of June 30, 2021, September 30, 2021 and December 31, 2021.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Options to purchase 14,286 were granted on May 14, 2021 of which 25% vested immediately and an additional 25% vested on each of June 30, 2021, September 30, 2021 and December 31, 2021.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Ms. Thorell joined our board of directors effective February 12, 2021 and was granted 15,000 options which vest monthly over a period of 24 months.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The following table shows the aggregate number of outstanding shares of common stock underlying outstanding options held by our non-employee directors as of December 31, 2021:</span></div><div style="text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding Option Awards</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Richard Ammer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">45,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Ofir Levi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25,204</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Joseph Payne</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">29,286</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Marella Thorell</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">15,000</span></td></tr></table></div><div id="i8c772b1568214a7294558171471dfda5_112"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information known to us regarding beneficial ownership of our capital stock as of December 31, 2021, as adjusted to reflect the sale of common stock offered by us in this offering, for:</span></div><div style="margin-top:8pt;padding-left:37.4pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">each person or group of affiliated persons known by us to be the beneficial owner of more than five percent of our capital stock;</span></div><div style="margin-top:8pt;padding-left:37.4pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">each of our named executive officers;</span></div><div style="margin-top:8pt;padding-left:37.4pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">each of our directors and our director nominees; and</span></div><div style="margin-top:8pt;padding-left:37.4pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">all of our executive officers, and directors and director nominees as a group.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined beneficial ownership in accordance with the rules and regulations of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under those rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power, and includes securities that the individual or entity has the right to acquire, such as through the exercise of stock options, within 60&#160;days of December 31, 2021. Except as noted by footnote, and subject to community property laws where applicable, we believe, based on the information provided to us, that the persons and entities named in the table below have sole voting and investment power with respect to all common stock shown as beneficially owned by them.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The&#160;percentage of beneficial ownership in the table below is based on 6,812,836 shares of common stock deemed to be outstanding as of December 31, 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, the address for each beneficial owner is c/o&#160;Vallon Pharmaceuticals, Inc., 100 N. 18th Street, Suite 300, Philadelphia, PA 19103.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common Stock Beneficially Owned</span></td></tr><tr style="height:38pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Shares and Nature of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beneficial Ownership</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percentage of Total Common Stock</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name and Address of Beneficial Owner</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Greater than 5% Stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SALMON Pharma GmbH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,523,797</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arcturus Therapeutics, Inc. (fka successor to Arcturus Therapeutics Ltd.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">843,750</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tomer Feingold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)(11)(12)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">509,781</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dov Malnik</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)(4)(11)(12)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">509,781</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Directors, Director Nominees and Named Executive Officers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">David Baker</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">128,468</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Leanne Kelly</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,250</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Ofir Levi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(8) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">223,125</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Richard Ammer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,539,626</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Joseph Payne</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(10) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">881,161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Marella Thorell</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(11)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">All directors, director nominees, and executive officers as a group (6 persons)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,786,130</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:14pt">Represents beneficial ownership of less than one percent of our outstanding common stock.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">SALMON Pharma GmbH&#8217;s address is Sankt-Jakobs-Strasse 90, CH-9002 Basel, Switzerland. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Arcturus Therapeutics Ltd.&#8217;s address is 10628 Science Center Drive, Suite 250, San Diego, California 92121.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Mr. Malnik has granted Ariel Malnik a power of attorney to vote and dispose of the shares held individually by Mr. Malnik.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">On March 3, 2020, the Securities and Exchange Commission filed an action against Tomer Feingold and Dov Malnik in the U.S. District Court for the Southern District of New York (SEC v. Feingold, et al., Civ. Action No. 20-cv-01881) alleging violations of Section 10(b) of the Exchange Act and Rule 10b-5 thereunder, Section 14(e) of the Exchange Act and Rule 14e-3 thereunder and requesting other equitable relief. Adamas is named as a relief defendant in the action. As of November 23, 2021, the action has been settled with regard to Mr. Malnik. Vallon Pharmaceuticals, Inc. is not a named party or identified in this action.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The address for each of our executive officers, directors and director nominees is c/o Vallon Pharmaceuticals, 100 N. 18th Street, Suite 300, Philadelphia, PA 19103.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of (i)7,843 shares of common stock and (ii) 120,625 shares of common stock issuable pursuant to stock options exercisable within 60 days of December&#160;31, 2021. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of 6,250 shares of common stock.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of (i) 196,875 shares of common stock and (ii) 26,250 shares of common stock issuable pursuant to stock options exercisable within 60 days of December&#160;31, 2021.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of (i) 1,523,797 shares of common stock held by SALMON Pharma GmbH (&#8220;Salmon Pharma&#8221;), of which Dr. Ammer is an affiliate and may be deemed to have shared voting and dispositive power over the shares beneficially owned by Salmon Pharma but disclaims such beneficial ownership except to the extent of his pecuniary interest therein, if any, and (ii) 15,829 shares of common stock issuable pursuant to stock options exercisable within 60 days of December&#160;31, 2021.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt">Consists of 843,750 shares of common stock held by Arcturus, of which Mr. Payne is an affiliate and may be deemed to have shared voting and dispositive power over the shares beneficially owned by Arcturus but disclaims such beneficial ownership except to the extent of his pecuniary interest therein, if any, (ii) 17,500 shares of common stock and (iii) 19,911 shares of common stock issuable pursuant to stock options exercisable within 60 days of December&#160;31, 2021.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(11)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt">Includes 7,500 shares of common stock issuable pursuant to stock options exercisable within 60 days of December&#160;31, 2021.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(12)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.68pt">On December 30, 2020, we entered into the 2020 Voting Agreement with Dov Malnik and Tomer Feingold, pursuant to which, following the date of effectiveness of this registration statement, at every meeting of our stockholders, and at every adjournment or postponement thereof, Messrs. Malnik and Feingold (in their capacity as stockholders) shall have the right to vote all common stock held by them collectively constituting no more than 9.99% of the total number of shares of common stock issued and outstanding as of the record date for voting on the matters presented at such meeting or taking action by written consent. The common stock held or otherwise beneficially owned by Messrs. Malnik and Feingold in excess of the Share Voting Cap shall be voted at every meeting of the stockholders of the Company, and at every adjournment or postponement thereof, and on every action or approval by written consent of the stockholders, in a manner that is proportionate to the manner in which all other holders of the issued and outstanding shares of Common Stock vote in respect of each matter presented at any such meeting and in respect of each action taken by written consent. See the section entitled &#8220;Certain Relationships and Related Party Transactions&#8212;2020 Voting Agreement&#8221;.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Information</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2018 Equity Incentive Plan is our sole equity incentive plan approved and adopted by our stockholders, and provides for the issuance of shares of our common stock to our officers and other employees, directors and consultants.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information as of December 31, 2021 with respect to compensation plans or arrangements under which shares of our common stock may be issued.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.010%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.615%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.561%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.853%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Plan category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of securities<br/>to be issued upon<br/>exercise of<br/>outstanding options,<br/>warrants and rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>average exercise<br/>price of<br/>outstanding<br/>options, warrants<br/>and rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>securities<br/>remaining<br/>available for<br/>future issuance<br/>under equity<br/>compensation<br/>plans</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity compensation plans approved by security holders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">690,365&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity compensation plans not approved by security holders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">708,490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes shares of our common stock under our 2018 Equity Incentive Plan. For a description of this plan, refer to Note F to the financial statements included in this Annual Report on Form 10-K.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The 18,125 stock options referenced above were granted to an advisor in January 2020 and May 2020 outside of the 2018 Equity Incentive Plan, and are subject to separate stock option award agreements.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Excludes 70,000 shares of common stock issuable upon the exercise of options for which the Company can, at its discretion, issue cash in lieu of shares to the extent the authorized option pool is depleted when exercised.</span></div><div id="i8c772b1568214a7294558171471dfda5_115"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;13.&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of each transaction or series of similar transactions since January 1, 2019, to which we have been a party that:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The amount involved exceeded or exceeds $120,000 or is greater than 1% of our total assets as of December 31, 2020 and 2019; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of our directors or executive officers, any holder of 5% of our capital stock or any member of their immediate family had or will have a direct or indirect material interest.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ofir Levi</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in June 2020 and ending in October 2020, Dr. Levi, a member of our board of directors, received a consulting fee of $6,000 per month for his advisory services.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medice</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medice, through its affiliated entity, Salmon Pharma, owns approximately 22.4% of our issued and outstanding shares of common stock, and accordingly controls approximately 22.4% of our voting power. On January 6, 2020, we entered into a license agreement with Medice, which grants Medice an exclusive license, with the right to grant sublicenses, to develop, use, manufacture, market and sell ADAIR throughout Europe. Medice currently markets several ADHD products in Europe and is the ADHD market leader in Europe based on branded prescription market share. Medice is responsible for obtaining regulatory approval of ADAIR in the licensed territory. Under the license agreement, Medice paid Vallon a minimal upfront payment and will pay milestone payments of up to $6.3 million in the aggregate upon first obtaining regulatory approval to market and sell ADAIR in any country, territory or region in the licensed territory and upon achieving certain annual net sales thresholds.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Voting Agreement</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2020, we entered into the 2020 Voting Agreement with Dov Malnik and Tomer Feingold, pursuant to which at every meeting of our stockholders and at every adjournment or postponement thereof, Messrs. Malnik and Feingold (in their capacity as stockholders) shall have the right to vote all common stock held by them collectively constituting no more than 9.99% of the total number of shares of common stock issued and outstanding as of the record date for voting on the matters presented at such meeting or taking action by written consent (Share Voting Cap). The common stock held or otherwise beneficially owned by Messrs. Malnik and Feingold in excess of the Share Voting Cap (Excess Shares) shall be voted at every meeting of the stockholders of the Company, and at every adjournment or postponement thereof, and on every action or approval by written consent of the stockholders, in a manner that is proportionate to the manner in which all other holders of the issued and outstanding shares of common stock vote in respect of each matter presented at any such meeting and in respect of each action taken by written consent. Furthermore, each of Messrs. Malnik and Feingold executed an irrevocable proxy for the voting of the Excess Shares in accordance with the 2020 Voting Agreement. The 2020 Voting Agreement terminates on the earliest to occur of (i) the date following the effective date of the 2020 Voting Agreement on which Messrs. Malnik and Feingold collective beneficial ownership of our common stock falls below 9.99%, (ii)the third anniversary of the effectiveness </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our registration statement relating to the IPO, or (iii) with respect to either Messrs. Malnik or Feingold, the date on which any proceeding before or brought by the SEC against such stockholder has been terminated or otherwise concluded.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Financings</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Convertible Note Financing</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, we entered into a Convertible Promissory Note Purchase Agreement (the 2019 Contrvertible Notes) with certain existing stockholders and Salmon Pharma, an affiliate of Medice, pursuant to which we issued the 2019 Convertible Notes for cash proceeds of $1,150,000. The 2019 Convertible Notes bore an interest rate of 7.0% per annum, non-compounding, and had a maturity date of January 1, 2020. The terms of the 2019 Convertible Notes included a mandatory conversion upon a qualified financing, such as the July 2019 Financing discussed below, and were convertible into shares of our capital stock that are offered to investors in a subsequent equity financing at a discount to the price per share offered in such subsequent financing.</span></div><div style="margin-bottom:9pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, upon the closing of the July 2019 Financing, the 2019 Convertible Notes converted into an aggregate of 383,849 shares of our common stock at a conversion price of $3.04 per share.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Private Placement</span></div><div style="margin-bottom:9pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, we entered into a Stock Purchase Agreement with Salmon Pharma (the July 2019 Financing), pursuant to which we sold and issued 1,309,861 shares of our common stock for aggregate cash proceeds of $5.0 million.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Convertible Note Financing </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma and David Baker, our Chief Executive Officer, pursuant to which we issued convertible promissory notes for cash proceeds of $350,000. The 2021 Convertible Notes bear an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September 30, 2021. The 2021 Convertible Notes were convertible into shares of our capital stock offered to investors in any subsequent equity financing, or Qualified Financing, after the date of their issuance in which we issued any of our equity securities and were convertible at a 20.0% discount to the price per share offered in such Qualified Financing. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 12, 2021, we consummated the IPO of our common stock, which was considered a Qualified Financing. Accordingly, the 2021 Convertible Notes converted into an aggregate of 54,906 shares of our common stock immediately prior to the closing of the IPO at a conversion price of $6.40 per share.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the principal amounts under the 2019 Convertible Notes and 2021 Convertible Notes, or the Convertible Notes, acquired by 5% holders in the financing transaction described above, and the number of shares of common stock such Convertible Notes converted into in connection with the July 2019 Financing and IPO.</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Participants</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Principal Amount under the Convertible Notes</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares of Common Stock upon Conversion of Convertible Notes</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Greater than 5% Stockholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tomer Feingold</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">66,812</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dov Malnik</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">66,812</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SALMON Pharma GmbH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">800,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">213,936</span></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Additional details regarding these stockholders and their equity holdings are provided in this report under the caption &#8220;Principal Stockholders.&#8221;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Dr. Ammer is affiliated with Salmon Pharma.</span></div><div style="margin-top:10pt;padding-left:43.2pt;text-indent:-43.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Review, Approval or Ratification of Transactions with Related Parties</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our written related party transactions policy states that our employees, officers and directors, and any members of the immediate family of and any entity affiliated with any of the foregoing persons are not permitted to enter into a material related party transaction with us without the review and approval of our Audit Committee. The policy provides that the our general counsel, or, if we do not then have a general counsel, our principal executive, financial, or accounting officer (each a&#160;Designated Officer), must be notified of any request for us to enter into a transaction with such parties in which the amount involved exceeds $120,000 as well as of the facts and circumstances of the proposed transaction. Should an employee of the Company become aware of a related party transaction, regardless of whether such employee is a party to such transaction, such </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employee will report the Related Party Transaction to the Designated Officer. The Designated Officer shall report such Related Party Transaction to the Committee for review. In approving or rejecting any such proposal, our Audit Committee considers the relevant facts and circumstances available and deemed relevant to the committee, including, but not limited to, (i) whether the transaction was undertaken in the ordinary course of business; (ii) whether the related party transaction was initiated by us, a subsidiary, or the related party; (iii) whether the transaction with the related party is proposed to be, or was, entered into on terms no less favorable to the company than terms that could have been reached with an unrelated third party; (iv) the purpose of, and the potential benefits to us of, the Related Party Transaction; (v) the approximate dollar value of the amount involved in the related party transaction, particularly as it relates to the related party; (vi) the related party&#8217;s interest in the related party transaction; (vii) whether the related party transaction would impair the independence of an otherwise independent director; and (viii) any other information regarding the related party transaction or the related party that would be material to investors in light of the circumstances of the particular transaction.</span></div><div style="margin-top:10pt;padding-left:43.2pt;text-indent:-43.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into employment agreements with certain of our executive officers. See &#8220;Item 11-Executive Compensation.&#8221;</span></div><div style="margin-top:10pt;padding-left:43.2pt;text-indent:-43.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Grants</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted stock options to certain of our executive officers and members of our board of directors. See &#8220;Item 11-Executive Compensation.&#8221;</span></div><div style="margin-top:10pt;padding-left:43.2pt;text-indent:-43.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification and Limitation on Liability</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 145 of the Delaware General Corporation Law (DGCL) authorizes a corporation to indemnify its directors and officers against liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses (including attorneys&#8217; fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section 145 permits corporations to pay expenses (including attorneys&#8217; fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section 145 provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the power to indemnify the director or officer against such liability under Section 145.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted provisions in our amended and restated certificate of incorporation and our amended and restated bylaws that limit or eliminate the personal liability of our directors to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, a director will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director, except for liability for:</span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any breach of the director&#8217;s duty of loyalty to us or our stockholders;</span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or</span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any transaction from which the director derived an improper personal benefit.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our bylaws provide that:</span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we will indemnify our directors, officers and, in the discretion of our board of directors, certain employees to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and</span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we will advance reasonable expenses, including attorneys&#8217; fees, to our directors and, in the discretion of our board of directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into indemnification agreements with each of our directors, and intend to enter into such agreements with our executive officers. These agreements provide that we will indemnify each of our directors, our executive officers and, at times, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">their affiliates to the fullest extent permitted by Delaware law. We will advance expenses, including attorneys&#8217; fees (but excluding judgments, fines and settlement amounts), to each indemnified director, executive officer or affiliate in connection with any proceeding in which indemnification is available and we will indemnify our directors and officers for any action or proceeding arising out of that person&#8217;s services as a director or officer brought on behalf of us or in furtherance of our rights. Additionally, certain of our directors or officers may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director&#8217;s or officer&#8217;s services as a director referenced herein. Nonetheless, we have agreed in the indemnification agreements that our obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Insurance</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also maintain general liability insurance which covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act of 1933, as amended, or the Securities Act.</span></div><div style="margin-top:10pt;padding-left:43.2pt;text-indent:-43.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Independence</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Item 10. Directors, Executive Officers and Corporate Governance Management&#8212;Director Independence.&#8221;</span></div><div style="margin-top:10pt;padding-left:43.2pt;text-indent:-43.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Committees of our Board of Directors</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee, each of which operates pursuant to a written charter adopted by our board of directors. See &#8220;Item 10. Directors, Executive Officers and Corporate Governance Management&#8212;Board Committees.&#8221;</span></div><div id="i8c772b1568214a7294558171471dfda5_118"></div><div style="margin-top:10pt;padding-left:43.2pt;text-indent:-43.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent registered public accounting firm is <ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMTgvZnJhZzpkZDk2MTQ0Nzg0ODQ0OGM1OTZhNDBhYWNkNzRlMTM0ZS90ZXh0cmVnaW9uOmRkOTYxNDQ3ODQ4NDQ4YzU5NmE0MGFhY2Q3NGUxMzRlXzU0OTc1NTgxNDUzODQ_b4a9bfd0-b47b-4baa-b0b4-948186da0cce">EisnerAmper LLP</ix:nonNumeric>, <ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMTgvZnJhZzpkZDk2MTQ0Nzg0ODQ0OGM1OTZhNDBhYWNkNzRlMTM0ZS90ZXh0cmVnaW9uOmRkOTYxNDQ3ODQ4NDQ4YzU5NmE0MGFhY2Q3NGUxMzRlXzU0OTc1NTgxNDUzODk_900d7da9-79ae-4f8f-926c-05214cfe0be1">Iselin, New Jersey</ix:nonNumeric>, Auditor Firm ID: <ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMTgvZnJhZzpkZDk2MTQ0Nzg0ODQ0OGM1OTZhNDBhYWNkNzRlMTM0ZS90ZXh0cmVnaW9uOmRkOTYxNDQ3ODQ4NDQ4YzU5NmE0MGFhY2Q3NGUxMzRlXzU0OTc1NTgxNDUzOTE_17cecf40-a600-43a9-b174-d84ea3a35261">274</ix:nonNumeric>. </span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents aggregate fees incurred for EisnerAmper LLP services during the years ended December 31, 2021 and 2020 by us.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Audit Fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">180,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">171,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Audit Related Fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax Fees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All Other Fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">180,760&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">171,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.68pt">Audit Fees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">represent the aggregate fees billed for professional services rendered by our independent registered public accounting firm for the audit of our annual financial statements, review of financial statements included in our quarterly reports or services that are normally provided in connection with statutory and regulatory filings or engagements for those fiscal years as well as the issuance of consents in connection with registration statement filings with the SEC and comfort letters in connection with securities offerings.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.68pt">Audit Related Fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> represent the aggregate fees billed for assurance and related professional services rendered by our independent registered public accounting firm that are reasonably related to the performance of the audit or review of our financial statements and are not reported under "Audit Fees" .</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.68pt">Tax Fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> represent the aggregate fees billed for professional services rendered by our independent registered public accounting firm for tax compliance, tax advice and tax planning services.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.68pt">All Other Fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> represent the aggregate fees billed for all other products and services rendered by our independent registered public accounting firm other than the services reported in the other categories</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee will approve in advance the engagement and fees of the independent registered public accounting firm for all audit services and non-audit services, based upon independence, qualifications and, if applicable, performance. The Audit Committee may form and delegate to subcommittees of one or more members of the Audit Committee the authority to grant pre-approvals for audit and permitted non-audit services, up to specific amounts. All audit services provided by EisnerAmper LLP for the periods presented were ratified by our board of directors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pre-Approval of Audit and Non-Audit Services</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit committee has adopted policies and procedures relating to the approval of all audit and non-audit services that are to be performed by our registered public accounting firm. These policies and procedures generally provide that we will not engage our registered public accounting firm to render audit or non-audit services unless the service is specifically approved in advance by our audit committee or the engagement is entered into pursuant to one of the pre-approval procedures described below.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, our audit committee may pre-approve specified types of services that are expected to be provided to us by our registered public accounting firm during the next twelve months. Any such pre-approval is detailed as to the particular service or type of services to be provided and is also generally subject to a maximum dollar amount.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with requirements of the SEC and the Public Company Accounting Oversight Board regarding auditor independence, our Audit Committee is responsible for the appointment, compensation and oversight of the work of our independent registered public accounting firm. In recognition of this responsibility, our Audit Committee, or the chair if such approval is needed between meetings of the audit committee, pre-approves all audit and permissible non-audit services provided by the independent registered public accounting firm. These services may include audit services, audit-related services, tax services and other services.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="i8c772b1568214a7294558171471dfda5_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;IV</span></div><div id="i8c772b1568214a7294558171471dfda5_124"></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15.&#160;&#160;&#160;&#160;EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">The following documents are filed as part of this report:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.34pt">Financial&#160;Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The financial statements of the Company, together with the report thereon of EisnerAmper LLP, an independent registered public accounting firm, are included in this Annual Report beginning on page F-1.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.34pt">Financial Statement&#160;Schedules</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See (b) below.</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits listed in the Exhibit&#160;Index below are filed or incorporated by reference as part of this Annual Report.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</span></div></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921022369/tm2030737d19_ex1-1.htm">Underwriting Agreement</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2/16/21</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.1</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921022369/tm2030737d19_ex3-1.htm">Amended and Restated Certificate of Incorporation of Vallon Pharmaceuticals, Inc. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2/16/21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.2</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921022369/tm2030737d19_ex3-2.htm">Amended and Restated Bylaws of Vallon Pharmaceuticals, Inc. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2/16/21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.1</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921008880/tm2030737d10_ex4-1.htm">Specimen certificate evidencing shares of common stock </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10/23/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.2</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465920117717/tm2030737d4_ex4-2.htm">Convertible Promissory Note Purchase Agreement, dated as of April&#160;11, 2019</a></span><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10/23/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.3</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465920117717/tm2030737d4_ex4-3.htm">Form of Convertible Promissory Note </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10/23/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.4</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921022369/tm2030737d19_ex4-1.htm">Form of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921022369/tm2030737d19_ex4-1.htm">Representative</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921022369/tm2030737d19_ex4-1.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921022369/tm2030737d19_ex4-1.htm">s</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921022369/tm2030737d19_ex4-1.htm"> Warrant</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2/16/21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.5</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921042819/tm2110271d1_ex4-5.htm">Description of the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921042819/tm2110271d1_ex4-5.htm">S</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921042819/tm2110271d1_ex4-5.htm">ecurities of Vallon Pharmaceuticals, Inc. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3/29/21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9.1</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921003928/tm2030737d8_ex10-17.htm">Voting Agreement, dated as of December&#160;30, 2020, by and among Vallon Pharmaceuticals, Inc. and certain of its stockholders </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1/14/21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.17</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921003928/tm2030737d8_ex10-1.htm">Amended and Restated Asset Purchase Agreement, dated as of June&#160;22, 2017, by and among&#160;Arcturus Therapeutics, Ltd. (and its subsidiary, Arcturus Therapeutics, Inc.), Amiservice&#160;Development Ltd. and Vallon Pharmaceuticals, Inc. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1/14/21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.2#</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921003928/tm2030737d8_ex10-2.htm">Consulting Agreement with Whitaker Biopharmaceutical Consulting LLC, dated April&#160;2, 2018 </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1/14/21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.3#</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921003928/tm2030737d8_ex10-3.htm">Employment Agreement between Vallon Pharmaceuticals, Inc. and Penny S. Toren, dated&#160;April&#160;2, 2018 </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1/14/21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.4#</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921003928/tm2030737d8_ex10-4.htm">Employment Agreement between Vallon Pharmaceuticals, Inc. and David Baker, dated&#160;January&#160;15, 2019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1/14/21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.5#</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465920117717/tm2030737d4_ex10-5.htm">Vallon Pharmaceuticals, Inc. 2018 Equity Incentive Plan </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10/23/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.6#</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465920117717/tm2030737d4_ex10-6.htm">Form of Stock Option Agreement under Vallon Pharmaceuticals, Inc. 2018 Equity Incentive&#160;Plan </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10/23/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.7#</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465920117717/tm2030737d4_ex10-7.htm">Form of Incentive Stock Option Agreement under Vallon Pharmaceuticals, Inc. 2018 Equity&#160;Incentive Plan </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10/23/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.8#</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921003928/tm2030737d8_ex10-8.htm">Form of Nonqualified Stock Option Agreement under Vallon Pharmaceuticals, Inc. 2018&#160;Equity Incentive Plan </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1/14/21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.9#</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921003928/tm2030737d8_ex10-9.htm">Form of Directors&#8217; and Officers&#8217; Indemnity Agreement </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1/14/21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.10</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921003928/tm2030737d8_ex10-10.htm">Patent and Patent Application Assignment Agreement between Arcturus Therapeutics, Ltd.&#160;and Vallon Pharmaceuticals, Inc., dated June&#160;22, 2018</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1/14/21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.10</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.11</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921003928/tm2030737d8_ex10-11.htm">Form of Subscription Agreement</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1/14/21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.11</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.12</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921003928/tm2030737d8_ex10-12.htm">Form of Stock Purchase Agreement, dated June&#160;7, 2018, among Vallon Pharmaceuticals, Inc.&#160;and the investors listed therein </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1/14/21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.12</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.13</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921003928/tm2030737d8_ex10-13.htm">Form of Stock Purchase Agreement, dated July&#160;25, 2019, between Vallon Pharmaceuticals, Inc. and SALMON Pharma GmbH </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1/14/21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.13</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.14</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921003928/tm2030737d8_ex10-14.htm">Investor&#8217;s Rights Agreement, dated as of July&#160;25, 2019, by and between Vallon Pharmaceuticals, Inc. and SALMON Pharma GmbH </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1/14/21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.14</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:none" href="https://www.sec.gov/Archives/edgar/data/1824293/000110465920125904/tm2030737d6_ex10-15.htm">10.15&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465920125904/tm2030737d6_ex10-15.htm">License Agreement, effective as of January&#160;6, 2020, by and between Vallon Pharmaceuticals, Inc. and MEDICE Arzneimittel Putter GmbH &amp; Co. KG</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11/16/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.15</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.16</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921003928/tm2030737d8_ex10-16.htm">Form of Lock Up Agreement </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1/14/21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.16</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.17</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921003928/tm2030737d8_ex10-18.htm">Form of Convertible Promissory Note Purchase Agreement, dated as of January&#160;11, 2021, by&#160;and among Vallon Pharmaceuticals and the investors named therein </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1/14/21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.18</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.18</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921003928/tm2030737d8_ex10-19.htm">Form of Convertible Promissory Note </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1/14/21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.19</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921065584/vlon-20210331xex10d1.htm">Employment Agreement between Vallon Pharmaceuticals, Inc. and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921065584/vlon-20210331xex10d1.htm">David Baker</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921065584/vlon-20210331xex10d1.htm">, dated&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921065584/vlon-20210331xex10d1.htm">April 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921065584/vlon-20210331xex10d1.htm">0, 2021 </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5/13/21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921065584/vlon-20210331xex10d2.htm">Employment Agreement between Vallon Pharmaceuticals, Inc. and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921065584/vlon-20210331xex10d2.htm">Leanne M. Kelly</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921065584/vlon-20210331xex10d2.htm">, dated&#160;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921065584/vlon-20210331xex10d2.htm">May 10</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921065584/vlon-20210331xex10d2.htm">, 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921065584/vlon-20210331xex10d2.htm">21</a></span><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5/13/21</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21.1</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465920117717/tm2030737d4_ex21-1.htm">List of subsidiaries</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10/23/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21.1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="vlon-202110k_ex231.htm">Consent of  Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24.1</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Powers of Attorney for directors and certain executive officers (contained on the signature page)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">31.1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="vlon-202110k_ex311.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15a-14(a) under the Exchange Act.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">31.2</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;margin-top:8pt"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="vlon-202110k_ex312.htm">Certification of Chief </a><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="vlon-202110k_ex312.htm">Financial </a><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="vlon-202110k_ex312.htm">Officer pursuant to Rule 13a-14(a) or 15a-14(a) under the Exchange Act.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">32.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="vlon-202110k_ex321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">32.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="vlon-202110k_ex322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">101 INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">XBRL Instance Document </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">101 SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Schema Linkbase Document </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">101 CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Calculation Linkbase Document </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">101 DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Definition Linkbase Document </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">101 LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Label Linkbase Document </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">101 PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Presentation Linkbase Document </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, exhibits are filed herewith.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;Indicates a management contract or any compensatory plan, contract or arrangement.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Indicates that portions of this exhibit (indicated by bracketed asterisks) are omitted in accordance with the rules of the Securities and Exchange Commission because they are both (i)&#160;not material and (ii)&#160;would be competitively harmful if publicly disclosed.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;The certification attached as Exhibit 32.1 that accompany this Annual Report on Form 10-K is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.</span></div><div id="i8c772b1568214a7294558171471dfda5_1208"></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i8c772b1568214a7294558171471dfda5_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VALLON PHARMACEUTICALS, INC.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: February 14, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ David Baker</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name: David Baker</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title: President and Chief Executive Officer</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES AND POWER OF ATTORNEY</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David Baker as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto and all documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that such attorneys-in-fact and agents or any of them, or his or her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</span></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ David Baker</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President, Chief Executive Officer and Director</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 14, 2022</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David Baker</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Leanne Kelly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Financial and Accounting Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 14, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leanne Kelly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ofir Levi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director, Chairman of the Board</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 14, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ofir Levi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Joseph Payne</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 14, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Joseph Payne</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Richard Ammer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 14, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Richard Ammer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Marella Thorell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 14, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marella Thorell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i8c772b1568214a7294558171471dfda5_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FINANCIAL STATEMENTS</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_136">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_136">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_139">Balance Sheets a</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_139">s of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_139"> December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_139">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_139"> and December 31, 20</a>20</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_139">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_142">Statements of Operations </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_142">and Comprehensive Loss </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_142">for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_142">y</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_142">ears </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_142">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_142">nded December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_142">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_142"> and 20</a>20</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_142">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_145">Statements of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_145">Changes in </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_145">Stockholders&#8217; Equity (Deficit) for the years ended December 31, 2021 and 20</a>20</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_145">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_148">Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_148">y</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_148">ears </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_148">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_148">nded December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_148">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_148"> and 20</a>20</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_148">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_151">Notes to Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_151">7</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i8c772b1568214a7294558171471dfda5_136"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Stockholders of</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying balance sheets of Vallon Pharmaceuticals, Inc. (the &#8220;Company&#8221;) as of December 31, 2021 and 2020, and the related statements of operations and comprehensive loss, changes in stockholders&#8217; equity (deficit), and cash flows for each of the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has sustained a net loss and has experienced cash outflows from operations since inception that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ EisnerAmper LLP</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditors since 2018.</span></div><div style="margin-top:20pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EISNERAMPER LLP</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Iselin, New Jersey</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;14, 2022</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="i8c772b1568214a7294558171471dfda5_139"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzQtMS0xLTEtMjM4NjY_ad99d1fd-06e1-4785-865d-15543323af86">3,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzQtMy0xLTEtMjM3OTE_0ff625d1-bb26-4438-a2c2-852a5e65ab9d">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities, available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzUtMS0xLTEtMjM4NjY_83aa36c0-ff5d-48b8-b6d0-c3564134da34">3,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzUtMy0xLTEtMjM4MDU_155fe17c-6e86-4e7e-ad63-53f3e4ff6d6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzYtMS0xLTEtMjM4NjY_583de96d-42b3-4839-acb7-aadb3a4ae7c7">619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzYtMy0xLTEtMjM3OTM_03343b6d-f5cb-42ee-a5be-24075b416e4c">565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzctMS0xLTEtMjM4OTU_01b30e1b-a8ad-4706-ad41-4e03fbbc54c5">8,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzctMy0xLTEtMjM3OTM_3cf5f273-0ab6-48c3-84f9-76a81b286282">674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzgtMS0xLTEtMjM4NzI_fb502b1f-10e7-4d49-9bde-4572e8427380">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzgtMy0xLTEtMjM3OTM_69b69299-9297-40fc-bbf6-92587b928c9f">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzktMS0xLTEtMjM4NzI_6bbcbc72-0bfb-4dcf-b602-2f2906724afa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzktMy0xLTEtMjM3OTM_d2f425e4-fde3-4a81-9183-ec90e1d40bca">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzEwLTEtMS0xLTIzODk1_5a508e07-69a1-400d-921f-7c8bf3945850">8,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzEwLTMtMS0xLTIzNzkz_567102ec-ae46-486c-8aeb-aaf2214c0763">955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities and stockholders' equity (deficit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzE0LTEtMS0xLTIzODc4_a74a0485-9063-4d61-9483-9b1df93f6ab4">918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzE0LTMtMS0xLTIzNzk1_da515ba5-0b8c-40ee-80c6-cea2fb7e3206">1,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzE1LTEtMS0xLTIzODc4_17ab9da8-b1d6-4e12-8fe6-c4d1fed99288">1,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzE1LTMtMS0xLTIzNzk1_27a04f85-1851-417e-a950-7bc404fa5f34">847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note payable, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:NotesPayableCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzE2LTEtMS0xLTIzODc4_09ff8f85-7e7c-4840-b3b4-90df6672348b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:NotesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzE2LTMtMS0xLTIzNzk1_b67a11f4-6c85-43bf-989e-2a42917fca30">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzE3LTEtMS0xLTIzODc4_47823c24-7bfe-4041-a6fc-7a89b2bb8762">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzE3LTMtMS0xLTIzNzk1_24d30ae7-0e17-4082-b69d-c1cc13eeb2db">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzE4LTEtMS0xLTIzODk1_5827b67d-0a50-489b-9d76-042cb2ab9aec">2,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzE4LTMtMS0xLTIzNzk1_0b055212-9e2e-4ffe-9b92-2ab41b641e7d">2,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note payable, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:LongTermNotesPayable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzE5LTEtMS0xLTIzODg1_28d15194-4ecf-4716-a51e-62dd96b07f02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:LongTermNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzE5LTMtMS0xLTIzNzk1_5f7bed86-e47b-4667-b39b-c5be8bb02b4d">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzIwLTEtMS0xLTIzODg1_b582d57a-0c17-4e9b-9e00-be421ab393f3">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzIwLTMtMS0xLTIzNzk1_e3fdfc2a-b334-4546-a265-32d99e914995">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzIxLTEtMS0xLTIzODk1_bdfcd1cb-bf2f-468a-bcbe-c13815382ed6">2,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzIxLTMtMS0xLTIzNzk1_708fa628-19df-4150-818e-ffaf03e0e469">2,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commitments and contingencies (Note 9)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzIzLTEtMS0xLTIzODk1_7c321d1e-309d-40af-aa78-451c0689179a"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzIzLTMtMS0xLTIzNzk3_de994bcc-5106-4d66-a0b1-e6e63e589716"></ix:nonFraction></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders' equity (deficit):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI1LTAtMS0xLTIzNzQ5L3RleHRyZWdpb246Zjg1NjQ0Yjg5MmIwNGQ2Y2IzZGZmMjM5ZTg0MjM0NjFfMTg_09606099-9061-41fe-b0d4-b121f1c937a4"><ix:nonFraction unitRef="usdPerShare" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI1LTAtMS0xLTIzNzQ5L3RleHRyZWdpb246Zjg1NjQ0Yjg5MmIwNGQ2Y2IzZGZmMjM5ZTg0MjM0NjFfMTg_187b337c-04d3-4664-8b06-e3c3e511cc2d">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI1LTAtMS0xLTIzNzQ5L3RleHRyZWdpb246Zjg1NjQ0Yjg5MmIwNGQ2Y2IzZGZmMjM5ZTg0MjM0NjFfMzI_1f742f1f-2866-47b7-aba8-5bee4f286669"><ix:nonFraction unitRef="shares" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI1LTAtMS0xLTIzNzQ5L3RleHRyZWdpb246Zjg1NjQ0Yjg5MmIwNGQ2Y2IzZGZmMjM5ZTg0MjM0NjFfMzI_2447a3f2-6eaf-4c81-822c-9a4c7bcd8647">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI1LTAtMS0xLTIzNzQ5L3RleHRyZWdpb246Zjg1NjQ0Yjg5MmIwNGQ2Y2IzZGZmMjM5ZTg0MjM0NjFfMjE5OTAyMzI1NTY2OA_399844e3-7428-4b06-9b19-2e255969b59b"><ix:nonFraction unitRef="shares" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI1LTAtMS0xLTIzNzQ5L3RleHRyZWdpb246Zjg1NjQ0Yjg5MmIwNGQ2Y2IzZGZmMjM5ZTg0MjM0NjFfMjE5OTAyMzI1NTY2OA_ee3edbd9-173c-4bc6-95c7-85d6334ceed5">6,812,836</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI1LTAtMS0xLTIzNzQ5L3RleHRyZWdpb246Zjg1NjQ0Yjg5MmIwNGQ2Y2IzZGZmMjM5ZTg0MjM0NjFfMjE5OTAyMzI1NTc4NA_afbb514c-f449-487f-9a2b-24a50aeb6723"><ix:nonFraction unitRef="shares" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI1LTAtMS0xLTIzNzQ5L3RleHRyZWdpb246Zjg1NjQ0Yjg5MmIwNGQ2Y2IzZGZmMjM5ZTg0MjM0NjFfMjE5OTAyMzI1NTc4NA_c6ec20c8-2b7c-42eb-8d9c-89d77b7f94c6">4,506,216</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2021 and 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI2LTEtMS0xLTIzODkx_01da2f2e-d3af-4066-8c02-b5d731cc9cc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI2LTMtMS0xLTIzNzk3_9d58e650-c22d-4ec7-ac0a-61ce43842473">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in-capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI3LTEtMS0xLTIzODkx_97c77fd2-41b8-49c8-b560-ce606717ae4b">27,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI3LTMtMS0xLTIzNzk3_a3860075-ab2b-4610-84e1-bbc2fe4b370e">11,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI4LTEtMS0xLTIzODkx_816d7cef-b337-4c6a-a38d-0d0d10d168a0">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI4LTMtMS0xLTIzODU1_9cf67c29-d388-4a52-8c21-14693d740012">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI5LTEtMS0xLTIzODkx_ca2f5510-9817-4a81-b96a-1c98c4527eb6">21,902</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI4LTMtMS0xLTIzNzk3_e980274d-62fa-4d6b-8270-289286669326">12,599</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders' equity (deficit) </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzMwLTEtMS0xLTIzODk5_63459bf9-3692-4677-8332-da413bdafdf9">5,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI5LTMtMS0xLTIzNzk3_8f871f36-4081-44f2-ac9d-d738f545b6af">1,454</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders' equity (deficit) </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzMxLTEtMS0xLTIzODk5_157d2485-fb34-4f2d-8846-de6e97092a29">8,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzMwLTMtMS0xLTIzNzk3_66ff9f57-4e08-4e27-972b-bd5d2b73194e">955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i8c772b1568214a7294558171471dfda5_142"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:72.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.753%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing revenue &#8211; related party</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzItMS0xLTEtMjQwMDk_31a4f353-b6ba-4178-a54e-9d2a3bd3099c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzItMy0xLTEtMjM5NjA_e4c979ee-9f1e-4401-8378-ce210a566bc9">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzQtMS0xLTEtMjQwMTU_7f6e3300-4aab-4477-8acf-18aca0319fa9">5,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzQtMy0xLTEtMjM5NjY_e527c8f5-7691-4aa5-a87f-fb2f88a072d1">3,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzUtMS0xLTEtMjQwMTU_8bbea440-d5a7-4925-bbe6-219e708ee614">4,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzUtMy0xLTEtMjM5NjY_243a2c91-b519-4562-8b46-faaff3bf83bb">1,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzYtMS0xLTEtMjQwMjE_ed26c6f9-a4f2-44c0-bb11-0240872d21fd">9,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzYtMy0xLTEtMjQwMTk_ce832831-6913-4797-841a-0311d203cf12">4,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzctMS0xLTEtMjQwMjU_7265a602-1e04-4cbc-8fb3-dd3e88469187">9,259</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzctMy0xLTEtMjQwMjM_4e43521b-51c0-4ee8-a4fc-173d93ddbd09">4,788</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzgtMS0xLTEtMjQwNDE_3599509c-6e87-4af4-90b6-a1938d04c421">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzgtMy0xLTEtMjM5NzI_778ed0c8-4ed9-47ed-bb53-a062c904a124">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revaluation of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzktMS0xLTEtMjQwNDE_6db8fcfd-f86b-414c-a27a-db1ab8f17192">89</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzktMy0xLTEtMjM5NzI_e903d123-62d7-4159-a398-daa489034369">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzEwLTEtMS0xLTI0MDQx_d477d12a-6feb-4cf9-8a56-c9df0bf5ad7b">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzEwLTMtMS0xLTIzOTcy_7e00ac48-ac3c-42b6-90da-71b1364810b9">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzExLTEtMS0xLTI0MDQ3_2c90ba76-338c-4d70-9922-2bff2150408c">9,303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzExLTMtMS0xLTI0MDQ4_87d6691b-e747-461c-bd60-f411baacb25c">4,822</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Unrealized loss on marketable securities, available-for-sale</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzEzLTEtMS0xLTI0MDU1_de226192-e002-4428-8956-18c0be2d362c">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzEzLTMtMS0xLTIzOTc4_b09943a4-3b7c-4991-8189-7ba9d16455f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzE0LTEtMS0xLTI0MDY0_e4e247b0-2456-441d-9c7f-f1216068dc5f">9,305</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzE0LTMtMS0xLTI0MDYz_187a305c-cbb1-4a22-9abd-52514a5ccfe1">4,822</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share of common stock, basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="INF" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzE1LTEtMS0xLTI0MDcz_200fba3f-e67e-423b-8351-325c347ac0fd"><ix:nonFraction unitRef="usdPerShare" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="INF" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzE1LTEtMS0xLTI0MDcz_2e66e8e5-22d5-4242-ade0-550b199b213c">1.42</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="INF" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzE1LTMtMS0xLTIzOTg0_acfb78b3-c8ae-4060-bb09-a0aacdb96c43"><ix:nonFraction unitRef="usdPerShare" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="INF" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzE1LTMtMS0xLTIzOTg0_ae147274-f160-47a8-90f6-8e68d9f13ab5">1.07</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="INF" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzE2LTEtMS0xLTI0MDcz_56cd5a5a-3e5a-45c0-b6f7-696879bb3826"><ix:nonFraction unitRef="shares" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="INF" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzE2LTEtMS0xLTI0MDcz_a7042e1a-51b6-4426-86f6-bce98dd8b6ac">6,541,097</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="INF" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzE2LTMtMS0xLTIzOTg0_c07bc198-8f68-4484-b32b-50cf4aeb6397"><ix:nonFraction unitRef="shares" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="INF" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzE2LTMtMS0xLTIzOTg0_ea33e5e5-1caa-4f81-ab94-0ec9cb07f1dd">4,506,216</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i8c772b1568214a7294558171471dfda5_145"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Changes in Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except shares)</span></div><div style="margin-top:8pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.187%"></td><td style="width:0.1%"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional<br/>Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217;<br/>Equity (Deficit)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance, December&#160;31, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iaa705715f28d4b5eacce471c76e4867b_I20191231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzItMS0xLTEtMjQxNTY_167af536-e4c4-4875-a6f3-ef6ee77d8a43">4,506,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8a303ff40d68410ea858ad97833960cc_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzItNS0xLTEtMjQxNjE_fc828259-4476-4cee-b1d1-7981e486b703">10,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i38e2e0b664e044f1ab6f20ebf44f6f59_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzItOS0xLTEtMjQxNzc_7739fe84-d71c-4818-8429-85ceaabbcb55">7,777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23ee9c62820d4f39a904524cfe778f00_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzItMTEtMS0xLTI0MzY1_0db53ef8-3e8e-44ba-9332-a0b54d683945">3,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifd9521358ab247c2b64d4cbe8a945e84_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzMtNS0xLTEtMjQxODE_34b7dee4-a7b8-4633-9117-a3e14f4e3b29">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzMtMTEtMS0xLTI0Mzcw_69049b4c-c2cf-484e-bfb3-76ae798ed123">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i60aca420575a440fa652609aad540150_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzQtOS0xLTEtMjQxODU_6cef1975-9f1d-442f-9cf8-e64258dcf4de">4,822</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzQtMTEtMS0xLTI0Mzcz_03238284-362a-4562-97ed-3939e81d4c4b">4,822</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance, December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i6476323fed784d85832b674bde1f5d2b_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzUtMS0xLTEtMjQzNzU_bffc1a32-ea6f-4898-a827-682097a6cd3c">4,506,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id5b0ac7b11494351935046ce5bf1cc8e_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzUtNS0xLTEtMjQyNzA_866f8e54-2a4f-4ea6-9bc2-f2f2fa451962">11,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia70712498a0f4941ab0ea3722b2be30f_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzUtOS0xLTEtMjQxOTk_4a3a988a-2a4f-48b8-acec-9f4ff71e7474">12,599</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzUtMTEtMS0xLTI0MjAw_9ebbf65e-026b-462e-b564-3ddc4d2cb5f8">1,454</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock for convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iffdd767329aa4cd59029b7fd066b141d_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzYtMS0xLTEtMjY3MzI_97ba60da-e377-4bfc-a8f5-fafe9a899d69">54,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i270b8e6dd74f41e4a133ae1c6754d770_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzYtNS0xLTEtMjQzNTM_326ca764-3280-4b7c-b8b4-bd47c378d7fd">439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzYtMTEtMS0xLTI0MzU2_c754995a-6a67-4f78-9b59-5e8cbd4b28aa">439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock for IPO, net of issuance expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iffdd767329aa4cd59029b7fd066b141d_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzctMS0xLTEtMjY3MzI_2034eaf8-d80c-404d-a4d6-0e065e732c0b">2,250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i270b8e6dd74f41e4a133ae1c6754d770_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzctNS0xLTEtMjQzNTM_4c9d86b4-d15b-4ba5-ad7f-53dbc1070558">15,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzctMTEtMS0xLTI3NDMx_6cf728cc-2d6c-4a43-8ea3-6651c6d52aed">15,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock for services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iffdd767329aa4cd59029b7fd066b141d_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzgtMS0xLTEtMjY3MzI_e60fd92d-567a-404a-8a63-86545f7a43d8">1,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i270b8e6dd74f41e4a133ae1c6754d770_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzgtNS0xLTEtMjQzNTM_d10250cd-8e44-461d-a605-3b4d29dc0735">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzgtMTEtMS0xLTI3NDMx_cce69f44-cd53-42c7-a3db-fbadd18d2425">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of Underwriters Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i270b8e6dd74f41e4a133ae1c6754d770_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzktNS0xLTEtMjQzNTM_91997af1-3760-466e-9215-2a3d6a3e9f67">399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzktMTEtMS0xLTI3NDMx_b96879d0-2161-447c-a141-3ec5ae206318">399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i270b8e6dd74f41e4a133ae1c6754d770_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzYtNS0xLTEtMjQyMjU_ae4dd264-871d-43ac-bd3c-5684d0931f6a">626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzEwLTExLTEtMS0yNDM1NQ_4a2c7b20-2293-452d-90b7-15d9a4130117">626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized loss on marketable securities, available-for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia203ce9d16f8445c984d50be01b6c4af_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzctNy0xLTEtMjQyNDI_dad46fa1-a726-48c6-85f1-78c9c375a80c">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzExLTExLTEtMS0yNzQzMw_d0aea2b6-1abb-40a0-b5c5-dcdf5c63657c">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2ede8e54df1449d8b82bb4b005ed5a86_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzctOS0xLTEtMjQyMzI_80a5eb2d-4172-4587-9bb5-aa229961b31a">9,303</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzEyLTExLTEtMS0yNDM4Ng_123358c2-f256-4b34-bd57-318e9fc180ef">9,303</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance, December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i92ca8836910146858994d27a6356eec0_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzktMS0xLTEtMjQzMzE_3b2a6319-adb0-4798-be6a-35e49e1568bd">6,812,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i033d2a786a29471796dbfe50eb424da2_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzktNS0xLTEtMjQzMTc_b414e1a4-13f6-4d51-b819-0d8908982815">27,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic5e826ed29c14a57ab4a163d538e1c37_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzktNy0xLTEtMjQzMDk_6025c4db-a806-42ec-9e1e-70ac80eef36d">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2716e8a4ca0545f8bbce622e4d52158f_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzktOS0xLTEtMjQzMDI_0fb8cfb9-2edf-4ff8-aa6c-bd5aa9ec5dea">21,902</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzktMTEtMS0xLTI0MzAx_685b2fbe-e705-44b3-be8b-3c682ee58858">5,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i8c772b1568214a7294558171471dfda5_148"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Tabl</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">e</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7"> of Contents</a></span></div><div style="margin-top:8pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzMtMS0xLTEtMjQ0ODY_36641889-9b09-450c-ac16-b70ff1ac2a7a">9,303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzMtMy0xLTEtMjQ0MDA_04e6789c-c470-468b-a87a-95b98b92a3b4">4,822</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of finance lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzYtMS0xLTEtMjQ0OTI_4257c3c2-d5b0-441e-8c13-3d2ffb6d990b">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzYtMy0xLTEtMjQ0MDc_15fec50c-a1d3-45f2-802f-31c0998e3da1">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of marketable securities premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzctMS0xLTEtMjQ0OTg_a8a76937-28f9-4d82-a6da-54d3fa674cfd">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzctMy0xLTEtMjQ1MDU_4d4f3f73-90f9-4b5c-b635-9b998f4a2f91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revaluation of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzgtMS0xLTEtMjQ1MTc_3a2ff576-5940-4336-83ae-9b06f127ce06">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzgtMy0xLTEtMjQ1MjM_f57c96ca-9df0-40de-a23a-d5e30f008052">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzEwLTEtMS0xLTI0NTEx_c3b45109-d0b8-4a45-a6bb-2d9ec9537598">626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzEwLTMtMS0xLTI0NDE1_7b35fa0a-618c-4c9d-8c5e-1471c3daf46c">154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forgiveness of PPP note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzExLTEtMS0xLTI0NTI5_af658aa8-3f2a-43e0-9115-ca9daad634e3">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzExLTMtMS0xLTI0NTM2_15095071-ee60-4892-88cd-fc05f3fbbf4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest, depreciation and other expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:OtherNoncashExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzEyLTEtMS0xLTI0NTQy_2a0f1644-36d4-4ba8-a844-bffdb374cdaa">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:OtherNoncashExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzEyLTMtMS0xLTI0NDIy_f817f24c-57e4-47a9-88c1-38f457ef06f7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzE0LTEtMS0xLTI0NTcy_52be1660-888c-4407-93b7-162f841f8ba0">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzE0LTMtMS0xLTI0NDMx_0ed78c6d-87a5-41e7-9ad4-0e1b86c74674">464</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzE1LTEtMS0xLTI0NTcy_7cbe2e54-3910-481b-bd56-7d8c398ebce8">308</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzE1LTMtMS0xLTI0NDMx_a52e7d7b-74dc-4d57-b80e-6ca19f8a7819">980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzE2LTEtMS0xLTI0NTcy_a43094cf-b4d5-42d2-948f-b0b456acca50">583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzE2LTMtMS0xLTI0NDMx_1c5e298f-3ab9-4444-9d36-004d3d3dc1ae">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzE3LTEtMS0xLTI0NDQ2_fec6a83c-1a22-4d3d-9b57-70afd7adfb37">8,312</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzE3LTMtMS0xLTI0NDQ1_89fd601b-4682-4c03-bf1a-fe8a2b0731b2">3,706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzIwLTEtMS0xLTI0NTc5_1797edc1-dfc6-4190-8a83-ee0630d2bdcb">3,842</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzIwLTMtMS0xLTI0NDM5_1b6021d1-eed1-40b0-bbc7-d3e58d84492e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzIxLTEtMS0xLTI0NTg1_acc01bd8-50c3-4d19-9bb1-0bc1141f91b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzIxLTMtMS0xLTI0NDM5_5a762208-8dee-449d-a276-6323d69f4b4c">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzIyLTEtMS0xLTI0NDUw_b534e265-eb39-4bbc-a811-5b70c2cfe818">3,842</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzIyLTMtMS0xLTI0NDQ4_bf6d0edb-a41c-4bd8-8b4c-28a046bb601f">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from common stock issuance, net of offering expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzI1LTEtMS0xLTI0NjE0_59f01675-92c4-44ff-885b-c33c1e3f01bb">15,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzIzLTMtMS0xLTI0Njkz_882e3c4c-d1f1-4aad-bdc4-175383eeca3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from issuance of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzI0LTEtMS0xLTI5NTQw_127bc68d-9807-486a-a1d3-55a08b57a342">399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzI0LTMtMS0xLTI5NzQ0_5eda4061-0d0c-44c6-a1e2-73bc08817054">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from PPP loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzI2LTEtMS0xLTI0NjI4_8e57bd1b-586a-4e59-95fa-1cd9725015e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzI2LTMtMS0xLTI0NDU0_60bde333-6df8-4912-b830-b39991be0b8e">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzI3LTEtMS0xLTI0NjIx_3fdd6c54-7623-41e5-a5f0-ea892159ca8f">350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzI1LTMtMS0xLTI0Njk5_d6d76f8d-31e8-4b13-a912-603da01b2fb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of finance lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzI5LTEtMS0xLTI0NjM0_fd3399c6-ef8a-473a-8f8c-246989e565b7">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzI5LTMtMS0xLTI0NDYx_d54e5af0-5f2a-45b1-ae72-846a64690341">65</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzMwLTEtMS0xLTI0NDcw_6947db9f-83c0-4746-8b31-21bf98d88991">15,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzMwLTMtMS0xLTI0NDY5_3b5c7708-2917-4ac0-9735-5b3b619c7a27">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzMyLTEtMS0xLTI0NjAw_d21e2854-18f3-4d1b-8f80-38be3094c609">3,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzMyLTMtMS0xLTI0NTk5_8a411e67-a2b6-46d6-821f-985dd6d5feb4">3,712</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzMzLTEtMS0xLTI0NjA3_276b412e-b313-4147-a41f-527f8168729a">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i23ee9c62820d4f39a904524cfe778f00_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzMzLTMtMS0xLTI0NDc1_9d6f1eef-0d54-4317-9dbe-a6c038de259a">3,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzM0LTEtMS0xLTI0NDgy_ce5ca63e-4932-491a-bb0a-667e92a95d81">3,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzM0LTMtMS0xLTI0NDgx_e314c4b4-5b64-4f38-a6ed-8d9b94c71fcf">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzM0LTEtMS0xLTI0NzMw_21bbaf93-0d71-4c3c-9634-aab210379fb9">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzM0LTMtMS0xLTI0NzMy_eb5ff639-74a3-494e-adbb-9f20d7094a9a">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conversion of convertible notes to common stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzM2LTEtMS0xLTI0NjYy_9ede49d5-10e8-411f-b70a-c91aa29c57dc">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzM2LTMtMS0xLTI0NjU1_918c6745-eecf-4cbc-b6df-fb1ea514c440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i8c772b1568214a7294558171471dfda5_151"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div style="text-align:center"><span><br/></span></div><div id="i8c772b1568214a7294558171471dfda5_154"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.  <ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTQvZnJhZzo1ZmFkMjg1ZWQwYzM0N2RhOWQ5Yjc1OTE5Zjk5YmU1Ni90ZXh0cmVnaW9uOjVmYWQyODVlZDBjMzQ3ZGE5ZDliNzU5MTlmOTliZTU2XzYyMDg_cfca1a01-8765-44a0-ae2d-62c78a5de5f9" continuedAt="ia14670ce49e947068578df14829aea45" escape="true">ORGANIZATION AND DESCRIPTION OF BUSINESS</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia14670ce49e947068578df14829aea45" continuedAt="ibd4ba2ca943f49ec8c2c09cb9c70c300">&#160;</ix:continuation></span></div><ix:continuation id="ibd4ba2ca943f49ec8c2c09cb9c70c300"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vallon Pharmaceuticals, Inc. (Vallon or the Company) was incorporated in Delaware in January 2018 (inception) and is based in Philadelphia, PA.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for central nervous system (CNS) disorders. The Company&#8217;s lead investigational product candidate, ADAIR, is a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine (the main active ingredient in Adderall&#174;) for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The Company plans to develop other abuse-deterrent products, which have potential for abuse in their current forms, beginning with the development of ADMIR, an abuse deterrent formulation of Ritalin, for which the Company has completed formulation development work.</span></div></ix:continuation><div id="i8c772b1568214a7294558171471dfda5_905"></div><div style="margin-top:8pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">       2.  <ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MDUvZnJhZzoxOWE0ODJhMmNiNTU0MjBlODhhNGMxNGVjYmY2ZmRkMi90ZXh0cmVnaW9uOjE5YTQ4MmEyY2I1NTQyMGU4OGE0YzE0ZWNiZjZmZGQyXzU0OTc1NTgxNDQ3OTU_22fd94a9-2fbe-4ad7-96ba-5697dd90e37d" continuedAt="i4502746fb9c54e1893269eb3912d87b3" escape="true">LIQUIDITY</ix:nonNumeric></span></div><ix:continuation id="i4502746fb9c54e1893269eb3912d87b3"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception, and does not expect to do so in the foreseeable future. The Company has incurred operating losses since inception and has incurred $<ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MDUvZnJhZzoxOWE0ODJhMmNiNTU0MjBlODhhNGMxNGVjYmY2ZmRkMi90ZXh0cmVnaW9uOjE5YTQ4MmEyY2I1NTQyMGU4OGE0YzE0ZWNiZjZmZGQyXzMyOTg1MzQ4ODkyMTQ_ca2f5510-9817-4a81-b96a-1c98c4527eb6">21,902</ix:nonFraction> in accumulated deficit through December 31, 2021. The Company has financed its working capital requirements to date through the issuance of common stock, convertible notes, short-term promissory notes, and a Paycheck Protection Program (PPP) note. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company completed a $<ix:nonFraction unitRef="usd" contextRef="i550459c5b5124776a49bbd935630fdc7_D20210111-20210111" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MDUvZnJhZzoxOWE0ODJhMmNiNTU0MjBlODhhNGMxNGVjYmY2ZmRkMi90ZXh0cmVnaW9uOjE5YTQ4MmEyY2I1NTQyMGU4OGE0YzE0ZWNiZjZmZGQyXzIxOTkwMjMyNTY3MTM_c6620209-3ccf-47a6-ab41-0bf1c8f4299a">350</ix:nonFraction> convertible note financing and in February 2021, the Company closed on its initial public offering (IPO) raising net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ia17353f6bf834b99aeb72bb19eed6773_D20210212-20210212" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MDUvZnJhZzoxOWE0ODJhMmNiNTU0MjBlODhhNGMxNGVjYmY2ZmRkMi90ZXh0cmVnaW9uOjE5YTQ4MmEyY2I1NTQyMGU4OGE0YzE0ZWNiZjZmZGQyXzIxOTkwMjMyNTY4MzY_e477aea9-a6c3-49bc-b692-200efe0691d5">15,500</ix:nonFraction>.&#160;As of December&#160;31, 2021, the Company had cash, cash equivalents and marketable securities of approximately $<ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MDUvZnJhZzoxOWE0ODJhMmNiNTU0MjBlODhhNGMxNGVjYmY2ZmRkMi90ZXh0cmVnaW9uOjE5YTQ4MmEyY2I1NTQyMGU4OGE0YzE0ZWNiZjZmZGQyXzMyOTg1MzQ4ODkyMjc_84909b1b-2997-4ce8-83aa-8f362927bf7c">7,510</ix:nonFraction>, which management expects will provide funding for its ongoing business activities into the third quarter of 2022.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue as a going concern is dependent on its ability to raise substantial additional capital to fund its business activities, including its research and development program. The Company intends to raise capital through additional issuances of common stock and /or short-term notes, but there can be no assurances any such financing will be available when needed or that the Company&#8217;s research and development efforts will be successful. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. Therefore, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.</span></div></ix:continuation><div id="i8c772b1568214a7294558171471dfda5_157"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzE2NjYy_05ab6547-9bd5-452e-905d-470bb90e3e08" continuedAt="i4483e157a9fa4425899f3c9f098dd5bb" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i4483e157a9fa4425899f3c9f098dd5bb" continuedAt="i1d15ea4a39d54659a63090b3a7dc71ca"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> References in this Annual Report on Form 10-K to &#8220;authoritative guidance&#8221; is meant to refer to accounting principles generally accepted in the United States of America (GAAP) as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recapitalization</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the closing of the  IPO (Note 10), the Company effected a one-for-40 reverse stock split of its common stock. All share and per share amounts, excluding the number of authorized shares and par value, contained in these financial statements and accompanying notes, and this Annual Report on Form 10-K give retroactive effect to the reverse split.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzE2NjYz_bfdc948a-97bb-4637-865a-c9aed2b58172" continuedAt="i36a468a779da49f5a3490781262223c7" escape="true">Use of estimates</ix:nonNumeric></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i36a468a779da49f5a3490781262223c7">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</ix:continuation> </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i1d15ea4a39d54659a63090b3a7dc71ca" continuedAt="ib4fa92699b974b3b918c79687ddd51ef"><div style="margin-top:8pt"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzU0OTc1NTgxODMxOTM_8ab8b659-df7d-4d74-a784-3d25f04ae061" continuedAt="i86c8ba388a174f2ca375cce6a43471f0" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of credit risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></ix:nonNumeric></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i86c8ba388a174f2ca375cce6a43471f0">The Company from time to time during the period covered by these financial statements may have had bank account balances in excess of federally insured limits. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</ix:continuation>&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzU0OTc1NTgxODMxOTI_7987ec41-f53e-4fcf-887f-f6004dbc060e" continuedAt="if8aa1be2af14469799bf6d81b87508dc" escape="true">Cash equivalents</ix:nonNumeric></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if8aa1be2af14469799bf6d81b87508dc">Cash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased and as of December&#160;31, 2021 and 2020 included investment in money market funds.</ix:continuation>&#160;</span></div><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzU0OTc1NTgxODMxOTE_e8af4bed-ec6c-47b8-83e1-36ae06771fc3" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of debt securities that are designated as available-for-sale. Marketable debt securities are recorded at fair value and unrealized holding gains or losses are reported as a component of accumulated other comprehensive income (loss). Amortization of premiums and discounts on marketable securities are included in interest expense, net on the statements of operations and comprehensive loss. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains or losses resulting from the sale of these securities are determined based on the specific identification of the securities sold. An impairment charge is recognized when the decline in the fair value of a debt security below the amortized cost basis is determined to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the duration and severity of any decline in fair value below the amortized cost basis, any adverse changes in the financial condition of the issuers and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzU0OTc1NTgxODMxOTA_031d6074-e771-4f86-a601-2361a0fe5d42" continuedAt="i8305f1cea14c4b8391bf33954ed46a4d" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of financial instruments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC 820,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 820), to measure the fair value of its financial statements and disclosures about fair value of its financial instruments. ASC 820 establishes a framework for measuring fair value in GAAP, and expands disclosures about fair value measurements. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:&#160;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.&#160;</span></div><div style="margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.&#160;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Pricing inputs that are generally unobservable inputs and not corroborated by market data.&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lower priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. The Company uses this framework for measuring fair value and disclosures about fair value measurement. The Company uses fair value measurements in areas that include derivative instruments.&#160;</span></div></ix:nonNumeric><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8305f1cea14c4b8391bf33954ed46a4d">The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. The carrying amounts reported in the balance sheets for cash and cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses, and note payable approximate their fair value based on the short-term maturity of these instruments.</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzU0OTc1NTgxODMxODk_c11de530-07fb-49e5-935d-c204109cb79d" continuedAt="iacaf2a9f02ab447b8cd016734303a881" escape="true">Property and equipment</ix:nonNumeric></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iacaf2a9f02ab447b8cd016734303a881">Property and equipment are stated at cost. The Company commences depreciation when the asset is placed in service. Computers and peripheral equipment are depreciated on a straight-line method over useful lives of <ix:nonNumeric contextRef="i5daddf114f0241b4a966bccf6d899e1c_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzE2NDkyNjc0NjkxNDE_c5ac46fd-86f5-4b42-b514-7a3f55ae358e"><ix:nonNumeric contextRef="ic638fa8850574f0f85cdf96878a4008b_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzE2NDkyNjc0NjkxNDE_fe3cb691-d1cf-4f4a-8fed-90602bcf4cc2">three years</ix:nonNumeric></ix:nonNumeric>.</ix:continuation>&#160;</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="ib4fa92699b974b3b918c79687ddd51ef" continuedAt="i13a20a9a889640879acd9f82d9aaffee"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzU0OTc1NTgxODc0Njg_ec54a8f0-8f4a-4bd4-8222-3cb590a190f1" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to use, or control the use of, identified property, plant, or equipment for a period of time in exchange for consideration. Leases may be classified as finance leases or operating leases. Lease right-of-use (ROU) assets and lease liabilities recognized in the accompanying balance sheet represent the right to use an underlying asset for the lease term and an obligation to make lease payments arising from the lease respectively.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting date, the finance lease liabilities are increased by interest and reduced by repayments made under the lease agreements. The ROU asset is subsequently measured at the amount of the remeasured lease liability (i.e. the present value of the remaining lease payments), any cumulative prepaid or accrued rent if the lease payments are uneven throughout the lease term, and any unamortized initial direct costs.</span></div></ix:nonNumeric><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzE2NjY2_e946a536-d39c-4861-ab51-c5c453560048" continuedAt="i79fbb7a4d4cb443997f1fe4f5ff54bf2" escape="true">Licensing revenues</ix:nonNumeric></span></div><div style="margin-top:8pt"><ix:continuation id="i79fbb7a4d4cb443997f1fe4f5ff54bf2" continuedAt="i3a2ea3a7535340a5a472f7cae58177a2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement (the Medice License Agreement) with  MEDICE&#160;Arzneimittel&#160;P&#252;tter&#160;GmbH &amp; Co. KG (Medice), a related party (Note 13). The license agreement provides for an exclusive license to develop, use, manufacture, market and sell ADAIR&#160;throughout&#160;Europe, a non-refundable up-front payment, potential regulatory and sales milestones and potential royalty payments. The Company analyzed the performance obligations under the license agreements, the consideration received to date and the consideration the Company could receive in the future as part of its analysis in accordance with ASC 606&#8211;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3a2ea3a7535340a5a472f7cae58177a2">(ASC 606).</ix:continuation> The Company recognized  $<ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzE2NDkyNjc0NzA2Mjk_da39e40b-7cc4-4e6a-9e25-612e0035b7f1">100</ix:nonFraction> as licensing revenue during the year ended December 31, 2020. <ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzU0OTc1NTgxODMxOTQ_d1c1a5cb-7751-488a-837d-76e53336c0b6">No</ix:nonFraction> licensing revenue was recognized during the year ended December 31, 2021.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzU0OTc1NTgxODMxODg_a67c794c-7a7d-4dc0-a0fa-df9c60ccd30e" continuedAt="i591e608aca814445acd8c34bd0e38db0" escape="true">Research and development</ix:nonNumeric></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i591e608aca814445acd8c34bd0e38db0">Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred.</ix:continuation>&#160;&#160;</span></div><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzE2NjY3_207e5d69-509f-4854-89a3-c8d2cf7cdc78" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are recorded as a cumulative adjustment in the period the estimates are revised. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzE2Njcx_fb25203c-cd54-4ad1-8ecb-b4fa7c78d07b" continuedAt="if2cd367e5aa74d2898752129f4febfe1" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative instruments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated its convertible notes to determine if those contracts or embedded components of those contracts qualified as derivatives to be separately accounted for in accordance with ASC 815,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The result of this accounting treatment is that the fair value of the embedded derivative is marked to market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statements of operations as other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity.&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.&#160;</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i13a20a9a889640879acd9f82d9aaffee" continuedAt="i5a8bdd2eadc8443db87e31f7c9aec330"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if2cd367e5aa74d2898752129f4febfe1">Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities are classified in the balance sheets as current or non-current to correspond with its host instrument.</ix:continuation></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzE2NjYw_c77e6a1f-3e62-49e1-a40d-a7532a85bb63" continuedAt="if76068065c0f476f8adb9d4b4ce7987a" escape="true">Income taxes</ix:nonNumeric></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if76068065c0f476f8adb9d4b4ce7987a">Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on the weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of December&#160;31, 2021 and 2020, the Company concluded that a full valuation allowance was necessary for all of its net deferred tax assets.</ix:continuation> The Company had no amounts recorded for uncertain tax positions, interest or penalties in the accompanying consolidated financial statements.&#160;</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzE2Njcy_813c99e6-2a5c-40e7-8f0e-8b40b3a72b76" continuedAt="ic9a127c06ec0406195104c8d41d2d431" escape="true">Net loss per common share</ix:nonNumeric></span></div><div style="margin-top:8pt"><ix:continuation id="ic9a127c06ec0406195104c8d41d2d431" continuedAt="ic5dcde0812474b94b616fc268d94eb8d"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year. Diluted net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year, plus the dilutive effect of options considered to be outstanding during each year, in accordance with ASC 260,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic5dcde0812474b94b616fc268d94eb8d">.</ix:continuation>&#160;</span></div><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzE2Njcz_ce5b7338-d6bc-4563-bf6a-fb4921b82e43" continuedAt="i783350381fbb4e0bb88716467dfd06f9" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the applicability and impact of all ASUs. ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on the financial statements.&#160;</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:8pt"><ix:continuation id="i5a8bdd2eadc8443db87e31f7c9aec330" continuedAt="i1caf93518b1b402b8895e3702211c0a3"><ix:continuation id="i783350381fbb4e0bb88716467dfd06f9" continuedAt="i45112c931e7d48bdb676723eceb90600"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, the Company adopted ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1caf93518b1b402b8895e3702211c0a3"><ix:continuation id="i45112c931e7d48bdb676723eceb90600">. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending the existing guidance.  The adoption of this standard did not have a material impact on the Company&#8217;s financial statements.</ix:continuation></ix:continuation>&#160;</span></div><div id="i8c772b1568214a7294558171471dfda5_163"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90ZXh0cmVnaW9uOmE5MzllNzA3ZDFjZjQ0NDFiYjlmYmI3MTQ2YmEyYTgxXzU0OTc1NTgxNDQ5NjM_95037e7d-863e-487d-87b0-833091707680" continuedAt="i151bfa9ccc824aab90d82dbb7fdf8417" escape="true">MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i151bfa9ccc824aab90d82dbb7fdf8417" continuedAt="i5c5ae282ab744ae7bd1611787f593ca7"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable Securities</span></div><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90ZXh0cmVnaW9uOmE5MzllNzA3ZDFjZjQ0NDFiYjlmYmI3MTQ2YmEyYTgxXzIxOTkwMjMyNjE2MzQ_f482e5b6-8d83-4a8f-9599-868069891976" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s available-for-sale securities as of the dates indicated:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.794%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Marketable Securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Corporate bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie118df7159634a91976e521f2425da1c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5NGRmNjFiMjk2OWE0MzllYWUyZjU1YTY0ODQxYzFkNi90YWJsZXJhbmdlOjk0ZGY2MWIyOTY5YTQzOWVhZTJmNTVhNjQ4NDFjMWQ2XzQtMS0xLTEtMjQ3NzY_06b6a5f7-d8b8-4173-b619-3ac23702f2b3">1,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie118df7159634a91976e521f2425da1c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5NGRmNjFiMjk2OWE0MzllYWUyZjU1YTY0ODQxYzFkNi90YWJsZXJhbmdlOjk0ZGY2MWIyOTY5YTQzOWVhZTJmNTVhNjQ4NDFjMWQ2XzQtMy0xLTEtMjQ4MDE_824a4a8d-52e2-4e13-89fb-6e223b3fe849">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie118df7159634a91976e521f2425da1c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5NGRmNjFiMjk2OWE0MzllYWUyZjU1YTY0ODQxYzFkNi90YWJsZXJhbmdlOjk0ZGY2MWIyOTY5YTQzOWVhZTJmNTVhNjQ4NDFjMWQ2XzQtNS0xLTEtMjQ3ODk_6fbb64da-cad1-48d6-b31c-46115d30e829">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie118df7159634a91976e521f2425da1c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5NGRmNjFiMjk2OWE0MzllYWUyZjU1YTY0ODQxYzFkNi90YWJsZXJhbmdlOjk0ZGY2MWIyOTY5YTQzOWVhZTJmNTVhNjQ4NDFjMWQ2XzQtNy0xLTEtMjc2NzU_be2586ef-6494-452e-aa59-3d348ad6096a">1,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icff8b71b9c8244dcb12cc9ac5efd5b53_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5NGRmNjFiMjk2OWE0MzllYWUyZjU1YTY0ODQxYzFkNi90YWJsZXJhbmdlOjk0ZGY2MWIyOTY5YTQzOWVhZTJmNTVhNjQ4NDFjMWQ2XzUtMS0xLTEtMjQ3ODM_6976294c-6dce-4f63-b531-ac8958c1aafa">2,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icff8b71b9c8244dcb12cc9ac5efd5b53_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5NGRmNjFiMjk2OWE0MzllYWUyZjU1YTY0ODQxYzFkNi90YWJsZXJhbmdlOjk0ZGY2MWIyOTY5YTQzOWVhZTJmNTVhNjQ4NDFjMWQ2XzUtMy0xLTEtMjc2ODA_1ae58ca2-52c9-4a22-824c-3a6553776472">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="icff8b71b9c8244dcb12cc9ac5efd5b53_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5NGRmNjFiMjk2OWE0MzllYWUyZjU1YTY0ODQxYzFkNi90YWJsZXJhbmdlOjk0ZGY2MWIyOTY5YTQzOWVhZTJmNTVhNjQ4NDFjMWQ2XzUtNS0xLTEtMjQ3OTU_1d745a1a-83c1-4f5e-a6ff-1da2095ff4f4">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icff8b71b9c8244dcb12cc9ac5efd5b53_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5NGRmNjFiMjk2OWE0MzllYWUyZjU1YTY0ODQxYzFkNi90YWJsZXJhbmdlOjk0ZGY2MWIyOTY5YTQzOWVhZTJmNTVhNjQ4NDFjMWQ2XzUtNy0xLTEtMjc2NzU_d383c7b6-2af5-437c-8983-251895cb413e">2,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5NGRmNjFiMjk2OWE0MzllYWUyZjU1YTY0ODQxYzFkNi90YWJsZXJhbmdlOjk0ZGY2MWIyOTY5YTQzOWVhZTJmNTVhNjQ4NDFjMWQ2XzYtMS0xLTEtMjc2Njk_f2701839-931a-4a41-9b9e-18c4df6fa7d8">3,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5NGRmNjFiMjk2OWE0MzllYWUyZjU1YTY0ODQxYzFkNi90YWJsZXJhbmdlOjk0ZGY2MWIyOTY5YTQzOWVhZTJmNTVhNjQ4NDFjMWQ2XzYtMy0xLTEtMjc2ODA_95aa675c-c6f0-4597-b1b4-5ba57f1aadd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5NGRmNjFiMjk2OWE0MzllYWUyZjU1YTY0ODQxYzFkNi90YWJsZXJhbmdlOjk0ZGY2MWIyOTY5YTQzOWVhZTJmNTVhNjQ4NDFjMWQ2XzYtNS0xLTEtMjc2NzI_f3246268-34b3-4aa8-8b71-da3e221c0738">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5NGRmNjFiMjk2OWE0MzllYWUyZjU1YTY0ODQxYzFkNi90YWJsZXJhbmdlOjk0ZGY2MWIyOTY5YTQzOWVhZTJmNTVhNjQ4NDFjMWQ2XzYtNy0xLTEtMjc2NzU_0f2f255c-5091-45f7-a4c7-c8ff3f29fe72">3,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s investments in marketable debt securities are accounted for as available-for-sale securities and  have contractual maturity dates of one year or less.</span></div></ix:nonNumeric><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, all of the Company&#8217;s marketable securities were classified as Level 2 assets.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i5c5ae282ab744ae7bd1611787f593ca7"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the embedded derivative liability identified in the 2021 Convertible Notes was a Level 3 fair value measurement. As of February 12, 2021, the embedded derivative was remeasured based upon the conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia10c21fff10b48d78e5b10b6645fdc7f_I20210212" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90ZXh0cmVnaW9uOmE5MzllNzA3ZDFjZjQ0NDFiYjlmYmI3MTQ2YmEyYTgxXzE2NDkyNjc0NDY4OTA_e774803b-4fc9-4be7-8dff-8d0822a8b5ea">8.00</ix:nonFraction> per share upon closing of the IPO. As such, an expense of $<ix:nonFraction unitRef="usdPerShare" contextRef="idef5c95d6a30458ebd4eb95332917688_I20210331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90ZXh0cmVnaW9uOmE5MzllNzA3ZDFjZjQ0NDFiYjlmYmI3MTQ2YmEyYTgxXzU0OTc1NTgxNDQ5NjY_b92da458-105b-4f1a-8173-db2c02460ec8">89</ix:nonFraction> was recorded in the first quarter of 2021.</span></div><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90ZXh0cmVnaW9uOmE5MzllNzA3ZDFjZjQ0NDFiYjlmYmI3MTQ2YmEyYTgxXzIxOTkwMjMyNjE2MzM_7b7fb94b-f237-4c6b-882c-e28c3bad553f" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity for the liability measured at estimated fair value using unobservable inputs for the year ended December 31, 2021:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning balance, January 1, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1531f974668b4107b1b1a1654cd76006_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5M2QzMjYwZmI1MzE0OGNmYWRhYjJhMDFiNDBmMWEzMi90YWJsZXJhbmdlOjkzZDMyNjBmYjUzMTQ4Y2ZhZGFiMmEwMWI0MGYxYTMyXzAtMS0xLTEtMjYyMDk_28338377-8552-45d5-96b0-64629f7aab13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions during the year ended December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f49d0df94644a32ab3d051a753eeb16_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5M2QzMjYwZmI1MzE0OGNmYWRhYjJhMDFiNDBmMWEzMi90YWJsZXJhbmdlOjkzZDMyNjBmYjUzMTQ4Y2ZhZGFiMmEwMWI0MGYxYTMyXzEtMS0xLTEtMjYyMTE_4245feb3-efcd-46d9-a0a2-50ba16a3ac9a">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transfer out of Level 3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f49d0df94644a32ab3d051a753eeb16_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5M2QzMjYwZmI1MzE0OGNmYWRhYjJhMDFiNDBmMWEzMi90YWJsZXJhbmdlOjkzZDMyNjBmYjUzMTQ4Y2ZhZGFiMmEwMWI0MGYxYTMyXzItMS0xLTEtMjYyMTM_fcfdbaba-fa5c-4db8-9004-8f173b0e7c05">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1531f974668b4107b1b1a1654cd76006_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5M2QzMjYwZmI1MzE0OGNmYWRhYjJhMDFiNDBmMWEzMi90YWJsZXJhbmdlOjkzZDMyNjBmYjUzMTQ4Y2ZhZGFiMmEwMWI0MGYxYTMyXzMtMS0xLTEtMjYyMTM_a848d2c2-6303-4142-8f2a-416be73c1b8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i8c772b1568214a7294558171471dfda5_178"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90ZXh0cmVnaW9uOmQ0Y2RiZjUxODg1MzRkZWNiNDgwOTgyNGY3MWZlMzA4XzI5NQ_b74cdf94-7a50-46af-a03c-e6fcdc8d3cb2" continuedAt="i8afdd5f468354604bafbb2e1d32475d1" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i8afdd5f468354604bafbb2e1d32475d1" continuedAt="ibbb53a780403475aa77d19b74c0cecc5"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a financing lease in relation to </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equipment utilized in the commercial scale manufacturing of ADAIR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company evaluates renewal options at lease inception on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. Lease agreements generally do not require material variable lease payments, residual value guarantees or restrictive covenants.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing lease ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of minimum lease payments over the lease term. The Company utilized the interest rate implicit in the lease. The lease term is based on the non-cancellable period in the lease contract. Any termination fees are included in the calculation of the ROU asset and lease liability when it is assumed that the lease will be terminated.</span></div><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90ZXh0cmVnaW9uOmQ0Y2RiZjUxODg1MzRkZWNiNDgwOTgyNGY3MWZlMzA4XzI5Mw_008f7186-9fab-4338-b894-b11b89070d21" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the finance lease assets and liabilities recognized on the Company's balance sheets:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.916%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance Sheet Line Item</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzItMi0xLTEtMjcwNjk_d0fa8a87-0583-4dbe-aa44-438729a21dce"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzItMi0xLTEtMjcwNjk_2c425270-8104-498b-805f-1d8b9b6480d9">206</ix:nonFraction></span>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzItNC0xLTEtMjcxMDQ_1d91015f-66ad-42d5-87ce-9f403c36c69c"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzItNC0xLTEtMjcxMDQ_f71167f1-7745-4a7e-bfac-610fe126fdc9">279</ix:nonFraction></span>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Current finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzQtMi0xLTEtMjcwNzY_4d9aad60-57b0-43cc-9c32-3717c31c5311"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzQtMi0xLTEtMjcwNzY_4ac8978a-daa8-46b4-b967-73a0f0e6b340">97</ix:nonFraction></span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzQtNC0xLTEtMjcxMTE_878bb0e5-bbd6-48e9-9988-7643436d0dee"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzQtNC0xLTEtMjcxMTE_41a828e8-3881-48ae-ab6f-7aeb938bb996">105</ix:nonFraction></span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Non-current finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzUtMi0xLTEtMjcwNzY_0cbe9984-707d-4160-b526-ea4fa4370ae5"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzUtMi0xLTEtMjcwNzY_b3916301-7f29-4e94-b045-ef1204bba8ad">72</ix:nonFraction></span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzUtNC0xLTEtMjcxMTE_15864d26-3ad3-4b32-a575-a615f5f41fef"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzUtNC0xLTEtMjcxMTE_8498fe20-b37a-4de5-b58a-0594a9e839c6">170</ix:nonFraction></span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Total finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzYtMi0xLTEtMjcxMjI_f37595fc-4f27-4bf7-a2e7-927fd85031f9">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzYtNC0xLTEtMjcxMjM_cd968853-db64-43d8-82c4-8c01c80c799a">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s weighted average remaining lease term and weighted average discount rate for its financing lease as of December 31, 2021 are:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average remaining lease term - finance lease</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTo2NmFlYzAwMWY2NTA0NDViYTA2YmE4MWI0ZmFjNDI1OC90YWJsZXJhbmdlOjY2YWVjMDAxZjY1MDQ0NWJhMDZiYTgxYjRmYWM0MjU4XzQtMS0xLTEtMjU4NjA_d76b84fa-121e-46cd-87e9-957f8dcb3661">1.75</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average discount rate - finance lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTo2NmFlYzAwMWY2NTA0NDViYTA2YmE4MWI0ZmFjNDI1OC90YWJsZXJhbmdlOjY2YWVjMDAxZjY1MDQ0NWJhMDZiYTgxYjRmYWM0MjU4XzUtMS0xLTEtMjU4NjA_90fce56f-7b16-4ab5-8a03-ba51ff648c34">13.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows related to the measurement of financing lease assets and liabilities were as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating cash flows from finance lease amortization</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZToyODc2NGMwYzBlMzc0NDMzYjFjYWIzYmQ1ZjU1NzEwOC90YWJsZXJhbmdlOjI4NzY0YzBjMGUzNzQ0MzNiMWNhYjNiZDVmNTU3MTA4XzItMS0xLTEtMjU5MDI_c434bc4f-41d2-4d29-a2ca-6c50d3eff930">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZToyODc2NGMwYzBlMzc0NDMzYjFjYWIzYmQ1ZjU1NzEwOC90YWJsZXJhbmdlOjI4NzY0YzBjMGUzNzQ0MzNiMWNhYjNiZDVmNTU3MTA4XzItMy0xLTEtMjU5MDg_7b58ef28-761d-476a-8889-a640f8b8df01">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financing cash flows from finance lease payments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZToyODc2NGMwYzBlMzc0NDMzYjFjYWIzYmQ1ZjU1NzEwOC90YWJsZXJhbmdlOjI4NzY0YzBjMGUzNzQ0MzNiMWNhYjNiZDVmNTU3MTA4XzMtMS0xLTEtMjU5MDI_2d98aced-5007-4398-a296-ae2ea48afd2b">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZToyODc2NGMwYzBlMzc0NDMzYjFjYWIzYmQ1ZjU1NzEwOC90YWJsZXJhbmdlOjI4NzY0YzBjMGUzNzQ0MzNiMWNhYjNiZDVmNTU3MTA4XzMtMy0xLTEtMjU5MDg_d793bbd8-8d7f-4abf-8a6c-3bb77ba69694">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="ibbb53a780403475aa77d19b74c0cecc5"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90ZXh0cmVnaW9uOmQ0Y2RiZjUxODg1MzRkZWNiNDgwOTgyNGY3MWZlMzA4XzI5NA_6282946d-0a57-4144-8e30-e94515e7be9d" escape="true"><div style="margin-top:8pt"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturities of the finance lease liability as of December&#160;31, 2021 are as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTozYmU0MTAyOWJhMGI0ZjczYjc2ZDliZGU0NjUzYWE1OC90YWJsZXJhbmdlOjNiZTQxMDI5YmEwYjRmNzNiNzZkOWJkZTQ2NTNhYTU4XzAtMS0xLTEtMjU5NTI_2ae4a818-8f27-4828-82ed-a34b7aa4da8c">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTozYmU0MTAyOWJhMGI0ZjczYjc2ZDliZGU0NjUzYWE1OC90YWJsZXJhbmdlOjNiZTQxMDI5YmEwYjRmNzNiNzZkOWJkZTQ2NTNhYTU4XzEtMS0xLTEtMjU5NTI_73c0b065-fdde-4a1f-8381-c9f7eb5936b3">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTozYmU0MTAyOWJhMGI0ZjczYjc2ZDliZGU0NjUzYWE1OC90YWJsZXJhbmdlOjNiZTQxMDI5YmEwYjRmNzNiNzZkOWJkZTQ2NTNhYTU4XzItMS0xLTEtMjU5NzI_9e83ff52-ffd9-4040-a504-2deb2f9f0461">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTozYmU0MTAyOWJhMGI0ZjczYjc2ZDliZGU0NjUzYWE1OC90YWJsZXJhbmdlOjNiZTQxMDI5YmEwYjRmNzNiNzZkOWJkZTQ2NTNhYTU4XzQtMS0xLTEtMjU5NjA_8709b49c-455e-4cc8-b928-2905e3929f38">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Present value of lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTozYmU0MTAyOWJhMGI0ZjczYjc2ZDliZGU0NjUzYWE1OC90YWJsZXJhbmdlOjNiZTQxMDI5YmEwYjRmNzNiNzZkOWJkZTQ2NTNhYTU4XzUtMS0xLTEtMjU5NjA_a1034a01-f361-46e4-8cf3-318601996b73">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i8c772b1568214a7294558171471dfda5_181"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90ZXh0cmVnaW9uOjM5ODlhZjUxNTcxYTQ2Zjg5YzU4ZjczNmRlZmZhMTFmXzMx_9e202638-f7ba-4590-8e45-54214f41434f" continuedAt="i9d4bc906524343f7ab0f28250766f736" escape="true">ACCRUED EXPENSES</ix:nonNumeric></span></div><ix:continuation id="i9d4bc906524343f7ab0f28250766f736"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of:</span></div><div style="margin-top:8pt"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90ZXh0cmVnaW9uOjM5ODlhZjUxNTcxYTQ2Zjg5YzU4ZjczNmRlZmZhMTFmXzMy_6f330044-7012-4828-9d4e-265fd529522e" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="ck0001824293:AccruedResearchAndDevelopmentCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90YWJsZTo0YTQ5YTdmMzQyNTU0ZGU2YWY0ZTNiYTdlODgxZjRjYS90YWJsZXJhbmdlOjRhNDlhN2YzNDI1NTRkZTZhZjRlM2JhN2U4ODFmNGNhXzItMS0xLTEtMjYwMjM_cabbad77-5466-41de-b369-3e6ffeac60ee">894</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="ck0001824293:AccruedResearchAndDevelopmentCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90YWJsZTo0YTQ5YTdmMzQyNTU0ZGU2YWY0ZTNiYTdlODgxZjRjYS90YWJsZXJhbmdlOjRhNDlhN2YzNDI1NTRkZTZhZjRlM2JhN2U4ODFmNGNhXzItMy0xLTEtMjYwMDk_8758752d-b072-4208-8fad-c568e431134c">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90YWJsZTo0YTQ5YTdmMzQyNTU0ZGU2YWY0ZTNiYTdlODgxZjRjYS90YWJsZXJhbmdlOjRhNDlhN2YzNDI1NTRkZTZhZjRlM2JhN2U4ODFmNGNhXzMtMS0xLTEtMjYwMjM_0db1c9cd-c417-4200-95b5-68c4a7bbc52a">183</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90YWJsZTo0YTQ5YTdmMzQyNTU0ZGU2YWY0ZTNiYTdlODgxZjRjYS90YWJsZXJhbmdlOjRhNDlhN2YzNDI1NTRkZTZhZjRlM2JhN2U4ODFmNGNhXzMtMy0xLTEtMjYwMjA_17df80a9-d02c-4cde-881f-9faeee7a1916">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Payroll and related</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90YWJsZTo0YTQ5YTdmMzQyNTU0ZGU2YWY0ZTNiYTdlODgxZjRjYS90YWJsZXJhbmdlOjRhNDlhN2YzNDI1NTRkZTZhZjRlM2JhN2U4ODFmNGNhXzQtMS0xLTEtMjYwMjM_12ecaee7-424a-4c0d-a2d0-3d1b66108a4b">291</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90YWJsZTo0YTQ5YTdmMzQyNTU0ZGU2YWY0ZTNiYTdlODgxZjRjYS90YWJsZXJhbmdlOjRhNDlhN2YzNDI1NTRkZTZhZjRlM2JhN2U4ODFmNGNhXzQtMy0xLTEtMjYwMjA_2173cc59-ae49-4ab1-bae9-e0b4c0dcf346">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Licensing related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="ck0001824293:AccruedLicensingFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90YWJsZTo0YTQ5YTdmMzQyNTU0ZGU2YWY0ZTNiYTdlODgxZjRjYS90YWJsZXJhbmdlOjRhNDlhN2YzNDI1NTRkZTZhZjRlM2JhN2U4ODFmNGNhXzUtMS0xLTEtMjYwMjM_da76b58a-11f7-48f7-8792-0ae096274b70">62</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="ck0001824293:AccruedLicensingFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90YWJsZTo0YTQ5YTdmMzQyNTU0ZGU2YWY0ZTNiYTdlODgxZjRjYS90YWJsZXJhbmdlOjRhNDlhN2YzNDI1NTRkZTZhZjRlM2JhN2U4ODFmNGNhXzUtMy0xLTEtMjYwMjA_529004d3-922a-4d2c-ac46-67133ab25281">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90YWJsZTo0YTQ5YTdmMzQyNTU0ZGU2YWY0ZTNiYTdlODgxZjRjYS90YWJsZXJhbmdlOjRhNDlhN2YzNDI1NTRkZTZhZjRlM2JhN2U4ODFmNGNhXzYtMS0xLTEtMjYwMjM_406c1acf-a3c3-4910-9ff5-047185b44551">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90YWJsZTo0YTQ5YTdmMzQyNTU0ZGU2YWY0ZTNiYTdlODgxZjRjYS90YWJsZXJhbmdlOjRhNDlhN2YzNDI1NTRkZTZhZjRlM2JhN2U4ODFmNGNhXzYtMy0xLTEtMjYwMjA_0c573a73-d9e8-4667-a697-6f3b88827efd">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90YWJsZTo0YTQ5YTdmMzQyNTU0ZGU2YWY0ZTNiYTdlODgxZjRjYS90YWJsZXJhbmdlOjRhNDlhN2YzNDI1NTRkZTZhZjRlM2JhN2U4ODFmNGNhXzctMS0xLTEtMjYwNDA_89c41c33-8dec-4450-a41d-b573627392c7">1,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90YWJsZTo0YTQ5YTdmMzQyNTU0ZGU2YWY0ZTNiYTdlODgxZjRjYS90YWJsZXJhbmdlOjRhNDlhN2YzNDI1NTRkZTZhZjRlM2JhN2U4ODFmNGNhXzctMy0xLTEtMjYwNDE_1f41c3c2-36df-406a-86fb-b440be482790">847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="i8c772b1568214a7294558171471dfda5_160"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjAvZnJhZzo0NGYyNDgzZmE3NGI0MWY2OWRlOGU2ZTVhNzZlOWM2Zi90ZXh0cmVnaW9uOjQ0ZjI0ODNmYTc0YjQxZjY5ZGU4ZTZlNWE3NmU5YzZmXzM2Nzg_8f0953fe-5d32-4583-8de1-4993418fad1d" continuedAt="i4a52a55fef4646cdaca4b71ae453b9b8" escape="true">PPP NOTE AND CONVERTIBLE NOTES</ix:nonNumeric></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4a52a55fef4646cdaca4b71ae453b9b8" continuedAt="i4959899875b8424a9be405287456acad">In May 2020, the Company issued a promissory note under the PPP (the PPP Note) totaling $<ix:nonFraction unitRef="usd" contextRef="i1944122310504f56b217249a0d49b19a_I20200531" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjAvZnJhZzo0NGYyNDgzZmE3NGI0MWY2OWRlOGU2ZTVhNzZlOWM2Zi90ZXh0cmVnaW9uOjQ0ZjI0ODNmYTc0YjQxZjY5ZGU4ZTZlNWE3NmU5YzZmXzE1NQ_4696ab27-74f7-41b3-9955-6594dafec0cb">61</ix:nonFraction>. The note had a stated interest rate of <ix:nonFraction unitRef="number" contextRef="i1944122310504f56b217249a0d49b19a_I20200531" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjAvZnJhZzo0NGYyNDgzZmE3NGI0MWY2OWRlOGU2ZTVhNzZlOWM2Zi90ZXh0cmVnaW9uOjQ0ZjI0ODNmYTc0YjQxZjY5ZGU4ZTZlNWE3NmU5YzZmXzU1NQ_83bea831-ad21-42f3-b7a1-b938c02597b7">1</ix:nonFraction>% and had a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjAvZnJhZzo0NGYyNDgzZmE3NGI0MWY2OWRlOGU2ZTVhNzZlOWM2Zi90ZXh0cmVnaW9uOjQ0ZjI0ODNmYTc0YjQxZjY5ZGU4ZTZlNWE3NmU5YzZmXzU2OA_a031568f-8be9-4dd8-8877-34662d6a2613">two</span>-year maturity. Payments were required to be made over a <ix:nonNumeric contextRef="if77c3753756e4eb8b7f0d6919514e0d1_D20200501-20200531" name="ck0001824293:DebtInstrumentPaymentTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjAvZnJhZzo0NGYyNDgzZmE3NGI0MWY2OWRlOGU2ZTVhNzZlOWM2Zi90ZXh0cmVnaW9uOjQ0ZjI0ODNmYTc0YjQxZjY5ZGU4ZTZlNWE3NmU5YzZmXzYyMQ_bc9b6aba-5901-4406-9ff5-ebe71bbfcb08">1.5</ix:nonNumeric> years period beginning in November 2020 unless forgiven. In January 2021, the Company was notified that the loan along with accumulated interest had been forgiven. As a result, the Company recorded income from the extinguishment of its obligation in the amount of $<ix:nonFraction unitRef="usd" contextRef="i4ff8206d11c1434cb0abe54052617449_D20210101-20210131" decimals="-3" name="ck0001824293:ForgivenessOfDebtInstrument" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjAvZnJhZzo0NGYyNDgzZmE3NGI0MWY2OWRlOGU2ZTVhNzZlOWM2Zi90ZXh0cmVnaW9uOjQ0ZjI0ODNmYTc0YjQxZjY5ZGU4ZTZlNWE3NmU5YzZmXzE2NDkyNjc0NTI3NjE_ff546cd3-e42c-4dd6-ab1c-194597bb1e1c">61</ix:nonFraction> as other income on the accompanying statements of operations and comprehensive loss.</ix:continuation></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4959899875b8424a9be405287456acad">In January 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#8217;s Chief Executive Officer, pursuant to which the Company issued the 2021 Convertible Notes, for cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="ib9d5b9a898334b7cb7f34285a2ddd313_D20210111-20210111" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjAvZnJhZzo0NGYyNDgzZmE3NGI0MWY2OWRlOGU2ZTVhNzZlOWM2Zi90ZXh0cmVnaW9uOjQ0ZjI0ODNmYTc0YjQxZjY5ZGU4ZTZlNWE3NmU5YzZmXzE2NDkyNjc0NTI3Njc_6dc19c23-f1b5-405f-9667-a17be7b506fa">350</ix:nonFraction>. The 2021 Convertible Notes bore an interest rate of <ix:nonFraction unitRef="number" contextRef="icfa130da617a43abb627558cf21129fe_I20210111" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjAvZnJhZzo0NGYyNDgzZmE3NGI0MWY2OWRlOGU2ZTVhNzZlOWM2Zi90ZXh0cmVnaW9uOjQ0ZjI0ODNmYTc0YjQxZjY5ZGU4ZTZlNWE3NmU5YzZmXzE2NDkyNjc0NTI3NzU_e28bf6b9-6d18-4cd2-94ca-668dbb9508ae">7.0</ix:nonFraction>% per annum, non-compounding, and had a maturity date of September&#160;30, 2021. The 2021 Convertible Notes converted into <ix:nonFraction unitRef="shares" contextRef="i3844e69fe7884e4db36fb500c88c1e90_D20210201-20210228" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjAvZnJhZzo0NGYyNDgzZmE3NGI0MWY2OWRlOGU2ZTVhNzZlOWM2Zi90ZXh0cmVnaW9uOjQ0ZjI0ODNmYTc0YjQxZjY5ZGU4ZTZlNWE3NmU5YzZmXzE2NDkyNjc0NTI3ODM_e5ed3e8e-8e36-4ae9-b156-f94f96fc5c4f">54,906</ix:nonFraction> shares of the Company&#8217;s common stock upon completion of the IPO. The Company identified the mandatory conversion into shares of the Company&#8217;s common stock as a redemption feature, which requires bifurcation from the 2021 Convertible Notes and treated it as a derivative liability under ASC 815 as the redemption feature was not clearly and closely related to the debt. The Company evaluated the fair value of the derivative liability. Upon the conversion of the 2021 Convertible Notes to common stock at the closing of the IPO, the embedded derivative liability was remeasured and removed from the balance sheet.</ix:continuation> </span></div><div id="i8c772b1568214a7294558171471dfda5_954"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.  <ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85NTQvZnJhZzphY2EwZjhjNTVkNGY0MjkxODZiMDU3MzU2ZjRiYTg2ZC90ZXh0cmVnaW9uOmFjYTBmOGM1NWQ0ZjQyOTE4NmIwNTczNTZmNGJhODZkXzU0OTc1NTgxNDA3MzE_e176c425-4133-4e81-8c62-8433395b8625" continuedAt="id97a6431c37f4283b2a15ca829c02fde" escape="true">EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id97a6431c37f4283b2a15ca829c02fde">The Company maintains a tax-qualified SIMPLE IRA retirement plan which covers all employees. Pursuant to the SIMPLE IRA program, employees are eligible to contribute to an individual SIMPLE IRA account on a tax-deferred basis. The Company makes matching contributions to the employee&#8217;s SIMPLE IRA account in an amount up to <ix:nonFraction unitRef="number" contextRef="i3f45c53a2fd14b19a55e65c0b6f087be_D20210101-20211231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85NTQvZnJhZzphY2EwZjhjNTVkNGY0MjkxODZiMDU3MzU2ZjRiYTg2ZC90ZXh0cmVnaW9uOmFjYTBmOGM1NWQ0ZjQyOTE4NmIwNTczNTZmNGJhODZkXzU0OTc1NTgxNDA3MzM_3bfc4431-952c-4a08-a408-f49ed2122f71">3</ix:nonFraction>% of the employee&#8217;s base salary (subject to applicable IRS compensation limits). Expenses related to Company contributions were $<ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85NTQvZnJhZzphY2EwZjhjNTVkNGY0MjkxODZiMDU3MzU2ZjRiYTg2ZC90ZXh0cmVnaW9uOmFjYTBmOGM1NWQ0ZjQyOTE4NmIwNTczNTZmNGJhODZkXzIxOTkwMjMyNTc1OTc_99f56d50-b075-4732-a07a-c80fd282f2bb">24</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="-3" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85NTQvZnJhZzphY2EwZjhjNTVkNGY0MjkxODZiMDU3MzU2ZjRiYTg2ZC90ZXh0cmVnaW9uOmFjYTBmOGM1NWQ0ZjQyOTE4NmIwNTczNTZmNGJhODZkXzIxOTkwMjMyNTc2MDQ_11eb2344-f5b6-40da-a460-75b53d021acb">17</ix:nonFraction> for the years ended December&#160;31, 2021 and 2020, respectively.</ix:continuation></span></div><div id="i8c772b1568214a7294558171471dfda5_166"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjYvZnJhZzpmYzg2MDcyMjQzNmE0YTU4YjMzY2IwYmE2OGYwZTExZi90ZXh0cmVnaW9uOmZjODYwNzIyNDM2YTRhNThiMzNjYjBiYTY4ZjBlMTFmXzY2MDY_6bf85a98-dcda-4771-a630-0e1516d3bc48" continuedAt="i63559cee58bc49f39560eb324a9bc5e0" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i63559cee58bc49f39560eb324a9bc5e0" continuedAt="i04a13a75035545d0a06e8c5312ed1c4b"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment agreements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i04a13a75035545d0a06e8c5312ed1c4b"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company was named as a defendant in a putative class action lawsuit filed in the California Superior Court, County of Los Angeles, styled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rendon v. Vallon, Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The complaint brought <ix:nonFraction unitRef="claim" contextRef="ic698111b087341fab1ee0949330016d5_I20211106" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjYvZnJhZzpmYzg2MDcyMjQzNmE0YTU4YjMzY2IwYmE2OGYwZTExZi90ZXh0cmVnaW9uOmZjODYwNzIyNDM2YTRhNThiMzNjYjBiYTY4ZjBlMTFmXzU0OTc1NTgxNTgyNTU_641c6a11-9a49-4eba-bb94-a8b4b8f6e1a9">one</ix:nonFraction> claim for violation of California&#8217;s Unruh Civil Rights Act (Unruh Act), alleging that the Company&#8217;s website is not compatible with software used by vision-impaired individuals.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company settled the lawsuit for an immaterial amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Impact</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global COVID-19 pandemic continues to present uncertainty and unforeseeable new risks to the Company&#8217;s operations and business plan. The Company has closely monitored recent COVID-19 developments, including states&#8217; lifting COVID-19 safety measures, drops in vaccination rates, and the spread of various coronavirus strains such as the Delta and Omicron variants. In light of these developments, the full impact of the COVID-19 pandemic on the Company&#8217;s business, operations and clinical development plans remains uncertain and will vary depending on the pandemic&#8217;s future impact on its clinical trial enrollment, clinical trial sites, clinical research organizations (CROs), third-party manufacturers, and other third parties with whom the Company does business, as well as any legal or regulatory consequences resulting therefrom. To the extent possible, the Company is conducting business as usual, with necessary or advisable modifications to employee travel and with most of its employees and consultants working remotely. The Company will continue to actively monitor the COVID-19 situation and may take further actions that alter its operations, including those that may be required by federal, state or local authorities, or that it determines is in the best interests of its employees and other third parties with whom the Company does business.</span></div></ix:continuation><div id="i8c772b1568214a7294558171471dfda5_933"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90ZXh0cmVnaW9uOmYzODY5MGU0NWM0ODQ1ZjZiMmEzOGNjMTRiZGU0NzkyXzcxNDY4MjU1ODMwOTI_dedc3bd2-1d24-4c1d-9395-18cf8444a44e" continuedAt="i2da94eb5935640e393933a76e01c0f00" escape="true">STOCKHOLDERS EQUITY (DEFICIT)</ix:nonNumeric></span></div><ix:continuation id="i2da94eb5935640e393933a76e01c0f00"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company completed its IPO of <ix:nonFraction unitRef="shares" contextRef="ia17353f6bf834b99aeb72bb19eed6773_D20210212-20210212" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90ZXh0cmVnaW9uOmYzODY5MGU0NWM0ODQ1ZjZiMmEzOGNjMTRiZGU0NzkyXzE2NDkyNjc0NDQyNTc_98e19324-4b40-4e6a-861e-3a38bfc62c4e">2,250,000</ix:nonFraction> shares of common stock at a public offering price of  $<ix:nonFraction unitRef="usdPerShare" contextRef="i9f824c725f73426d90c2105cddf2d5ca_I20210212" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90ZXh0cmVnaW9uOmYzODY5MGU0NWM0ODQ1ZjZiMmEzOGNjMTRiZGU0NzkyXzE2NDkyNjc0NDQyNzQ_18e5693e-480a-429a-8b87-84f9b4736083">8.00</ix:nonFraction> per share. As a result of the IPO, the Company received approximately $<ix:nonFraction unitRef="usd" contextRef="ia17353f6bf834b99aeb72bb19eed6773_D20210212-20210212" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90ZXh0cmVnaW9uOmYzODY5MGU0NWM0ODQ1ZjZiMmEzOGNjMTRiZGU0NzkyXzE2NDkyNjc0NDQyODU_0c2fd096-6e8a-4ce0-a7ae-fc822d9d9b9e">15,500</ix:nonFraction> in net proceeds, after deducting discounts and commissions of $<ix:nonFraction unitRef="usd" contextRef="ia17353f6bf834b99aeb72bb19eed6773_D20210212-20210212" decimals="-3" name="ck0001824293:StockIssuanceCostsDiscountsAndCommissions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90ZXh0cmVnaW9uOmYzODY5MGU0NWM0ODQ1ZjZiMmEzOGNjMTRiZGU0NzkyXzcxNDY4MjU1ODMwOTU_d115aa79-b1ae-4465-8664-0842ae8e502b">1,600</ix:nonFraction> and offering expenses of approximately $<ix:nonFraction unitRef="usd" contextRef="i9318b4034bf247a7bf81e79df11bc14e_D20210212-20210212" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90ZXh0cmVnaW9uOmYzODY5MGU0NWM0ODQ1ZjZiMmEzOGNjMTRiZGU0NzkyXzcxNDY4MjU1ODMxMDc_5d8dd4f7-bc3a-4e57-abb6-1d1f05893a75">905</ix:nonFraction>.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the IPO, the Company granted the underwriters warrants (the Underwriters' Warrants) to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="if6d11153da3c4046926d1df8862e08df_I20210212" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90ZXh0cmVnaW9uOmYzODY5MGU0NWM0ODQ1ZjZiMmEzOGNjMTRiZGU0NzkyXzE2NDkyNjc0NDQyOTA_3ce643c6-de3b-4530-8df0-7bbd6d1838b4">112,500</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if6d11153da3c4046926d1df8862e08df_I20210212" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90ZXh0cmVnaW9uOmYzODY5MGU0NWM0ODQ1ZjZiMmEzOGNjMTRiZGU0NzkyXzE2NDkyNjc0NDQyOTc_63aa6772-42f7-45d8-98c8-bab993c499ee">10.00</ix:nonFraction> per share. The Underwriters&#8217; Warrants have a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90ZXh0cmVnaW9uOmYzODY5MGU0NWM0ODQ1ZjZiMmEzOGNjMTRiZGU0NzkyXzE2NDkyNjc0NDQzMDI_d0b1e4ec-bc6a-4c22-8fd2-7d9f5a4cd028">five</span>-year term and became exercisable after August 12, 2021. </span></div><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90ZXh0cmVnaW9uOmYzODY5MGU0NWM0ODQ1ZjZiMmEzOGNjMTRiZGU0NzkyXzIxOTkwMjMyNTgwOTE_34e36fed-8325-4120-9e55-4a43823eb2d8" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i5f7f365dc72f44f98ddaa19c2a6fe7c2_I20211231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90YWJsZTplMzk0NTRhYjRiNWI0NmI1OGZlMDYxMTY5ODk4MWNhMC90YWJsZXJhbmdlOmUzOTQ1NGFiNGI1YjQ2YjU4ZmUwNjExNjk4OTgxY2EwXzAtMS0xLTEtMjM2Mjg_88c1924d-fcf7-4e0c-928d-ae9cecb6338e">85.0</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i233cc24405d641289d6ab6f271edbce0_I20211231" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90YWJsZTplMzk0NTRhYjRiNWI0NmI1OGZlMDYxMTY5ODk4MWNhMC90YWJsZXJhbmdlOmUzOTQ1NGFiNGI1YjQ2YjU4ZmUwNjExNjk4OTgxY2EwXzEtMS0xLTEtMjM2Mjg_b25a5687-f418-41af-bf47-3b727422ea2d">2.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i0508ecc21bf1424db461226872bd262c_I20211231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90YWJsZTplMzk0NTRhYjRiNWI0NmI1OGZlMDYxMTY5ODk4MWNhMC90YWJsZXJhbmdlOmUzOTQ1NGFiNGI1YjQ2YjU4ZmUwNjExNjk4OTgxY2EwXzItMS0xLTEtMjM2Mjg_4ad2327d-38c6-4ff2-9fda-51fb3d14b569">0.0</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i6dc2bc5f633b4fe997a55197c7618e72_I20211231" decimals="5" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90YWJsZTplMzk0NTRhYjRiNWI0NmI1OGZlMDYxMTY5ODk4MWNhMC90YWJsZXJhbmdlOmUzOTQ1NGFiNGI1YjQ2YjU4ZmUwNjExNjk4OTgxY2EwXzMtMS0xLTEtMjM2Mjg_8ae68fa5-fdf7-4156-9c22-8626911f369a">0.155</ix:nonFraction>&#160;%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, all of the Underwriters&#8217; Warrants were outstanding.</span></div></ix:continuation><div id="i8c772b1568214a7294558171471dfda5_169"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90ZXh0cmVnaW9uOjNkN2QyMGZlMGUyYjRkOTJiOTFjY2Y2OTIyNzY5M2VjXzQ1MjU_65649de2-4ff3-4d06-b2aa-1bf360f0f325" continuedAt="i43ce012ec7c14e42aeed22a9ace37322" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i43ce012ec7c14e42aeed22a9ace37322" continuedAt="i9a24193474bd4286b2acc95639fe12ee"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues stock-based awards pursuant to its 2018 Equity Incentive Plan (the 2018 Plan). The 2018 Plan provides for the granting of stock options, restricted stock, or restricted stock units. The Company's employees, officers, directors and other persons are eligible to receive awards under the Plan.  The number of shares of the Company's common stock authorized under the 2018 Plan will automatically increase on January 1st of each year until the expiration of the 2018 Plan, in an amount equal to <ix:nonFraction unitRef="number" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="2" name="ck0001824293:ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear" format="ixt-sec:numwordsen" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90ZXh0cmVnaW9uOjNkN2QyMGZlMGUyYjRkOTJiOTFjY2Y2OTIyNzY5M2VjXzU0OTc1NTgxNTIyNTM_4b01660e-6c2d-4432-97b6-34737ae8ba90">four</ix:nonFraction> percent of the total number of shares of the Company's common stock outstanding on December 31st of the preceding calendar year, subject to the discretion of the Company's board of directors or compensation committee to determine a lesser number of shares shall be added for such year. The total number of shares authorized for issuance under the 2018 Plan was <ix:nonFraction unitRef="shares" contextRef="i01c972ebfcea4e9f9fb0d25b4590b552_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90ZXh0cmVnaW9uOjNkN2QyMGZlMGUyYjRkOTJiOTFjY2Y2OTIyNzY5M2VjXzIxOTkwMjMyNjg5MDM_09c6945f-0d7c-4df4-8779-db5fc0a797b0">621,022</ix:nonFraction> as of December&#160;31, 2021. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount, terms of grants, and exercisability provisions are determined and set by the Company's board of directors or compensation committee. The Company measures employee stock-based awards at grant-date fair value and records compensation </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="i9a24193474bd4286b2acc95639fe12ee" continuedAt="ibe9ae04756bd485d965c68258b21b064"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense on a straight-line basis over the vesting period of the award. Stock-based awards issued to non-employees are revalued until the award vests.</span></div><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90ZXh0cmVnaW9uOjNkN2QyMGZlMGUyYjRkOTJiOTFjY2Y2OTIyNzY5M2VjXzIxOTkwMjMyNjg3Mzk_6eecf8f5-8aad-4246-8055-a907abaacb05" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded  stock-based compensation related to stock options issued under the 2018 Plan in the following expense categories of its accompanying statements of operations for the years ended December&#160;31, 2021 and 2020  :</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i414ab16442df41e0a789424f9dcdbb64_D20211001-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpjM2UzNmE3OTlhNTg0NmE2YThhNGFiY2YzMDdhYzFjYi90YWJsZXJhbmdlOmMzZTM2YTc5OWE1ODQ2YTZhOGE0YWJjZjMwN2FjMWNiXzItNS0xLTEtMjM2NDE_d9cc12be-29a9-4e1f-9fc2-5f4bee6e1720">83</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic219cdbb38f64f029ff62ec56ce54f18_D20201001-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpjM2UzNmE3OTlhNTg0NmE2YThhNGFiY2YzMDdhYzFjYi90YWJsZXJhbmdlOmMzZTM2YTc5OWE1ODQ2YTZhOGE0YWJjZjMwN2FjMWNiXzItNy0xLTEtMjM2NDE_72da2c47-90d2-42b3-ab75-b5dcc3960c3d">103</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic19d630a0cfb4614bc03d9687c1b1adf_D20211001-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpjM2UzNmE3OTlhNTg0NmE2YThhNGFiY2YzMDdhYzFjYi90YWJsZXJhbmdlOmMzZTM2YTc5OWE1ODQ2YTZhOGE0YWJjZjMwN2FjMWNiXzMtNS0xLTEtMjM2NDE_a345ebfd-4443-4033-887b-dfa108a2d347">543</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i25bc9e21732d46a495fab6ec37e81bd6_D20201001-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpjM2UzNmE3OTlhNTg0NmE2YThhNGFiY2YzMDdhYzFjYi90YWJsZXJhbmdlOmMzZTM2YTc5OWE1ODQ2YTZhOGE0YWJjZjMwN2FjMWNiXzMtNy0xLTEtMjM2NDE_f55633c1-cd04-4e8a-a1d7-645dff85ecbc">51</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia48dc025b4ca46bfbb1119e73f604f09_D20211001-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpjM2UzNmE3OTlhNTg0NmE2YThhNGFiY2YzMDdhYzFjYi90YWJsZXJhbmdlOmMzZTM2YTc5OWE1ODQ2YTZhOGE0YWJjZjMwN2FjMWNiXzQtMS0xLTEtMjYxMjU_f2789815-3f58-45fa-946e-24d3617517a8">626</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iefc0efe048504719968099425a5fc1f0_D20201001-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpjM2UzNmE3OTlhNTg0NmE2YThhNGFiY2YzMDdhYzFjYi90YWJsZXJhbmdlOmMzZTM2YTc5OWE1ODQ2YTZhOGE0YWJjZjMwN2FjMWNiXzQtMy0xLTEtMjYxMjg_aff236cb-8f35-4e24-9adc-75205f2825a1">154</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has granted stock options to purchase its common stock to employees and consultants under the 2018 Plan that generally have a contractual life of up to <ix:nonNumeric contextRef="i2042fe817e6b415d99dcd18a2761b5b7_D20181001-20181001" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90ZXh0cmVnaW9uOjNkN2QyMGZlMGUyYjRkOTJiOTFjY2Y2OTIyNzY5M2VjXzI3NDg3NzkwODIzNjU_320cfbee-f62c-42d8-99b6-612099c3b1a7">10</ix:nonNumeric> years. The Company has also granted certain stock options outside of the 2018  Plan. As of December&#160;31, 2021, all equity awards granted from the 2018 Plan were in the form of stock options.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures equity-based awards granted to employees, and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for equity awards is the date of grant, and equity-based compensation costs are recognized as expense over the requisite service period, which is the vesting period or for certain performance-based awards. The Company records the expense for these awards if it concludes that it is probable that the performance condition will be achieved.</span></div><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90ZXh0cmVnaW9uOjNkN2QyMGZlMGUyYjRkOTJiOTFjY2Y2OTIyNzY5M2VjXzIxOTkwMjMyNjg3NDA_f94fa49b-e770-4785-aac1-f66ddd58bfda" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the year ended December&#160;31, 2021:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term&#160;(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzEtMS0xLTEtMjM2NDE_41a372bb-00e1-41f3-96b4-76bcd8785fb1">266,250</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzEtMy0xLTEtMjM2NDE_ffa9a5bf-5979-4c12-b700-f61abd355fa1">2.94</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7543349bff1e4b3d8106535d9eae2358_D20210101-20210331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzEtNS0xLTEtMjM2NDE_835812b2-3c7d-468a-84dd-7b706ac1624a">8.22</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzItMS0xLTEtMjM2NDE_6aeb7d29-2170-47bf-8cab-f02dadfd28df">442,240</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzItMy0xLTEtMjM2NDE_f9fc0dc3-21d5-4da9-b453-4c18386fa6b9">4.00</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzUtMS0xLTEtMjYxMzQ_beb021b7-c87c-4276-a365-9f732a167c47">708,490</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzUtMy0xLTEtMjM2NDE_4a58427c-9b6f-45ef-a96f-13747ba2ffbd">3.60</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzUtNS0xLTEtMjM2NDE_7680d65e-ed90-487a-8a1a-55464a2fcb2e">8.64</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercisable at December 31, 2021</span></td><td colspan="3" style="border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzYtMS0xLTEtMjM2NDE_cedfdb6a-8ef3-4a0d-a204-1f45501df0b0">205,888</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzYtMy0xLTEtMjM2NDE_bc7d39b5-650b-42b6-8cc3-4b0b442471b9">2.94</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzYtNS0xLTEtMjM2NDE_1ffc48c4-baac-463c-b995-5410abb4c741">7.80</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vested and expected to vest at December 31, 2021</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzctMS0xLTEtMjkxMDg_d751353d-c240-49e6-a274-ae2f9878de48">708,490</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzctMy0xLTEtMjkxMTY_05b97b78-02c4-4de1-a5fb-a82cf92ae6a7">3.60</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzctNS0xLTEtMjkxNjU_1e91c925-558a-4856-ab2e-d882abf5ebdc">8.64</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90ZXh0cmVnaW9uOjNkN2QyMGZlMGUyYjRkOTJiOTFjY2Y2OTIyNzY5M2VjXzIxOTkwMjMyNjg3NDE_d8d62c3e-f986-4a68-bcd3-272d068401ff" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.707%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTo4ZmI2MGU2OTIwODI0YmZjYjA2YWQ5MzgzYWU0YzczZC90YWJsZXJhbmdlOjhmYjYwZTY5MjA4MjRiZmNiMDZhZDkzODNhZTRjNzNkXzItMS0xLTEtMjM2NDE_258c57f7-41d2-484e-9e1d-c7c9bcd9e105">83.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTo4ZmI2MGU2OTIwODI0YmZjYjA2YWQ5MzgzYWU0YzczZC90YWJsZXJhbmdlOjhmYjYwZTY5MjA4MjRiZmNiMDZhZDkzODNhZTRjNzNkXzItMy0xLTEtMjM2NDE_f10e67ea-33eb-4ab0-a5cc-aa7a3495fc04">85.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTo4ZmI2MGU2OTIwODI0YmZjYjA2YWQ5MzgzYWU0YzczZC90YWJsZXJhbmdlOjhmYjYwZTY5MjA4MjRiZmNiMDZhZDkzODNhZTRjNzNkXzMtMS0xLTEtMjM2NDE_43e25e1f-512a-4360-82b2-7ae7b48aee19">5.85</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTo4ZmI2MGU2OTIwODI0YmZjYjA2YWQ5MzgzYWU0YzczZC90YWJsZXJhbmdlOjhmYjYwZTY5MjA4MjRiZmNiMDZhZDkzODNhZTRjNzNkXzMtMy0xLTEtMjM2NDE_8bd8d676-5465-4b78-82a5-cd75890a8504">5.80</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTo4ZmI2MGU2OTIwODI0YmZjYjA2YWQ5MzgzYWU0YzczZC90YWJsZXJhbmdlOjhmYjYwZTY5MjA4MjRiZmNiMDZhZDkzODNhZTRjNzNkXzQtMS0xLTEtMjM2NDE_a97ce02b-2a17-4cd5-a867-075d3410f686">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTo4ZmI2MGU2OTIwODI0YmZjYjA2YWQ5MzgzYWU0YzczZC90YWJsZXJhbmdlOjhmYjYwZTY5MjA4MjRiZmNiMDZhZDkzODNhZTRjNzNkXzQtMy0xLTEtMjM2NDE_42873156-053d-486c-8b30-568b26389938">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTo4ZmI2MGU2OTIwODI0YmZjYjA2YWQ5MzgzYWU0YzczZC90YWJsZXJhbmdlOjhmYjYwZTY5MjA4MjRiZmNiMDZhZDkzODNhZTRjNzNkXzUtMS0xLTEtMjM2NDE_05505e71-e020-4447-8a37-62f6865e7614">1.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTo4ZmI2MGU2OTIwODI0YmZjYjA2YWQ5MzgzYWU0YzczZC90YWJsZXJhbmdlOjhmYjYwZTY5MjA4MjRiZmNiMDZhZDkzODNhZTRjNzNkXzUtMy0xLTEtMjM2NDE_78420572-d451-4e11-ae5b-b49f779e81c7">0.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value of common stock on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTo4ZmI2MGU2OTIwODI0YmZjYjA2YWQ5MzgzYWU0YzczZC90YWJsZXJhbmdlOjhmYjYwZTY5MjA4MjRiZmNiMDZhZDkzODNhZTRjNzNkXzYtMS0xLTEtMjM2NDE_400ebfb6-3932-4b0f-94ab-652d9e670439">4.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTo4ZmI2MGU2OTIwODI0YmZjYjA2YWQ5MzgzYWU0YzczZC90YWJsZXJhbmdlOjhmYjYwZTY5MjA4MjRiZmNiMDZhZDkzODNhZTRjNzNkXzYtMy0xLTEtMjM2NDE_89ac8d83-7a33-4fae-b8bc-09f98a918446">4.72</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibe9ae04756bd485d965c68258b21b064">The aggregate intrinsic value of stock options outstanding and stock options exercisable as of December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90ZXh0cmVnaW9uOjNkN2QyMGZlMGUyYjRkOTJiOTFjY2Y2OTIyNzY5M2VjXzE2NDkyNjc0NTU3NDg_3860f3f1-6c2d-4797-a35d-b51d50e36cc8">1,716</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90ZXh0cmVnaW9uOjNkN2QyMGZlMGUyYjRkOTJiOTFjY2Y2OTIyNzY5M2VjXzE2NDkyNjc0NTU3NTU_1797c476-7b01-4e9b-97ea-0a065d610ad2">640</ix:nonFraction>, respectively. At December&#160;31, 2021, the unrecognized compensation cost related to unvested stock options expected to vest was $<ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90ZXh0cmVnaW9uOjNkN2QyMGZlMGUyYjRkOTJiOTFjY2Y2OTIyNzY5M2VjXzI3NDg3NzkwODA1MjQ_1f9ee6a1-5a68-4813-a770-0f520346c1a1">885</ix:nonFraction>. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of <ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90ZXh0cmVnaW9uOjNkN2QyMGZlMGUyYjRkOTJiOTFjY2Y2OTIyNzY5M2VjXzI3NDg3NzkwODA1Mjg_8001a681-f21f-41b3-b42c-17095e646ba0">2.49</ix:nonNumeric> years.</ix:continuation> </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><div id="i8c772b1568214a7294558171471dfda5_184"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90ZXh0cmVnaW9uOjkyMmVhMDE4OGZjZTRkZGQ4NWRmMTFiMzkxOWEzNWE4XzI1Mzk_b52ad8a7-2de7-4900-9fbd-50b2d46b1122" continuedAt="i141486d469574233b942d8d96d1eead8" escape="true">INCOME TAX</ix:nonNumeric></span></div><ix:continuation id="i141486d469574233b942d8d96d1eead8"><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90ZXh0cmVnaW9uOjkyMmVhMDE4OGZjZTRkZGQ4NWRmMTFiMzkxOWEzNWE4XzcxNDY4MjU1ODM1NTQ_12ddbd4c-16c8-4a46-9060-0400e9ad9d12" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense (benefit) at the US federal statutory income tax rate and the income tax provision in the financial statements is as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected income tax benefit at the federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZTo4MGQxNmYxNGQ5NzM0OTUzYmFkYmI3ZTJiZDc1Zjk4Yy90YWJsZXJhbmdlOjgwZDE2ZjE0ZDk3MzQ5NTNiYWRiYjdlMmJkNzVmOThjXzItMS0xLTEtMjU0MTY_1df9cfb1-0111-45b3-949b-cb0db63615e3">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZTo4MGQxNmYxNGQ5NzM0OTUzYmFkYmI3ZTJiZDc1Zjk4Yy90YWJsZXJhbmdlOjgwZDE2ZjE0ZDk3MzQ5NTNiYWRiYjdlMmJkNzVmOThjXzItMy0xLTEtMjU0NDk_0ab7de08-2a96-44d5-9c59-2dbccd9bef18">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">State and local taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZTo4MGQxNmYxNGQ5NzM0OTUzYmFkYmI3ZTJiZDc1Zjk4Yy90YWJsZXJhbmdlOjgwZDE2ZjE0ZDk3MzQ5NTNiYWRiYjdlMmJkNzVmOThjXzMtMS0xLTEtMjU0MTY_347afd1c-70d0-408c-8c16-cc59ceba87fd">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZTo4MGQxNmYxNGQ5NzM0OTUzYmFkYmI3ZTJiZDc1Zjk4Yy90YWJsZXJhbmdlOjgwZDE2ZjE0ZDk3MzQ5NTNiYWRiYjdlMmJkNzVmOThjXzMtMy0xLTEtMjU0NDk_555a18cb-7e3d-4416-8f20-bb1da079cbac">12.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-deductible items and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZTo4MGQxNmYxNGQ5NzM0OTUzYmFkYmI3ZTJiZDc1Zjk4Yy90YWJsZXJhbmdlOjgwZDE2ZjE0ZDk3MzQ5NTNiYWRiYjdlMmJkNzVmOThjXzUtMS0xLTEtMjU0MjM_d1b5bbac-d3a0-4799-9dd9-dabec3d8bd24">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZTo4MGQxNmYxNGQ5NzM0OTUzYmFkYmI3ZTJiZDc1Zjk4Yy90YWJsZXJhbmdlOjgwZDE2ZjE0ZDk3MzQ5NTNiYWRiYjdlMmJkNzVmOThjXzQtMy0xLTEtMjU0NTY_f44c6434-6a2b-4e65-b81d-bcb10d8cb285">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior year provision to return adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZTo4MGQxNmYxNGQ5NzM0OTUzYmFkYmI3ZTJiZDc1Zjk4Yy90YWJsZXJhbmdlOjgwZDE2ZjE0ZDk3MzQ5NTNiYWRiYjdlMmJkNzVmOThjXzYtMS0xLTEtMjU0MjM_90db3553-7fbe-4ad7-85eb-8db1acfc6168">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZTo4MGQxNmYxNGQ5NzM0OTUzYmFkYmI3ZTJiZDc1Zjk4Yy90YWJsZXJhbmdlOjgwZDE2ZjE0ZDk3MzQ5NTNiYWRiYjdlMmJkNzVmOThjXzUtMy0xLTEtMjU0NTY_2dfacc8f-50e8-41b9-902a-0fe5e75c8b28">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZTo4MGQxNmYxNGQ5NzM0OTUzYmFkYmI3ZTJiZDc1Zjk4Yy90YWJsZXJhbmdlOjgwZDE2ZjE0ZDk3MzQ5NTNiYWRiYjdlMmJkNzVmOThjXzgtMS0xLTEtMjU0MzA_e4269391-b851-449e-9e37-002ab61b26dd">31.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZTo4MGQxNmYxNGQ5NzM0OTUzYmFkYmI3ZTJiZDc1Zjk4Yy90YWJsZXJhbmdlOjgwZDE2ZjE0ZDk3MzQ5NTNiYWRiYjdlMmJkNzVmOThjXzYtMy0xLTEtMjU0NjM_afe1e45b-312c-47ef-ab7c-d5cedbeb4232">40.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZTo4MGQxNmYxNGQ5NzM0OTUzYmFkYmI3ZTJiZDc1Zjk4Yy90YWJsZXJhbmdlOjgwZDE2ZjE0ZDk3MzQ5NTNiYWRiYjdlMmJkNzVmOThjXzktMS0xLTEtMjU0MzA_503ddab9-2b81-420a-9da8-fe9f35a9b085">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZTo4MGQxNmYxNGQ5NzM0OTUzYmFkYmI3ZTJiZDc1Zjk4Yy90YWJsZXJhbmdlOjgwZDE2ZjE0ZDk3MzQ5NTNiYWRiYjdlMmJkNzVmOThjXzctMy0xLTEtMjU0NjM_20d37d0e-500c-4f79-9a32-b528fc6f6e8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</span></div><ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90ZXh0cmVnaW9uOjkyMmVhMDE4OGZjZTRkZGQ4NWRmMTFiMzkxOWEzNWE4XzI1NDE_7c2c0517-960a-44af-bb9b-b98f0353b0bd" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal components of the Company&#8217;s deferred tax assets  and liabilities are as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Federal and state net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzMtMS0xLTEtMjU1MDg_ec225afd-5283-42ad-a1c5-d44473b9066d">6,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzMtMy0xLTEtMjU1NDA_501d0362-6a1b-4ce9-b915-0ef9d0cf4826">3,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzQtMS0xLTEtMjU1MDg_4be9be90-d975-4b42-80a6-cfbd95761d7a">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzQtMy0xLTEtMjU1NDA_c017d2b0-21f9-4b45-a449-e2da91f8fe62">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="ck0001824293:DeferredTaxAssetsLeaseOligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzUtMS0xLTEtMjU1MDg_6c661e15-dae2-4178-80ee-4c37aa74ec48">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="ck0001824293:DeferredTaxAssetsLeaseOligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzUtMy0xLTEtMjU1NDA_daa0d696-29e1-4d66-a58c-52f94ae449a1">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accruals and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzctMS0xLTEtMjU1MTU_7d0a0878-77e7-4e3c-9582-ee76cd53a33a">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzctMy0xLTEtMjU1NDY_c19f1d35-dcb4-4954-829e-7f51555c3a47">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzgtMS0xLTEtMjU1MTU_61eec97c-8524-48f5-9183-c961a247594a">7,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzgtMy0xLTEtMjU1NTk_c4bd215e-9765-47da-a212-c5d973a608bf">4,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzktMS0xLTEtMjU1MjE_10afd87f-bb22-47bb-8855-91f643ca2066">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzktMy0xLTEtMjU1NjU_90829de2-8c90-4653-813a-0f41a44a09ef">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzEwLTEtMS0xLTI1NTI3_28a4c29d-28d0-4979-8e13-aeb30257f5a9">7,010</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzEwLTMtMS0xLTI1NTcx_925c6840-d505-408b-978d-b3068a3d9945">4,146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id84cb895052844b483a1ef69b0f12655_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzExLTEtMS0xLTI1NTMz_dff85afd-02c9-41d8-85e2-11de54cf94c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzExLTMtMS0xLTI1NTc3_ccf71a15-47c2-4b65-9fb5-3ea468911e3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s history of losses, the Company recorded a full valuation allowance against its deferred tax assets as of December&#160;31, 2021 and 2020. The Company increased its valuation allowance by approximately $<ix:nonFraction unitRef="usd" contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90ZXh0cmVnaW9uOjkyMmVhMDE4OGZjZTRkZGQ4NWRmMTFiMzkxOWEzNWE4XzI3NDg3NzkwNzIzNzg_69bf7880-816f-4746-883d-7706571a4372">2,864</ix:nonFraction> for the&#160;year ended December&#160;31, 2021. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support a reversal of the allowance.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had federal, state and local net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i1d5a202b2ddb4a648aebf40b599e2cf3_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90ZXh0cmVnaW9uOjkyMmVhMDE4OGZjZTRkZGQ4NWRmMTFiMzkxOWEzNWE4XzI3NDg3NzkwNzIzODY_7133128e-1261-4444-9c76-83e31a8eb02b">20,125</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i7f9b7fb9cf6a4e3a91f85fc43dab1e80_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90ZXh0cmVnaW9uOjkyMmVhMDE4OGZjZTRkZGQ4NWRmMTFiMzkxOWEzNWE4XzI3NDg3NzkwNzIzOTE_147cea5f-873d-414a-bb85-6ac52b046467">20,362</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="i2ffe46279ad1467fbb2755ef0532a308_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90ZXh0cmVnaW9uOjkyMmVhMDE4OGZjZTRkZGQ4NWRmMTFiMzkxOWEzNWE4XzI3NDg3NzkwNzIzOTc_3a95978a-c4f7-4e39-a1c8-ce003efd6cab">15,866</ix:nonFraction>, respectively. The federal net operating loss carryforwards do not expire. The state and local losses begin to expire in the&#160;year ending December&#160;31, 2038.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the provisions of Sections&#160;382 and 383 of the Internal Revenue Code (IRC), certain substantial changes in the Company&#8217;s ownership may have limited, or may limit in the future, the amount of net operating loss and credit carryforwards that can be used to reduce future income taxes if there has been a significant change in ownership of the Company, as defined by the IRC. Future owner or equity shifts could result in limitations on net operating loss and credit carryforwards.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of December&#160;31, 2021 and 2020, the Company had no unrecognized income tax benefits that would affect the Company&#8217;s effective tax rate if recognized. The Company would recognize both accrued interest and penalties related to unrecognized benefits in income tax expense. The Company&#8217;s uncertain tax positions yet to be determined would be related to years that remain subject to examination by relevant tax authorities. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><div id="i8c772b1568214a7294558171471dfda5_175"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i8c772b1568214a7294558171471dfda5_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzUvZnJhZzo0Zjc5YWJlOWZjOTU0OTE3OWZjMWNkNTdmZWNmZDZmZS90ZXh0cmVnaW9uOjRmNzlhYmU5ZmM5NTQ5MTc5ZmMxY2Q1N2ZlY2ZkNmZlXzE0MTI_7008e21e-8905-4d1f-a3b3-41492ad0956e" continuedAt="i3286e6255fdb46f6a955c90b514adfed" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><ix:continuation id="i3286e6255fdb46f6a955c90b514adfed"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2020, the Company&#160;entered into a license agreement with Medice which grants&#160;Medice&#160;an exclusive license, with the right to grant sublicenses, to develop, use, manufacture, market and sell ADAIR&#160;throughout&#160;Europe.&#160;&#160;Medice&#160;is responsible for obtaining regulatory approval of ADAIR in the licensed territory.&#160; Under the license agreement,&#160;Medice&#160;paid&#160;Vallon&#160;a $<ix:nonFraction unitRef="usd" contextRef="ib1b89a713dfe46188f25b2cff340c80d_D20200101-20200131" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzUvZnJhZzo0Zjc5YWJlOWZjOTU0OTE3OWZjMWNkNTdmZWNmZDZmZS90ZXh0cmVnaW9uOjRmNzlhYmU5ZmM5NTQ5MTc5ZmMxY2Q1N2ZlY2ZkNmZlXzU0OTc1NTgxNDI2MTg_9d1997bc-8e0b-4dc4-bd2a-348c449df715">100</ix:nonFraction> upfront payment&#160;and is required to pay milestone payments upon first obtaining regulatory approval to market and sell ADAIR in any country, territory or region in the licensed territory and upon achieving certain annual net sales thresholds.&#160;&#160;Medice&#160;will also pay tiered royalties on annual net sales of ADAIR at rates in the low double-digits. The initial term of the license agreement will expire <ix:nonNumeric contextRef="ib1b89a713dfe46188f25b2cff340c80d_D20200101-20200131" name="ck0001824293:RelatedPartyTransactionLicenseAgreementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzUvZnJhZzo0Zjc5YWJlOWZjOTU0OTE3OWZjMWNkNTdmZWNmZDZmZS90ZXh0cmVnaW9uOjRmNzlhYmU5ZmM5NTQ5MTc5ZmMxY2Q1N2ZlY2ZkNmZlXzU0OTc1NTgxNDI2Mjc_6436d258-ba3b-408a-b00f-ea5b6f8a68e0">five years</ix:nonNumeric> after the date on which&#160;Medice&#160;first obtains regulatory approval in any country, territory or region in the licensed territory. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#8217;s Chief Executive Officer, pursuant to which the Company issued the 2021 Convertible Notes for cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i3b1123c092e44fef8394165e79c1a211_D20210101-20210131" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzUvZnJhZzo0Zjc5YWJlOWZjOTU0OTE3OWZjMWNkNTdmZWNmZDZmZS90ZXh0cmVnaW9uOjRmNzlhYmU5ZmM5NTQ5MTc5ZmMxY2Q1N2ZlY2ZkNmZlXzIxOTkwMjMyNTg0Mzc_a7892222-2cc8-4700-bd3f-b11e42952644">350</ix:nonFraction>. The 2021 Convertible Notes bore an interest rate of <ix:nonFraction unitRef="number" contextRef="i55442e45b4004aa1ab3f8d35b70ac615_I20210131" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzUvZnJhZzo0Zjc5YWJlOWZjOTU0OTE3OWZjMWNkNTdmZWNmZDZmZS90ZXh0cmVnaW9uOjRmNzlhYmU5ZmM5NTQ5MTc5ZmMxY2Q1N2ZlY2ZkNmZlXzIxOTkwMjMyNTg0OTQ_1149d0fb-95fb-446a-a4e9-6252792ad5fe">7.0</ix:nonFraction>% per annum, non-compounding, and had a maturity date of September 30, 2021. The 2021 Convertible Notes converted into <ix:nonFraction unitRef="shares" contextRef="i3b1123c092e44fef8394165e79c1a211_D20210101-20210131" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzUvZnJhZzo0Zjc5YWJlOWZjOTU0OTE3OWZjMWNkNTdmZWNmZDZmZS90ZXh0cmVnaW9uOjRmNzlhYmU5ZmM5NTQ5MTc5ZmMxY2Q1N2ZlY2ZkNmZlXzIxOTkwMjMyNTg2MTU_e9abbe06-9b58-44b6-9504-3d21127a86d6">54,906</ix:nonFraction> shares of the Company&#8217;s common stock upon completion of the IPO.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>vlon-202110k_ex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8942b94bb9e148988cac7f42c0d969fd_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We consent to the incorporation by reference in the Registration Statement of Vallon Pharmaceuticals, Inc. on Form S-8 (No. 333-255972) of our report dated February 14, 2022, on our audits of the financial statements as of December 31, 2021 and 2020 and for each of the years then ended, which report is included in this Annual Report on Form 10-K to be filed on or about February 14, 2022.  Our report includes an explanatory paragraph about the existence of substantial doubt concerning the Company's ability to continue as a going concern. </font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; EisnerAmper LLP</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EISNERAMPER LLP</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Iselin, New Jersey</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 14, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>vlon-202110k_ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib7b558826a6f4d4093035cb19d6a854c_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE AND FINANCIAL OFFICER PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David Baker, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Vallon Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 14, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David Baker</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Baker</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive, Financial and Accounting Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>vlon-202110k_ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia1e5379ce479444fb22e17442c1e6a9e_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE AND FINANCIAL OFFICER PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Leanne Kelly, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Vallon Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 14, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Leanne Kelly</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leanne Kelly</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>vlon-202110k_ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i93b6e5198e5947739ee3474bd32c7efa_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE AND FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David Baker, President and Chief Executive Officer of Vallon Pharmaceuticals, Inc. (the Company), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the Annual Report on Form 10-K of the Company for the year ended December 31, 2021 (the Annual Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 14, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; David Baker</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Baker</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>vlon-202110k_ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1e94ed8c0ed94dc087febdf6fefd70d9_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE AND FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Leanne Kelly,  Chief Financial Officer of Vallon Pharmaceuticals, Inc. (the Company), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the Annual Report on Form 10-K of the Company for the year ended December 31, 2021 (the Annual Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 14, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Leanne Kelly</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leanne Kelly</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ck0001824293-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b31decee-d9de-40ed-b802-73f93418660f,g:197f3557-28e9-444a-8b20-482cd1ad7630-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ck0001824293="http://www.vallon-pharma.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.vallon-pharma.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.vallon-pharma.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.vallon-pharma.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheets" roleURI="http://www.vallon-pharma.com/role/BalanceSheets">
        <link:definition>1001003 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsParenthetical" roleURI="http://www.vallon-pharma.com/role/BalanceSheetsParenthetical">
        <link:definition>1002004 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementofOperationsandComprehensiveLoss" roleURI="http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss">
        <link:definition>1003005 - Statement - Statement of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofChangesinStockholdersEquityDeficit" roleURI="http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit">
        <link:definition>1004006 - Statement - Statements of Changes in Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofCashFlows" roleURI="http://www.vallon-pharma.com/role/StatementsofCashFlows">
        <link:definition>1005007 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDDESCRIPTIONOFBUSINESS" roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS">
        <link:definition>2101101 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIQUIDITY" roleURI="http://www.vallon-pharma.com/role/LIQUIDITY">
        <link:definition>2102102 - Disclosure - LIQUIDITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIQUIDITYDetails" roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails">
        <link:definition>2403401 - Disclosure - LIQUIDITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2104103 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2205201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRecapitalizationandLicenseRevenueDetails" roleURI="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRecapitalizationandLicenseRevenueDetails">
        <link:definition>2406402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recapitalization and License Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" roleURI="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails">
        <link:definition>2407403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS" roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS">
        <link:definition>2108104 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables" roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables">
        <link:definition>2309301 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails" roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails">
        <link:definition>2410404 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of the Company&#8217;s Available for Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails">
        <link:definition>2411405 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails">
        <link:definition>2412406 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.vallon-pharma.com/role/LEASES">
        <link:definition>2113105 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.vallon-pharma.com/role/LEASESTables">
        <link:definition>2314302 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESAssetsandLiabilitiesDetails" roleURI="http://www.vallon-pharma.com/role/LEASESAssetsandLiabilitiesDetails">
        <link:definition>2415407 - Disclosure - LEASES - Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESMaturityScheduleDetails" roleURI="http://www.vallon-pharma.com/role/LEASESMaturityScheduleDetails">
        <link:definition>2416408 - Disclosure - LEASES - Maturity Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESMaturityScheduleDetails_1" roleURI="http://www.vallon-pharma.com/role/LEASESMaturityScheduleDetails_1">
        <link:definition>2416408 - Disclosure - LEASES - Maturity Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSES" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES">
        <link:definition>2117106 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESTables" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables">
        <link:definition>2318303 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESDetails" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails">
        <link:definition>2419409 - Disclosure - ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PPPNOTEANDCONVERTIBLENOTES" roleURI="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES">
        <link:definition>2120107 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PPPNOTEANDCONVERTIBLENOTESDetails" roleURI="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails">
        <link:definition>2421410 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANS" roleURI="http://www.vallon-pharma.com/role/EMPLOYEEBENEFITPLANS">
        <link:definition>2122108 - Disclosure - EMPLOYEE BENEFIT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSDetails" roleURI="http://www.vallon-pharma.com/role/EMPLOYEEBENEFITPLANSDetails">
        <link:definition>2423411 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2124109 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESLitigationDetails" roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESLitigationDetails">
        <link:definition>2425412 - Disclosure - COMMITMENTS AND CONTINGENCIES - Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICIT" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICIT">
        <link:definition>2126110 - Disclosure - STOCKHOLDERS EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITTables" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables">
        <link:definition>2327304 - Disclosure - STOCKHOLDERS EQUITY (DEFICIT) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails">
        <link:definition>2428413 - Disclosure - STOCKHOLDERS EQUITY (DEFICIT) - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails">
        <link:definition>2429414 - Disclosure - STOCKHOLDERS EQUITY (DEFICIT) - Estimate of the Fair Value of the Warrants and Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>2130111 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>2331305 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>2432415 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>2433416 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails">
        <link:definition>2434417 - Disclosure - STOCK-BASED COMPENSATION - Activity of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails">
        <link:definition>2435418 - Disclosure - STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAX" roleURI="http://www.vallon-pharma.com/role/INCOMETAX">
        <link:definition>2136112 - Disclosure - INCOME TAX</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXTables" roleURI="http://www.vallon-pharma.com/role/INCOMETAXTables">
        <link:definition>2337306 - Disclosure - INCOME TAX (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails" roleURI="http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails">
        <link:definition>2438419 - Disclosure - INCOME TAX - Reconciliation of Federal Statutory Income Tax Rate to the Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXComponentsofDeferredTaxAssetsDetails" roleURI="http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxAssetsDetails">
        <link:definition>2439420 - Disclosure - INCOME TAX- Components of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails">
        <link:definition>2440421 - Disclosure - INCOME TAX - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>2141113 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSDetails" roleURI="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails">
        <link:definition>2442422 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS">
        <link:definition>2143114 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ck0001824293_MediceMember" abstract="true" name="MediceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" abstract="true" name="ConvertiblePromissoryNotePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear" abstract="false" name="ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ck0001824293_PaycheckProtectionProgramCARESActMember" abstract="true" name="PaycheckProtectionProgramCARESActMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_LeaseCashFlowInformationAbstract" abstract="true" name="LeaseCashFlowInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ck0001824293_DeferredTaxAssetsLeaseOligations" abstract="false" name="DeferredTaxAssetsLeaseOligations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ck0001824293_DebtInstrumentPaymentTerm" abstract="false" name="DebtInstrumentPaymentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ck0001824293_StateTaxAuthorityMember" abstract="true" name="StateTaxAuthorityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_StockIssuanceCostsDiscountsAndCommissions" abstract="false" name="StockIssuanceCostsDiscountsAndCommissions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ForgivenessOfDebtInstrument" abstract="false" name="ForgivenessOfDebtInstrument" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" abstract="false" name="AccruedResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_A2018EquityIncentivePlanMember" abstract="true" name="A2018EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_RelatedPartyTransactionLicenseAgreementTerm" abstract="false" name="RelatedPartyTransactionLicenseAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ck0001824293_StockIssuanceCostsOfferingExpenses" abstract="false" name="StockIssuanceCostsOfferingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" abstract="true" name="AffiliateOfMediceAndDavidBakerCEOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_LocalTaxAuthorityMember" abstract="true" name="LocalTaxAuthorityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_AccruedLicensingFeesCurrent" abstract="false" name="AccruedLicensingFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" abstract="false" name="AccruedGeneralAndAdministrativeExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_RendonVVallonIncEtAlMember" abstract="true" name="RendonVVallonIncEtAlMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>ck0001824293-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b31decee-d9de-40ed-b802-73f93418660f,g:197f3557-28e9-444a-8b20-482cd1ad7630-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BalanceSheets" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#BalanceSheets"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_302d2c85-f2c0-46ec-abb1-b9cc2e2b8786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_128074d7-dc05-4e72-ba81-273941a398b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_302d2c85-f2c0-46ec-abb1-b9cc2e2b8786" xlink:to="loc_us-gaap_Liabilities_128074d7-dc05-4e72-ba81-273941a398b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8472d54d-72e6-4503-8667-a6e13bec2f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_302d2c85-f2c0-46ec-abb1-b9cc2e2b8786" xlink:to="loc_us-gaap_StockholdersEquity_8472d54d-72e6-4503-8667-a6e13bec2f6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_908c7133-1617-46e9-8197-24fdc97c75b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_302d2c85-f2c0-46ec-abb1-b9cc2e2b8786" xlink:to="loc_us-gaap_CommitmentsAndContingencies_908c7133-1617-46e9-8197-24fdc97c75b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ad312781-1a73-41ee-b069-86fbfb5bc3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3d9c2ac8-436b-4d95-a084-f3506c27d45b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ad312781-1a73-41ee-b069-86fbfb5bc3c7" xlink:to="loc_us-gaap_AccountsPayableCurrent_3d9c2ac8-436b-4d95-a084-f3506c27d45b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_77863d87-c2cb-42dd-8afa-b0def3aa6a35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ad312781-1a73-41ee-b069-86fbfb5bc3c7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_77863d87-c2cb-42dd-8afa-b0def3aa6a35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0cd9f9b8-97c8-43ba-a377-858f7a1d6b82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ad312781-1a73-41ee-b069-86fbfb5bc3c7" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_0cd9f9b8-97c8-43ba-a377-858f7a1d6b82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_ce5e17ec-dad9-4219-b604-d5f3f2b232c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ad312781-1a73-41ee-b069-86fbfb5bc3c7" xlink:to="loc_us-gaap_NotesPayableCurrent_ce5e17ec-dad9-4219-b604-d5f3f2b232c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f966b293-3965-4fa0-a131-8bc977d7814f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_e1fc2d4e-30b4-4b31-8e04-fdc802a016d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f966b293-3965-4fa0-a131-8bc977d7814f" xlink:to="loc_us-gaap_CommonStockValueOutstanding_e1fc2d4e-30b4-4b31-8e04-fdc802a016d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f74f88c9-0a7f-486f-8b2b-ced0fd9d37e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f966b293-3965-4fa0-a131-8bc977d7814f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f74f88c9-0a7f-486f-8b2b-ced0fd9d37e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b645b56f-41ae-469c-b09c-a22f383a183c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f966b293-3965-4fa0-a131-8bc977d7814f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b645b56f-41ae-469c-b09c-a22f383a183c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1bdbc4b7-cde1-49f8-8ef1-6a46030e8055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f966b293-3965-4fa0-a131-8bc977d7814f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1bdbc4b7-cde1-49f8-8ef1-6a46030e8055" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8bff28ec-46f5-4b5a-9abb-dda8c6e88984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8dadafea-5e6f-45f5-8d9a-8131b953a74d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8bff28ec-46f5-4b5a-9abb-dda8c6e88984" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8dadafea-5e6f-45f5-8d9a-8131b953a74d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e120f252-9cb9-4ff9-9b77-9e408ed12cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8bff28ec-46f5-4b5a-9abb-dda8c6e88984" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e120f252-9cb9-4ff9-9b77-9e408ed12cc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0401150f-fe60-44f6-9c01-3b5712f60dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8bff28ec-46f5-4b5a-9abb-dda8c6e88984" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0401150f-fe60-44f6-9c01-3b5712f60dd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3c0c52a3-eaa6-4534-9766-cb31329679ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_487962d0-51b4-49d6-ba75-76e255b8feb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c0c52a3-eaa6-4534-9766-cb31329679ec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_487962d0-51b4-49d6-ba75-76e255b8feb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e8696572-a69a-4d62-b905-57dc6583902c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c0c52a3-eaa6-4534-9766-cb31329679ec" xlink:to="loc_us-gaap_AssetsCurrent_e8696572-a69a-4d62-b905-57dc6583902c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_54ebf589-0c14-4b08-81dc-5e398af3e95e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c0c52a3-eaa6-4534-9766-cb31329679ec" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_54ebf589-0c14-4b08-81dc-5e398af3e95e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5a13963c-1469-4ccb-82a6-8cfcf50453cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_82114a5e-2dfd-404c-b289-ce907e7a790f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5a13963c-1469-4ccb-82a6-8cfcf50453cf" xlink:to="loc_us-gaap_LongTermNotesPayable_82114a5e-2dfd-404c-b289-ce907e7a790f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3c432295-05b3-4b63-a2d3-88e93e2e7e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5a13963c-1469-4ccb-82a6-8cfcf50453cf" xlink:to="loc_us-gaap_LiabilitiesCurrent_3c432295-05b3-4b63-a2d3-88e93e2e7e01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ebd46481-0b6b-41f1-bf20-17a8cbfe0acc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5a13963c-1469-4ccb-82a6-8cfcf50453cf" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ebd46481-0b6b-41f1-bf20-17a8cbfe0acc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#StatementofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d6b3e77d-51ca-406f-ab8b-815197b5ae2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c64ab455-92a4-40f5-954d-4c1a96be6fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d6b3e77d-51ca-406f-ab8b-815197b5ae2a" xlink:to="loc_us-gaap_NetIncomeLoss_c64ab455-92a4-40f5-954d-4c1a96be6fb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_df04bdfc-2ba3-46df-996e-c08029b08abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d6b3e77d-51ca-406f-ab8b-815197b5ae2a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_df04bdfc-2ba3-46df-996e-c08029b08abe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_79c11e2c-d0f9-4913-9b05-10f72125128b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d2d3ea69-328d-4e3f-bd81-f528c474d36c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_79c11e2c-d0f9-4913-9b05-10f72125128b" xlink:to="loc_us-gaap_OperatingExpenses_d2d3ea69-328d-4e3f-bd81-f528c474d36c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3b62c544-8440-4561-91c4-d614a662421d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_79c11e2c-d0f9-4913-9b05-10f72125128b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3b62c544-8440-4561-91c4-d614a662421d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8bd7ae26-2374-4707-9e32-fccc264e2e58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a0d2cd48-4141-45d8-90a7-7acabdcc8b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8bd7ae26-2374-4707-9e32-fccc264e2e58" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a0d2cd48-4141-45d8-90a7-7acabdcc8b17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_85c0ddd9-f4cd-4f6c-9788-330b4abe2cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8bd7ae26-2374-4707-9e32-fccc264e2e58" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_85c0ddd9-f4cd-4f6c-9788-330b4abe2cf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bd4220e7-ae8e-45c1-857a-a0e1a177c1a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_083a987b-1098-4d1d-b99d-3971f4065313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_bd4220e7-ae8e-45c1-857a-a0e1a177c1a8" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_083a987b-1098-4d1d-b99d-3971f4065313" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_52cb0a47-4034-4a96-87b8-9a12fea3b046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_bd4220e7-ae8e-45c1-857a-a0e1a177c1a8" xlink:to="loc_us-gaap_OperatingIncomeLoss_52cb0a47-4034-4a96-87b8-9a12fea3b046" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_97bd7152-4fcb-4f95-bcec-b5bb217d7dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_bd4220e7-ae8e-45c1-857a-a0e1a177c1a8" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_97bd7152-4fcb-4f95-bcec-b5bb217d7dab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_149efefd-0079-4455-b6a5-ca126d2a3032" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_bd4220e7-ae8e-45c1-857a-a0e1a177c1a8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_149efefd-0079-4455-b6a5-ca126d2a3032" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#StatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f5ef301-ba9c-40f2-abdd-4944d03eaade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_cb95e7c0-c8b9-474d-8a26-e3c98725b63a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f5ef301-ba9c-40f2-abdd-4944d03eaade" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_cb95e7c0-c8b9-474d-8a26-e3c98725b63a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_322c358c-8a8b-44e1-add2-dfcef8255866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f5ef301-ba9c-40f2-abdd-4944d03eaade" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_322c358c-8a8b-44e1-add2-dfcef8255866" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7d800cbc-f5ee-44c0-8224-981cee3b392e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f5ef301-ba9c-40f2-abdd-4944d03eaade" xlink:to="loc_us-gaap_NetIncomeLoss_7d800cbc-f5ee-44c0-8224-981cee3b392e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7cb02ed3-e4ba-4429-a270-5a5c4635a994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f5ef301-ba9c-40f2-abdd-4944d03eaade" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7cb02ed3-e4ba-4429-a270-5a5c4635a994" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4689106a-d63c-4fe4-831b-745019b5bc18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f5ef301-ba9c-40f2-abdd-4944d03eaade" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4689106a-d63c-4fe4-831b-745019b5bc18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_54553671-f321-4b41-9682-02554c7c08a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f5ef301-ba9c-40f2-abdd-4944d03eaade" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_54553671-f321-4b41-9682-02554c7c08a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense_0161b155-8aad-4275-83d3-a8edc116e4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f5ef301-ba9c-40f2-abdd-4944d03eaade" xlink:to="loc_us-gaap_OtherNoncashExpense_0161b155-8aad-4275-83d3-a8edc116e4f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_921e9c02-9730-48c5-8efb-ca908dd5ff26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f5ef301-ba9c-40f2-abdd-4944d03eaade" xlink:to="loc_us-gaap_ShareBasedCompensation_921e9c02-9730-48c5-8efb-ca908dd5ff26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_cc3f1187-352a-4b1c-b739-eb246d082238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f5ef301-ba9c-40f2-abdd-4944d03eaade" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_cc3f1187-352a-4b1c-b739-eb246d082238" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_144067c6-4ecb-4d17-b79f-31945ffb875b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f5ef301-ba9c-40f2-abdd-4944d03eaade" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_144067c6-4ecb-4d17-b79f-31945ffb875b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d60ff321-bf18-4d46-81b2-08236793079d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_32b80032-77c1-4f97-a24d-7b30721f6aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d60ff321-bf18-4d46-81b2-08236793079d" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_32b80032-77c1-4f97-a24d-7b30721f6aa8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3672e4b9-7797-4678-882b-d03a057e3a82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d60ff321-bf18-4d46-81b2-08236793079d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3672e4b9-7797-4678-882b-d03a057e3a82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6ead4ce8-e2e2-4196-a109-5ea7be3df80d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_66179d6f-d444-46d1-851b-a70ba164fe50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6ead4ce8-e2e2-4196-a109-5ea7be3df80d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_66179d6f-d444-46d1-851b-a70ba164fe50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c30fcbda-da9f-4f9b-a6be-8a49397a9e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6ead4ce8-e2e2-4196-a109-5ea7be3df80d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c30fcbda-da9f-4f9b-a6be-8a49397a9e88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a9f8be30-438c-45fd-8dce-b479942c03fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6ead4ce8-e2e2-4196-a109-5ea7be3df80d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a9f8be30-438c-45fd-8dce-b479942c03fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b2f3254e-50a9-45fc-9f46-a6c7b2b036e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_abd75c59-da74-492f-aa01-2f1865bca308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b2f3254e-50a9-45fc-9f46-a6c7b2b036e0" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_abd75c59-da74-492f-aa01-2f1865bca308" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_57badb8b-1cef-4fe3-82f5-294680c20021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b2f3254e-50a9-45fc-9f46-a6c7b2b036e0" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_57badb8b-1cef-4fe3-82f5-294680c20021" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_679bad6d-bb09-47fa-9add-8fd758d8a1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b2f3254e-50a9-45fc-9f46-a6c7b2b036e0" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_679bad6d-bb09-47fa-9add-8fd758d8a1ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_d3f5cf1d-b00f-4c1b-93db-f12f3ea13ede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b2f3254e-50a9-45fc-9f46-a6c7b2b036e0" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_d3f5cf1d-b00f-4c1b-93db-f12f3ea13ede" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_d885e8e3-c12a-41a6-ae1f-2b89d6a53c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b2f3254e-50a9-45fc-9f46-a6c7b2b036e0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_d885e8e3-c12a-41a6-ae1f-2b89d6a53c4b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cd806195-5202-4f63-af2d-f837e5dd340a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_06cc6640-5408-4db1-8f24-2120b4fe9f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cd806195-5202-4f63-af2d-f837e5dd340a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_06cc6640-5408-4db1-8f24-2120b4fe9f24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_95c61960-3228-4d01-9b51-ba74ce022d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cd806195-5202-4f63-af2d-f837e5dd340a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_95c61960-3228-4d01-9b51-ba74ce022d18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b1ea9013-6226-4c0b-9199-7d4b660a40e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cd806195-5202-4f63-af2d-f837e5dd340a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b1ea9013-6226-4c0b-9199-7d4b660a40e9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LEASESAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#LEASESAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/LEASESAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_57d8993b-df82-4ce8-9a5d-de130811b26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_632825ee-67d8-45e9-80c3-e52beae0d979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_57d8993b-df82-4ce8-9a5d-de130811b26d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_632825ee-67d8-45e9-80c3-e52beae0d979" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_fbb29f47-2349-41b5-a66c-75256edf9165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_57d8993b-df82-4ce8-9a5d-de130811b26d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_fbb29f47-2349-41b5-a66c-75256edf9165" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LEASESMaturityScheduleDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#LEASESMaturityScheduleDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/LEASESMaturityScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_a7a6875b-fed8-4097-b9f1-a7a1aa905cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_35a2e4b6-dd45-47e4-9703-69edf5e5cf99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_a7a6875b-fed8-4097-b9f1-a7a1aa905cc0" xlink:to="loc_us-gaap_FinanceLeaseLiability_35a2e4b6-dd45-47e4-9703-69edf5e5cf99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_1ddb792c-0ec9-454f-9c52-40e695182fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_a7a6875b-fed8-4097-b9f1-a7a1aa905cc0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_1ddb792c-0ec9-454f-9c52-40e695182fb5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LEASESMaturityScheduleDetails_1" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#LEASESMaturityScheduleDetails_1"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/LEASESMaturityScheduleDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_28169725-1087-43f8-9214-43b2d7f735f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_c50201ac-5ed5-4093-8d08-114207f6a86e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_28169725-1087-43f8-9214-43b2d7f735f1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_c50201ac-5ed5-4093-8d08-114207f6a86e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_0c216012-40bb-4ec8-ade7-ec83e9c86920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_28169725-1087-43f8-9214-43b2d7f735f1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_0c216012-40bb-4ec8-ade7-ec83e9c86920" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#ACCRUEDEXPENSESDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_59acf8f6-51ac-475a-bd9b-5c737cb66fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_c475be39-cc44-4d14-9999-146c8c79f75c" xlink:href="ck0001824293-20211231.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_59acf8f6-51ac-475a-bd9b-5c737cb66fd2" xlink:to="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_c475be39-cc44-4d14-9999-146c8c79f75c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedLicensingFeesCurrent_ff5a78ec-0667-47bf-ab0e-12ecfe96b19b" xlink:href="ck0001824293-20211231.xsd#ck0001824293_AccruedLicensingFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_59acf8f6-51ac-475a-bd9b-5c737cb66fd2" xlink:to="loc_ck0001824293_AccruedLicensingFeesCurrent_ff5a78ec-0667-47bf-ab0e-12ecfe96b19b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_b3d1e51d-a305-425c-a485-919afccac8fa" xlink:href="ck0001824293-20211231.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_59acf8f6-51ac-475a-bd9b-5c737cb66fd2" xlink:to="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_b3d1e51d-a305-425c-a485-919afccac8fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_20a23fc2-e5d5-42d0-ae46-c8777eecebce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_59acf8f6-51ac-475a-bd9b-5c737cb66fd2" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_20a23fc2-e5d5-42d0-ae46-c8777eecebce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_757c7513-60d9-4516-81cd-0c133831f452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_59acf8f6-51ac-475a-bd9b-5c737cb66fd2" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_757c7513-60d9-4516-81cd-0c133831f452" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0f994266-da15-47f9-bcdc-861f079e0876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_573d85e4-a899-459b-a2ec-ed7819e7c7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0f994266-da15-47f9-bcdc-861f079e0876" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_573d85e4-a899-459b-a2ec-ed7819e7c7e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_5f3c5fed-0f9c-4b55-a968-b3984a6a038a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0f994266-da15-47f9-bcdc-861f079e0876" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_5f3c5fed-0f9c-4b55-a968-b3984a6a038a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_cf91b983-8438-4638-ab6f-5195d3fb1cab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0f994266-da15-47f9-bcdc-861f079e0876" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_cf91b983-8438-4638-ab6f-5195d3fb1cab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_bef28de0-3987-4d99-990b-e114e7136cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0f994266-da15-47f9-bcdc-861f079e0876" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_bef28de0-3987-4d99-990b-e114e7136cc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_d14e2b0b-f7c6-42ad-96a7-b0f0dee343c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0f994266-da15-47f9-bcdc-861f079e0876" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_d14e2b0b-f7c6-42ad-96a7-b0f0dee343c5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#INCOMETAXComponentsofDeferredTaxAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_130c5e13-18b0-4d50-9623-5e5339dfaecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_e116723b-0a00-483b-bb0b-3dd145e69cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_130c5e13-18b0-4d50-9623-5e5339dfaecf" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_e116723b-0a00-483b-bb0b-3dd145e69cdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_0022aba0-54b9-4ac9-920b-d3dbb3f64a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_130c5e13-18b0-4d50-9623-5e5339dfaecf" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_0022aba0-54b9-4ac9-920b-d3dbb3f64a6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DeferredTaxAssetsLeaseOligations_2996cca7-1daf-4772-a9c4-45853540fd7d" xlink:href="ck0001824293-20211231.xsd#ck0001824293_DeferredTaxAssetsLeaseOligations"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_130c5e13-18b0-4d50-9623-5e5339dfaecf" xlink:to="loc_ck0001824293_DeferredTaxAssetsLeaseOligations_2996cca7-1daf-4772-a9c4-45853540fd7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_721d78e9-dc25-41c5-abfb-ffcea6262233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_130c5e13-18b0-4d50-9623-5e5339dfaecf" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_721d78e9-dc25-41c5-abfb-ffcea6262233" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_cd20f2e3-31e7-4864-be98-2cc98848e054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ef89a7db-aca9-4751-93e5-c412424662e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_cd20f2e3-31e7-4864-be98-2cc98848e054" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_ef89a7db-aca9-4751-93e5-c412424662e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a361f04f-f7ba-485a-bc31-6ed7352d0bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_cd20f2e3-31e7-4864-be98-2cc98848e054" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a361f04f-f7ba-485a-bc31-6ed7352d0bfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_8a796766-b1ad-4e1b-bf47-fbbd93d7676b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_cd20f2e3-31e7-4864-be98-2cc98848e054" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_8a796766-b1ad-4e1b-bf47-fbbd93d7676b" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>ck0001824293-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b31decee-d9de-40ed-b802-73f93418660f,g:197f3557-28e9-444a-8b20-482cd1ad7630-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#StatementsofChangesinStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit" xlink:type="extended" id="i8c3691f88d894db88e7c42b837763924_StatementsofChangesinStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e4610e18-5054-46fc-8a91-2e7380170e63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e4610e18-5054-46fc-8a91-2e7380170e63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e3097957-cb89-467e-b476-f7715f855175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_StockholdersEquity_e3097957-cb89-467e-b476-f7715f855175" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b7639dbf-eab9-42ea-adee-21e9c682d8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b7639dbf-eab9-42ea-adee-21e9c682d8a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9069c1c4-c3d7-46ff-923d-1ee3f06b4fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9069c1c4-c3d7-46ff-923d-1ee3f06b4fd2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_03ae68de-e200-4ee1-9d71-d03a28ca4fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_03ae68de-e200-4ee1-9d71-d03a28ca4fc0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9e36a109-62ba-43e4-bda3-7a1487ab45b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9e36a109-62ba-43e4-bda3-7a1487ab45b4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_fac95a75-effb-4baa-95e5-0af7833ac669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_fac95a75-effb-4baa-95e5-0af7833ac669" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_5148357c-d132-4324-9b92-20413b382981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_5148357c-d132-4324-9b92-20413b382981" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_b065e223-4bee-4eb5-ada1-6beeab56f5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_b065e223-4bee-4eb5-ada1-6beeab56f5e7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d46c2a84-4a7e-49b1-b0a8-8f79b58c4f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d46c2a84-4a7e-49b1-b0a8-8f79b58c4f7d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_632fa7d9-b693-4f86-9d3b-5817ca459925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_632fa7d9-b693-4f86-9d3b-5817ca459925" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7d04d168-62e9-465e-91e5-8f2a788da214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_NetIncomeLoss_7d04d168-62e9-465e-91e5-8f2a788da214" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a679048c-2988-49f6-830c-a244b8bb92c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c8dde59b-6316-45c6-93d2-d3519e9fc49f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9e73f28d-1e96-4fa2-b25a-72a4184d7c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_StatementTable_9e73f28d-1e96-4fa2-b25a-72a4184d7c9b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_db5665e5-3bcc-454e-9441-698f61f761aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9e73f28d-1e96-4fa2-b25a-72a4184d7c9b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_db5665e5-3bcc-454e-9441-698f61f761aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_db5665e5-3bcc-454e-9441-698f61f761aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_db5665e5-3bcc-454e-9441-698f61f761aa" xlink:to="loc_us-gaap_EquityComponentDomain_db5665e5-3bcc-454e-9441-698f61f761aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8bb90a41-24cf-4cba-9f23-804a9113430a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_db5665e5-3bcc-454e-9441-698f61f761aa" xlink:to="loc_us-gaap_EquityComponentDomain_8bb90a41-24cf-4cba-9f23-804a9113430a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_46daf73b-c532-4a1e-b3c4-482b3d61cb98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8bb90a41-24cf-4cba-9f23-804a9113430a" xlink:to="loc_us-gaap_CommonStockMember_46daf73b-c532-4a1e-b3c4-482b3d61cb98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_651efe98-45c5-4ba7-b6eb-142c24617476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8bb90a41-24cf-4cba-9f23-804a9113430a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_651efe98-45c5-4ba7-b6eb-142c24617476" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4bdf1dd5-1916-4bcc-85b1-4cc6d35c18d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8bb90a41-24cf-4cba-9f23-804a9113430a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4bdf1dd5-1916-4bcc-85b1-4cc6d35c18d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_fc96f770-1ede-4214-bf17-8cb2189d5107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8bb90a41-24cf-4cba-9f23-804a9113430a" xlink:to="loc_us-gaap_RetainedEarningsMember_fc96f770-1ede-4214-bf17-8cb2189d5107" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#LIQUIDITYDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="extended" id="ie40d9577b38a4cb3b488c1a7c955bfe4_LIQUIDITYDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f7d79e70-2b85-43ce-ba6d-5d0dc4139696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_929983e3-27db-4337-95c6-559a209bec06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f7d79e70-2b85-43ce-ba6d-5d0dc4139696" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_929983e3-27db-4337-95c6-559a209bec06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_085c3127-d6f7-4790-a7fe-1b1251e97b48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f7d79e70-2b85-43ce-ba6d-5d0dc4139696" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_085c3127-d6f7-4790-a7fe-1b1251e97b48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_96c6d403-b5c4-42c5-8c4c-932b16829e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f7d79e70-2b85-43ce-ba6d-5d0dc4139696" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_96c6d403-b5c4-42c5-8c4c-932b16829e3e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_7b6b6068-bd22-4f48-b912-c703afacb689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f7d79e70-2b85-43ce-ba6d-5d0dc4139696" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_7b6b6068-bd22-4f48-b912-c703afacb689" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7a248369-3a2c-4101-a4a9-336febcb67b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_f7d79e70-2b85-43ce-ba6d-5d0dc4139696" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7a248369-3a2c-4101-a4a9-336febcb67b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_743037fb-fd0a-4e68-b274-77bf6278dd85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7a248369-3a2c-4101-a4a9-336febcb67b8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_743037fb-fd0a-4e68-b274-77bf6278dd85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_743037fb-fd0a-4e68-b274-77bf6278dd85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_743037fb-fd0a-4e68-b274-77bf6278dd85" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_743037fb-fd0a-4e68-b274-77bf6278dd85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dae31d7b-4d06-4f03-943c-919084feea01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_743037fb-fd0a-4e68-b274-77bf6278dd85" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dae31d7b-4d06-4f03-943c-919084feea01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_b882021d-40c6-4e13-b61d-96ff12c5d2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dae31d7b-4d06-4f03-943c-919084feea01" xlink:to="loc_us-gaap_IPOMember_b882021d-40c6-4e13-b61d-96ff12c5d2c9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" xlink:type="extended" id="i1afe5f0e01a242cdacbb409d22551377_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1498bf4b-a2b9-462a-9965-1b593cf245e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_3ef18546-965c-49dc-a051-fc72890e8feb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1498bf4b-a2b9-462a-9965-1b593cf245e8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_3ef18546-965c-49dc-a051-fc72890e8feb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2c8e99ac-0478-43c6-82e1-1a38bde02969" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1498bf4b-a2b9-462a-9965-1b593cf245e8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2c8e99ac-0478-43c6-82e1-1a38bde02969" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f7232b80-ccdb-47d4-8398-045c72ffe1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2c8e99ac-0478-43c6-82e1-1a38bde02969" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f7232b80-ccdb-47d4-8398-045c72ffe1c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f7232b80-ccdb-47d4-8398-045c72ffe1c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f7232b80-ccdb-47d4-8398-045c72ffe1c5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f7232b80-ccdb-47d4-8398-045c72ffe1c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_267cb62c-2cb6-4abb-aa9c-1d46ba46520e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f7232b80-ccdb-47d4-8398-045c72ffe1c5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_267cb62c-2cb6-4abb-aa9c-1d46ba46520e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_d30b7872-c4e0-43ec-aa66-ba0b2753d1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_267cb62c-2cb6-4abb-aa9c-1d46ba46520e" xlink:to="loc_us-gaap_ComputerEquipmentMember_d30b7872-c4e0-43ec-aa66-ba0b2753d1f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_2f302f59-8017-4b4a-a326-18a47c49b0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_267cb62c-2cb6-4abb-aa9c-1d46ba46520e" xlink:to="loc_us-gaap_EquipmentMember_2f302f59-8017-4b4a-a326-18a47c49b0f9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails" xlink:type="extended" id="i300ea3220c704b088b144fb5342f569d_MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_f340668a-09f5-469e-889d-cf2b2695d5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d20f1c95-f243-452c-aa98-75179b177b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f340668a-09f5-469e-889d-cf2b2695d5c7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d20f1c95-f243-452c-aa98-75179b177b9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a3669dd7-94cd-40ea-85ed-7fcb4434f613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f340668a-09f5-469e-889d-cf2b2695d5c7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a3669dd7-94cd-40ea-85ed-7fcb4434f613" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_eafb7166-920a-45aa-adf2-e0d14f62898e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f340668a-09f5-469e-889d-cf2b2695d5c7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_eafb7166-920a-45aa-adf2-e0d14f62898e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b2eaac5c-daf6-4163-871a-e1fb6f3a51b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f340668a-09f5-469e-889d-cf2b2695d5c7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b2eaac5c-daf6-4163-871a-e1fb6f3a51b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_c79a2646-1537-4ce6-a153-a2948d0e60e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f340668a-09f5-469e-889d-cf2b2695d5c7" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_c79a2646-1537-4ce6-a153-a2948d0e60e1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_78cf7813-385c-4649-8062-7a700639616c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_c79a2646-1537-4ce6-a153-a2948d0e60e1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_78cf7813-385c-4649-8062-7a700639616c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78cf7813-385c-4649-8062-7a700639616c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_78cf7813-385c-4649-8062-7a700639616c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_78cf7813-385c-4649-8062-7a700639616c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d081e095-d2f4-48e6-b3c8-7978144ff2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_78cf7813-385c-4649-8062-7a700639616c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d081e095-d2f4-48e6-b3c8-7978144ff2cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_7a54617e-f4c6-4bf6-8a6b-3cb68bee0a93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d081e095-d2f4-48e6-b3c8-7978144ff2cf" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_7a54617e-f4c6-4bf6-8a6b-3cb68bee0a93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_6f940adc-fa66-43ca-b287-99585a8d05d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d081e095-d2f4-48e6-b3c8-7978144ff2cf" xlink:to="loc_us-gaap_MunicipalBondsMember_6f940adc-fa66-43ca-b287-99585a8d05d0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails" xlink:type="extended" id="i3a60649dc534482c9546742072046708_MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c59b3cf1-874b-4557-9892-95c5e06113d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1eeec8e2-77f6-4d1c-8fd4-b512d0a460fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c59b3cf1-874b-4557-9892-95c5e06113d8" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1eeec8e2-77f6-4d1c-8fd4-b512d0a460fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5a6e349b-d14a-4053-8e38-b98ab1c25e90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c59b3cf1-874b-4557-9892-95c5e06113d8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5a6e349b-d14a-4053-8e38-b98ab1c25e90" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_bfcf5427-63dc-4a23-adf9-2b924877572d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5a6e349b-d14a-4053-8e38-b98ab1c25e90" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_bfcf5427-63dc-4a23-adf9-2b924877572d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_bfcf5427-63dc-4a23-adf9-2b924877572d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_bfcf5427-63dc-4a23-adf9-2b924877572d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_bfcf5427-63dc-4a23-adf9-2b924877572d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_314cd63f-0490-42b1-b1b5-2cbefed77924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_bfcf5427-63dc-4a23-adf9-2b924877572d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_314cd63f-0490-42b1-b1b5-2cbefed77924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_7f1c2237-4c08-420a-b969-113fe90e5a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_314cd63f-0490-42b1-b1b5-2cbefed77924" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_7f1c2237-4c08-420a-b969-113fe90e5a63" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="extended" id="i60ffa5c37bdf419da1b376866b2029c0_MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_43ee9af2-01d3-49b0-9198-f2b07a53e93b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2f199a8a-e26a-4e08-9a35-2a1f64f89928" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_43ee9af2-01d3-49b0-9198-f2b07a53e93b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2f199a8a-e26a-4e08-9a35-2a1f64f89928" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_18f8b783-fe0c-4774-ab49-20467a31b1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_43ee9af2-01d3-49b0-9198-f2b07a53e93b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_18f8b783-fe0c-4774-ab49-20467a31b1e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_e1999ff2-5dc8-48a1-bc67-034083bb18e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_43ee9af2-01d3-49b0-9198-f2b07a53e93b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_e1999ff2-5dc8-48a1-bc67-034083bb18e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6f9cabe0-0e59-435e-87b2-459ef312dcfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5dc1f6b8-d41b-4087-8dfe-9f5b71533e75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_43ee9af2-01d3-49b0-9198-f2b07a53e93b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5dc1f6b8-d41b-4087-8dfe-9f5b71533e75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_3b370d58-644e-4f6b-8a65-4c94474833b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5dc1f6b8-d41b-4087-8dfe-9f5b71533e75" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_3b370d58-644e-4f6b-8a65-4c94474833b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3b370d58-644e-4f6b-8a65-4c94474833b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_3b370d58-644e-4f6b-8a65-4c94474833b9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_3b370d58-644e-4f6b-8a65-4c94474833b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_537ae67d-f7aa-4800-ba33-44794b9c2af2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_3b370d58-644e-4f6b-8a65-4c94474833b9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_537ae67d-f7aa-4800-ba33-44794b9c2af2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_243bda8e-13ed-4b43-91b5-47bbffd6b72d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_537ae67d-f7aa-4800-ba33-44794b9c2af2" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_243bda8e-13ed-4b43-91b5-47bbffd6b72d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#PPPNOTEANDCONVERTIBLENOTESDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails" xlink:type="extended" id="ib854babd82894b91a8220480c0849c2b_PPPNOTEANDCONVERTIBLENOTESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_48d2fe18-9dac-405b-8848-fbd0c0b35622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0d7f9a06-d41a-4321-bce5-231329344725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48d2fe18-9dac-405b-8848-fbd0c0b35622" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0d7f9a06-d41a-4321-bce5-231329344725" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5ac8167c-8472-4aab-8e38-097a00b857b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48d2fe18-9dac-405b-8848-fbd0c0b35622" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5ac8167c-8472-4aab-8e38-097a00b857b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_a72f0d61-27c1-4c56-bcfe-ea75966f94f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48d2fe18-9dac-405b-8848-fbd0c0b35622" xlink:to="loc_us-gaap_DebtInstrumentTerm_a72f0d61-27c1-4c56-bcfe-ea75966f94f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentPaymentTerm_52becb63-3b93-42b9-a104-618de46f06dd" xlink:href="ck0001824293-20211231.xsd#ck0001824293_DebtInstrumentPaymentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48d2fe18-9dac-405b-8848-fbd0c0b35622" xlink:to="loc_ck0001824293_DebtInstrumentPaymentTerm_52becb63-3b93-42b9-a104-618de46f06dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ForgivenessOfDebtInstrument_2f628837-7a17-442c-b52b-6b027cfafb84" xlink:href="ck0001824293-20211231.xsd#ck0001824293_ForgivenessOfDebtInstrument"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48d2fe18-9dac-405b-8848-fbd0c0b35622" xlink:to="loc_ck0001824293_ForgivenessOfDebtInstrument_2f628837-7a17-442c-b52b-6b027cfafb84" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_cb8307f3-a608-4bd4-abbd-cbdc5eef3681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48d2fe18-9dac-405b-8848-fbd0c0b35622" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_cb8307f3-a608-4bd4-abbd-cbdc5eef3681" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ef0be5a8-468f-4fed-bd62-f38ed2424116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_0503b936-e077-4498-80e1-1c2cccb68763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48d2fe18-9dac-405b-8848-fbd0c0b35622" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_0503b936-e077-4498-80e1-1c2cccb68763" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1109a452-fbe2-41fc-bf56-bb6d2331349b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48d2fe18-9dac-405b-8848-fbd0c0b35622" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1109a452-fbe2-41fc-bf56-bb6d2331349b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_87513798-134f-4d59-8d73-a122a2cc3e21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1109a452-fbe2-41fc-bf56-bb6d2331349b" xlink:to="loc_us-gaap_DebtInstrumentAxis_87513798-134f-4d59-8d73-a122a2cc3e21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_87513798-134f-4d59-8d73-a122a2cc3e21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_87513798-134f-4d59-8d73-a122a2cc3e21" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_87513798-134f-4d59-8d73-a122a2cc3e21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7dd0cbfe-38ec-421f-b3c8-342b5fafa716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_87513798-134f-4d59-8d73-a122a2cc3e21" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7dd0cbfe-38ec-421f-b3c8-342b5fafa716" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaycheckProtectionProgramCARESActMember_38c4e1a8-c482-4ca6-a5c9-37961ec3d497" xlink:href="ck0001824293-20211231.xsd#ck0001824293_PaycheckProtectionProgramCARESActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7dd0cbfe-38ec-421f-b3c8-342b5fafa716" xlink:to="loc_ck0001824293_PaycheckProtectionProgramCARESActMember_38c4e1a8-c482-4ca6-a5c9-37961ec3d497" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9fda991f-76cd-4eba-9520-54850904377f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1109a452-fbe2-41fc-bf56-bb6d2331349b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9fda991f-76cd-4eba-9520-54850904377f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9fda991f-76cd-4eba-9520-54850904377f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9fda991f-76cd-4eba-9520-54850904377f" xlink:to="loc_us-gaap_RelatedPartyDomain_9fda991f-76cd-4eba-9520-54850904377f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2990aa6c-aab9-4a1b-9b5c-e4f7233172e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9fda991f-76cd-4eba-9520-54850904377f" xlink:to="loc_us-gaap_RelatedPartyDomain_2990aa6c-aab9-4a1b-9b5c-e4f7233172e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_b3ff73bb-da5b-4626-acfc-a40379d703b7" xlink:href="ck0001824293-20211231.xsd#ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2990aa6c-aab9-4a1b-9b5c-e4f7233172e5" xlink:to="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_b3ff73bb-da5b-4626-acfc-a40379d703b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_48ef677a-8202-4aa8-ab82-1b124cf3b95f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1109a452-fbe2-41fc-bf56-bb6d2331349b" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_48ef677a-8202-4aa8-ab82-1b124cf3b95f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_48ef677a-8202-4aa8-ab82-1b124cf3b95f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_48ef677a-8202-4aa8-ab82-1b124cf3b95f" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_48ef677a-8202-4aa8-ab82-1b124cf3b95f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d39272f5-c3d8-4341-a1b6-5008f14c73d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_48ef677a-8202-4aa8-ab82-1b124cf3b95f" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d39272f5-c3d8-4341-a1b6-5008f14c73d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_5122ef83-1af0-4ba6-8281-c90ea37f1419" xlink:href="ck0001824293-20211231.xsd#ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d39272f5-c3d8-4341-a1b6-5008f14c73d2" xlink:to="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_5122ef83-1af0-4ba6-8281-c90ea37f1419" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#EMPLOYEEBENEFITPLANSDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="extended" id="i632723dba7da4b679777a88bb831e0c6_EMPLOYEEBENEFITPLANSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_656b8736-0bf1-4fec-b679-c56b384fbafb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_583d2c0e-9ea3-4938-9560-e3cea24d6cad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_656b8736-0bf1-4fec-b679-c56b384fbafb" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_583d2c0e-9ea3-4938-9560-e3cea24d6cad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1adfbc7f-27d1-4a5d-b0ac-acf5008c4686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_656b8736-0bf1-4fec-b679-c56b384fbafb" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1adfbc7f-27d1-4a5d-b0ac-acf5008c4686" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable_c482fe7d-9c41-4ba2-b490-379454c5cf4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_656b8736-0bf1-4fec-b679-c56b384fbafb" xlink:to="loc_us-gaap_DefinedContributionPlanTable_c482fe7d-9c41-4ba2-b490-379454c5cf4c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_85c6423e-52a9-4dd3-8209-04d155116890" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_c482fe7d-9c41-4ba2-b490-379454c5cf4c" xlink:to="loc_srt_RangeAxis_85c6423e-52a9-4dd3-8209-04d155116890" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_85c6423e-52a9-4dd3-8209-04d155116890_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_85c6423e-52a9-4dd3-8209-04d155116890" xlink:to="loc_srt_RangeMember_85c6423e-52a9-4dd3-8209-04d155116890_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_516b49a6-07c6-46c8-8e16-72a7cd29acc5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_85c6423e-52a9-4dd3-8209-04d155116890" xlink:to="loc_srt_RangeMember_516b49a6-07c6-46c8-8e16-72a7cd29acc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9c5a03c5-c168-4b3d-acc7-9aba944e649f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_516b49a6-07c6-46c8-8e16-72a7cd29acc5" xlink:to="loc_srt_MaximumMember_9c5a03c5-c168-4b3d-acc7-9aba944e649f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESLitigationDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#COMMITMENTSANDCONTINGENCIESLitigationDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESLitigationDetails" xlink:type="extended" id="i42b4db4d0493479b973454eba7ebf48c_COMMITMENTSANDCONTINGENCIESLitigationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_1d4d57df-5250-4edc-98b6-6488c42b9383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_bd709ca7-b53f-4200-b61b-65b1a0106453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1d4d57df-5250-4edc-98b6-6488c42b9383" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_bd709ca7-b53f-4200-b61b-65b1a0106453" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_7015a01a-b1d4-4c74-bbc1-d0299b23e8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_1d4d57df-5250-4edc-98b6-6488c42b9383" xlink:to="loc_us-gaap_LossContingenciesTable_7015a01a-b1d4-4c74-bbc1-d0299b23e8e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_babc4dda-28e3-4ff8-b68b-46f68bbe849c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7015a01a-b1d4-4c74-bbc1-d0299b23e8e7" xlink:to="loc_srt_LitigationCaseAxis_babc4dda-28e3-4ff8-b68b-46f68bbe849c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_babc4dda-28e3-4ff8-b68b-46f68bbe849c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_babc4dda-28e3-4ff8-b68b-46f68bbe849c" xlink:to="loc_srt_LitigationCaseTypeDomain_babc4dda-28e3-4ff8-b68b-46f68bbe849c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c8442b69-deea-445f-893f-3f31e9d07247" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_babc4dda-28e3-4ff8-b68b-46f68bbe849c" xlink:to="loc_srt_LitigationCaseTypeDomain_c8442b69-deea-445f-893f-3f31e9d07247" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RendonVVallonIncEtAlMember_66bd03f4-c41c-4da3-92f9-3e84ac9f745d" xlink:href="ck0001824293-20211231.xsd#ck0001824293_RendonVVallonIncEtAlMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c8442b69-deea-445f-893f-3f31e9d07247" xlink:to="loc_ck0001824293_RendonVVallonIncEtAlMember_66bd03f4-c41c-4da3-92f9-3e84ac9f745d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_ea5780b0-d9be-4d68-aef5-a1fe9319cebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7015a01a-b1d4-4c74-bbc1-d0299b23e8e7" xlink:to="loc_us-gaap_LitigationStatusAxis_ea5780b0-d9be-4d68-aef5-a1fe9319cebf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_ea5780b0-d9be-4d68-aef5-a1fe9319cebf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_ea5780b0-d9be-4d68-aef5-a1fe9319cebf" xlink:to="loc_us-gaap_LitigationStatusDomain_ea5780b0-d9be-4d68-aef5-a1fe9319cebf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_623f7fee-80e0-4dfc-8f1c-cc76eb9d8c84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_ea5780b0-d9be-4d68-aef5-a1fe9319cebf" xlink:to="loc_us-gaap_LitigationStatusDomain_623f7fee-80e0-4dfc-8f1c-cc76eb9d8c84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_d3cd69c7-41e9-4736-86a8-a68f3e3e710f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_623f7fee-80e0-4dfc-8f1c-cc76eb9d8c84" xlink:to="loc_us-gaap_SettledLitigationMember_d3cd69c7-41e9-4736-86a8-a68f3e3e710f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#STOCKHOLDERSEQUITYDEFICITNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails" xlink:type="extended" id="i463fee0a9a644c1f8c971c2e1cefb61b_STOCKHOLDERSEQUITYDEFICITNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0745e762-2b18-46c4-903d-cf1e620dbe2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_23d71c61-8ce7-4d03-9ce8-bad9fd6881f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0745e762-2b18-46c4-903d-cf1e620dbe2f" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_23d71c61-8ce7-4d03-9ce8-bad9fd6881f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_71381723-be08-42c9-9048-4054a9ef0df3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0745e762-2b18-46c4-903d-cf1e620dbe2f" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_71381723-be08-42c9-9048-4054a9ef0df3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_79b63474-c701-4535-a7cb-caa8bf131cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0745e762-2b18-46c4-903d-cf1e620dbe2f" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_79b63474-c701-4535-a7cb-caa8bf131cf3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_ea45280e-97a1-42fa-b888-c40c687f659c" xlink:href="ck0001824293-20211231.xsd#ck0001824293_StockIssuanceCostsDiscountsAndCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0745e762-2b18-46c4-903d-cf1e620dbe2f" xlink:to="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_ea45280e-97a1-42fa-b888-c40c687f659c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_0ff32db6-44d8-456e-a7a9-dd245576b9b4" xlink:href="ck0001824293-20211231.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0745e762-2b18-46c4-903d-cf1e620dbe2f" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_0ff32db6-44d8-456e-a7a9-dd245576b9b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c0693b71-60b2-4498-a25f-fb6ea9db7970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0745e762-2b18-46c4-903d-cf1e620dbe2f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c0693b71-60b2-4498-a25f-fb6ea9db7970" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9d4951bd-af4c-4983-84cd-3c4d0557daf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0745e762-2b18-46c4-903d-cf1e620dbe2f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9d4951bd-af4c-4983-84cd-3c4d0557daf9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_5ffd55d1-d998-46b6-8ab8-5ebe8466e9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0745e762-2b18-46c4-903d-cf1e620dbe2f" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_5ffd55d1-d998-46b6-8ab8-5ebe8466e9a6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_48437fa9-ea7d-4fcd-886f-d93fb7db1eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0745e762-2b18-46c4-903d-cf1e620dbe2f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_48437fa9-ea7d-4fcd-886f-d93fb7db1eb0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c453fff6-1a1e-4981-9151-d564fed58895" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_48437fa9-ea7d-4fcd-886f-d93fb7db1eb0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c453fff6-1a1e-4981-9151-d564fed58895" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c453fff6-1a1e-4981-9151-d564fed58895_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c453fff6-1a1e-4981-9151-d564fed58895" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c453fff6-1a1e-4981-9151-d564fed58895_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_243a60e1-a1ab-4dd2-be6a-98f75f5cd4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c453fff6-1a1e-4981-9151-d564fed58895" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_243a60e1-a1ab-4dd2-be6a-98f75f5cd4a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_b5cc26d0-9647-4897-998e-a32683d4a29a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_243a60e1-a1ab-4dd2-be6a-98f75f5cd4a5" xlink:to="loc_us-gaap_IPOMember_b5cc26d0-9647-4897-998e-a32683d4a29a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_54a1c25c-c776-4f3e-a3f1-56612045e3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_243a60e1-a1ab-4dd2-be6a-98f75f5cd4a5" xlink:to="loc_us-gaap_OverAllotmentOptionMember_54a1c25c-c776-4f3e-a3f1-56612045e3b7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="extended" id="i6a12d414314b4d7ca01fa8294d5fb78a_STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9655c693-5bbf-4ca5-a13a-372e67e9f43c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_767fdb99-3cae-4439-8202-ab2dc2c13173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9655c693-5bbf-4ca5-a13a-372e67e9f43c" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_767fdb99-3cae-4439-8202-ab2dc2c13173" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3304681f-f279-4568-a434-903518f1355b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_9655c693-5bbf-4ca5-a13a-372e67e9f43c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3304681f-f279-4568-a434-903518f1355b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_bc5bef13-b900-4355-b6c5-fb62f124940a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3304681f-f279-4568-a434-903518f1355b" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_bc5bef13-b900-4355-b6c5-fb62f124940a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_bc5bef13-b900-4355-b6c5-fb62f124940a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_bc5bef13-b900-4355-b6c5-fb62f124940a" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_bc5bef13-b900-4355-b6c5-fb62f124940a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_19d3847c-293c-474f-be16-b7a5a76835cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_bc5bef13-b900-4355-b6c5-fb62f124940a" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_19d3847c-293c-474f-be16-b7a5a76835cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_df4e61a9-9cbd-437b-8258-9f64c6cebfa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_19d3847c-293c-474f-be16-b7a5a76835cf" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_df4e61a9-9cbd-437b-8258-9f64c6cebfa4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_56f2bafe-a1a6-4b76-ad6e-d1c4ddce4185" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_19d3847c-293c-474f-be16-b7a5a76835cf" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_56f2bafe-a1a6-4b76-ad6e-d1c4ddce4185" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_11c545c4-782b-437d-b58b-5354ead2e1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_19d3847c-293c-474f-be16-b7a5a76835cf" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_11c545c4-782b-437d-b58b-5354ead2e1a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3e49c2c9-f6f2-4644-a6d1-cf719f3fcb47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_19d3847c-293c-474f-be16-b7a5a76835cf" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3e49c2c9-f6f2-4644-a6d1-cf719f3fcb47" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="i30fb115900e3406986e084c2ea3a7eb9_STOCKBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fbc1f81-1efd-44e3-972b-d899d7ca4074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear_640a80cb-2e22-40c0-bcac-8d2968649833" xlink:href="ck0001824293-20211231.xsd#ck0001824293_ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fbc1f81-1efd-44e3-972b-d899d7ca4074" xlink:to="loc_ck0001824293_ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear_640a80cb-2e22-40c0-bcac-8d2968649833" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c29ab095-feb3-422a-b608-b24f45b76790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fbc1f81-1efd-44e3-972b-d899d7ca4074" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c29ab095-feb3-422a-b608-b24f45b76790" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_bfc3dc55-aafe-4e42-876d-030cf7e536dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fbc1f81-1efd-44e3-972b-d899d7ca4074" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_bfc3dc55-aafe-4e42-876d-030cf7e536dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a60e5578-7cf3-4648-bae1-20b45f5f2d95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fbc1f81-1efd-44e3-972b-d899d7ca4074" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a60e5578-7cf3-4648-bae1-20b45f5f2d95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_276a44cd-e1a3-4d2d-a579-c7ef4223230e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fbc1f81-1efd-44e3-972b-d899d7ca4074" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_276a44cd-e1a3-4d2d-a579-c7ef4223230e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a887b0a4-ca7b-4966-814a-9c314391ec1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fbc1f81-1efd-44e3-972b-d899d7ca4074" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a887b0a4-ca7b-4966-814a-9c314391ec1f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7be6c419-33f2-4439-b0fc-36279d92d191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fbc1f81-1efd-44e3-972b-d899d7ca4074" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7be6c419-33f2-4439-b0fc-36279d92d191" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3f85ca49-9e35-4352-bd7d-e1456324268a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fbc1f81-1efd-44e3-972b-d899d7ca4074" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3f85ca49-9e35-4352-bd7d-e1456324268a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ae6d20a3-0c87-4a1e-b394-260478eb7577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3f85ca49-9e35-4352-bd7d-e1456324268a" xlink:to="loc_us-gaap_PlanNameAxis_ae6d20a3-0c87-4a1e-b394-260478eb7577" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ae6d20a3-0c87-4a1e-b394-260478eb7577_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_ae6d20a3-0c87-4a1e-b394-260478eb7577" xlink:to="loc_us-gaap_PlanNameDomain_ae6d20a3-0c87-4a1e-b394-260478eb7577_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8d1f5586-3866-47b7-b554-08cdb2219d83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_ae6d20a3-0c87-4a1e-b394-260478eb7577" xlink:to="loc_us-gaap_PlanNameDomain_8d1f5586-3866-47b7-b554-08cdb2219d83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_A2018EquityIncentivePlanMember_e1269e9e-9627-4a70-804b-0bd40b81d503" xlink:href="ck0001824293-20211231.xsd#ck0001824293_A2018EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8d1f5586-3866-47b7-b554-08cdb2219d83" xlink:to="loc_ck0001824293_A2018EquityIncentivePlanMember_e1269e9e-9627-4a70-804b-0bd40b81d503" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended" id="i64ad4a173b484a3994bd16a51b81210f_STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_effdf421-8e38-4260-a81e-a44ef045b7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8411801f-7418-4af1-839b-3cb5c64dbce4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_effdf421-8e38-4260-a81e-a44ef045b7b0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8411801f-7418-4af1-839b-3cb5c64dbce4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_01b770bc-c323-45b7-b6c3-a971395a153e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_effdf421-8e38-4260-a81e-a44ef045b7b0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_01b770bc-c323-45b7-b6c3-a971395a153e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a5df791b-ac77-49a1-92c4-a221d3488636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_01b770bc-c323-45b7-b6c3-a971395a153e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a5df791b-ac77-49a1-92c4-a221d3488636" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a5df791b-ac77-49a1-92c4-a221d3488636_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a5df791b-ac77-49a1-92c4-a221d3488636" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a5df791b-ac77-49a1-92c4-a221d3488636_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_79b26ae7-89b9-403a-b6b0-c608b8bb6e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a5df791b-ac77-49a1-92c4-a221d3488636" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_79b26ae7-89b9-403a-b6b0-c608b8bb6e0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_37efdd91-18f0-40fb-b87f-05ae8629b742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_79b26ae7-89b9-403a-b6b0-c608b8bb6e0a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_37efdd91-18f0-40fb-b87f-05ae8629b742" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_b360c4ed-89f1-4d63-9813-3ee01e4481d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_79b26ae7-89b9-403a-b6b0-c608b8bb6e0a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_b360c4ed-89f1-4d63-9813-3ee01e4481d3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#INCOMETAXNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails" xlink:type="extended" id="if5833df745f6467e9d0d9f7ea1c1ba62_INCOMETAXNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_c9e4e584-fd69-4b12-8550-34f860736a99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_3ecafc8d-25e2-495b-938f-7efc7bee2d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c9e4e584-fd69-4b12-8550-34f860736a99" xlink:to="loc_us-gaap_OperatingLossCarryforwards_3ecafc8d-25e2-495b-938f-7efc7bee2d2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_b39d7b01-4a57-4eff-b7d3-91b88c414026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c9e4e584-fd69-4b12-8550-34f860736a99" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_b39d7b01-4a57-4eff-b7d3-91b88c414026" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_7c78d13a-f6bd-4054-bcff-02b80cec18d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_b39d7b01-4a57-4eff-b7d3-91b88c414026" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_7c78d13a-f6bd-4054-bcff-02b80cec18d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_7c78d13a-f6bd-4054-bcff-02b80cec18d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_7c78d13a-f6bd-4054-bcff-02b80cec18d9" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_7c78d13a-f6bd-4054-bcff-02b80cec18d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_66812205-6637-4d64-a39b-bcb30e3d4cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_7c78d13a-f6bd-4054-bcff-02b80cec18d9" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_66812205-6637-4d64-a39b-bcb30e3d4cf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_16434840-0ff9-4b09-a745-b20436a083da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_66812205-6637-4d64-a39b-bcb30e3d4cf0" xlink:to="loc_us-gaap_DomesticCountryMember_16434840-0ff9-4b09-a745-b20436a083da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StateTaxAuthorityMember_df689240-fe5f-4d1e-823c-f8466fbd489d" xlink:href="ck0001824293-20211231.xsd#ck0001824293_StateTaxAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_66812205-6637-4d64-a39b-bcb30e3d4cf0" xlink:to="loc_ck0001824293_StateTaxAuthorityMember_df689240-fe5f-4d1e-823c-f8466fbd489d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_LocalTaxAuthorityMember_325782d7-a8fe-4b4f-b348-50ab107f5fb6" xlink:href="ck0001824293-20211231.xsd#ck0001824293_LocalTaxAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_66812205-6637-4d64-a39b-bcb30e3d4cf0" xlink:to="loc_ck0001824293_LocalTaxAuthorityMember_325782d7-a8fe-4b4f-b348-50ab107f5fb6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended" id="i38be4e19684641deae8984a1f3987fec_RELATEDPARTYTRANSACTIONSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1c9d07a8-4331-4a4b-a632-1cd07d92c01d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8dace6a6-7c03-47c7-b3c3-3ed4a3725755" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1c9d07a8-4331-4a4b-a632-1cd07d92c01d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8dace6a6-7c03-47c7-b3c3-3ed4a3725755" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm_0f24c209-de42-4cf9-b0fd-e0b4e0bd58ab" xlink:href="ck0001824293-20211231.xsd#ck0001824293_RelatedPartyTransactionLicenseAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1c9d07a8-4331-4a4b-a632-1cd07d92c01d" xlink:to="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm_0f24c209-de42-4cf9-b0fd-e0b4e0bd58ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_aca20d58-229f-4a7a-8e5d-a1893e3d43c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1c9d07a8-4331-4a4b-a632-1cd07d92c01d" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_aca20d58-229f-4a7a-8e5d-a1893e3d43c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e9ce6557-280e-478e-9c5f-5889b98da0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1c9d07a8-4331-4a4b-a632-1cd07d92c01d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e9ce6557-280e-478e-9c5f-5889b98da0c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_31be03d1-57e2-44b7-a5f7-37c1909e677c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1c9d07a8-4331-4a4b-a632-1cd07d92c01d" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_31be03d1-57e2-44b7-a5f7-37c1909e677c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ab5e2acf-2cdd-4f48-834d-115eeccf939e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1c9d07a8-4331-4a4b-a632-1cd07d92c01d" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ab5e2acf-2cdd-4f48-834d-115eeccf939e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fb2a996a-f727-4947-8adb-46cf808537d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ab5e2acf-2cdd-4f48-834d-115eeccf939e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fb2a996a-f727-4947-8adb-46cf808537d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_fb2a996a-f727-4947-8adb-46cf808537d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fb2a996a-f727-4947-8adb-46cf808537d2" xlink:to="loc_us-gaap_RelatedPartyDomain_fb2a996a-f727-4947-8adb-46cf808537d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_18ef6671-aee3-4dd0-9f24-57519a1bc1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fb2a996a-f727-4947-8adb-46cf808537d2" xlink:to="loc_us-gaap_RelatedPartyDomain_18ef6671-aee3-4dd0-9f24-57519a1bc1d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_MediceMember_72e68769-7a56-4a8c-8699-d6f060b059e1" xlink:href="ck0001824293-20211231.xsd#ck0001824293_MediceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_18ef6671-aee3-4dd0-9f24-57519a1bc1d9" xlink:to="loc_ck0001824293_MediceMember_72e68769-7a56-4a8c-8699-d6f060b059e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_74d397e8-24f7-43ba-8f85-6723f53c7c30" xlink:href="ck0001824293-20211231.xsd#ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_18ef6671-aee3-4dd0-9f24-57519a1bc1d9" xlink:to="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_74d397e8-24f7-43ba-8f85-6723f53c7c30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_b10f19b5-c630-4088-abc8-da6ab49a2631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ab5e2acf-2cdd-4f48-834d-115eeccf939e" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_b10f19b5-c630-4088-abc8-da6ab49a2631" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_b10f19b5-c630-4088-abc8-da6ab49a2631_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b10f19b5-c630-4088-abc8-da6ab49a2631" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_b10f19b5-c630-4088-abc8-da6ab49a2631_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_c6bb1ee6-64d2-468f-88fc-450ced40b516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b10f19b5-c630-4088-abc8-da6ab49a2631" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_c6bb1ee6-64d2-468f-88fc-450ced40b516" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_0959c266-b0af-4ef9-8280-7120d2b483fa" xlink:href="ck0001824293-20211231.xsd#ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_c6bb1ee6-64d2-468f-88fc-450ced40b516" xlink:to="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_0959c266-b0af-4ef9-8280-7120d2b483fa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>ck0001824293-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b31decee-d9de-40ed-b802-73f93418660f,g:197f3557-28e9-444a-8b20-482cd1ad7630-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_8fb6ff48-f81d-4cee-a033-ec32bc70a455_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_b3bee5fc-3029-42b7-b3f3-ceb65acc9934_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_cd1a77e0-e110-4fb1-b845-c41a6543005d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_c0a5cd90-2112-4473-ba11-d968b1d842fb_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_326f5b1b-16cf-4497-9c1c-51d418b3d590_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected income tax benefit at the federal statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_3edf3c13-d9a6-4d10-bfae-892b6131cdfe_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_ae0273f0-e172-4397-a52a-c998c366cc8b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_89871413-d07f-49db-a02c-34e5fb373599_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_4bd6e039-dc98-43fc-bd62-a705e40be80f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_29db8bdd-28bd-416c-a082-c9d6901a398c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_414bd6fe-a882-499a-a785-b12762949d51_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_a23b34ba-bec7-483d-b421-b8f1da91777d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and related</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_1c4805fa-1757-4a25-944d-f6e3d7d3bb0a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm_8d6239cf-421e-4d49-b780-b490cdfef259_terseLabel_en-US" xlink:label="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, term</link:label>
    <link:label id="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm_label_en-US" xlink:label="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, License Agreement, Term</link:label>
    <link:label id="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm_documentation_en-US" xlink:label="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, License Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm" xlink:href="ck0001824293-20211231.xsd#ck0001824293_RelatedPartyTransactionLicenseAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm" xlink:to="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_033fc945-96ef-41bc-993e-1c4d57a13b70_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of option on grant date (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_7e083c0f-1ce6-410e-b506-ac894df67d50_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_08f42484-76bf-415c-80cd-9c39f0458001_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_03b75875-d00d-4f6d-8d6a-c2e1b3b03ef6_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_9e9c2992-37b5-4015-9aed-316dbe8925ee_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior year provision to return adjustments</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_bd4c824d-f2f7-4ef6-bdad-71056fcc0c8d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock awards, contractual life (up to)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_691bf956-c830-4ecc-92c0-7885e82536fa_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_59dedb9b-85a7-4251-8412-88cd62c29a7d_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_369dce4b-598f-4f85-81aa-3c62b6f1f772_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_eae7335c-f04d-4f2b-86bc-8a8ce0bc1878_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_4f6c6aba-3313-486a-8613-0307a07da410_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3776b3e9-9457-4ab7-a89b-4c6ddcd9b470_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0705eee6-3c0d-4d98-ac6e-927baaa157f2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_72e80cf0-8ec6-4aba-b405-31602cce89e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_86c12081-2e51-4709-b6fd-fdfcf4a60295_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_6eb00cd3-c344-4668-8488-62d1b7053964_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in-capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4ed43441-bf07-4b3f-a7e3-6d1e7da8e3e8_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7ece47bc-2ae0-43b0-a428-047ecd77745c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activity for the Liability Measured at Estimated Fair Value Using Unobservable Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_993dc228-7cce-4e37-88d1-ec3dac7f8acb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cf057260-4a79-46e9-984e-a6e6ad312265_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_127357f4-4a98-4a31-845a-99e1183a0c06_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2d9a6005-f3e5-4401-98d8-b1182b3730da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_0e8d19b5-5cc3-4b45-954a-d918da04bbf7_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a076d50c-824f-4dcb-a1c4-981bb1363211_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_67e40237-cdd2-491d-b7ec-be7572a17af0_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_5f814edb-1d46-47f1-8008-bf9194f9319c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_08932e47-faa2-470e-b27a-cb17c717ba55_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_afb0a624-2769-44d2-9f69-21012e06015a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_234a030d-1795-4a90-9024-67acb4348f1a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b53aadbc-299a-4b8f-b612-e684ed9a6597_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_945c55d4-436a-46f6-9df4-3a4b9715f252_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_654b00ac-1071-4868-91f6-d4199ba46109_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_f17908f1-55c0-471b-994b-b95e95c24beb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_57e18243-f6c1-40f4-b056-b9d02763efad_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_4a208046-d52a-4f02-9b5b-01d499ddf7d5_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedLicensingFeesCurrent_647be7a8-358a-48cd-b4a7-8e4b8ec448c0_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedLicensingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing related</link:label>
    <link:label id="lab_ck0001824293_AccruedLicensingFeesCurrent_label_en-US" xlink:label="lab_ck0001824293_AccruedLicensingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Licensing Fees, Current</link:label>
    <link:label id="lab_ck0001824293_AccruedLicensingFeesCurrent_documentation_en-US" xlink:label="lab_ck0001824293_AccruedLicensingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Licensing Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedLicensingFeesCurrent" xlink:href="ck0001824293-20211231.xsd#ck0001824293_AccruedLicensingFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedLicensingFeesCurrent" xlink:to="lab_ck0001824293_AccruedLicensingFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_b61619a8-b276-4c7c-a644-b3dcdb47067b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_736882f5-885e-4cb8-8875-7e69714eadef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_372e32bb-181d-43ce-a075-44398f8ca2d9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_d93f7674-2d36-413e-91e2-870c954ef866_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Underwriters Warrants</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_c3c2c4e1-4de8-4ea1-9a44-62aa95b54d11_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_46cac73f-cacd-4a4d-a9a5-cc60ec97f65b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance, increase</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_5bf65426-b299-435d-8e50-ad128ce4eab2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1296da6c-1c11-46b4-b970-cce9f1c55e75_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_a4da17e1-28e1-48e3-ae33-e50dd0224140_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_8795fd5b-6c3a-4614-9dbc-cd1360f34c99_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_48c9de2f-1c6b-4676-bb17-28acc849ad6c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StateTaxAuthorityMember_9f0e2e9a-b280-4975-b93f-f1c4ac3fc468_terseLabel_en-US" xlink:label="lab_ck0001824293_StateTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_ck0001824293_StateTaxAuthorityMember_label_en-US" xlink:label="lab_ck0001824293_StateTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State Tax Authority [Member]</link:label>
    <link:label id="lab_ck0001824293_StateTaxAuthorityMember_documentation_en-US" xlink:label="lab_ck0001824293_StateTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State Tax Authority</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StateTaxAuthorityMember" xlink:href="ck0001824293-20211231.xsd#ck0001824293_StateTaxAuthorityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StateTaxAuthorityMember" xlink:to="lab_ck0001824293_StateTaxAuthorityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_86572ab7-ab71-4ff2-bf6f-8b2cb386088a_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_bf53c330-77f6-4513-8f08-878dadfe35f9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_MediceMember_2f27e38a-707a-4742-a54d-e648f3e5bc0f_terseLabel_en-US" xlink:label="lab_ck0001824293_MediceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medice</link:label>
    <link:label id="lab_ck0001824293_MediceMember_label_en-US" xlink:label="lab_ck0001824293_MediceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medice [Member]</link:label>
    <link:label id="lab_ck0001824293_MediceMember_documentation_en-US" xlink:label="lab_ck0001824293_MediceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_MediceMember" xlink:href="ck0001824293-20211231.xsd#ck0001824293_MediceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_MediceMember" xlink:to="lab_ck0001824293_MediceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_LocalTaxAuthorityMember_4620914d-734d-40d6-bcaa-70e901dd6bdd_terseLabel_en-US" xlink:label="lab_ck0001824293_LocalTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local</link:label>
    <link:label id="lab_ck0001824293_LocalTaxAuthorityMember_label_en-US" xlink:label="lab_ck0001824293_LocalTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Tax Authority [Member]</link:label>
    <link:label id="lab_ck0001824293_LocalTaxAuthorityMember_documentation_en-US" xlink:label="lab_ck0001824293_LocalTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Tax Authority</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_LocalTaxAuthorityMember" xlink:href="ck0001824293-20211231.xsd#ck0001824293_LocalTaxAuthorityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_LocalTaxAuthorityMember" xlink:to="lab_ck0001824293_LocalTaxAuthorityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_735bffd2-dce3-4782-b43f-aa8f26e658f3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_ce73e26d-26ac-4d23-a8e6-38a92cd476d7_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_eb9e32cf-3190-4d5f-beb0-d1c2b3c0ed70_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on marketable securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_5be1fa1b-7fd5-44b3-a972-895fe88dacac_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes, converted, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_da683467-ee12-45db-a4c4-6461fd27d19d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermNotesPayable_ed5866f8-9938-480f-990d-7dadfaa1af0e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note payable, non-current</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="lab_us-gaap_LongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_79cfb8dd-466d-4c87-b79f-8c3633a65df2_terseLabel_en-US" xlink:label="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Promissory Note Purchase Agreement</link:label>
    <link:label id="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_label_en-US" xlink:label="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Promissory Note Purchase Agreement [Member]</link:label>
    <link:label id="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_documentation_en-US" xlink:label="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Promissory Note Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:href="ck0001824293-20211231.xsd#ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:to="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_18dd1924-59d2-4659-8cb4-5c7d2ec082b8_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_46bc4832-a54a-46ef-ae6f-80e8bc5e4e80_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ec3995c5-928b-436b-b21b-cdb71ab1dbe5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term&#160;(years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_27961abe-ef5f-4ad2-ae7c-f6f81be32cca_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_73e755d0-2842-48a9-8014-fe46c1657fa3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e586dbdf-ed0c-4818-97dd-ddeb09cf7217_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_f9898f8a-8ca4-43d5-8437-8a3a1c5327f7_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_0d097310-5087-431d-89c2-7947ece7e24b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8c16faec-0820-4f5e-a032-5b5a498d5c3b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_9da65d7c-2533-4129-96b4-80babcfa0b29_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_134ce11e-4699-49ad-9fb6-887421f41a72_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions during the year ended December 31, 2021</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_8a6ce106-211d-4b53-9c31-27853a6456d7_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a92d3c73-979f-4b94-80db-fbcadb04eb64_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bfc941a1-fe20-4737-90a8-618a072c3abb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b74fad85-a63d-4379-ba52-4119792421ea_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_4c03bcd5-8055-4a4c-a429-56a25c5e0445_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_a59a4856-b126-40b8-b1c5-bafdd94dabac_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_441fe704-37d1-4f5f-a6c1-1b00f2d13258_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_c719abcf-5604-429b-81e7-2ad7a0a9af48_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_8d00e544-9edd-4b7b-ba4c-2653c17a8470_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cfc12f42-9727-409a-a2cc-6d5af4f1f0f2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_009c7af1-4ccc-4052-b193-44dffed98be1_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity of Stock Options Granted</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_9aad9b40-9896-467e-8f94-a4ee4b5249b0_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f82f64d9-af71-4280-8c01-f93b01923e97_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_d7200170-b15d-43b7-9901-7f83b26a1883_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for convertible notes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_31929959-7e90-40c1-a9a7-a9900f98e427_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_e3b9cafb-b577-452d-b0d5-51fc4229d572_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_5aa51c43-a778-4dc2-95e8-448ad7668839_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_6a276ac8-70a8-4460-9f7e-189ef22186d9_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityAbstract_65b5405c-6b6e-4b5b-a9fd-6e725704bc86_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Liability [Abstract]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_67206d02-8e63-4874-b2ae-68e83abd3a3e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfWarrants_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d59227ff-b5b4-4b91-ba4d-2c9abcb6857b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_a300529f-5c6a-4de7-84ef-358c7c77456b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bfe04d57-fff8-4892-82e5-a59042bfb8ba_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_8821b3e1-0e52-43ef-9671-5a9da47e0a39_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMPLOYEE BENEFIT PLANS</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_ad42521b-3f52-466b-b355-c8d3f5512ea7_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8c031ee5-c55d-424f-ace6-faf6a3286482_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9c0fc7f1-d4c1-43f6-8f7d-f4a856fb738d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_02f7711a-cfd0-492e-9bae-b144ca001382_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_e77f7508-7d31-45fa-aceb-e2d4c0b77599_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_f25cf094-83cc-4856-83ab-c6397c3cde1b_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_824d6a7c-1f23-4f03-93ac-a0d0cf01587d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_b687771b-ba11-4add-a98b-890045357f6a_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ae9d3bca-9314-474d-98a3-0a6509fb87fe_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_21fb8e4e-1130-46ff-879d-31beaa9629e5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_350a351d-151e-4ec0-bc2a-7756c2320359_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of finance lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_4768d66f-49c4-447c-b7b2-bdb97140a962_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flows from finance lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_3e3e2217-de65-4343-afdc-2aa04303bde4_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_191a3162-3f9d-46f6-8a9c-732c2feedd31_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_30ccd6ec-f1d4-452e-a623-87414b341885_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4d117f2e-60e0-4837-aed2-40dc7fd762a4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_97b24ed5-3ad9-4616-9077-46bcd9712219_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of common stock, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_5e21cdb7-8d3b-43a1-9c80-78f15f19fa87_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_b4f801c8-3ae2-4c7f-bf06-a9042bf5c89a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending claim</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_af319ac4-a350-455b-8acd-90f307592bee_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_c7819f52-5bcc-4580-8ffb-52395db9986a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9aea2659-298d-4854-97fd-206ab04a5a1c_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4517718c-0897-4066-88f2-f8f25b129ecf_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7b133e90-59fe-4b16-a2df-8d40031a2522_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e61f8dd8-19eb-4f4c-b636-72dfbab86ed5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8d754690-554d-4ad8-8bd7-c101e191c4a3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_37d8c180-6899-4f6f-b345-85c908f85a7c_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance costs, discounts and commissions</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_label_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs, Discounts And Commissions</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs, Discounts And Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions" xlink:href="ck0001824293-20211231.xsd#ck0001824293_StockIssuanceCostsDiscountsAndCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions" xlink:to="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_c8d54ff6-ccae-4634-8e4c-45dba2ba13bf_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_91fdbf5d-1b00-4e5c-a97e-cc5a4ef5cf5f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finance Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_edbf37fc-2a97-46e4-995f-82e22a36bb99_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d8db36d9-a1f5-4c1c-90ec-a58105c1fd03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_534fde58-9cbf-4443-813c-5d54b86a557f_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_74bfd12a-fa0a-4535-b347-5aa54175713c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer out of Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_fabb0cee-3b50-47b9-ae08-225c066b4224_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible items and other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0f6aeb9f-0047-4a55-83e2-58df9958b052_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_13831bd0-0fea-41c2-b5d3-a8844d499593_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_07dd5af2-fd64-48ea-9818-29fb78cfc812_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of common stock, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_9cea68b3-31f2-4759-8915-827360cdabc6_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_label_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Costs, Current</link:label>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:href="ck0001824293-20211231.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_3cdf56cc-5864-4a3a-a6a2-cdc56aa40b90_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_68b0fa37-71b0-4248-a277-5799631bac2c_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_7aab8fe2-3eb6-4cb0-a287-1fd6a28338d8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_3ea2abc0-b698-48be-8d9e-7ea0ae001866_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_0018b659-047d-4606-9ad9-b8280224d0d0_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_77f3041e-e4d0-40ce-8b2d-e77d0474a95e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current finance lease assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bee49bd4-dc2f-4214-916b-59d06e18fcc1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_22cd693b-9a14-438c-b3a5-ecfd499a2f36_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_dc2277c1-295c-4ece-b4d9-83046cca715e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_d3e73572-bc1a-42b2-9f34-779e7752f9ff_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_99079687-a5bd-4711-804b-fe34746760bc_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_553d4176-2bbc-4861-baeb-b7b9c8439a9b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses:</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0f0bd386-b4ac-4ffc-8e16-b861c534f6fa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for convertible notes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f0455870-b4cd-4cd4-aa7c-b89661cbc83a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_85befd5a-9c42-40de-929f-66c29442c235_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_af1645ff-45de-4fad-b50e-01d45235f33f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Federal Statutory Income Tax Rate to the Effective Income tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_8b05b49c-1cba-485b-87b7-c48be8f012c0_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity of Finance Lease Liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_24d2df62-cd71-4725-aa27-7e1a9dc3fd1a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a28e3c6d-0e3b-473d-a725-5aa688cf772e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashExpense_da7772fb-e384-4572-ac78-aef43548dab6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest, depreciation and other expense</link:label>
    <link:label id="lab_us-gaap_OtherNoncashExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashExpense" xlink:to="lab_us-gaap_OtherNoncashExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_c281d7ae-43cf-46d1-988c-5ab6c6e51c12_verboseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional offering expense</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_label_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs, Offering Expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs, Offering Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:href="ck0001824293-20211231.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:to="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_018d3ac8-53dd-4239-a2ae-9cbc6cdbceba_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_50d9aeff-d0ec-4a36-b2af-68dc8ef689c8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_550ac5e4-11a1-417a-8c3f-1ca8d69f0d14_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from common stock issuance, net of offering expenses</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_f90fd124-8ffd-4552-9a31-8c915f9ffa21_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_a14c33ef-d6ce-4d0e-9c8b-ad39709dcd4b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from convertible notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3ef7aa12-1aeb-43da-8979-7b114c83f23c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_b7322e4b-43c3-49e8-a239-4c22dac9eb50_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_2c096c52-5bce-497a-8eaf-91d632cb07d4_terseLabel_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIQUIDITY</link:label>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_label_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f21de2df-fda1-4810-b387-af92f5205d45_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_81ba001b-2d85-45be-8954-1e75740edb47_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_39b15c1b-6657-4d89-b6fe-36f0b27d1f6e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_50a99a2d-7e78-49e2-aa1f-b6983ba0d903_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_be6ed457-8fde-4a77-bb71-89a1a1dfd22f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PaycheckProtectionProgramCARESActMember_dd12227c-2978-4c7d-aa7c-9c6f9f50dda4_terseLabel_en-US" xlink:label="lab_ck0001824293_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act</link:label>
    <link:label id="lab_ck0001824293_PaycheckProtectionProgramCARESActMember_label_en-US" xlink:label="lab_ck0001824293_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act [Member]</link:label>
    <link:label id="lab_ck0001824293_PaycheckProtectionProgramCARESActMember_documentation_en-US" xlink:label="lab_ck0001824293_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaycheckProtectionProgramCARESActMember" xlink:href="ck0001824293-20211231.xsd#ck0001824293_PaycheckProtectionProgramCARESActMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PaycheckProtectionProgramCARESActMember" xlink:to="lab_ck0001824293_PaycheckProtectionProgramCARESActMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_d8974d77-e4a6-41ca-9093-c1ceee1c897d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_36257fb6-fc20-42b2-a9ba-4ee78a1c94df_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_cbe7c198-5fdd-44eb-9a63-eb3afdf7b2f0_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_17ee306a-a569-4ef7-894a-67ef4632b103_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_label_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued General and Administrative Expenses, Current</link:label>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_documentation_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued General and Administrative Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:href="ck0001824293-20211231.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:to="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_98735916-d765-472d-b074-c09c1adf87c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_e11c940e-bb81-4eea-9da8-72210aaa0e9a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_798dbcfc-90c6-48b8-8c0a-419ad06655a7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_369a9d80-845a-44de-9362-2e7af7e40bad_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from PPP loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0a874985-94ef-4d3c-9b10-d86760f1b359_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_1a73fd35-ba73-456b-b421-1be7931dce84_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_0d390fea-dc03-401f-868a-39bfbe70ab32_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_ce40b078-698b-49cb-909d-7b7d79768729_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note maturity</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_f4924256-b22d-4ce5-be26-88175b139f98_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_18e4b7c9-e3f3-4f8f-9c7a-f79ba269c2b8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9e0e68dd-8bb3-47aa-a56e-cc2ffa23c8c3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_7606176b-0951-4f55-b496-7d705846dd89_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_444bc496-11ed-4aec-bc17-b08149c55e73_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_71b004d6-0c92-4aa5-b487-cd344a5cfa91_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_07c14ec8-04ec-41de-9cdf-ef1a65d3b6af_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AuditInformationAbstract_7307c661-dc4d-4d4a-9922-ecbed6d5adad_terseLabel_en-US" xlink:label="lab_ck0001824293_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_ck0001824293_AuditInformationAbstract_label_en-US" xlink:label="lab_ck0001824293_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_ck0001824293_AuditInformationAbstract_documentation_en-US" xlink:label="lab_ck0001824293_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AuditInformationAbstract" xlink:href="ck0001824293-20211231.xsd#ck0001824293_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AuditInformationAbstract" xlink:to="lab_ck0001824293_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_74c72b10-313e-4fe4-9cdb-1fb690bf9d13_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_df8ca5d0-3928-438d-9090-dce136add48f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_ef4b04a1-aecf-4bb1-ad3b-1f255a164b52_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for IPO, net of issuance expenses</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_fa40c932-8640-4b87-94f9-aff4290f1fd7_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0e7cfc3a-7c52-400c-866c-d5ffdb55cb24_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_fb6905b5-1504-4422-99ec-f139441b577a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPP NOTE AND CONVERTIBLE NOTES</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2e1152fd-2bf0-42f8-9112-49f96970b9e1_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_RendonVVallonIncEtAlMember_ae506867-589e-4387-91b4-586e01ca0b3c_terseLabel_en-US" xlink:label="lab_ck0001824293_RendonVVallonIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rendon v. Vallon, Inc., et al</link:label>
    <link:label id="lab_ck0001824293_RendonVVallonIncEtAlMember_label_en-US" xlink:label="lab_ck0001824293_RendonVVallonIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rendon v. Vallon, Inc., et al [Member]</link:label>
    <link:label id="lab_ck0001824293_RendonVVallonIncEtAlMember_documentation_en-US" xlink:label="lab_ck0001824293_RendonVVallonIncEtAlMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rendon v. Vallon, Inc., et al</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RendonVVallonIncEtAlMember" xlink:href="ck0001824293-20211231.xsd#ck0001824293_RendonVVallonIncEtAlMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_RendonVVallonIncEtAlMember" xlink:to="lab_ck0001824293_RendonVVallonIncEtAlMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_262729c1-ac83-4f6e-bb07-e17f3dd51a9c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Ending Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4727a63a-a983-4082-87c5-791d78ae6c26_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1833e669-5aa3-46fa-b07c-4a6ee49b80a9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_fa35981d-de57-403f-8a1f-d0442e4d6f5b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_34da1757-78cf-4f2d-b96c-702d7d148863_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3dd0416f-7c13-4d63-968b-2fab7d39f64d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning Balance (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ed38dd12-db2f-453d-bb2d-330752ce5cd8_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending Balance (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_252d3062-860c-4e79-9310-dfc1af9f1b1c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_cd35b7d5-884a-486f-9e5f-cd55612c3378_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0cc5ffeb-6f28-4aae-8ca9-f0c0496dd54b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for IPO, net of issuance expenses (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_20b1a80a-1626-4d12-81b0-c94ba1230557_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_92a39a6f-f477-4260-8482-6a341377d520_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ee03cbe5-4537-4613-a13c-853dce219794_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_810c2372-7c48-437c-8ba0-eb8249a9e329_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_8f6c8e1d-f1c1-4ad2-8327-c2e75c98c7a3_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate - finance lease</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_676c59a7-6d18-47c0-b171-4e5954ccdbb2_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7fa0ad9f-cc1a-4fbc-b60a-a81f8869a592_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation, weighted average amortization period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_a55f5fd4-ddf1-4d00-8614-e1335567b7b7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 9)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4e5c2b71-c5bc-4469-8a2f-f4fa449a5cad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_e5e8f2b7-117e-4120-883c-4a1bd2f08734_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e331584b-d3fb-4281-80dd-5ca1bddfe6cc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_8cbaa796-1752-4329-84f1-6a9c4cb036e4_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_31c4b6b5-dc7e-41d5-9058-308ec6215838_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Balance Ending (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_176f2ede-aad4-4def-9139-7254fc9e4f55_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from finance lease amortization</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_b64d7720-f9da-4dd7-b1c8-b60e7a8f0319_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_d2196ade-7ed7-4658-9ea6-1764015be7fa_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_af3710ef-cb4a-4b87-a887-3762e4293176_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ForgivenessOfDebtInstrument_2ebb85c7-d446-4add-a257-8ba293362042_terseLabel_en-US" xlink:label="lab_ck0001824293_ForgivenessOfDebtInstrument" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness of PPP note</link:label>
    <link:label id="lab_ck0001824293_ForgivenessOfDebtInstrument_label_en-US" xlink:label="lab_ck0001824293_ForgivenessOfDebtInstrument" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness Of Debt Instrument</link:label>
    <link:label id="lab_ck0001824293_ForgivenessOfDebtInstrument_documentation_en-US" xlink:label="lab_ck0001824293_ForgivenessOfDebtInstrument" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness Of Debt Instrument</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ForgivenessOfDebtInstrument" xlink:href="ck0001824293-20211231.xsd#ck0001824293_ForgivenessOfDebtInstrument"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ForgivenessOfDebtInstrument" xlink:to="lab_ck0001824293_ForgivenessOfDebtInstrument" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_93c7616c-5820-4df7-ad33-62f136882c7e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_4460aeee-6e33-4724-9637-d4feb34bc768_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0d2e57a5-8dcb-4ae4-92a3-fe65c51f3454_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_bc1c2cd5-5bd1-4168-bc8e-5b29b8e5f125_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of marketable securities premiums</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_fcf85f18-7d36-4c46-9693-c408d7907462_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_3fe15a32-19de-4d5d-a73d-0ca8c30bda3a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bee13232-31ef-419b-ae22-67b397d0de08_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_678b13a8-5a0d-483e-bd67-f3481d1ec7b9_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DeferredTaxAssetsLeaseOligations_c798bc4a-8994-4442-8acf-9ca39766f1f8_terseLabel_en-US" xlink:label="lab_ck0001824293_DeferredTaxAssetsLeaseOligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_ck0001824293_DeferredTaxAssetsLeaseOligations_label_en-US" xlink:label="lab_ck0001824293_DeferredTaxAssetsLeaseOligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Oligations</link:label>
    <link:label id="lab_ck0001824293_DeferredTaxAssetsLeaseOligations_documentation_en-US" xlink:label="lab_ck0001824293_DeferredTaxAssetsLeaseOligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Oligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DeferredTaxAssetsLeaseOligations" xlink:href="ck0001824293-20211231.xsd#ck0001824293_DeferredTaxAssetsLeaseOligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DeferredTaxAssetsLeaseOligations" xlink:to="lab_ck0001824293_DeferredTaxAssetsLeaseOligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_1cd15555-e2cf-4723-a601-fd450fb43514_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_5ed9fddb-b5e3-4a7d-99df-9399976c6f25_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_8bfbde77-2c82-47c1-8a70-e483d2cd46ee_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals and other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_192a5c34-3bbd-4cba-9572-de90da24992a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_95dc3723-7430-4d1c-90f1-ef3d00ae4c1a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_2ec0e91c-04c8-410f-9c0c-3e027a8117f1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DebtInstrumentPaymentTerm_3e51af93-6145-4c47-9ced-91c9a8980f69_terseLabel_en-US" xlink:label="lab_ck0001824293_DebtInstrumentPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note, payment period</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentPaymentTerm_label_en-US" xlink:label="lab_ck0001824293_DebtInstrumentPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Term</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentPaymentTerm_documentation_en-US" xlink:label="lab_ck0001824293_DebtInstrumentPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentPaymentTerm" xlink:href="ck0001824293-20211231.xsd#ck0001824293_DebtInstrumentPaymentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DebtInstrumentPaymentTerm" xlink:to="lab_ck0001824293_DebtInstrumentPaymentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_de42a73a-30fc-4a9d-8b33-ae55f74eb922_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_ee9e8533-aa5f-4dd3-a5e2-58eba64184e9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_8b650b4d-490d-4ab4-82cf-cfcf4d6a5dfa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_ebfb081b-6dd8-462e-a301-591d0dfe3f32_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_52de1224-0b82-402e-8485-8fcf54cda2ac_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_93c01131-02bf-4685-bb91-5f70b13f6101_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_11f9a3df-833e-44d9-9a7e-29d0d4a8ef43_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a7ec8692-b479-494f-ae01-4a53aa24b6b8_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_451cff8a-4982-4398-83a1-7a7482a4d70e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_c23ef91a-80a2-428c-ba72-c553cfc8d114_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_4d8c6f02-b541-4512-85cf-17b127c7bdab_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_02e12062-d47f-4716-b45b-a225a8e833a9_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current, Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_833e24ff-98f9-4a29-8246-7c4f4cf3c447_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing revenue &#8211; related party</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f5eb992a-e8f4-4b12-9641-ef68b7a69ba6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_93c0a858-7edc-4f23-97ce-90fba1e636f7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_18ca6c94-5659-418c-a055-33dc3c940f48_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAX</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_fb5f9062-4671-4535-b025-c91210482673_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters' Allotment</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_dd13ab56-9822-431d-89e9-3380544bdadf_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and marketable securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_7e024610-4cbf-4953-a478-a8b059bf262c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_2c4fa602-f69e-41e5-a310-77f0cd6dbb0d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_ac9c0c6e-35de-4270-bde4-a842ebeafc61_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_430711c0-b922-498b-9543-dcf65e470ce0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS EQUITY (DEFICIT)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_836855a8-90c1-4906-ab16-b8bf6c8f1cf7_terseLabel_en-US" xlink:label="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salmon Pharma, Affiliate of Medice and David Baker, CEO</link:label>
    <link:label id="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_label_en-US" xlink:label="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliate of Medice and David Baker, CEO [Member]</link:label>
    <link:label id="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_documentation_en-US" xlink:label="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliate of Medice and David Baker, CEO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" xlink:href="ck0001824293-20211231.xsd#ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" xlink:to="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_1e507048-f598-403b-b1eb-833452b5d88e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_eebb94c0-4d4f-4c5b-9133-6dbd6d8fa274_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for services</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_0aba85a8-da80-4d00-a015-7453c438a171_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_f98363db-1118-4661-bea2-6a23299bc64d_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_7e7b78c6-0b1f-4f53-9273-9cf3bebc237b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_e1bbba6e-d562-4c51-8c7c-7491f9069768_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_1e406205-cff5-4327-a8d4-71378b25f1d1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear_59338054-086a-4ef6-88af-c66a49ff449a_terseLabel_en-US" xlink:label="lab_ck0001824293_ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Automatic increase in shares authorized based on percent of total shares outstanding on December 31st of the preceding calendar year.</link:label>
    <link:label id="lab_ck0001824293_ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear_label_en-US" xlink:label="lab_ck0001824293_ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Award, Automatic Increase in Number of Shares Authorized, Based on Percent of Total Shares Outstanding End of Prior Year</link:label>
    <link:label id="lab_ck0001824293_ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear_documentation_en-US" xlink:label="lab_ck0001824293_ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Award, Number of Additional Shares Authorized, Based on Percent of Total Shares Outstanding End of Prior Year, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear" xlink:href="ck0001824293-20211231.xsd#ck0001824293_ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear" xlink:to="lab_ck0001824293_ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_aefa98af-d628-4b51-a5ab-58352aaaf47d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_0a624527-7440-46d9-9573-6528f031099a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21c23ccd-4212-4c6c-a52a-0ceb723fe0f2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_03f3535c-e1a2-4d48-9ca6-f4b4bfcae72f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term - finance lease</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_59484988-4ff4-48fe-8f67-0b615759e73c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_32172e4a-699f-49b5-9f53-d3e7e6790437_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_78cf76b0-c98b-4c9d-85e0-d96347b00b13_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4af6719f-bd02-4bdb-b212-9432b44627b0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_8d9da798-04c1-4914-baf0-823eacd970e0_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_730b777d-3755-4bbe-b147-845e22488f55_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1d76a148-5325-4e48-b77e-c8e036827f98_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2ac56dad-0623-4dce-aa06-55454e1b7c97_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_b8bcdd14-fd7e-4f4e-8484-cf418fcb712e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_fed13887-4b05-4a89-b734-4ee0a962776f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_bfb03d66-04e1-422f-ae40-692b47305a99_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_f3d977e1-f731-4cbf-98b2-66467caed697_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9658b144-1c13-4fa7-9cd6-3313b105f5f1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_719294b1-edce-4ad0-aa96-1c139e1ba417_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_25105069-9abd-410d-84b2-cbc621977cb8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTable" xlink:to="lab_us-gaap_DefinedContributionPlanTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_A2018EquityIncentivePlanMember_f4e0d52f-d2ec-438b-99cc-bd7d964c7808_terseLabel_en-US" xlink:label="lab_ck0001824293_A2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Equity Incentive Plan</link:label>
    <link:label id="lab_ck0001824293_A2018EquityIncentivePlanMember_label_en-US" xlink:label="lab_ck0001824293_A2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_ck0001824293_A2018EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_ck0001824293_A2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_A2018EquityIncentivePlanMember" xlink:href="ck0001824293-20211231.xsd#ck0001824293_A2018EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_A2018EquityIncentivePlanMember" xlink:to="lab_ck0001824293_A2018EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_395342cb-3173-4663-a2a4-2b32eac96595_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_20af8a1b-e310-49d2-9994-1976f8c16dfa_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution, percent of employees' gross pay (up to)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_9cb50359-8ba3-464a-88ec-d19b6a4b57b8_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_db8d9815-0c71-475f-b853-bf6a185395f3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_291b129e-37fc-44d9-9b71-f1c825b02171_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revaluation of derivative liability</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_d88134ea-2927-46a7-a76b-f5f910b8f97c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revaluation of derivative liability</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_30d018f3-fe7e-446d-9142-2bb803e62c64_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d3014788-48d1-4913-91d4-fae7ccbcb0d4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_b7448024-cddb-4a41-b3e8-7c74108b7aae_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_bc5e87cf-9ddf-46c8-8b6f-fe2f237a03f4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_d9c95a53-f6a2-4384-a6ea-98f510a1bbca_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_LeaseCashFlowInformationAbstract_73177820-26ef-484b-a774-91d4789eb06c_terseLabel_en-US" xlink:label="lab_ck0001824293_LeaseCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Information</link:label>
    <link:label id="lab_ck0001824293_LeaseCashFlowInformationAbstract_label_en-US" xlink:label="lab_ck0001824293_LeaseCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cash Flow Information [Abstract]</link:label>
    <link:label id="lab_ck0001824293_LeaseCashFlowInformationAbstract_documentation_en-US" xlink:label="lab_ck0001824293_LeaseCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cash Flow Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_LeaseCashFlowInformationAbstract" xlink:href="ck0001824293-20211231.xsd#ck0001824293_LeaseCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_LeaseCashFlowInformationAbstract" xlink:to="lab_ck0001824293_LeaseCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e969e753-f81f-423f-87a1-97d7dfe6f3f4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_951ace3b-b9f5-400d-8274-a00184b25d97_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_954470d4-a9e4-4d75-8c48-0b5343403cc0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_9840efa6-ccb3-4f17-870a-109735a94470_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_43842fd7-9333-4b45-a57a-5f3abe0c2406_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_ef15f206-264d-41b7-b935-1dab6b86c24d_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_378b32ce-00a3-4a65-adf0-42a02bdc5038_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_416910de-44a6-44f8-97d1-5b10dc434d6e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b94a05bc-4386-432c-b68f-4a5a6e3f4078_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8eb682e0-2292-46f5-9269-9915f90c5b81_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5a28c5d9-3a18-4e64-87c2-970ed469a190_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_202a09ec-a48a-4792-b161-6ce0bdaa9d2c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_3811f2cc-71b2-4669-ad16-7b919e30e2c9_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d7d0e021-70bf-4b70-a029-d8665d97caee_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_4cc71530-a7e6-4c1f-bac5-4019d2ace7d3_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_a5e6efe3-08d7-4ea0-ba52-009e20778917_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_52cca5e3-80a5-4b23-a56c-4e03aac8da6b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_79ea0ec0-6193-4124-a9ea-1386df575cde_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_0005bd1d-6402-42f1-b4f4-d409e16d0163_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for services (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_c269707e-7419-4811-b45e-5b37f3a64438_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5be916a6-424a-4d3b-a307-cb069b1824c6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_e69a9e92-c134-4e7e-8985-88d8067c6276_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_62630afc-ff82-4152-a9d1-5d61ec8ae54c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_e27133a0-ddbd-4e9c-8e7f-b9a53c1a2fe1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal and state net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_e765f578-cb64-4ffe-bfeb-c7e4f8d052a8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_11271207-b52d-49a0-a1f6-cf18dfc90714_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2868ea15-72ee-427f-a2d3-34e31a1ebcba_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_3990dbc1-98bd-4808-adbe-8a95e503b438_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 250,000,000 shares authorized; 6,812,836 and 4,506,216 shares issued and outstanding as of December&#160;31, 2021 and 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_2cdad52e-2227-412e-a1f7-a3d4c7dda01b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f7adf37d-b3cf-4648-a54f-438af3c8261a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_39cc49d4-9d07-4642-8b2d-6ed49401dd42_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_12f56365-96c2-49ed-9f65-909dd0309db7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible notes to common stock</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_4eddda65-4801-4ce1-ac54-2d57ac900fe5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness of PPP note</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_5048c28e-e910-41b3-a85b-59eeaa6b9338_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_49048742-760a-4dff-bf20-9065e6b8ad35_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity (deficit):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_ddacbafe-5335-44c2-bca0-d39fb3fa934c_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note payable, current</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6176ff50-7b57-407f-850d-47a802e937ab_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a47ef4d9-ee86-4786-9017-b004569141e2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>ck0001824293-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b31decee-d9de-40ed-b802-73f93418660f,g:197f3557-28e9-444a-8b20-482cd1ad7630-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/Cover" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_df54bcd1-0cbc-4f83-82b7-86443cc5f39c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_DocumentType_df54bcd1-0cbc-4f83-82b7-86443cc5f39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_dd4ada47-1740-4f95-9760-de993ce22aaa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_DocumentAnnualReport_dd4ada47-1740-4f95-9760-de993ce22aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b7182675-8ef1-4dc3-8b1d-93fe6852d9b6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_DocumentPeriodEndDate_b7182675-8ef1-4dc3-8b1d-93fe6852d9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a968eee6-dccc-4c0b-a254-1da60703dccf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_CurrentFiscalYearEndDate_a968eee6-dccc-4c0b-a254-1da60703dccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_ab1ad0a4-9ad0-49e4-9ab3-ea74b721328d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_DocumentTransitionReport_ab1ad0a4-9ad0-49e4-9ab3-ea74b721328d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_3fd21e3f-c924-4f17-ab93-97f19632ee71" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_EntityFileNumber_3fd21e3f-c924-4f17-ab93-97f19632ee71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c5bae842-46b7-41af-ad5f-956290a1a913" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_EntityRegistrantName_c5bae842-46b7-41af-ad5f-956290a1a913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d5b1ef8d-b635-485f-9860-cdc3629c3214" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d5b1ef8d-b635-485f-9860-cdc3629c3214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_bd14d98f-ad25-4bf9-bafe-15e09240e917" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_EntityTaxIdentificationNumber_bd14d98f-ad25-4bf9-bafe-15e09240e917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d14a8802-66a3-4f38-86fe-bf460c4d0331" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_EntityAddressPostalZipCode_d14a8802-66a3-4f38-86fe-bf460c4d0331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f1777262-f945-4c49-b4fa-e8c9c380c6ff" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_EntityAddressAddressLine1_f1777262-f945-4c49-b4fa-e8c9c380c6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_c6929ffe-159f-4f13-83d9-30c2f506e839" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_EntityAddressAddressLine2_c6929ffe-159f-4f13-83d9-30c2f506e839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_35b3a5d5-5e01-4382-9143-e9ec5f6f0d8f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_EntityAddressCityOrTown_35b3a5d5-5e01-4382-9143-e9ec5f6f0d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_93853dd8-880a-4ba6-8874-06c93733327c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_EntityAddressStateOrProvince_93853dd8-880a-4ba6-8874-06c93733327c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b00283dc-8289-4820-a8a3-77970699c23b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_CityAreaCode_b00283dc-8289-4820-a8a3-77970699c23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_fc0a9562-d96a-41b2-9ead-2ca378cca900" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_LocalPhoneNumber_fc0a9562-d96a-41b2-9ead-2ca378cca900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_37ec73f3-8616-44c1-8ec7-80ccf62f67e0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_Security12bTitle_37ec73f3-8616-44c1-8ec7-80ccf62f67e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b7b41220-2f39-4896-ae8e-f91bcd7485bc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_TradingSymbol_b7b41220-2f39-4896-ae8e-f91bcd7485bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c05d0f19-e3fc-4c4d-b23d-3cdcd8fd4d5d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_SecurityExchangeName_c05d0f19-e3fc-4c4d-b23d-3cdcd8fd4d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_529a25d3-96d8-421c-8242-63cd98d8021d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_529a25d3-96d8-421c-8242-63cd98d8021d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_e933918c-abe1-4361-8fd3-5f7661a10680" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_EntityVoluntaryFilers_e933918c-abe1-4361-8fd3-5f7661a10680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_35c68f55-be6f-40b4-a5f2-0756f8cba6bf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_EntityCurrentReportingStatus_35c68f55-be6f-40b4-a5f2-0756f8cba6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_0b69e6c1-2c8e-4c5f-825f-fc6e26a9e336" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_EntityInteractiveDataCurrent_0b69e6c1-2c8e-4c5f-825f-fc6e26a9e336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_875d5cba-fd4e-45fe-af88-da8d046c30ef" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_EntityFilerCategory_875d5cba-fd4e-45fe-af88-da8d046c30ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_1d7f2109-2e9f-4d18-a4b4-3bd2ea624c92" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_EntitySmallBusiness_1d7f2109-2e9f-4d18-a4b4-3bd2ea624c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_58e67822-3187-4d36-97c4-b1c3b669ca1b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_EntityEmergingGrowthCompany_58e67822-3187-4d36-97c4-b1c3b669ca1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_62fa2234-6fb4-4368-82db-b2ea99f602a0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_EntityExTransitionPeriod_62fa2234-6fb4-4368-82db-b2ea99f602a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_1315dca0-bf2d-4dbd-a4f2-d92c4a607443" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_IcfrAuditorAttestationFlag_1315dca0-bf2d-4dbd-a4f2-d92c4a607443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_c02a872c-8296-4bfb-a23b-2153768e6cd6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_EntityShellCompany_c02a872c-8296-4bfb-a23b-2153768e6cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_dfa6c97e-f349-4061-b750-974eb1ebb252" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_EntityPublicFloat_dfa6c97e-f349-4061-b750-974eb1ebb252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_b87640d8-4ed1-4284-a2f9-bc086e4ebd07" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_b87640d8-4ed1-4284-a2f9-bc086e4ebd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4489ad8f-17db-4a90-9044-19c504dc378f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_EntityCentralIndexKey_4489ad8f-17db-4a90-9044-19c504dc378f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_0a5b4f71-b3c5-4103-9278-74a08253c6b0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_DocumentFiscalYearFocus_0a5b4f71-b3c5-4103-9278-74a08253c6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_94e236f6-58ee-49f2-995f-e538ac10c3b3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_DocumentFiscalPeriodFocus_94e236f6-58ee-49f2-995f-e538ac10c3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2159c01f-de49-4660-9e32-1beaf45e2b56" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22c259bc-b1c0-403c-9f9d-a67e52a4fe71" xlink:to="loc_dei_AmendmentFlag_2159c01f-de49-4660-9e32-1beaf45e2b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/AuditInformation" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AuditInformationAbstract_336c85c6-e00e-46dc-8eac-0f25a5d83415" xlink:href="ck0001824293-20211231.xsd#ck0001824293_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_bbb0bc74-ed71-4a55-9680-c4bf215d7180" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001824293_AuditInformationAbstract_336c85c6-e00e-46dc-8eac-0f25a5d83415" xlink:to="loc_dei_AuditorName_bbb0bc74-ed71-4a55-9680-c4bf215d7180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_77ab6298-7a3d-4e1d-902f-2e6b68f3500f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001824293_AuditInformationAbstract_336c85c6-e00e-46dc-8eac-0f25a5d83415" xlink:to="loc_dei_AuditorLocation_77ab6298-7a3d-4e1d-902f-2e6b68f3500f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_57df0c20-ab5b-4971-88f4-9719b771b960" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001824293_AuditInformationAbstract_336c85c6-e00e-46dc-8eac-0f25a5d83415" xlink:to="loc_dei_AuditorFirmId_57df0c20-ab5b-4971-88f4-9719b771b960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BalanceSheets" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#BalanceSheets"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fc742f65-4227-4254-901e-338b61123739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_dff14d3a-3d27-432b-bc64-3be1f96ba0df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fc742f65-4227-4254-901e-338b61123739" xlink:to="loc_us-gaap_AssetsAbstract_dff14d3a-3d27-432b-bc64-3be1f96ba0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d9fb1216-473a-4c3d-8ba4-9628b00111de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dff14d3a-3d27-432b-bc64-3be1f96ba0df" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d9fb1216-473a-4c3d-8ba4-9628b00111de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3bc5be8a-08eb-4902-a283-f7325a3fc374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d9fb1216-473a-4c3d-8ba4-9628b00111de" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3bc5be8a-08eb-4902-a283-f7325a3fc374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d429c3d0-cad6-4689-8729-f1d29199c045" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d9fb1216-473a-4c3d-8ba4-9628b00111de" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d429c3d0-cad6-4689-8729-f1d29199c045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_54bbd5f0-54a0-4025-8d21-dae6c9663dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d9fb1216-473a-4c3d-8ba4-9628b00111de" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_54bbd5f0-54a0-4025-8d21-dae6c9663dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7e4d8687-e7d5-489f-b617-bc3237c0a64a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d9fb1216-473a-4c3d-8ba4-9628b00111de" xlink:to="loc_us-gaap_AssetsCurrent_7e4d8687-e7d5-489f-b617-bc3237c0a64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d0626b49-4ad6-472b-9804-59549f0b71c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d9fb1216-473a-4c3d-8ba4-9628b00111de" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d0626b49-4ad6-472b-9804-59549f0b71c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bd4e7e2c-424d-4463-a60f-00114c41419d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dff14d3a-3d27-432b-bc64-3be1f96ba0df" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bd4e7e2c-424d-4463-a60f-00114c41419d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6fd07c93-f0c1-4e2d-8516-9268ce7eed68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_dff14d3a-3d27-432b-bc64-3be1f96ba0df" xlink:to="loc_us-gaap_Assets_6fd07c93-f0c1-4e2d-8516-9268ce7eed68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4a979831-25ec-4b22-8c33-41a47fdbcdff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fc742f65-4227-4254-901e-338b61123739" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4a979831-25ec-4b22-8c33-41a47fdbcdff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_f6b1ff84-5f4d-471d-8763-326478dc6bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4a979831-25ec-4b22-8c33-41a47fdbcdff" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_f6b1ff84-5f4d-471d-8763-326478dc6bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_055fa091-4649-4c91-bdbc-c07bfa11400a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f6b1ff84-5f4d-471d-8763-326478dc6bcb" xlink:to="loc_us-gaap_AccountsPayableCurrent_055fa091-4649-4c91-bdbc-c07bfa11400a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b41b766f-ccaf-4c83-8381-78344114c082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f6b1ff84-5f4d-471d-8763-326478dc6bcb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b41b766f-ccaf-4c83-8381-78344114c082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_ff49901b-880c-44d8-99f5-a81c1de16855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f6b1ff84-5f4d-471d-8763-326478dc6bcb" xlink:to="loc_us-gaap_NotesPayableCurrent_ff49901b-880c-44d8-99f5-a81c1de16855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_dd197254-fb3a-4b5a-b410-9d849a782b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f6b1ff84-5f4d-471d-8763-326478dc6bcb" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_dd197254-fb3a-4b5a-b410-9d849a782b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c341a95d-0ef0-492d-aec5-a406b4a4920b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f6b1ff84-5f4d-471d-8763-326478dc6bcb" xlink:to="loc_us-gaap_LiabilitiesCurrent_c341a95d-0ef0-492d-aec5-a406b4a4920b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermNotesPayable_2a8697b2-1848-4c06-bf58-9d6927ca3b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4a979831-25ec-4b22-8c33-41a47fdbcdff" xlink:to="loc_us-gaap_LongTermNotesPayable_2a8697b2-1848-4c06-bf58-9d6927ca3b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_32c29d7a-2ae2-4c7a-89f6-31aefc298f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4a979831-25ec-4b22-8c33-41a47fdbcdff" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_32c29d7a-2ae2-4c7a-89f6-31aefc298f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d07c8a03-611c-474e-8791-7c0d06efa5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4a979831-25ec-4b22-8c33-41a47fdbcdff" xlink:to="loc_us-gaap_Liabilities_d07c8a03-611c-474e-8791-7c0d06efa5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_eb3cea38-65b4-4bc1-8760-3411d7ed7122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4a979831-25ec-4b22-8c33-41a47fdbcdff" xlink:to="loc_us-gaap_CommitmentsAndContingencies_eb3cea38-65b4-4bc1-8760-3411d7ed7122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4d32d9a0-196e-4678-a56f-364ac2083205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4a979831-25ec-4b22-8c33-41a47fdbcdff" xlink:to="loc_us-gaap_StockholdersEquityAbstract_4d32d9a0-196e-4678-a56f-364ac2083205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_cc2e8c2d-0f52-45b1-9db9-9be98827a8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4d32d9a0-196e-4678-a56f-364ac2083205" xlink:to="loc_us-gaap_CommonStockValueOutstanding_cc2e8c2d-0f52-45b1-9db9-9be98827a8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a9029add-efad-4120-868d-e36045a6805b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4d32d9a0-196e-4678-a56f-364ac2083205" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a9029add-efad-4120-868d-e36045a6805b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3d7c3d82-4cd8-4be3-8661-01cd775d1389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4d32d9a0-196e-4678-a56f-364ac2083205" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3d7c3d82-4cd8-4be3-8661-01cd775d1389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_866c5f1f-1313-4a21-ace1-83e10ff3b0aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4d32d9a0-196e-4678-a56f-364ac2083205" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_866c5f1f-1313-4a21-ace1-83e10ff3b0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3e8586d6-0b9a-4984-af6a-a41d34fb62c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4d32d9a0-196e-4678-a56f-364ac2083205" xlink:to="loc_us-gaap_StockholdersEquity_3e8586d6-0b9a-4984-af6a-a41d34fb62c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1a723199-a1dd-4011-be08-408f6de436a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4a979831-25ec-4b22-8c33-41a47fdbcdff" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1a723199-a1dd-4011-be08-408f6de436a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#BalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c86810bc-ab55-4a4d-a4bd-a61f9c9bd467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_bd287324-4666-4447-b79a-f8d31714fc9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c86810bc-ab55-4a4d-a4bd-a61f9c9bd467" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_bd287324-4666-4447-b79a-f8d31714fc9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_79d586e8-b491-42d1-8387-4f2d506f6901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c86810bc-ab55-4a4d-a4bd-a61f9c9bd467" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_79d586e8-b491-42d1-8387-4f2d506f6901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c10196bc-22c7-45b6-b248-5156e6fa4743" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c86810bc-ab55-4a4d-a4bd-a61f9c9bd467" xlink:to="loc_us-gaap_CommonStockSharesIssued_c10196bc-22c7-45b6-b248-5156e6fa4743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_57b2377f-4984-49b1-ba90-6e6f700abb66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c86810bc-ab55-4a4d-a4bd-a61f9c9bd467" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_57b2377f-4984-49b1-ba90-6e6f700abb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#StatementofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_d91e1e6e-7dae-4dc6-9ef5-49c7fb76b0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6858abe3-4fe7-4856-89e1-f746ef9faae4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d91e1e6e-7dae-4dc6-9ef5-49c7fb76b0a9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6858abe3-4fe7-4856-89e1-f746ef9faae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_e75dcbd2-e5fa-4b62-9576-dcafbdbc2daf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d91e1e6e-7dae-4dc6-9ef5-49c7fb76b0a9" xlink:to="loc_us-gaap_OperatingExpensesAbstract_e75dcbd2-e5fa-4b62-9576-dcafbdbc2daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1c5c87b7-f775-47a9-b13a-49e53fb45397" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e75dcbd2-e5fa-4b62-9576-dcafbdbc2daf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1c5c87b7-f775-47a9-b13a-49e53fb45397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_242cc774-b108-434d-b057-6eff0a47c2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e75dcbd2-e5fa-4b62-9576-dcafbdbc2daf" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_242cc774-b108-434d-b057-6eff0a47c2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_42a64117-0fec-48be-9d86-b467c775107f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_e75dcbd2-e5fa-4b62-9576-dcafbdbc2daf" xlink:to="loc_us-gaap_OperatingExpenses_42a64117-0fec-48be-9d86-b467c775107f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_920f04c9-57fd-4fe6-82e7-6de170e60957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d91e1e6e-7dae-4dc6-9ef5-49c7fb76b0a9" xlink:to="loc_us-gaap_OperatingIncomeLoss_920f04c9-57fd-4fe6-82e7-6de170e60957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a1c89930-665f-4739-9f67-235109b663e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d91e1e6e-7dae-4dc6-9ef5-49c7fb76b0a9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a1c89930-665f-4739-9f67-235109b663e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_962d4f1f-74cc-4d2f-8f57-666e78b8a74e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d91e1e6e-7dae-4dc6-9ef5-49c7fb76b0a9" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_962d4f1f-74cc-4d2f-8f57-666e78b8a74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_65269795-8a9a-47a6-996b-afe7881116d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d91e1e6e-7dae-4dc6-9ef5-49c7fb76b0a9" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_65269795-8a9a-47a6-996b-afe7881116d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_96af9894-801c-473c-906b-ebd03add72a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d91e1e6e-7dae-4dc6-9ef5-49c7fb76b0a9" xlink:to="loc_us-gaap_NetIncomeLoss_96af9894-801c-473c-906b-ebd03add72a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_cfdd4c87-d264-462b-91bf-cd16598dd178" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d91e1e6e-7dae-4dc6-9ef5-49c7fb76b0a9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_cfdd4c87-d264-462b-91bf-cd16598dd178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b535d31c-8fe6-4d27-ad43-268da087b1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_cfdd4c87-d264-462b-91bf-cd16598dd178" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b535d31c-8fe6-4d27-ad43-268da087b1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_412d6ce2-0cb0-4ef7-ba75-69e5d59f7289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_cfdd4c87-d264-462b-91bf-cd16598dd178" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_412d6ce2-0cb0-4ef7-ba75-69e5d59f7289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c725734c-759a-4ef0-bb1b-42abaef1f004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d91e1e6e-7dae-4dc6-9ef5-49c7fb76b0a9" xlink:to="loc_us-gaap_EarningsPerShareBasic_c725734c-759a-4ef0-bb1b-42abaef1f004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e3c07df1-007c-41d2-b646-e6e8a71d405d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d91e1e6e-7dae-4dc6-9ef5-49c7fb76b0a9" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e3c07df1-007c-41d2-b646-e6e8a71d405d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_442b17f8-0c2e-46c5-955b-220dd8ffcaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d91e1e6e-7dae-4dc6-9ef5-49c7fb76b0a9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_442b17f8-0c2e-46c5-955b-220dd8ffcaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4d5df124-db64-4038-8064-dfcef3fce7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_d91e1e6e-7dae-4dc6-9ef5-49c7fb76b0a9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4d5df124-db64-4038-8064-dfcef3fce7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#StatementsofChangesinStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_c3c5c772-ac28-4888-962f-797d3a6094d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9e73f28d-1e96-4fa2-b25a-72a4184d7c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c3c5c772-ac28-4888-962f-797d3a6094d3" xlink:to="loc_us-gaap_StatementTable_9e73f28d-1e96-4fa2-b25a-72a4184d7c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_db5665e5-3bcc-454e-9441-698f61f761aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9e73f28d-1e96-4fa2-b25a-72a4184d7c9b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_db5665e5-3bcc-454e-9441-698f61f761aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8bb90a41-24cf-4cba-9f23-804a9113430a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_db5665e5-3bcc-454e-9441-698f61f761aa" xlink:to="loc_us-gaap_EquityComponentDomain_8bb90a41-24cf-4cba-9f23-804a9113430a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_46daf73b-c532-4a1e-b3c4-482b3d61cb98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8bb90a41-24cf-4cba-9f23-804a9113430a" xlink:to="loc_us-gaap_CommonStockMember_46daf73b-c532-4a1e-b3c4-482b3d61cb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_651efe98-45c5-4ba7-b6eb-142c24617476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8bb90a41-24cf-4cba-9f23-804a9113430a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_651efe98-45c5-4ba7-b6eb-142c24617476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4bdf1dd5-1916-4bcc-85b1-4cc6d35c18d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8bb90a41-24cf-4cba-9f23-804a9113430a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4bdf1dd5-1916-4bcc-85b1-4cc6d35c18d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_fc96f770-1ede-4214-bf17-8cb2189d5107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8bb90a41-24cf-4cba-9f23-804a9113430a" xlink:to="loc_us-gaap_RetainedEarningsMember_fc96f770-1ede-4214-bf17-8cb2189d5107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9e73f28d-1e96-4fa2-b25a-72a4184d7c9b" xlink:to="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e4610e18-5054-46fc-8a91-2e7380170e63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e4610e18-5054-46fc-8a91-2e7380170e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e3097957-cb89-467e-b476-f7715f855175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_StockholdersEquity_e3097957-cb89-467e-b476-f7715f855175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b7639dbf-eab9-42ea-adee-21e9c682d8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b7639dbf-eab9-42ea-adee-21e9c682d8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9069c1c4-c3d7-46ff-923d-1ee3f06b4fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9069c1c4-c3d7-46ff-923d-1ee3f06b4fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_03ae68de-e200-4ee1-9d71-d03a28ca4fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_03ae68de-e200-4ee1-9d71-d03a28ca4fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9e36a109-62ba-43e4-bda3-7a1487ab45b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9e36a109-62ba-43e4-bda3-7a1487ab45b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_fac95a75-effb-4baa-95e5-0af7833ac669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_fac95a75-effb-4baa-95e5-0af7833ac669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_5148357c-d132-4324-9b92-20413b382981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_5148357c-d132-4324-9b92-20413b382981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_b065e223-4bee-4eb5-ada1-6beeab56f5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_b065e223-4bee-4eb5-ada1-6beeab56f5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d46c2a84-4a7e-49b1-b0a8-8f79b58c4f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d46c2a84-4a7e-49b1-b0a8-8f79b58c4f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_632fa7d9-b693-4f86-9d3b-5817ca459925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_632fa7d9-b693-4f86-9d3b-5817ca459925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7d04d168-62e9-465e-91e5-8f2a788da214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_NetIncomeLoss_7d04d168-62e9-465e-91e5-8f2a788da214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a679048c-2988-49f6-830c-a244b8bb92c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a679048c-2988-49f6-830c-a244b8bb92c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c8dde59b-6316-45c6-93d2-d3519e9fc49f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_269c6348-339e-46a8-bac9-75b33ef55256" xlink:to="loc_us-gaap_StockholdersEquity_c8dde59b-6316-45c6-93d2-d3519e9fc49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#StatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_32806f75-68f4-4826-8df7-398ea95fbf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_be0cf2f9-0846-4af6-8500-2af38a7f438d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_32806f75-68f4-4826-8df7-398ea95fbf6d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_be0cf2f9-0846-4af6-8500-2af38a7f438d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_662ddf07-b082-4c17-aec5-d4fe9b4eb34e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_be0cf2f9-0846-4af6-8500-2af38a7f438d" xlink:to="loc_us-gaap_NetIncomeLoss_662ddf07-b082-4c17-aec5-d4fe9b4eb34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0744078b-83b2-4edb-9fbe-830204734538" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_be0cf2f9-0846-4af6-8500-2af38a7f438d" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0744078b-83b2-4edb-9fbe-830204734538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_f4ae5735-c667-400f-a4a6-6b100f2f0cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0744078b-83b2-4edb-9fbe-830204734538" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_f4ae5735-c667-400f-a4a6-6b100f2f0cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_67bfbda8-bd91-4baa-bffa-7f5e53c9cc46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0744078b-83b2-4edb-9fbe-830204734538" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_67bfbda8-bd91-4baa-bffa-7f5e53c9cc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_a518be3f-0ee1-4c64-a652-81d77c653572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0744078b-83b2-4edb-9fbe-830204734538" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_a518be3f-0ee1-4c64-a652-81d77c653572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b1197981-fa61-437e-a029-515696275d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0744078b-83b2-4edb-9fbe-830204734538" xlink:to="loc_us-gaap_ShareBasedCompensation_b1197981-fa61-437e-a029-515696275d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7c7ca3b0-46e0-4e99-ae73-a5076261ad49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0744078b-83b2-4edb-9fbe-830204734538" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7c7ca3b0-46e0-4e99-ae73-a5076261ad49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense_06865633-9a03-458b-93ab-d45781eac7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0744078b-83b2-4edb-9fbe-830204734538" xlink:to="loc_us-gaap_OtherNoncashExpense_06865633-9a03-458b-93ab-d45781eac7b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27057c75-04b4-4714-982a-846e41955e04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0744078b-83b2-4edb-9fbe-830204734538" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27057c75-04b4-4714-982a-846e41955e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_efeb4978-30de-42fa-95e1-02a264358c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27057c75-04b4-4714-982a-846e41955e04" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_efeb4978-30de-42fa-95e1-02a264358c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f0e45e1d-9e7e-4a7b-b54e-e0bf6466f510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27057c75-04b4-4714-982a-846e41955e04" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_f0e45e1d-9e7e-4a7b-b54e-e0bf6466f510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_0498df71-5789-4112-8e63-e522efa6bc83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_27057c75-04b4-4714-982a-846e41955e04" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_0498df71-5789-4112-8e63-e522efa6bc83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39dc77dc-f3ef-44db-84e0-f1b307c29afe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0744078b-83b2-4edb-9fbe-830204734538" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_39dc77dc-f3ef-44db-84e0-f1b307c29afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f988c739-08b9-4347-ae0c-f5d13297c3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_32806f75-68f4-4826-8df7-398ea95fbf6d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f988c739-08b9-4347-ae0c-f5d13297c3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_56607fd2-22e3-4b9f-98ff-8e2796bde186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f988c739-08b9-4347-ae0c-f5d13297c3cb" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_56607fd2-22e3-4b9f-98ff-8e2796bde186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cb137173-faf3-48ca-8fd2-4d8c507990fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f988c739-08b9-4347-ae0c-f5d13297c3cb" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cb137173-faf3-48ca-8fd2-4d8c507990fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6647d7fa-cc94-484c-9276-47ad09434b92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f988c739-08b9-4347-ae0c-f5d13297c3cb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6647d7fa-cc94-484c-9276-47ad09434b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99eb8f0d-bc44-471b-bc30-5697fef69ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_32806f75-68f4-4826-8df7-398ea95fbf6d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99eb8f0d-bc44-471b-bc30-5697fef69ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1fdc582f-1de1-44e8-aa5d-19e3276bca26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99eb8f0d-bc44-471b-bc30-5697fef69ab8" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1fdc582f-1de1-44e8-aa5d-19e3276bca26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_5aeb20ed-b09f-4ce7-9179-b68c9d6e1b82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99eb8f0d-bc44-471b-bc30-5697fef69ab8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_5aeb20ed-b09f-4ce7-9179-b68c9d6e1b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_d949c0d5-35d9-41de-9cf2-3f2f80b2b294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99eb8f0d-bc44-471b-bc30-5697fef69ab8" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_d949c0d5-35d9-41de-9cf2-3f2f80b2b294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_9518eae2-fae1-4aee-9d7f-b19ea42071c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99eb8f0d-bc44-471b-bc30-5697fef69ab8" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_9518eae2-fae1-4aee-9d7f-b19ea42071c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_ec6751e4-3aa5-4c27-9cdc-21361db2996c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99eb8f0d-bc44-471b-bc30-5697fef69ab8" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_ec6751e4-3aa5-4c27-9cdc-21361db2996c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c03f29a8-8ee9-453b-be42-51f078f43473" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_99eb8f0d-bc44-471b-bc30-5697fef69ab8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c03f29a8-8ee9-453b-be42-51f078f43473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a76c6a38-2a23-41ab-b77e-d500193eb7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_32806f75-68f4-4826-8df7-398ea95fbf6d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a76c6a38-2a23-41ab-b77e-d500193eb7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_591db9e4-8e50-4c9e-9728-fe9188eae293" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_32806f75-68f4-4826-8df7-398ea95fbf6d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_591db9e4-8e50-4c9e-9728-fe9188eae293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9fbc2e10-3d88-41c2-81fe-41763beeb0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_32806f75-68f4-4826-8df7-398ea95fbf6d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9fbc2e10-3d88-41c2-81fe-41763beeb0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_3363a09a-d0ff-44d0-8dba-ac91fba47f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_32806f75-68f4-4826-8df7-398ea95fbf6d" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_3363a09a-d0ff-44d0-8dba-ac91fba47f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_71e26d7e-6ed1-40ac-ae7f-7a61c365d24e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3363a09a-d0ff-44d0-8dba-ac91fba47f0e" xlink:to="loc_us-gaap_InterestPaidNet_71e26d7e-6ed1-40ac-ae7f-7a61c365d24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_f7e4ce2e-ea17-4d7e-8cc1-63970baa6c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_32806f75-68f4-4826-8df7-398ea95fbf6d" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_f7e4ce2e-ea17-4d7e-8cc1-63970baa6c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_eb9e58a4-c222-41c4-a07a-606558771ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_f7e4ce2e-ea17-4d7e-8cc1-63970baa6c6d" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_eb9e58a4-c222-41c4-a07a-606558771ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#ORGANIZATIONANDDESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b98c50b3-32da-45c4-a60b-78344e1d2469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_1a8eae22-3f64-43ed-a3e8-db3874f146c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b98c50b3-32da-45c4-a60b-78344e1d2469" xlink:to="loc_us-gaap_NatureOfOperations_1a8eae22-3f64-43ed-a3e8-db3874f146c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITY" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#LIQUIDITY"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0f91649d-68f4-4a56-8c39-7a86b69ad152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_30dcb267-9221-4ed0-a15a-b07913d11476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0f91649d-68f4-4a56-8c39-7a86b69ad152" xlink:to="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_30dcb267-9221-4ed0-a15a-b07913d11476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#LIQUIDITYDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ed2dd455-83af-47ca-bbe6-7930678ca3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7a248369-3a2c-4101-a4a9-336febcb67b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ed2dd455-83af-47ca-bbe6-7930678ca3e2" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7a248369-3a2c-4101-a4a9-336febcb67b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_743037fb-fd0a-4e68-b274-77bf6278dd85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7a248369-3a2c-4101-a4a9-336febcb67b8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_743037fb-fd0a-4e68-b274-77bf6278dd85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dae31d7b-4d06-4f03-943c-919084feea01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_743037fb-fd0a-4e68-b274-77bf6278dd85" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dae31d7b-4d06-4f03-943c-919084feea01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_b882021d-40c6-4e13-b61d-96ff12c5d2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dae31d7b-4d06-4f03-943c-919084feea01" xlink:to="loc_us-gaap_IPOMember_b882021d-40c6-4e13-b61d-96ff12c5d2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f7d79e70-2b85-43ce-ba6d-5d0dc4139696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7a248369-3a2c-4101-a4a9-336febcb67b8" xlink:to="loc_us-gaap_ClassOfStockLineItems_f7d79e70-2b85-43ce-ba6d-5d0dc4139696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_929983e3-27db-4337-95c6-559a209bec06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f7d79e70-2b85-43ce-ba6d-5d0dc4139696" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_929983e3-27db-4337-95c6-559a209bec06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_085c3127-d6f7-4790-a7fe-1b1251e97b48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f7d79e70-2b85-43ce-ba6d-5d0dc4139696" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_085c3127-d6f7-4790-a7fe-1b1251e97b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_96c6d403-b5c4-42c5-8c4c-932b16829e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f7d79e70-2b85-43ce-ba6d-5d0dc4139696" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_96c6d403-b5c4-42c5-8c4c-932b16829e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_7b6b6068-bd22-4f48-b912-c703afacb689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f7d79e70-2b85-43ce-ba6d-5d0dc4139696" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_7b6b6068-bd22-4f48-b912-c703afacb689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e0ac78c3-a027-47d1-a24b-321416dc0459" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_b204bb4a-adc6-4f55-8126-15c1d93f797a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e0ac78c3-a027-47d1-a24b-321416dc0459" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_b204bb4a-adc6-4f55-8126-15c1d93f797a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c105f886-118c-4033-a23b-3bdc8698b011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_a74d3fda-c1aa-4554-832c-6e1ba3784435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c105f886-118c-4033-a23b-3bdc8698b011" xlink:to="loc_us-gaap_UseOfEstimates_a74d3fda-c1aa-4554-832c-6e1ba3784435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_28b9f303-146f-4cc4-99f9-0fac3c81c433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c105f886-118c-4033-a23b-3bdc8698b011" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_28b9f303-146f-4cc4-99f9-0fac3c81c433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4eb0d491-029c-43bd-9d17-79edb540c81a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c105f886-118c-4033-a23b-3bdc8698b011" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4eb0d491-029c-43bd-9d17-79edb540c81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_2493fdbf-7ce7-4f28-82b2-e9f5fda05c66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c105f886-118c-4033-a23b-3bdc8698b011" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_2493fdbf-7ce7-4f28-82b2-e9f5fda05c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_796e4166-97e4-4e8c-95ec-bf1fe1c8d3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c105f886-118c-4033-a23b-3bdc8698b011" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_796e4166-97e4-4e8c-95ec-bf1fe1c8d3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_d2bd3d2c-0576-447c-a834-e73c93754b01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c105f886-118c-4033-a23b-3bdc8698b011" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_d2bd3d2c-0576-447c-a834-e73c93754b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_2c1d0717-6e47-406f-8204-44d10e2ec816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c105f886-118c-4033-a23b-3bdc8698b011" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_2c1d0717-6e47-406f-8204-44d10e2ec816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0bdc655a-5a90-4a3f-bfd8-b8612e66ffa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c105f886-118c-4033-a23b-3bdc8698b011" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0bdc655a-5a90-4a3f-bfd8-b8612e66ffa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_26f94d88-c11f-4d67-90fb-e5ccd2c4d208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c105f886-118c-4033-a23b-3bdc8698b011" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_26f94d88-c11f-4d67-90fb-e5ccd2c4d208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b795d210-fb29-460f-9ba7-7fbf11fc755a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c105f886-118c-4033-a23b-3bdc8698b011" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b795d210-fb29-460f-9ba7-7fbf11fc755a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_8e857af4-caae-472c-a3c7-a45bc6c9c12f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c105f886-118c-4033-a23b-3bdc8698b011" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_8e857af4-caae-472c-a3c7-a45bc6c9c12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_8c4786cf-9fa1-494b-aa0a-22b73d920f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c105f886-118c-4033-a23b-3bdc8698b011" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_8c4786cf-9fa1-494b-aa0a-22b73d920f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_a31cc38a-bf20-4ca9-93bb-deb6534c069e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c105f886-118c-4033-a23b-3bdc8698b011" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_a31cc38a-bf20-4ca9-93bb-deb6534c069e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bb58369e-99da-403d-8def-11c3597f7b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c105f886-118c-4033-a23b-3bdc8698b011" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bb58369e-99da-403d-8def-11c3597f7b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRecapitalizationandLicenseRevenueDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRecapitalizationandLicenseRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRecapitalizationandLicenseRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5bee14b0-dec2-4b82-8201-2374016fc6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_630b9e8e-c746-4443-bc46-0af43e4099c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bee14b0-dec2-4b82-8201-2374016fc6f0" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_630b9e8e-c746-4443-bc46-0af43e4099c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4c634171-0d97-4a69-b0de-13b14fd1a83a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5bee14b0-dec2-4b82-8201-2374016fc6f0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4c634171-0d97-4a69-b0de-13b14fd1a83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6e943f22-05a0-4f0e-bf3b-8bc32b54639f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2c8e99ac-0478-43c6-82e1-1a38bde02969" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6e943f22-05a0-4f0e-bf3b-8bc32b54639f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2c8e99ac-0478-43c6-82e1-1a38bde02969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f7232b80-ccdb-47d4-8398-045c72ffe1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2c8e99ac-0478-43c6-82e1-1a38bde02969" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f7232b80-ccdb-47d4-8398-045c72ffe1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_267cb62c-2cb6-4abb-aa9c-1d46ba46520e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f7232b80-ccdb-47d4-8398-045c72ffe1c5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_267cb62c-2cb6-4abb-aa9c-1d46ba46520e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_d30b7872-c4e0-43ec-aa66-ba0b2753d1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_267cb62c-2cb6-4abb-aa9c-1d46ba46520e" xlink:to="loc_us-gaap_ComputerEquipmentMember_d30b7872-c4e0-43ec-aa66-ba0b2753d1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_2f302f59-8017-4b4a-a326-18a47c49b0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_267cb62c-2cb6-4abb-aa9c-1d46ba46520e" xlink:to="loc_us-gaap_EquipmentMember_2f302f59-8017-4b4a-a326-18a47c49b0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1498bf4b-a2b9-462a-9965-1b593cf245e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2c8e99ac-0478-43c6-82e1-1a38bde02969" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1498bf4b-a2b9-462a-9965-1b593cf245e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_3ef18546-965c-49dc-a051-fc72890e8feb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1498bf4b-a2b9-462a-9965-1b593cf245e8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_3ef18546-965c-49dc-a051-fc72890e8feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7410ee84-c484-4ae4-ab54-6a9aadc0e24b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_818c5461-6b96-436e-829e-a83509f8bdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7410ee84-c484-4ae4-ab54-6a9aadc0e24b" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_818c5461-6b96-436e-829e-a83509f8bdcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fe85ace2-aea1-4fb4-9061-632f21108dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_e2c52a5b-36f4-4f86-b575-034c9175cdeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fe85ace2-aea1-4fb4-9061-632f21108dbc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_e2c52a5b-36f4-4f86-b575-034c9175cdeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_0ede7dba-f8f9-4d2d-8cfd-c32cae78a27a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fe85ace2-aea1-4fb4-9061-632f21108dbc" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_0ede7dba-f8f9-4d2d-8cfd-c32cae78a27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2646b762-8537-4e13-907a-4555019e0a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_c79a2646-1537-4ce6-a153-a2948d0e60e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2646b762-8537-4e13-907a-4555019e0a8a" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_c79a2646-1537-4ce6-a153-a2948d0e60e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_78cf7813-385c-4649-8062-7a700639616c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_c79a2646-1537-4ce6-a153-a2948d0e60e1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_78cf7813-385c-4649-8062-7a700639616c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d081e095-d2f4-48e6-b3c8-7978144ff2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_78cf7813-385c-4649-8062-7a700639616c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d081e095-d2f4-48e6-b3c8-7978144ff2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_7a54617e-f4c6-4bf6-8a6b-3cb68bee0a93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d081e095-d2f4-48e6-b3c8-7978144ff2cf" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_7a54617e-f4c6-4bf6-8a6b-3cb68bee0a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_6f940adc-fa66-43ca-b287-99585a8d05d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d081e095-d2f4-48e6-b3c8-7978144ff2cf" xlink:to="loc_us-gaap_MunicipalBondsMember_6f940adc-fa66-43ca-b287-99585a8d05d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_f340668a-09f5-469e-889d-cf2b2695d5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_c79a2646-1537-4ce6-a153-a2948d0e60e1" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_f340668a-09f5-469e-889d-cf2b2695d5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d20f1c95-f243-452c-aa98-75179b177b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f340668a-09f5-469e-889d-cf2b2695d5c7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d20f1c95-f243-452c-aa98-75179b177b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a3669dd7-94cd-40ea-85ed-7fcb4434f613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f340668a-09f5-469e-889d-cf2b2695d5c7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a3669dd7-94cd-40ea-85ed-7fcb4434f613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_eafb7166-920a-45aa-adf2-e0d14f62898e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f340668a-09f5-469e-889d-cf2b2695d5c7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_eafb7166-920a-45aa-adf2-e0d14f62898e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b2eaac5c-daf6-4163-871a-e1fb6f3a51b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_f340668a-09f5-469e-889d-cf2b2695d5c7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b2eaac5c-daf6-4163-871a-e1fb6f3a51b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_28224e54-931a-42af-a4f2-32d73d0f234f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5a6e349b-d14a-4053-8e38-b98ab1c25e90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_28224e54-931a-42af-a4f2-32d73d0f234f" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5a6e349b-d14a-4053-8e38-b98ab1c25e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_bfcf5427-63dc-4a23-adf9-2b924877572d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5a6e349b-d14a-4053-8e38-b98ab1c25e90" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_bfcf5427-63dc-4a23-adf9-2b924877572d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_314cd63f-0490-42b1-b1b5-2cbefed77924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_bfcf5427-63dc-4a23-adf9-2b924877572d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_314cd63f-0490-42b1-b1b5-2cbefed77924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_7f1c2237-4c08-420a-b969-113fe90e5a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_314cd63f-0490-42b1-b1b5-2cbefed77924" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_7f1c2237-4c08-420a-b969-113fe90e5a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c59b3cf1-874b-4557-9892-95c5e06113d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5a6e349b-d14a-4053-8e38-b98ab1c25e90" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c59b3cf1-874b-4557-9892-95c5e06113d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1eeec8e2-77f6-4d1c-8fd4-b512d0a460fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_c59b3cf1-874b-4557-9892-95c5e06113d8" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_1eeec8e2-77f6-4d1c-8fd4-b512d0a460fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_eee9abae-e433-4a8f-9ef5-7a018774c045" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5dc1f6b8-d41b-4087-8dfe-9f5b71533e75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_eee9abae-e433-4a8f-9ef5-7a018774c045" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5dc1f6b8-d41b-4087-8dfe-9f5b71533e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_3b370d58-644e-4f6b-8a65-4c94474833b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5dc1f6b8-d41b-4087-8dfe-9f5b71533e75" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_3b370d58-644e-4f6b-8a65-4c94474833b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_537ae67d-f7aa-4800-ba33-44794b9c2af2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_3b370d58-644e-4f6b-8a65-4c94474833b9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_537ae67d-f7aa-4800-ba33-44794b9c2af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_243bda8e-13ed-4b43-91b5-47bbffd6b72d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_537ae67d-f7aa-4800-ba33-44794b9c2af2" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_243bda8e-13ed-4b43-91b5-47bbffd6b72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_43ee9af2-01d3-49b0-9198-f2b07a53e93b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5dc1f6b8-d41b-4087-8dfe-9f5b71533e75" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_43ee9af2-01d3-49b0-9198-f2b07a53e93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2f199a8a-e26a-4e08-9a35-2a1f64f89928" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_43ee9af2-01d3-49b0-9198-f2b07a53e93b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2f199a8a-e26a-4e08-9a35-2a1f64f89928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_18f8b783-fe0c-4774-ab49-20467a31b1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_43ee9af2-01d3-49b0-9198-f2b07a53e93b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_18f8b783-fe0c-4774-ab49-20467a31b1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_e1999ff2-5dc8-48a1-bc67-034083bb18e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_43ee9af2-01d3-49b0-9198-f2b07a53e93b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_e1999ff2-5dc8-48a1-bc67-034083bb18e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6f9cabe0-0e59-435e-87b2-459ef312dcfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_43ee9af2-01d3-49b0-9198-f2b07a53e93b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6f9cabe0-0e59-435e-87b2-459ef312dcfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LEASES" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_85e2e74a-0559-487c-9dde-f36c6bf36b66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_8b75d12d-5bbb-4001-adaa-64d5dfc8eb87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_85e2e74a-0559-487c-9dde-f36c6bf36b66" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_8b75d12d-5bbb-4001-adaa-64d5dfc8eb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LEASESTables" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_86a19e5d-7365-4e30-83b7-d5a2da84b588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_5a6c454f-76b4-439f-91b5-15b63055c6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_86a19e5d-7365-4e30-83b7-d5a2da84b588" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_5a6c454f-76b4-439f-91b5-15b63055c6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_a9a62b57-6de3-4d9f-840d-2e2ed19ccaae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_86a19e5d-7365-4e30-83b7-d5a2da84b588" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_a9a62b57-6de3-4d9f-840d-2e2ed19ccaae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LEASESAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#LEASESAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LEASESAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d3a95bc4-5260-4de3-beee-9d659b49ea54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_c32be5ba-e433-4c53-baf3-824d97968e05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d3a95bc4-5260-4de3-beee-9d659b49ea54" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_c32be5ba-e433-4c53-baf3-824d97968e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_da24da9b-af72-4e97-ae3f-581e94b29e66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d3a95bc4-5260-4de3-beee-9d659b49ea54" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_da24da9b-af72-4e97-ae3f-581e94b29e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityAbstract_1cb18950-d781-4f44-a507-1ab3ad520591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d3a95bc4-5260-4de3-beee-9d659b49ea54" xlink:to="loc_us-gaap_FinanceLeaseLiabilityAbstract_1cb18950-d781-4f44-a507-1ab3ad520591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_9f6fef69-acf4-4538-a7ba-8c76c36f145c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_1cb18950-d781-4f44-a507-1ab3ad520591" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_9f6fef69-acf4-4538-a7ba-8c76c36f145c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_dabfcf99-6451-458b-875d-ab10ae47a6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_1cb18950-d781-4f44-a507-1ab3ad520591" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_dabfcf99-6451-458b-875d-ab10ae47a6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_da918679-bdaa-4fee-b671-ab84840dad20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_1cb18950-d781-4f44-a507-1ab3ad520591" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_da918679-bdaa-4fee-b671-ab84840dad20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_623f5d93-752d-4a7c-a85f-393281b8aaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_1cb18950-d781-4f44-a507-1ab3ad520591" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_623f5d93-752d-4a7c-a85f-393281b8aaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_a532caaa-8367-45b3-8e7f-eb105574a146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_1cb18950-d781-4f44-a507-1ab3ad520591" xlink:to="loc_us-gaap_FinanceLeaseLiability_a532caaa-8367-45b3-8e7f-eb105574a146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_51b770ff-dd66-4df4-8bd7-9d6f56c0e0df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d3a95bc4-5260-4de3-beee-9d659b49ea54" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_51b770ff-dd66-4df4-8bd7-9d6f56c0e0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_774f614c-1d08-4a92-bdc7-de6e363c0c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d3a95bc4-5260-4de3-beee-9d659b49ea54" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_774f614c-1d08-4a92-bdc7-de6e363c0c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_LeaseCashFlowInformationAbstract_79ea4046-eeb3-4e8d-a595-25b74340bc45" xlink:href="ck0001824293-20211231.xsd#ck0001824293_LeaseCashFlowInformationAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d3a95bc4-5260-4de3-beee-9d659b49ea54" xlink:to="loc_ck0001824293_LeaseCashFlowInformationAbstract_79ea4046-eeb3-4e8d-a595-25b74340bc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_7c6cad01-6c7e-4efa-a6ef-cfed1535e3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001824293_LeaseCashFlowInformationAbstract_79ea4046-eeb3-4e8d-a595-25b74340bc45" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_7c6cad01-6c7e-4efa-a6ef-cfed1535e3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_bcf6ebcf-b52f-4163-8012-186517b48cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001824293_LeaseCashFlowInformationAbstract_79ea4046-eeb3-4e8d-a595-25b74340bc45" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_bcf6ebcf-b52f-4163-8012-186517b48cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LEASESMaturityScheduleDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#LEASESMaturityScheduleDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LEASESMaturityScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b6bed1ee-da59-47a2-a1e1-3bcc91c779b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_7b40fc86-7e66-4360-824b-515ca6992ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b6bed1ee-da59-47a2-a1e1-3bcc91c779b1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_7b40fc86-7e66-4360-824b-515ca6992ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_21f111ec-4386-4543-905f-6ef84a823711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b6bed1ee-da59-47a2-a1e1-3bcc91c779b1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_21f111ec-4386-4543-905f-6ef84a823711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_a18590f7-988e-4bb3-bb92-63b5071c5d35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b6bed1ee-da59-47a2-a1e1-3bcc91c779b1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_a18590f7-988e-4bb3-bb92-63b5071c5d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_9c745d0b-c22d-43c8-aff2-6d82418c57e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b6bed1ee-da59-47a2-a1e1-3bcc91c779b1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_9c745d0b-c22d-43c8-aff2-6d82418c57e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_44c6d6cc-abf0-4758-a511-639fd122e9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b6bed1ee-da59-47a2-a1e1-3bcc91c779b1" xlink:to="loc_us-gaap_FinanceLeaseLiability_44c6d6cc-abf0-4758-a511-639fd122e9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LEASESMaturityScheduleDetails_1" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#LEASESMaturityScheduleDetails_1"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LEASESMaturityScheduleDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#ACCRUEDEXPENSES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_70666c49-786b-4c83-a16c-51ffa537027b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_b23b1668-c64c-4d7a-baf0-1170d405c1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_70666c49-786b-4c83-a16c-51ffa537027b" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_b23b1668-c64c-4d7a-baf0-1170d405c1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#ACCRUEDEXPENSESTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_f46ce7cf-bd62-4191-a227-a178d0ace1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6e2fc336-c2df-493c-9b17-d49849579065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f46ce7cf-bd62-4191-a227-a178d0ace1b8" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6e2fc336-c2df-493c-9b17-d49849579065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#ACCRUEDEXPENSESDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_399178db-a175-4da7-9e55-fd6362603c94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_3d7fbc14-d534-42f3-a230-31c2350a5555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_399178db-a175-4da7-9e55-fd6362603c94" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_3d7fbc14-d534-42f3-a230-31c2350a5555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_a5bb4ca7-c390-4b10-b8a9-e3407bbb1670" xlink:href="ck0001824293-20211231.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_3d7fbc14-d534-42f3-a230-31c2350a5555" xlink:to="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_a5bb4ca7-c390-4b10-b8a9-e3407bbb1670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_dd9076f4-36c9-42de-b230-a69380e8b6bf" xlink:href="ck0001824293-20211231.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_3d7fbc14-d534-42f3-a230-31c2350a5555" xlink:to="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_dd9076f4-36c9-42de-b230-a69380e8b6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8cfbd967-f709-4b79-9a6c-e53d1b1103c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_3d7fbc14-d534-42f3-a230-31c2350a5555" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8cfbd967-f709-4b79-9a6c-e53d1b1103c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedLicensingFeesCurrent_f139e890-ae6a-43f9-a910-5411827fba4c" xlink:href="ck0001824293-20211231.xsd#ck0001824293_AccruedLicensingFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_3d7fbc14-d534-42f3-a230-31c2350a5555" xlink:to="loc_ck0001824293_AccruedLicensingFeesCurrent_f139e890-ae6a-43f9-a910-5411827fba4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f1b9f3e9-9c20-4d80-831f-947a87ad26bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_3d7fbc14-d534-42f3-a230-31c2350a5555" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f1b9f3e9-9c20-4d80-831f-947a87ad26bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7b45f615-85dc-41d2-a685-4d309948cbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_3d7fbc14-d534-42f3-a230-31c2350a5555" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7b45f615-85dc-41d2-a685-4d309948cbb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#PPPNOTEANDCONVERTIBLENOTES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9241f220-3bce-402b-b618-4f4298e0ccc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_16dd3b82-9db4-43b1-b3c1-3a4676533ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9241f220-3bce-402b-b618-4f4298e0ccc8" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_16dd3b82-9db4-43b1-b3c1-3a4676533ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#PPPNOTEANDCONVERTIBLENOTESDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a4e7a762-d5af-4ade-86f3-ad9a0afd71e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1109a452-fbe2-41fc-bf56-bb6d2331349b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a4e7a762-d5af-4ade-86f3-ad9a0afd71e4" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1109a452-fbe2-41fc-bf56-bb6d2331349b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_87513798-134f-4d59-8d73-a122a2cc3e21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1109a452-fbe2-41fc-bf56-bb6d2331349b" xlink:to="loc_us-gaap_DebtInstrumentAxis_87513798-134f-4d59-8d73-a122a2cc3e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7dd0cbfe-38ec-421f-b3c8-342b5fafa716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_87513798-134f-4d59-8d73-a122a2cc3e21" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7dd0cbfe-38ec-421f-b3c8-342b5fafa716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaycheckProtectionProgramCARESActMember_38c4e1a8-c482-4ca6-a5c9-37961ec3d497" xlink:href="ck0001824293-20211231.xsd#ck0001824293_PaycheckProtectionProgramCARESActMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7dd0cbfe-38ec-421f-b3c8-342b5fafa716" xlink:to="loc_ck0001824293_PaycheckProtectionProgramCARESActMember_38c4e1a8-c482-4ca6-a5c9-37961ec3d497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9fda991f-76cd-4eba-9520-54850904377f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1109a452-fbe2-41fc-bf56-bb6d2331349b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9fda991f-76cd-4eba-9520-54850904377f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2990aa6c-aab9-4a1b-9b5c-e4f7233172e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9fda991f-76cd-4eba-9520-54850904377f" xlink:to="loc_us-gaap_RelatedPartyDomain_2990aa6c-aab9-4a1b-9b5c-e4f7233172e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_b3ff73bb-da5b-4626-acfc-a40379d703b7" xlink:href="ck0001824293-20211231.xsd#ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2990aa6c-aab9-4a1b-9b5c-e4f7233172e5" xlink:to="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_b3ff73bb-da5b-4626-acfc-a40379d703b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_48ef677a-8202-4aa8-ab82-1b124cf3b95f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1109a452-fbe2-41fc-bf56-bb6d2331349b" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_48ef677a-8202-4aa8-ab82-1b124cf3b95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d39272f5-c3d8-4341-a1b6-5008f14c73d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_48ef677a-8202-4aa8-ab82-1b124cf3b95f" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d39272f5-c3d8-4341-a1b6-5008f14c73d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_5122ef83-1af0-4ba6-8281-c90ea37f1419" xlink:href="ck0001824293-20211231.xsd#ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d39272f5-c3d8-4341-a1b6-5008f14c73d2" xlink:to="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_5122ef83-1af0-4ba6-8281-c90ea37f1419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_48d2fe18-9dac-405b-8848-fbd0c0b35622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1109a452-fbe2-41fc-bf56-bb6d2331349b" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_48d2fe18-9dac-405b-8848-fbd0c0b35622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0d7f9a06-d41a-4321-bce5-231329344725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48d2fe18-9dac-405b-8848-fbd0c0b35622" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0d7f9a06-d41a-4321-bce5-231329344725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5ac8167c-8472-4aab-8e38-097a00b857b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48d2fe18-9dac-405b-8848-fbd0c0b35622" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5ac8167c-8472-4aab-8e38-097a00b857b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_a72f0d61-27c1-4c56-bcfe-ea75966f94f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48d2fe18-9dac-405b-8848-fbd0c0b35622" xlink:to="loc_us-gaap_DebtInstrumentTerm_a72f0d61-27c1-4c56-bcfe-ea75966f94f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentPaymentTerm_52becb63-3b93-42b9-a104-618de46f06dd" xlink:href="ck0001824293-20211231.xsd#ck0001824293_DebtInstrumentPaymentTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48d2fe18-9dac-405b-8848-fbd0c0b35622" xlink:to="loc_ck0001824293_DebtInstrumentPaymentTerm_52becb63-3b93-42b9-a104-618de46f06dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ForgivenessOfDebtInstrument_2f628837-7a17-442c-b52b-6b027cfafb84" xlink:href="ck0001824293-20211231.xsd#ck0001824293_ForgivenessOfDebtInstrument"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48d2fe18-9dac-405b-8848-fbd0c0b35622" xlink:to="loc_ck0001824293_ForgivenessOfDebtInstrument_2f628837-7a17-442c-b52b-6b027cfafb84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_cb8307f3-a608-4bd4-abbd-cbdc5eef3681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48d2fe18-9dac-405b-8848-fbd0c0b35622" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_cb8307f3-a608-4bd4-abbd-cbdc5eef3681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ef0be5a8-468f-4fed-bd62-f38ed2424116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_0503b936-e077-4498-80e1-1c2cccb68763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_48d2fe18-9dac-405b-8848-fbd0c0b35622" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_0503b936-e077-4498-80e1-1c2cccb68763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/EMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#EMPLOYEEBENEFITPLANS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/EMPLOYEEBENEFITPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4e1fdb8d-6c3e-4e39-8cdf-850dabe4b289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_a94d8492-9200-4f82-bfc6-ed338f8f9871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4e1fdb8d-6c3e-4e39-8cdf-850dabe4b289" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_a94d8492-9200-4f82-bfc6-ed338f8f9871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#EMPLOYEEBENEFITPLANSDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6bca7471-017f-4738-94a4-c621c43b7725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable_c482fe7d-9c41-4ba2-b490-379454c5cf4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6bca7471-017f-4738-94a4-c621c43b7725" xlink:to="loc_us-gaap_DefinedContributionPlanTable_c482fe7d-9c41-4ba2-b490-379454c5cf4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_85c6423e-52a9-4dd3-8209-04d155116890" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_c482fe7d-9c41-4ba2-b490-379454c5cf4c" xlink:to="loc_srt_RangeAxis_85c6423e-52a9-4dd3-8209-04d155116890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_516b49a6-07c6-46c8-8e16-72a7cd29acc5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_85c6423e-52a9-4dd3-8209-04d155116890" xlink:to="loc_srt_RangeMember_516b49a6-07c6-46c8-8e16-72a7cd29acc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9c5a03c5-c168-4b3d-acc7-9aba944e649f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_516b49a6-07c6-46c8-8e16-72a7cd29acc5" xlink:to="loc_srt_MaximumMember_9c5a03c5-c168-4b3d-acc7-9aba944e649f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_656b8736-0bf1-4fec-b679-c56b384fbafb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_c482fe7d-9c41-4ba2-b490-379454c5cf4c" xlink:to="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_656b8736-0bf1-4fec-b679-c56b384fbafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_583d2c0e-9ea3-4938-9560-e3cea24d6cad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_656b8736-0bf1-4fec-b679-c56b384fbafb" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_583d2c0e-9ea3-4938-9560-e3cea24d6cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1adfbc7f-27d1-4a5d-b0ac-acf5008c4686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_656b8736-0bf1-4fec-b679-c56b384fbafb" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1adfbc7f-27d1-4a5d-b0ac-acf5008c4686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_39690249-8ca1-4a55-82fb-29392ba1a06e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ed6e64d2-a156-432c-875b-38e92f85604d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_39690249-8ca1-4a55-82fb-29392ba1a06e" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ed6e64d2-a156-432c-875b-38e92f85604d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESLitigationDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#COMMITMENTSANDCONTINGENCIESLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0d2724cd-52a6-4b7a-a40c-d3b9c80463de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_7015a01a-b1d4-4c74-bbc1-d0299b23e8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0d2724cd-52a6-4b7a-a40c-d3b9c80463de" xlink:to="loc_us-gaap_LossContingenciesTable_7015a01a-b1d4-4c74-bbc1-d0299b23e8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_babc4dda-28e3-4ff8-b68b-46f68bbe849c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7015a01a-b1d4-4c74-bbc1-d0299b23e8e7" xlink:to="loc_srt_LitigationCaseAxis_babc4dda-28e3-4ff8-b68b-46f68bbe849c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c8442b69-deea-445f-893f-3f31e9d07247" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_babc4dda-28e3-4ff8-b68b-46f68bbe849c" xlink:to="loc_srt_LitigationCaseTypeDomain_c8442b69-deea-445f-893f-3f31e9d07247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RendonVVallonIncEtAlMember_66bd03f4-c41c-4da3-92f9-3e84ac9f745d" xlink:href="ck0001824293-20211231.xsd#ck0001824293_RendonVVallonIncEtAlMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c8442b69-deea-445f-893f-3f31e9d07247" xlink:to="loc_ck0001824293_RendonVVallonIncEtAlMember_66bd03f4-c41c-4da3-92f9-3e84ac9f745d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_ea5780b0-d9be-4d68-aef5-a1fe9319cebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7015a01a-b1d4-4c74-bbc1-d0299b23e8e7" xlink:to="loc_us-gaap_LitigationStatusAxis_ea5780b0-d9be-4d68-aef5-a1fe9319cebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_623f7fee-80e0-4dfc-8f1c-cc76eb9d8c84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_ea5780b0-d9be-4d68-aef5-a1fe9319cebf" xlink:to="loc_us-gaap_LitigationStatusDomain_623f7fee-80e0-4dfc-8f1c-cc76eb9d8c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_d3cd69c7-41e9-4736-86a8-a68f3e3e710f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_623f7fee-80e0-4dfc-8f1c-cc76eb9d8c84" xlink:to="loc_us-gaap_SettledLitigationMember_d3cd69c7-41e9-4736-86a8-a68f3e3e710f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_1d4d57df-5250-4edc-98b6-6488c42b9383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7015a01a-b1d4-4c74-bbc1-d0299b23e8e7" xlink:to="loc_us-gaap_LossContingenciesLineItems_1d4d57df-5250-4edc-98b6-6488c42b9383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_bd709ca7-b53f-4200-b61b-65b1a0106453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1d4d57df-5250-4edc-98b6-6488c42b9383" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_bd709ca7-b53f-4200-b61b-65b1a0106453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#STOCKHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_11e43583-5f61-4bc0-9cad-35099d88ab6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4e876169-fd56-4348-a5bf-52601caf7dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_11e43583-5f61-4bc0-9cad-35099d88ab6b" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4e876169-fd56-4348-a5bf-52601caf7dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#STOCKHOLDERSEQUITYDEFICITTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1ba1e3f3-d86d-40ec-ab41-99f77528fee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_994a6c61-de3f-4e2a-ab4a-6168f3248904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1ba1e3f3-d86d-40ec-ab41-99f77528fee9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_994a6c61-de3f-4e2a-ab4a-6168f3248904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#STOCKHOLDERSEQUITYDEFICITNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7a1a2ed4-7a16-4413-9fc9-8ff8aec467cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_48437fa9-ea7d-4fcd-886f-d93fb7db1eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7a1a2ed4-7a16-4413-9fc9-8ff8aec467cb" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_48437fa9-ea7d-4fcd-886f-d93fb7db1eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c453fff6-1a1e-4981-9151-d564fed58895" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_48437fa9-ea7d-4fcd-886f-d93fb7db1eb0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c453fff6-1a1e-4981-9151-d564fed58895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_243a60e1-a1ab-4dd2-be6a-98f75f5cd4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c453fff6-1a1e-4981-9151-d564fed58895" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_243a60e1-a1ab-4dd2-be6a-98f75f5cd4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_b5cc26d0-9647-4897-998e-a32683d4a29a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_243a60e1-a1ab-4dd2-be6a-98f75f5cd4a5" xlink:to="loc_us-gaap_IPOMember_b5cc26d0-9647-4897-998e-a32683d4a29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_54a1c25c-c776-4f3e-a3f1-56612045e3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_243a60e1-a1ab-4dd2-be6a-98f75f5cd4a5" xlink:to="loc_us-gaap_OverAllotmentOptionMember_54a1c25c-c776-4f3e-a3f1-56612045e3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0745e762-2b18-46c4-903d-cf1e620dbe2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_48437fa9-ea7d-4fcd-886f-d93fb7db1eb0" xlink:to="loc_us-gaap_ClassOfStockLineItems_0745e762-2b18-46c4-903d-cf1e620dbe2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_23d71c61-8ce7-4d03-9ce8-bad9fd6881f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0745e762-2b18-46c4-903d-cf1e620dbe2f" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_23d71c61-8ce7-4d03-9ce8-bad9fd6881f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_71381723-be08-42c9-9048-4054a9ef0df3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0745e762-2b18-46c4-903d-cf1e620dbe2f" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_71381723-be08-42c9-9048-4054a9ef0df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_79b63474-c701-4535-a7cb-caa8bf131cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0745e762-2b18-46c4-903d-cf1e620dbe2f" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_79b63474-c701-4535-a7cb-caa8bf131cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_ea45280e-97a1-42fa-b888-c40c687f659c" xlink:href="ck0001824293-20211231.xsd#ck0001824293_StockIssuanceCostsDiscountsAndCommissions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0745e762-2b18-46c4-903d-cf1e620dbe2f" xlink:to="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_ea45280e-97a1-42fa-b888-c40c687f659c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_0ff32db6-44d8-456e-a7a9-dd245576b9b4" xlink:href="ck0001824293-20211231.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0745e762-2b18-46c4-903d-cf1e620dbe2f" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_0ff32db6-44d8-456e-a7a9-dd245576b9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c0693b71-60b2-4498-a25f-fb6ea9db7970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0745e762-2b18-46c4-903d-cf1e620dbe2f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c0693b71-60b2-4498-a25f-fb6ea9db7970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9d4951bd-af4c-4983-84cd-3c4d0557daf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0745e762-2b18-46c4-903d-cf1e620dbe2f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9d4951bd-af4c-4983-84cd-3c4d0557daf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_5ffd55d1-d998-46b6-8ab8-5ebe8466e9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0745e762-2b18-46c4-903d-cf1e620dbe2f" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_5ffd55d1-d998-46b6-8ab8-5ebe8466e9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f4ae0faa-1615-4aea-8ce5-2dcc4b47e93b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3304681f-f279-4568-a434-903518f1355b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f4ae0faa-1615-4aea-8ce5-2dcc4b47e93b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3304681f-f279-4568-a434-903518f1355b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_bc5bef13-b900-4355-b6c5-fb62f124940a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3304681f-f279-4568-a434-903518f1355b" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_bc5bef13-b900-4355-b6c5-fb62f124940a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_19d3847c-293c-474f-be16-b7a5a76835cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_bc5bef13-b900-4355-b6c5-fb62f124940a" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_19d3847c-293c-474f-be16-b7a5a76835cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_df4e61a9-9cbd-437b-8258-9f64c6cebfa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_19d3847c-293c-474f-be16-b7a5a76835cf" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_df4e61a9-9cbd-437b-8258-9f64c6cebfa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_56f2bafe-a1a6-4b76-ad6e-d1c4ddce4185" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_19d3847c-293c-474f-be16-b7a5a76835cf" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_56f2bafe-a1a6-4b76-ad6e-d1c4ddce4185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_11c545c4-782b-437d-b58b-5354ead2e1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_19d3847c-293c-474f-be16-b7a5a76835cf" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_11c545c4-782b-437d-b58b-5354ead2e1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3e49c2c9-f6f2-4644-a6d1-cf719f3fcb47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_19d3847c-293c-474f-be16-b7a5a76835cf" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3e49c2c9-f6f2-4644-a6d1-cf719f3fcb47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9655c693-5bbf-4ca5-a13a-372e67e9f43c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3304681f-f279-4568-a434-903518f1355b" xlink:to="loc_us-gaap_ClassOfStockLineItems_9655c693-5bbf-4ca5-a13a-372e67e9f43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_767fdb99-3cae-4439-8202-ab2dc2c13173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9655c693-5bbf-4ca5-a13a-372e67e9f43c" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_767fdb99-3cae-4439-8202-ab2dc2c13173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8861054-e12d-41eb-b990-d22c7a743bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c1726e82-57f5-421d-b1f1-dcfbc2a77ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8861054-e12d-41eb-b990-d22c7a743bc0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c1726e82-57f5-421d-b1f1-dcfbc2a77ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_83d56a7b-4615-4921-87a6-fe2419d404d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_97dcf46e-0501-47d6-bdfc-6a2692fd463f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_83d56a7b-4615-4921-87a6-fe2419d404d9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_97dcf46e-0501-47d6-bdfc-6a2692fd463f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_5ccc6cb7-f062-461b-a774-ecead3492852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_83d56a7b-4615-4921-87a6-fe2419d404d9" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_5ccc6cb7-f062-461b-a774-ecead3492852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c097723d-9431-41ac-9a84-34a260713f66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_83d56a7b-4615-4921-87a6-fe2419d404d9" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c097723d-9431-41ac-9a84-34a260713f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_02b31fc8-e15f-488d-acb5-cc0d0954d771" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3f85ca49-9e35-4352-bd7d-e1456324268a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_02b31fc8-e15f-488d-acb5-cc0d0954d771" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3f85ca49-9e35-4352-bd7d-e1456324268a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ae6d20a3-0c87-4a1e-b394-260478eb7577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3f85ca49-9e35-4352-bd7d-e1456324268a" xlink:to="loc_us-gaap_PlanNameAxis_ae6d20a3-0c87-4a1e-b394-260478eb7577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8d1f5586-3866-47b7-b554-08cdb2219d83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_ae6d20a3-0c87-4a1e-b394-260478eb7577" xlink:to="loc_us-gaap_PlanNameDomain_8d1f5586-3866-47b7-b554-08cdb2219d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_A2018EquityIncentivePlanMember_e1269e9e-9627-4a70-804b-0bd40b81d503" xlink:href="ck0001824293-20211231.xsd#ck0001824293_A2018EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8d1f5586-3866-47b7-b554-08cdb2219d83" xlink:to="loc_ck0001824293_A2018EquityIncentivePlanMember_e1269e9e-9627-4a70-804b-0bd40b81d503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fbc1f81-1efd-44e3-972b-d899d7ca4074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3f85ca49-9e35-4352-bd7d-e1456324268a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fbc1f81-1efd-44e3-972b-d899d7ca4074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear_640a80cb-2e22-40c0-bcac-8d2968649833" xlink:href="ck0001824293-20211231.xsd#ck0001824293_ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fbc1f81-1efd-44e3-972b-d899d7ca4074" xlink:to="loc_ck0001824293_ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear_640a80cb-2e22-40c0-bcac-8d2968649833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c29ab095-feb3-422a-b608-b24f45b76790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fbc1f81-1efd-44e3-972b-d899d7ca4074" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c29ab095-feb3-422a-b608-b24f45b76790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_bfc3dc55-aafe-4e42-876d-030cf7e536dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fbc1f81-1efd-44e3-972b-d899d7ca4074" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_bfc3dc55-aafe-4e42-876d-030cf7e536dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a60e5578-7cf3-4648-bae1-20b45f5f2d95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fbc1f81-1efd-44e3-972b-d899d7ca4074" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a60e5578-7cf3-4648-bae1-20b45f5f2d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_276a44cd-e1a3-4d2d-a579-c7ef4223230e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fbc1f81-1efd-44e3-972b-d899d7ca4074" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_276a44cd-e1a3-4d2d-a579-c7ef4223230e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a887b0a4-ca7b-4966-814a-9c314391ec1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fbc1f81-1efd-44e3-972b-d899d7ca4074" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a887b0a4-ca7b-4966-814a-9c314391ec1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7be6c419-33f2-4439-b0fc-36279d92d191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fbc1f81-1efd-44e3-972b-d899d7ca4074" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7be6c419-33f2-4439-b0fc-36279d92d191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b873e608-2adf-4246-98cd-983a28cb4543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_01b770bc-c323-45b7-b6c3-a971395a153e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b873e608-2adf-4246-98cd-983a28cb4543" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_01b770bc-c323-45b7-b6c3-a971395a153e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a5df791b-ac77-49a1-92c4-a221d3488636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_01b770bc-c323-45b7-b6c3-a971395a153e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a5df791b-ac77-49a1-92c4-a221d3488636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_79b26ae7-89b9-403a-b6b0-c608b8bb6e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a5df791b-ac77-49a1-92c4-a221d3488636" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_79b26ae7-89b9-403a-b6b0-c608b8bb6e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_37efdd91-18f0-40fb-b87f-05ae8629b742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_79b26ae7-89b9-403a-b6b0-c608b8bb6e0a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_37efdd91-18f0-40fb-b87f-05ae8629b742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_b360c4ed-89f1-4d63-9813-3ee01e4481d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_79b26ae7-89b9-403a-b6b0-c608b8bb6e0a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_b360c4ed-89f1-4d63-9813-3ee01e4481d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_effdf421-8e38-4260-a81e-a44ef045b7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_01b770bc-c323-45b7-b6c3-a971395a153e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_effdf421-8e38-4260-a81e-a44ef045b7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8411801f-7418-4af1-839b-3cb5c64dbce4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_effdf421-8e38-4260-a81e-a44ef045b7b0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8411801f-7418-4af1-839b-3cb5c64dbce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12811473-bb29-44aa-99e8-d31c2099c046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5f1f371e-c5f1-4ef6-ab88-0098d4ee48bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12811473-bb29-44aa-99e8-d31c2099c046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5f1f371e-c5f1-4ef6-ab88-0098d4ee48bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9ae275df-a6bf-49d1-bb7b-f79f0da7838b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5f1f371e-c5f1-4ef6-ab88-0098d4ee48bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9ae275df-a6bf-49d1-bb7b-f79f0da7838b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a7c15cde-0f1e-4702-835e-82de8a2b253d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5f1f371e-c5f1-4ef6-ab88-0098d4ee48bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a7c15cde-0f1e-4702-835e-82de8a2b253d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fd6e41d9-9d72-4d1c-8cbb-c7d1994bc66b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5f1f371e-c5f1-4ef6-ab88-0098d4ee48bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fd6e41d9-9d72-4d1c-8cbb-c7d1994bc66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2f7bade8-b10e-4c2f-8199-3d459dd4d9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5f1f371e-c5f1-4ef6-ab88-0098d4ee48bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2f7bade8-b10e-4c2f-8199-3d459dd4d9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_d485ed00-9e95-43c1-9a78-9f18a5721d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5f1f371e-c5f1-4ef6-ab88-0098d4ee48bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_d485ed00-9e95-43c1-9a78-9f18a5721d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d4f58103-8c80-421d-8fb0-f44ea2b36b67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12811473-bb29-44aa-99e8-d31c2099c046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d4f58103-8c80-421d-8fb0-f44ea2b36b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5638e091-8597-44a9-a371-fabc9743d552" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d4f58103-8c80-421d-8fb0-f44ea2b36b67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5638e091-8597-44a9-a371-fabc9743d552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4861e947-f933-4a15-ad62-ea11dca5cf78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d4f58103-8c80-421d-8fb0-f44ea2b36b67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4861e947-f933-4a15-ad62-ea11dca5cf78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5163fcf4-9c0d-40d6-8452-42c988d9e45b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d4f58103-8c80-421d-8fb0-f44ea2b36b67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5163fcf4-9c0d-40d6-8452-42c988d9e45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d3306783-ec1a-449c-8bc6-f249ac3af85b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d4f58103-8c80-421d-8fb0-f44ea2b36b67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d3306783-ec1a-449c-8bc6-f249ac3af85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_128ae867-386f-4f9d-b6c5-1ef6938a9c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d4f58103-8c80-421d-8fb0-f44ea2b36b67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_128ae867-386f-4f9d-b6c5-1ef6938a9c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b032faf2-488f-4a12-99fa-1fc0f678ab1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12811473-bb29-44aa-99e8-d31c2099c046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b032faf2-488f-4a12-99fa-1fc0f678ab1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2b4b2ffa-10f6-4a80-b345-cc9db5da44f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b032faf2-488f-4a12-99fa-1fc0f678ab1f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2b4b2ffa-10f6-4a80-b345-cc9db5da44f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b428edc6-af17-494a-81a7-5b9d53301a05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b032faf2-488f-4a12-99fa-1fc0f678ab1f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b428edc6-af17-494a-81a7-5b9d53301a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_367ff18c-fe89-4d2b-a9e7-c11e287ce3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b032faf2-488f-4a12-99fa-1fc0f678ab1f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_367ff18c-fe89-4d2b-a9e7-c11e287ce3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_2f442b10-b5bf-4211-9b45-ae914b903049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b032faf2-488f-4a12-99fa-1fc0f678ab1f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_2f442b10-b5bf-4211-9b45-ae914b903049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_86d6fe83-72f5-4298-a3e7-0862874a97ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cc919bcd-c659-4595-b95c-040103a6770d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_86d6fe83-72f5-4298-a3e7-0862874a97ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_cc919bcd-c659-4595-b95c-040103a6770d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1d2613f2-dcf5-42c0-a2f2-6b6a87587ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_86d6fe83-72f5-4298-a3e7-0862874a97ca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1d2613f2-dcf5-42c0-a2f2-6b6a87587ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_91e7e577-5c76-4067-b05b-47376cdedbba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_86d6fe83-72f5-4298-a3e7-0862874a97ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_91e7e577-5c76-4067-b05b-47376cdedbba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0ba52f65-5e3f-44ae-ba3e-38c00cf99829" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_86d6fe83-72f5-4298-a3e7-0862874a97ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0ba52f65-5e3f-44ae-ba3e-38c00cf99829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_dae81a05-47ba-4259-a72d-1aef3c8e2175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_86d6fe83-72f5-4298-a3e7-0862874a97ca" xlink:to="loc_us-gaap_SharePrice_dae81a05-47ba-4259-a72d-1aef3c8e2175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/INCOMETAX" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#INCOMETAX"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/INCOMETAX" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bb1112cb-37a4-41ba-814c-c4d39af09837" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_41afde92-5608-4f85-9e3a-3cb66e674427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bb1112cb-37a4-41ba-814c-c4d39af09837" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_41afde92-5608-4f85-9e3a-3cb66e674427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/INCOMETAXTables" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#INCOMETAXTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/INCOMETAXTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a166d7b6-fdd2-448c-b27f-da9b26ca2ded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1c790f0e-ecfa-4625-a454-4c3377d41e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a166d7b6-fdd2-448c-b27f-da9b26ca2ded" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1c790f0e-ecfa-4625-a454-4c3377d41e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_3943f301-3015-4890-bd06-04a04d9fc9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a166d7b6-fdd2-448c-b27f-da9b26ca2ded" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_3943f301-3015-4890-bd06-04a04d9fc9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a36c1b66-505f-40cc-84df-8c6a16df9e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ce325600-0083-412d-a16c-d247bfceefe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a36c1b66-505f-40cc-84df-8c6a16df9e8c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ce325600-0083-412d-a16c-d247bfceefe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_de95d34f-996e-491f-b5e8-0e08046adf2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a36c1b66-505f-40cc-84df-8c6a16df9e8c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_de95d34f-996e-491f-b5e8-0e08046adf2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_0c7d6067-8409-4366-a41f-ec5037a8053c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a36c1b66-505f-40cc-84df-8c6a16df9e8c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_0c7d6067-8409-4366-a41f-ec5037a8053c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_ce70f604-1ccd-47a4-925e-be6c86620d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a36c1b66-505f-40cc-84df-8c6a16df9e8c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_ce70f604-1ccd-47a4-925e-be6c86620d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_853f14c4-7e10-4e79-8491-d41c4550e23e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a36c1b66-505f-40cc-84df-8c6a16df9e8c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_853f14c4-7e10-4e79-8491-d41c4550e23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3f343bc0-35d4-4b89-b296-dd5fde26dd94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a36c1b66-505f-40cc-84df-8c6a16df9e8c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3f343bc0-35d4-4b89-b296-dd5fde26dd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#INCOMETAXComponentsofDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0c3d9125-f33d-4420-bbf8-7e297fdc2b02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ccbd1a76-8c21-4291-afc9-5ac373893484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0c3d9125-f33d-4420-bbf8-7e297fdc2b02" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ccbd1a76-8c21-4291-afc9-5ac373893484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_41e14516-d1d5-453a-ad58-48bf04927219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ccbd1a76-8c21-4291-afc9-5ac373893484" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_41e14516-d1d5-453a-ad58-48bf04927219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f8f7f516-30e1-41b5-9c55-e4296c597739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ccbd1a76-8c21-4291-afc9-5ac373893484" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f8f7f516-30e1-41b5-9c55-e4296c597739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DeferredTaxAssetsLeaseOligations_34a7bfbf-8919-4a04-ad86-e50357e4ee41" xlink:href="ck0001824293-20211231.xsd#ck0001824293_DeferredTaxAssetsLeaseOligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ccbd1a76-8c21-4291-afc9-5ac373893484" xlink:to="loc_ck0001824293_DeferredTaxAssetsLeaseOligations_34a7bfbf-8919-4a04-ad86-e50357e4ee41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_8a9e6a2e-f23d-4480-9940-6c274fc3ffe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ccbd1a76-8c21-4291-afc9-5ac373893484" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_8a9e6a2e-f23d-4480-9940-6c274fc3ffe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c7c7f8f4-a6bd-4ec9-ac81-fb704c066853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_ccbd1a76-8c21-4291-afc9-5ac373893484" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_c7c7f8f4-a6bd-4ec9-ac81-fb704c066853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_472a5c2d-93eb-41ee-b64e-9ea8cafef5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0c3d9125-f33d-4420-bbf8-7e297fdc2b02" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_472a5c2d-93eb-41ee-b64e-9ea8cafef5d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_98a1159c-4387-4d89-88da-433760db68a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0c3d9125-f33d-4420-bbf8-7e297fdc2b02" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_98a1159c-4387-4d89-88da-433760db68a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_332d540c-e7c9-446c-b3d7-24195e68c393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0c3d9125-f33d-4420-bbf8-7e297fdc2b02" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_332d540c-e7c9-446c-b3d7-24195e68c393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#INCOMETAXNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6079aa83-5e67-4428-946c-909b02929647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_4bcdcc49-afaf-4212-bf64-d65f39b1e7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6079aa83-5e67-4428-946c-909b02929647" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_4bcdcc49-afaf-4212-bf64-d65f39b1e7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_b39d7b01-4a57-4eff-b7d3-91b88c414026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6079aa83-5e67-4428-946c-909b02929647" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_b39d7b01-4a57-4eff-b7d3-91b88c414026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_7c78d13a-f6bd-4054-bcff-02b80cec18d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_b39d7b01-4a57-4eff-b7d3-91b88c414026" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_7c78d13a-f6bd-4054-bcff-02b80cec18d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_66812205-6637-4d64-a39b-bcb30e3d4cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_7c78d13a-f6bd-4054-bcff-02b80cec18d9" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_66812205-6637-4d64-a39b-bcb30e3d4cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_16434840-0ff9-4b09-a745-b20436a083da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_66812205-6637-4d64-a39b-bcb30e3d4cf0" xlink:to="loc_us-gaap_DomesticCountryMember_16434840-0ff9-4b09-a745-b20436a083da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StateTaxAuthorityMember_df689240-fe5f-4d1e-823c-f8466fbd489d" xlink:href="ck0001824293-20211231.xsd#ck0001824293_StateTaxAuthorityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_66812205-6637-4d64-a39b-bcb30e3d4cf0" xlink:to="loc_ck0001824293_StateTaxAuthorityMember_df689240-fe5f-4d1e-823c-f8466fbd489d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_LocalTaxAuthorityMember_325782d7-a8fe-4b4f-b348-50ab107f5fb6" xlink:href="ck0001824293-20211231.xsd#ck0001824293_LocalTaxAuthorityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_66812205-6637-4d64-a39b-bcb30e3d4cf0" xlink:to="loc_ck0001824293_LocalTaxAuthorityMember_325782d7-a8fe-4b4f-b348-50ab107f5fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_c9e4e584-fd69-4b12-8550-34f860736a99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_b39d7b01-4a57-4eff-b7d3-91b88c414026" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_c9e4e584-fd69-4b12-8550-34f860736a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_3ecafc8d-25e2-495b-938f-7efc7bee2d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_c9e4e584-fd69-4b12-8550-34f860736a99" xlink:to="loc_us-gaap_OperatingLossCarryforwards_3ecafc8d-25e2-495b-938f-7efc7bee2d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_011bd273-fa6c-4b26-a184-e49cebb9e8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_7e295078-4dfa-498b-ac40-70475ea8a372" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_011bd273-fa6c-4b26-a184-e49cebb9e8b7" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_7e295078-4dfa-498b-ac40-70475ea8a372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_00d94ead-396a-4a99-8b7d-28931f33421d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ab5e2acf-2cdd-4f48-834d-115eeccf939e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_00d94ead-396a-4a99-8b7d-28931f33421d" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ab5e2acf-2cdd-4f48-834d-115eeccf939e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fb2a996a-f727-4947-8adb-46cf808537d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ab5e2acf-2cdd-4f48-834d-115eeccf939e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fb2a996a-f727-4947-8adb-46cf808537d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_18ef6671-aee3-4dd0-9f24-57519a1bc1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fb2a996a-f727-4947-8adb-46cf808537d2" xlink:to="loc_us-gaap_RelatedPartyDomain_18ef6671-aee3-4dd0-9f24-57519a1bc1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_MediceMember_72e68769-7a56-4a8c-8699-d6f060b059e1" xlink:href="ck0001824293-20211231.xsd#ck0001824293_MediceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_18ef6671-aee3-4dd0-9f24-57519a1bc1d9" xlink:to="loc_ck0001824293_MediceMember_72e68769-7a56-4a8c-8699-d6f060b059e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_74d397e8-24f7-43ba-8f85-6723f53c7c30" xlink:href="ck0001824293-20211231.xsd#ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_18ef6671-aee3-4dd0-9f24-57519a1bc1d9" xlink:to="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_74d397e8-24f7-43ba-8f85-6723f53c7c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_b10f19b5-c630-4088-abc8-da6ab49a2631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ab5e2acf-2cdd-4f48-834d-115eeccf939e" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_b10f19b5-c630-4088-abc8-da6ab49a2631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_c6bb1ee6-64d2-468f-88fc-450ced40b516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_b10f19b5-c630-4088-abc8-da6ab49a2631" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_c6bb1ee6-64d2-468f-88fc-450ced40b516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_0959c266-b0af-4ef9-8280-7120d2b483fa" xlink:href="ck0001824293-20211231.xsd#ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_c6bb1ee6-64d2-468f-88fc-450ced40b516" xlink:to="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_0959c266-b0af-4ef9-8280-7120d2b483fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1c9d07a8-4331-4a4b-a632-1cd07d92c01d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ab5e2acf-2cdd-4f48-834d-115eeccf939e" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_1c9d07a8-4331-4a4b-a632-1cd07d92c01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8dace6a6-7c03-47c7-b3c3-3ed4a3725755" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1c9d07a8-4331-4a4b-a632-1cd07d92c01d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8dace6a6-7c03-47c7-b3c3-3ed4a3725755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm_0f24c209-de42-4cf9-b0fd-e0b4e0bd58ab" xlink:href="ck0001824293-20211231.xsd#ck0001824293_RelatedPartyTransactionLicenseAgreementTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1c9d07a8-4331-4a4b-a632-1cd07d92c01d" xlink:to="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm_0f24c209-de42-4cf9-b0fd-e0b4e0bd58ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_aca20d58-229f-4a7a-8e5d-a1893e3d43c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1c9d07a8-4331-4a4b-a632-1cd07d92c01d" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_aca20d58-229f-4a7a-8e5d-a1893e3d43c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e9ce6557-280e-478e-9c5f-5889b98da0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1c9d07a8-4331-4a4b-a632-1cd07d92c01d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e9ce6557-280e-478e-9c5f-5889b98da0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_31be03d1-57e2-44b7-a5f7-37c1909e677c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1c9d07a8-4331-4a4b-a632-1cd07d92c01d" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_31be03d1-57e2-44b7-a5f7-37c1909e677c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="ck0001824293-20211231.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_e5650f09-286b-42e8-9dd7-aff6b871a19d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_655b0107-ef2e-4ac5-9aae-3d0dbdb78b83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_e5650f09-286b-42e8-9dd7-aff6b871a19d" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_655b0107-ef2e-4ac5-9aae-3d0dbdb78b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367072981560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 11, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VALLON PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-4369909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 N. 18th Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">607-8255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VLON<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001824293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367072944712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">EisnerAmper LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Iselin, New Jersey<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">274<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367073189816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,702<span></span>
</td>
<td class="nump">$ 109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">3,808<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">619<span></span>
</td>
<td class="nump">565<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">8,129<span></span>
</td>
<td class="nump">674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">8,335<span></span>
</td>
<td class="nump">955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">918<span></span>
</td>
<td class="nump">1,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,430<span></span>
</td>
<td class="nump">847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Note payable, current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,445<span></span>
</td>
<td class="nump">2,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Note payable, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,517<span></span>
</td>
<td class="nump">2,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.0001 par value; 250,000,000 shares authorized; 6,812,836 and 4,506,216 shares issued and outstanding as of December&#160;31, 2021 and 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">27,722<span></span>
</td>
<td class="nump">11,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(21,902)<span></span>
</td>
<td class="num">(12,599)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">5,818<span></span>
</td>
<td class="num">(1,454)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (deficit)</a></td>
<td class="nump">$ 8,335<span></span>
</td>
<td class="nump">$ 955<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367072971560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">6,812,836<span></span>
</td>
<td class="nump">4,506,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">6,812,836<span></span>
</td>
<td class="nump">4,506,216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367069630680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statement of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Licensing revenue &#8211; related party</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">5,187,000<span></span>
</td>
<td class="nump">3,707,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,072,000<span></span>
</td>
<td class="nump">1,181,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">9,259,000<span></span>
</td>
<td class="nump">4,888,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(9,259,000)<span></span>
</td>
<td class="num">(4,788,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">61,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Revaluation of derivative liability</a></td>
<td class="num">(89,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="num">(16,000)<span></span>
</td>
<td class="num">(34,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,303,000)<span></span>
</td>
<td class="num">(4,822,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities, available-for-sale</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (9,305,000)<span></span>
</td>
<td class="num">$ (4,822,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock, basic (in usd per share)</a></td>
<td class="num">$ (1.42)<span></span>
</td>
<td class="num">$ (1.07)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock, diluted (in usd per share)</a></td>
<td class="num">$ (1.42)<span></span>
</td>
<td class="num">$ (1.07)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">6,541,097<span></span>
</td>
<td class="nump">4,506,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">6,541,097<span></span>
</td>
<td class="nump">4,506,216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367069830968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Stockholders&#8217; Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, shares (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,506,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 3,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,777)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,822)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,822)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, shares (in shares) at Dec. 31, 2020</a></td>
<td class="nump">4,506,216<span></span>
</td>
<td class="nump">4,506,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="num">$ (1,454)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,599)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock for convertible notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock for convertible notes</a></td>
<td class="nump">439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for IPO, net of issuance expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for IPO, net of issuance expenses</a></td>
<td class="nump">15,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of Underwriters Warrants</a></td>
<td class="nump">399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities, available-for-sale</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,303)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,303)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, shares (in shares) at Dec. 31, 2021</a></td>
<td class="nump">6,812,836<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 5,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,722<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (21,902)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367000081000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Net Cash Provided by (Used in) Operating Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,303)<span></span>
</td>
<td class="num">$ (4,822)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Operating cash flows from finance lease amortization</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of marketable securities premiums</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Revaluation of derivative liability</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">626<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Forgiveness of PPP note</a></td>
<td class="num">(61)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash interest, depreciation and other expense</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(464)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(308)<span></span>
</td>
<td class="nump">980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">583<span></span>
</td>
<td class="nump">371<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="num">(8,312)<span></span>
</td>
<td class="num">(3,706)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of marketable securities</a></td>
<td class="num">(3,842)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash used in investing activities</a></td>
<td class="num">(3,842)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from common stock issuance, net of offering expenses</a></td>
<td class="nump">15,104<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="nump">399<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from PPP loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease liability</a></td>
<td class="num">(106)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by (used in) financing activities</a></td>
<td class="nump">15,747<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">3,593<span></span>
</td>
<td class="num">(3,712)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">3,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">3,702<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible notes to common stock</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367075204760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">ORGANIZATION AND DESCRIPTION OF BUSINESS</a></td>
<td class="text">ORGANIZATION AND DESCRIPTION OF BUSINESS&#160;<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vallon Pharmaceuticals, Inc. (Vallon or the Company) was incorporated in Delaware in January 2018 (inception) and is based in Philadelphia, PA.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for central nervous system (CNS) disorders. The Company&#8217;s lead investigational product candidate, ADAIR, is a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine (the main active ingredient in Adderall&#174;) for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The Company plans to develop other abuse-deterrent products, which have potential for abuse in their current forms, beginning with the development of ADMIR, an abuse deterrent formulation of Ritalin, for which the Company has completed formulation development work.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367075333832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">LIQUIDITY</a></td>
<td class="text">LIQUIDITY<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception, and does not expect to do so in the foreseeable future. The Company has incurred operating losses since inception and has incurred $21,902 in accumulated deficit through December 31, 2021. The Company has financed its working capital requirements to date through the issuance of common stock, convertible notes, short-term promissory notes, and a Paycheck Protection Program (PPP) note. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company completed a $350 convertible note financing and in February 2021, the Company closed on its initial public offering (IPO) raising net proceeds of approximately $15,500.&#160;As of December&#160;31, 2021, the Company had cash, cash equivalents and marketable securities of approximately $7,510, which management expects will provide funding for its ongoing business activities into the third quarter of 2022.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue as a going concern is dependent on its ability to raise substantial additional capital to fund its business activities, including its research and development program. The Company intends to raise capital through additional issuances of common stock and /or short-term notes, but there can be no assurances any such financing will be available when needed or that the Company&#8217;s research and development efforts will be successful. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. Therefore, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367075351224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> References in this Annual Report on Form 10-K to &#8220;authoritative guidance&#8221; is meant to refer to accounting principles generally accepted in the United States of America (GAAP) as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recapitalization</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the closing of the  IPO (Note 10), the Company effected a one-for-40 reverse stock split of its common stock. All share and per share amounts, excluding the number of authorized shares and par value, contained in these financial statements and accompanying notes, and this Annual Report on Form 10-K give retroactive effect to the reverse split.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s results of operations could either benefit from, or be adversely affected by, any such change in estimate. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of credit risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company from time to time during the period covered by these financial statements may have had bank account balances in excess of federally insured limits. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash equivalents</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased and as of December&#160;31, 2021 and 2020 included investment in money market funds.&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of debt securities that are designated as available-for-sale. Marketable debt securities are recorded at fair value and unrealized holding gains or losses are reported as a component of accumulated other comprehensive income (loss). Amortization of premiums and discounts on marketable securities are included in interest expense, net on the statements of operations and comprehensive loss. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains or losses resulting from the sale of these securities are determined based on the specific identification of the securities sold. An impairment charge is recognized when the decline in the fair value of a debt security below the amortized cost basis is determined to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the duration and severity of any decline in fair value below the amortized cost basis, any adverse changes in the financial condition of the issuers and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of financial instruments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC 820,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 820), to measure the fair value of its financial statements and disclosures about fair value of its financial instruments. ASC 820 establishes a framework for measuring fair value in GAAP, and expands disclosures about fair value measurements. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:&#160;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.&#160;</span></div><div style="margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.&#160;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Pricing inputs that are generally unobservable inputs and not corroborated by market data.&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lower priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. The Company uses this framework for measuring fair value and disclosures about fair value measurement. The Company uses fair value measurements in areas that include derivative instruments.&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. The carrying amounts reported in the balance sheets for cash and cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses, and note payable approximate their fair value based on the short-term maturity of these instruments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and equipment</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost. The Company commences depreciation when the asset is placed in service. Computers and peripheral equipment are depreciated on a straight-line method over useful lives of three years.&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to use, or control the use of, identified property, plant, or equipment for a period of time in exchange for consideration. Leases may be classified as finance leases or operating leases. Lease right-of-use (ROU) assets and lease liabilities recognized in the accompanying balance sheet represent the right to use an underlying asset for the lease term and an obligation to make lease payments arising from the lease respectively.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting date, the finance lease liabilities are increased by interest and reduced by repayments made under the lease agreements. The ROU asset is subsequently measured at the amount of the remeasured lease liability (i.e. the present value of the remaining lease payments), any cumulative prepaid or accrued rent if the lease payments are uneven throughout the lease term, and any unamortized initial direct costs.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Licensing revenues</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement (the Medice License Agreement) with  MEDICE&#160;Arzneimittel&#160;P&#252;tter&#160;GmbH &amp; Co. KG (Medice), a related party (Note 13). The license agreement provides for an exclusive license to develop, use, manufacture, market and sell ADAIR&#160;throughout&#160;Europe, a non-refundable up-front payment, potential regulatory and sales milestones and potential royalty payments. The Company analyzed the performance obligations under the license agreements, the consideration received to date and the consideration the Company could receive in the future as part of its analysis in accordance with ASC 606&#8211;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 606). The Company recognized  $100 as licensing revenue during the year ended December 31, 2020. No licensing revenue was recognized during the year ended December 31, 2021.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred.&#160;&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are recorded as a cumulative adjustment in the period the estimates are revised. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative instruments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated its convertible notes to determine if those contracts or embedded components of those contracts qualified as derivatives to be separately accounted for in accordance with ASC 815,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The result of this accounting treatment is that the fair value of the embedded derivative is marked to market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statements of operations as other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity.&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities are classified in the balance sheets as current or non-current to correspond with its host instrument.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on the weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of December&#160;31, 2021 and 2020, the Company concluded that a full valuation allowance was necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest or penalties in the accompanying consolidated financial statements.&#160;</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss per common share</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year. Diluted net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year, plus the dilutive effect of options considered to be outstanding during each year, in accordance with ASC 260,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the applicability and impact of all ASUs. ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on the financial statements.&#160;</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, the Company adopted ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span>. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending the existing guidance.  The adoption of this standard did not have a material impact on the Company&#8217;s financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367077466616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS</a></td>
<td class="text">MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s available-for-sale securities as of the dates indicated:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Marketable Securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Corporate bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,810&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,808&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s investments in marketable debt securities are accounted for as available-for-sale securities and  have contractual maturity dates of one year or less.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, all of the Company&#8217;s marketable securities were classified as Level 2 assets.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the embedded derivative liability identified in the 2021 Convertible Notes was a Level 3 fair value measurement. As of February 12, 2021, the embedded derivative was remeasured based upon the conversion price of $8.00 per share upon closing of the IPO. As such, an expense of $89 was recorded in the first quarter of 2021.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity for the liability measured at estimated fair value using unobservable inputs for the year ended December 31, 2021:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning balance, January 1, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions during the year ended December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transfer out of Level 3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367075204200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a financing lease in relation to </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equipment utilized in the commercial scale manufacturing of ADAIR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company evaluates renewal options at lease inception on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. Lease agreements generally do not require material variable lease payments, residual value guarantees or restrictive covenants.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing lease ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of minimum lease payments over the lease term. The Company utilized the interest rate implicit in the lease. The lease term is based on the non-cancellable period in the lease contract. Any termination fees are included in the calculation of the ROU asset and lease liability when it is assumed that the lease will be terminated.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the finance lease assets and liabilities recognized on the Company's balance sheets:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.916%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance Sheet Line Item</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzItMi0xLTEtMjcwNjk_d0fa8a87-0583-4dbe-aa44-438729a21dce">206</span>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzItNC0xLTEtMjcxMDQ_1d91015f-66ad-42d5-87ce-9f403c36c69c">279</span>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Current finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzQtMi0xLTEtMjcwNzY_4d9aad60-57b0-43cc-9c32-3717c31c5311">97</span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzQtNC0xLTEtMjcxMTE_878bb0e5-bbd6-48e9-9988-7643436d0dee">105</span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Non-current finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzUtMi0xLTEtMjcwNzY_0cbe9984-707d-4160-b526-ea4fa4370ae5">72</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzUtNC0xLTEtMjcxMTE_15864d26-3ad3-4b32-a575-a615f5f41fef">170</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Total finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">275&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s weighted average remaining lease term and weighted average discount rate for its financing lease as of December 31, 2021 are:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average remaining lease term - finance lease</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.75 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average discount rate - finance lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows related to the measurement of financing lease assets and liabilities were as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating cash flows from finance lease amortization</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financing cash flows from finance lease payments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturities of the finance lease liability as of December&#160;31, 2021 are as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Present value of lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367075206440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text">ACCRUED EXPENSES<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">894</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">183</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Payroll and related</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">291</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Licensing related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,430&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">847&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367075247368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PPP NOTE AND CONVERTIBLE NOTES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">PPP NOTE AND CONVERTIBLE NOTES</a></td>
<td class="text">PPP NOTE AND CONVERTIBLE NOTESIn May 2020, the Company issued a promissory note under the PPP (the PPP Note) totaling $61. The note had a stated interest rate of 1% and had a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjAvZnJhZzo0NGYyNDgzZmE3NGI0MWY2OWRlOGU2ZTVhNzZlOWM2Zi90ZXh0cmVnaW9uOjQ0ZjI0ODNmYTc0YjQxZjY5ZGU4ZTZlNWE3NmU5YzZmXzU2OA_a031568f-8be9-4dd8-8877-34662d6a2613">two</span>-year maturity. Payments were required to be made over a 1.5 years period beginning in November 2020 unless forgiven. In January 2021, the Company was notified that the loan along with accumulated interest had been forgiven. As a result, the Company recorded income from the extinguishment of its obligation in the amount of $61 as other income on the accompanying statements of operations and comprehensive loss.In January 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#8217;s Chief Executive Officer, pursuant to which the Company issued the 2021 Convertible Notes, for cash proceeds of $350. The 2021 Convertible Notes bore an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September&#160;30, 2021. The 2021 Convertible Notes converted into 54,906 shares of the Company&#8217;s common stock upon completion of the IPO. The Company identified the mandatory conversion into shares of the Company&#8217;s common stock as a redemption feature, which requires bifurcation from the 2021 Convertible Notes and treated it as a derivative liability under ASC 815 as the redemption feature was not clearly and closely related to the debt. The Company evaluated the fair value of the derivative liability. Upon the conversion of the 2021 Convertible Notes to common stock at the closing of the IPO, the embedded derivative liability was remeasured and removed from the balance sheet.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367077480008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">EMPLOYEE BENEFIT PLANS</a></td>
<td class="text">EMPLOYEE BENEFIT PLANSThe Company maintains a tax-qualified SIMPLE IRA retirement plan which covers all employees. Pursuant to the SIMPLE IRA program, employees are eligible to contribute to an individual SIMPLE IRA account on a tax-deferred basis. The Company makes matching contributions to the employee&#8217;s SIMPLE IRA account in an amount up to 3% of the employee&#8217;s base salary (subject to applicable IRS compensation limits). Expenses related to Company contributions were $24 and $17 for the years ended December&#160;31, 2021 and 2020, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367075326696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment agreements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company was named as a defendant in a putative class action lawsuit filed in the California Superior Court, County of Los Angeles, styled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rendon v. Vallon, Inc., et al</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The complaint brought one claim for violation of California&#8217;s Unruh Civil Rights Act (Unruh Act), alleging that the Company&#8217;s website is not compatible with software used by vision-impaired individuals.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company settled the lawsuit for an immaterial amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Impact</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global COVID-19 pandemic continues to present uncertainty and unforeseeable new risks to the Company&#8217;s operations and business plan. The Company has closely monitored recent COVID-19 developments, including states&#8217; lifting COVID-19 safety measures, drops in vaccination rates, and the spread of various coronavirus strains such as the Delta and Omicron variants. In light of these developments, the full impact of the COVID-19 pandemic on the Company&#8217;s business, operations and clinical development plans remains uncertain and will vary depending on the pandemic&#8217;s future impact on its clinical trial enrollment, clinical trial sites, clinical research organizations (CROs), third-party manufacturers, and other third parties with whom the Company does business, as well as any legal or regulatory consequences resulting therefrom. To the extent possible, the Company is conducting business as usual, with necessary or advisable modifications to employee travel and with most of its employees and consultants working remotely. The Company will continue to actively monitor the COVID-19 situation and may take further actions that alter its operations, including those that may be required by federal, state or local authorities, or that it determines is in the best interests of its employees and other third parties with whom the Company does business.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367076808888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (DEFICIT)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS EQUITY (DEFICIT)</a></td>
<td class="text">STOCKHOLDERS EQUITY (DEFICIT)<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company completed its IPO of 2,250,000 shares of common stock at a public offering price of  $8.00 per share. As a result of the IPO, the Company received approximately $15,500 in net proceeds, after deducting discounts and commissions of $1,600 and offering expenses of approximately $905.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the IPO, the Company granted the underwriters warrants (the Underwriters' Warrants) to purchase an aggregate of 112,500 shares of common stock at an exercise price of $10.00 per share. The Underwriters&#8217; Warrants have a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90ZXh0cmVnaW9uOmYzODY5MGU0NWM0ODQ1ZjZiMmEzOGNjMTRiZGU0NzkyXzE2NDkyNjc0NDQzMDI_d0b1e4ec-bc6a-4c22-8fd2-7d9f5a4cd028">five</span>-year term and became exercisable after August 12, 2021. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.155&#160;%</span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, all of the Underwriters&#8217; Warrants were outstanding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367075172360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues stock-based awards pursuant to its 2018 Equity Incentive Plan (the 2018 Plan). The 2018 Plan provides for the granting of stock options, restricted stock, or restricted stock units. The Company's employees, officers, directors and other persons are eligible to receive awards under the Plan.  The number of shares of the Company's common stock authorized under the 2018 Plan will automatically increase on January 1st of each year until the expiration of the 2018 Plan, in an amount equal to four percent of the total number of shares of the Company's common stock outstanding on December 31st of the preceding calendar year, subject to the discretion of the Company's board of directors or compensation committee to determine a lesser number of shares shall be added for such year. The total number of shares authorized for issuance under the 2018 Plan was 621,022 as of December&#160;31, 2021. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount, terms of grants, and exercisability provisions are determined and set by the Company's board of directors or compensation committee. The Company measures employee stock-based awards at grant-date fair value and records compensation </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense on a straight-line basis over the vesting period of the award. Stock-based awards issued to non-employees are revalued until the award vests.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded  stock-based compensation related to stock options issued under the 2018 Plan in the following expense categories of its accompanying statements of operations for the years ended December&#160;31, 2021 and 2020  :</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">103</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">543</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">626</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">154</span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has granted stock options to purchase its common stock to employees and consultants under the 2018 Plan that generally have a contractual life of up to 10 years. The Company has also granted certain stock options outside of the 2018  Plan. As of December&#160;31, 2021, all equity awards granted from the 2018 Plan were in the form of stock options.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures equity-based awards granted to employees, and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for equity awards is the date of grant, and equity-based compensation costs are recognized as expense over the requisite service period, which is the vesting period or for certain performance-based awards. The Company records the expense for these awards if it concludes that it is probable that the performance condition will be achieved.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the year ended December&#160;31, 2021:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term&#160;(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">266,250</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.94</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.22</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">442,240</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.00</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">708,490</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.64</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercisable at December 31, 2021</span></td><td colspan="3" style="border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">205,888</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.94</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.80</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vested and expected to vest at December 31, 2021</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">708,490</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.60</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.64</span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.707%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.85</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.80</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value of common stock on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.72</span></td></tr></table></div>The aggregate intrinsic value of stock options outstanding and stock options exercisable as of December&#160;31, 2021 was $1,716 and $640, respectively. At December&#160;31, 2021, the unrecognized compensation cost related to unvested stock options expected to vest was $885. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of 2.49 years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367075207000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAX</a></td>
<td class="text">INCOME TAX<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense (benefit) at the US federal statutory income tax rate and the income tax provision in the financial statements is as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected income tax benefit at the federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">State and local taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-deductible items and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior year provision to return adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(31.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(40.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal components of the Company&#8217;s deferred tax assets  and liabilities are as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Federal and state net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accruals and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,080&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,240&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,010)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s history of losses, the Company recorded a full valuation allowance against its deferred tax assets as of December&#160;31, 2021 and 2020. The Company increased its valuation allowance by approximately $2,864 for the&#160;year ended December&#160;31, 2021. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support a reversal of the allowance.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had federal, state and local net operating loss carryforwards of $20,125, $20,362, and $15,866, respectively. The federal net operating loss carryforwards do not expire. The state and local losses begin to expire in the&#160;year ending December&#160;31, 2038.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the provisions of Sections&#160;382 and 383 of the Internal Revenue Code (IRC), certain substantial changes in the Company&#8217;s ownership may have limited, or may limit in the future, the amount of net operating loss and credit carryforwards that can be used to reduce future income taxes if there has been a significant change in ownership of the Company, as defined by the IRC. Future owner or equity shifts could result in limitations on net operating loss and credit carryforwards.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of December&#160;31, 2021 and 2020, the Company had no unrecognized income tax benefits that would affect the Company&#8217;s effective tax rate if recognized. The Company would recognize both accrued interest and penalties related to unrecognized benefits in income tax expense. The Company&#8217;s uncertain tax positions yet to be determined would be related to years that remain subject to examination by relevant tax authorities. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367075207000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONS<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2020, the Company&#160;entered into a license agreement with Medice which grants&#160;Medice&#160;an exclusive license, with the right to grant sublicenses, to develop, use, manufacture, market and sell ADAIR&#160;throughout&#160;Europe.&#160;&#160;Medice&#160;is responsible for obtaining regulatory approval of ADAIR in the licensed territory.&#160; Under the license agreement,&#160;Medice&#160;paid&#160;Vallon&#160;a $100 upfront payment&#160;and is required to pay milestone payments upon first obtaining regulatory approval to market and sell ADAIR in any country, territory or region in the licensed territory and upon achieving certain annual net sales thresholds.&#160;&#160;Medice&#160;will also pay tiered royalties on annual net sales of ADAIR at rates in the low double-digits. The initial term of the license agreement will expire five years after the date on which&#160;Medice&#160;first obtains regulatory approval in any country, territory or region in the licensed territory. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#8217;s Chief Executive Officer, pursuant to which the Company issued the 2021 Convertible Notes for cash proceeds of $350. The 2021 Convertible Notes bore an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September 30, 2021. The 2021 Convertible Notes converted into 54,906 shares of the Company&#8217;s common stock upon completion of the IPO.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367076796776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS[TBD]<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367000056808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of estimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s results of operations could either benefit from, or be adversely affected by, any such change in estimate.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Credit Risk</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of credit risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span>The Company from time to time during the period covered by these financial statements may have had bank account balances in excess of federally insured limits. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text">Cash equivalentsCash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased and as of December&#160;31, 2021 and 2020 included investment in money market funds.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of debt securities that are designated as available-for-sale. Marketable debt securities are recorded at fair value and unrealized holding gains or losses are reported as a component of accumulated other comprehensive income (loss). Amortization of premiums and discounts on marketable securities are included in interest expense, net on the statements of operations and comprehensive loss. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains or losses resulting from the sale of these securities are determined based on the specific identification of the securities sold. An impairment charge is recognized when the decline in the fair value of a debt security below the amortized cost basis is determined to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the duration and severity of any decline in fair value below the amortized cost basis, any adverse changes in the financial condition of the issuers and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of financial instruments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC 820,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 820), to measure the fair value of its financial statements and disclosures about fair value of its financial instruments. ASC 820 establishes a framework for measuring fair value in GAAP, and expands disclosures about fair value measurements. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:&#160;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.&#160;</span></div><div style="margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.&#160;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Pricing inputs that are generally unobservable inputs and not corroborated by market data.&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lower priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. The Company uses this framework for measuring fair value and disclosures about fair value measurement. The Company uses fair value measurements in areas that include derivative instruments.&#160;</span></div>The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. The carrying amounts reported in the balance sheets for cash and cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses, and note payable approximate their fair value based on the short-term maturity of these instruments.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and equipmentProperty and equipment are stated at cost. The Company commences depreciation when the asset is placed in service. Computers and peripheral equipment are depreciated on a straight-line method over useful lives of three years.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to use, or control the use of, identified property, plant, or equipment for a period of time in exchange for consideration. Leases may be classified as finance leases or operating leases. Lease right-of-use (ROU) assets and lease liabilities recognized in the accompanying balance sheet represent the right to use an underlying asset for the lease term and an obligation to make lease payments arising from the lease respectively.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each reporting date, the finance lease liabilities are increased by interest and reduced by repayments made under the lease agreements. The ROU asset is subsequently measured at the amount of the remeasured lease liability (i.e. the present value of the remaining lease payments), any cumulative prepaid or accrued rent if the lease payments are uneven throughout the lease term, and any unamortized initial direct costs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Licensing Revenue</a></td>
<td class="text">Licensing revenues<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement (the Medice License Agreement) with  MEDICE&#160;Arzneimittel&#160;P&#252;tter&#160;GmbH &amp; Co. KG (Medice), a related party (Note 13). The license agreement provides for an exclusive license to develop, use, manufacture, market and sell ADAIR&#160;throughout&#160;Europe, a non-refundable up-front payment, potential regulatory and sales milestones and potential royalty payments. The Company analyzed the performance obligations under the license agreements, the consideration received to date and the consideration the Company could receive in the future as part of its analysis in accordance with ASC 606&#8211;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span>(ASC 606).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">Research and developmentResearch and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are recorded as a cumulative adjustment in the period the estimates are revised. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives Instruments</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative instruments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated its convertible notes to determine if those contracts or embedded components of those contracts qualified as derivatives to be separately accounted for in accordance with ASC 815,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The result of this accounting treatment is that the fair value of the embedded derivative is marked to market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statements of operations as other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity.&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.&#160;</span></div>Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities are classified in the balance sheets as current or non-current to correspond with its host instrument.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">Income taxesIncome taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on the weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of December&#160;31, 2021 and 2020, the Company concluded that a full valuation allowance was necessary for all of its net deferred tax assets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share</a></td>
<td class="text">Net loss per common share<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year. Diluted net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year, plus the dilutive effect of options considered to be outstanding during each year, in accordance with ASC 260,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span>.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the applicability and impact of all ASUs. ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on the financial statements.&#160;</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, the Company adopted ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span>. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending the existing guidance.  The adoption of this standard did not have a material impact on the Company&#8217;s financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367076843800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Debt Securities, Available-for-sale</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s available-for-sale securities as of the dates indicated:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Marketable Securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Corporate bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,810&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,808&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s investments in marketable debt securities are accounted for as available-for-sale securities and  have contractual maturity dates of one year or less.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Activity for the Liability Measured at Estimated Fair Value Using Unobservable Inputs</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity for the liability measured at estimated fair value using unobservable inputs for the year ended December 31, 2021:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning balance, January 1, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions during the year ended December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transfer out of Level 3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at December 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367076834056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Finance Lease Cost</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the finance lease assets and liabilities recognized on the Company's balance sheets:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.916%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance Sheet Line Item</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current finance lease assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzItMi0xLTEtMjcwNjk_d0fa8a87-0583-4dbe-aa44-438729a21dce">206</span>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzItNC0xLTEtMjcxMDQ_1d91015f-66ad-42d5-87ce-9f403c36c69c">279</span>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Current finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzQtMi0xLTEtMjcwNzY_4d9aad60-57b0-43cc-9c32-3717c31c5311">97</span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzQtNC0xLTEtMjcxMTE_878bb0e5-bbd6-48e9-9988-7643436d0dee">105</span>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Non-current finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzUtMi0xLTEtMjcwNzY_0cbe9984-707d-4160-b526-ea4fa4370ae5">72</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzUtNC0xLTEtMjcxMTE_15864d26-3ad3-4b32-a575-a615f5f41fef">170</span>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Total finance lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">275&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s weighted average remaining lease term and weighted average discount rate for its financing lease as of December 31, 2021 are:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average remaining lease term - finance lease</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.75 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average discount rate - finance lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows related to the measurement of financing lease assets and liabilities were as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating cash flows from finance lease amortization</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financing cash flows from finance lease payments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Finance Lease Liability</a></td>
<td class="text"><div style="margin-top:8pt"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturities of the finance lease liability as of December&#160;31, 2021 are as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Present value of lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367075333832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">894</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">183</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Payroll and related</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">291</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Licensing related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,430&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">847&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367075206440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (DEFICIT) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.155&#160;%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367078586968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded  stock-based compensation related to stock options issued under the 2018 Plan in the following expense categories of its accompanying statements of operations for the years ended December&#160;31, 2021 and 2020  :</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">103</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">543</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">626</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">154</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Activity of Stock Options Granted</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the year ended December&#160;31, 2021:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term&#160;(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">266,250</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.94</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.22</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">442,240</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.00</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">708,490</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.64</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercisable at December 31, 2021</span></td><td colspan="3" style="border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">205,888</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.94</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.80</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vested and expected to vest at December 31, 2021</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">708,490</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.60</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.64</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.707%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.85</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.80</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value of common stock on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.72</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367075168600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Federal Statutory Income Tax Rate to the Effective Income tax Rate</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense (benefit) at the US federal statutory income tax rate and the income tax provision in the financial statements is as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected income tax benefit at the federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">State and local taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-deductible items and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior year provision to return adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(31.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(40.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal components of the Company&#8217;s deferred tax assets  and liabilities are as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Federal and state net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,939&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accruals and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,080&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,240&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,010)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367075539976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 12, 2021</div></th>
<th class="th"><div>Jan. 11, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,902<span></span>
</td>
<td class="nump">$ 12,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="nump">$ 15,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367072924136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recapitalization and License Revenue (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 12, 2021</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="nump">0.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367072970296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Useful lives</a></td>
<td class="text">three years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Useful lives</a></td>
<td class="text">three years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123364984&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367069649960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of the Company&#8217;s Available for Sale Securities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted Cost</a></td>
<td class="nump">$ 3,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">3,808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted Cost</a></td>
<td class="nump">1,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted Cost</a></td>
<td class="nump">2,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 2,656<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367077703096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Narrative (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Feb. 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in usd per share)</a></td>
<td class="nump">$ 89,000<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367075807768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details) - Embedded Derivative Liability<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions during the year ended December 31, 2021</a></td>
<td class="nump">$ 89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Transfer out of Level 3</a></td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, ending</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367069890936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Non-current finance lease assets</a></td>
<td class="nump">$ 206<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityAbstract', window );"><strong>Finance Lease Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current finance lease liabilities</a></td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Non-current finance lease liabilities</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other liabilities<span></span>
</td>
<td class="text">Other liabilities<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liabilities</a></td>
<td class="nump">$ 169<span></span>
</td>
<td class="nump">$ 275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term - finance lease</a></td>
<td class="text">1 year 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - finance lease</a></td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_LeaseCashFlowInformationAbstract', window );"><strong>Other Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Operating cash flows from finance lease amortization</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from finance lease payments</a></td>
<td class="nump">$ 106<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_LeaseCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Cash Flow Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_LeaseCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367069866728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Maturity Schedule (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liability</a></td>
<td class="nump">$ 169<span></span>
</td>
<td class="nump">$ 275<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367075433896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent', window );">Research and development</a></td>
<td class="nump">$ 894<span></span>
</td>
<td class="nump">$ 259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent', window );">General and administrative</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related</a></td>
<td class="nump">291<span></span>
</td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_AccruedLicensingFeesCurrent', window );">Licensing related</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued Liabilities, Current, Total</a></td>
<td class="nump">$ 1,430<span></span>
</td>
<td class="nump">$ 847<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued General and Administrative Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedLicensingFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Licensing Fees, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedLicensingFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Research and Development Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140366999911672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PPP NOTE AND CONVERTIBLE NOTES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 11, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_ForgivenessOfDebtInstrument', window );">Forgiveness of PPP note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember', window );">Salmon Pharma, Affiliate of Medice and David Baker, CEO | Convertible Promissory Note Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Note interest rate</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Convertible notes, converted, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,906<span></span>
</td>
<td class="nump">54,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ck0001824293_PaycheckProtectionProgramCARESActMember', window );">Paycheck Protection Program, CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Note interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Note maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_DebtInstrumentPaymentTerm', window );">Note, payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DebtInstrumentPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Payment Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DebtInstrumentPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ForgivenessOfDebtInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forgiveness Of Debt Instrument</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ForgivenessOfDebtInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ck0001824293_PaycheckProtectionProgramCARESActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ck0001824293_PaycheckProtectionProgramCARESActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367069720744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Company contributions</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution, percent of employees' gross pay (up to)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367075277512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Litigation (Details)<br></strong></div></th>
<th class="th">
<div>Nov. 06, 2021 </div>
<div>claim</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=ck0001824293_RendonVVallonIncEtAlMember', window );">Rendon v. Vallon, Inc., et al | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Pending claim</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ck0001824293_RendonVVallonIncEtAlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ck0001824293_RendonVVallonIncEtAlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367075448552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (DEFICIT) - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th">
<div>Feb. 12, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Additional offering expense</a></td>
<td class="nump">$ 905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares) | shares</a></td>
<td class="nump">2,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 8.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="nump">$ 15,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsDiscountsAndCommissions', window );">Stock issuance costs, discounts and commissions</a></td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters' Allotment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares) | shares</a></td>
<td class="nump">112,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants outstanding, term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuanceCostsDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs, Discounts And Commissions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuanceCostsDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuanceCostsOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs, Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuanceCostsOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367000063416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (DEFICIT) - Estimate of the Fair Value of the Warrants and Assumptions (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.00155<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367072786632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear', window );">Automatic increase in shares authorized based on percent of total shares outstanding on December 31st of the preceding calendar year.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation, weighted average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 5 months 26 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ck0001824293_A2018EquityIncentivePlanMember', window );">2018 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">621,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock awards, contractual life (up to)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Award, Number of Additional Shares Authorized, Based on Percent of Total Shares Outstanding End of Prior Year, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ck0001824293_A2018EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ck0001824293_A2018EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367073202264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 626<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 543<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140366999920776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Activity of Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning Balance (in shares)</a></td>
<td class="nump">266,250<span></span>
</td>
<td class="nump">266,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">442,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">708,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">708,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning Balance (in usd per share)</a></td>
<td class="nump">$ 2.94<span></span>
</td>
<td class="nump">$ 2.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending Balance (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Ending Balance (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual term&#160;(years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Beginning Balance (years)</a></td>
<td class="text">8 years 2 months 19 days<span></span>
</td>
<td class="text">8 years 7 months 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Ending Balance (years)</a></td>
<td class="text">8 years 2 months 19 days<span></span>
</td>
<td class="text">8 years 7 months 20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Balance Ending (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 7 months 20 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367069836392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">83.78%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">5 years 10 months 6 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.01%<span></span>
</td>
<td class="nump">0.64%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of option on grant date (in dollars per share)</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="nump">$ 4.72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367075450984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX - Reconciliation of Federal Statutory Income Tax Rate to the Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Expected income tax benefit at the federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local taxes, net of federal benefit</a></td>
<td class="nump">10.60%<span></span>
</td>
<td class="nump">12.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible items and other</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Prior year provision to return adjustments</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">6.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(31.10%)<span></span>
</td>
<td class="num">(40.20%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367073194728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAX- Components of Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Federal and state net operating loss carryforwards</a></td>
<td class="nump">$ 6,617<span></span>
</td>
<td class="nump">$ 3,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share based compensation</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_DeferredTaxAssetsLeaseOligations', window );">Lease liabilities</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accruals and other</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">7,080<span></span>
</td>
<td class="nump">4,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Less: deferred tax liabilities</a></td>
<td class="num">(70)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(7,010)<span></span>
</td>
<td class="num">(4,146)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DeferredTaxAssetsLeaseOligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Oligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DeferredTaxAssetsLeaseOligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367073197160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance, increase</a></td>
<td class="num">$ (2,864)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">20,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=ck0001824293_StateTaxAuthorityMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">20,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=ck0001824293_LocalTaxAuthorityMember', window );">Local</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 15,866<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=ck0001824293_StateTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=ck0001824293_StateTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=ck0001824293_LocalTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=ck0001824293_LocalTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140367072822648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 11, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_MediceMember', window );">Medice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm', window );">License agreement, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember', window );">Salmon Pharma, Affiliate of Medice and David Baker, CEO | Convertible Promissory Note Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Note interest rate</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Convertible notes, converted, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,906<span></span>
</td>
<td class="nump">54,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, License Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_RelatedPartyTransactionLicenseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_MediceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_MediceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>ck0001824293-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ck0001824293="http://www.vallon-pharma.com/20211231"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ck0001824293-20211231.xsd" xlink:type="simple"/>
    <context id="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i65072bfeaf3a4457ad6a97aa44ce8820_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iabb727de2d49441ba5658b9b5a183b63_I20220211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2022-02-11</instant>
        </period>
    </context>
    <context id="id84cb895052844b483a1ef69b0f12655_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7361a85c9d0470a8ca351dad193b452_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaa705715f28d4b5eacce471c76e4867b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8a303ff40d68410ea858ad97833960cc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i38e2e0b664e044f1ab6f20ebf44f6f59_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i23ee9c62820d4f39a904524cfe778f00_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifd9521358ab247c2b64d4cbe8a945e84_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i60aca420575a440fa652609aad540150_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6476323fed784d85832b674bde1f5d2b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id5b0ac7b11494351935046ce5bf1cc8e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia70712498a0f4941ab0ea3722b2be30f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iffdd767329aa4cd59029b7fd066b141d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i270b8e6dd74f41e4a133ae1c6754d770_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia203ce9d16f8445c984d50be01b6c4af_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2ede8e54df1449d8b82bb4b005ed5a86_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i92ca8836910146858994d27a6356eec0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i033d2a786a29471796dbfe50eb424da2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5e826ed29c14a57ab4a163d538e1c37_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2716e8a4ca0545f8bbce622e4d52158f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i550459c5b5124776a49bbd935630fdc7_D20210111-20210111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-01-11</startDate>
            <endDate>2021-01-11</endDate>
        </period>
    </context>
    <context id="ia17353f6bf834b99aeb72bb19eed6773_D20210212-20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="i5daddf114f0241b4a966bccf6d899e1c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic638fa8850574f0f85cdf96878a4008b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9318b4034bf247a7bf81e79df11bc14e_D20210212-20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="ie118df7159634a91976e521f2425da1c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icff8b71b9c8244dcb12cc9ac5efd5b53_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia10c21fff10b48d78e5b10b6645fdc7f_I20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="idef5c95d6a30458ebd4eb95332917688_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1531f974668b4107b1b1a1654cd76006_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f49d0df94644a32ab3d051a753eeb16_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1944122310504f56b217249a0d49b19a_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="if77c3753756e4eb8b7f0d6919514e0d1_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i4ff8206d11c1434cb0abe54052617449_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="ib9d5b9a898334b7cb7f34285a2ddd313_D20210111-20210111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-11</startDate>
            <endDate>2021-01-11</endDate>
        </period>
    </context>
    <context id="icfa130da617a43abb627558cf21129fe_I20210111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-11</instant>
        </period>
    </context>
    <context id="i3844e69fe7884e4db36fb500c88c1e90_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i3f45c53a2fd14b19a55e65c0b6f087be_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic698111b087341fab1ee0949330016d5_I20211106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ck0001824293:RendonVVallonIncEtAlMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-06</instant>
        </period>
    </context>
    <context id="i9f824c725f73426d90c2105cddf2d5ca_I20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="if6d11153da3c4046926d1df8862e08df_I20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="i5f7f365dc72f44f98ddaa19c2a6fe7c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i233cc24405d641289d6ab6f271edbce0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0508ecc21bf1424db461226872bd262c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6dc2bc5f633b4fe997a55197c7618e72_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i01c972ebfcea4e9f9fb0d25b4590b552_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:A2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i414ab16442df41e0a789424f9dcdbb64_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic219cdbb38f64f029ff62ec56ce54f18_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic19d630a0cfb4614bc03d9687c1b1adf_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i25bc9e21732d46a495fab6ec37e81bd6_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia48dc025b4ca46bfbb1119e73f604f09_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iefc0efe048504719968099425a5fc1f0_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2042fe817e6b415d99dcd18a2761b5b7_D20181001-20181001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:A2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-01</endDate>
        </period>
    </context>
    <context id="i7543349bff1e4b3d8106535d9eae2358_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1d5a202b2ddb4a648aebf40b599e2cf3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f9b7fb9cf6a4e3a91f85fc43dab1e80_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">ck0001824293:StateTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ffe46279ad1467fbb2755ef0532a308_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">ck0001824293:LocalTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib1b89a713dfe46188f25b2cff340c80d_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:MediceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i3b1123c092e44fef8394165e79c1a211_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i55442e45b4004aa1ab3f8d35b70ac615_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="claim">
        <measure>ck0001824293:claim</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV80L2ZyYWc6YjA5NWRmYjQ0YWYyNGVkNzllMGM1NTY1ZDg4ZGY4M2QvdGFibGU6YTNiNjY5OGI1NjU5NDhkZmJjZjhlNjNjZjY5MWJhNzIvdGFibGVyYW5nZTphM2I2Njk4YjU2NTk0OGRmYmNmOGU2M2NmNjkxYmE3Ml8yMS0xLTEtMS0yMTAwMg_e3feac2a-30eb-4940-9213-adf9b948eb91">0001824293</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV80L2ZyYWc6YjA5NWRmYjQ0YWYyNGVkNzllMGM1NTY1ZDg4ZGY4M2QvdGFibGU6YTNiNjY5OGI1NjU5NDhkZmJjZjhlNjNjZjY5MWJhNzIvdGFibGVyYW5nZTphM2I2Njk4YjU2NTk0OGRmYmNmOGU2M2NmNjkxYmE3Ml8zMC0xLTEtMS0yMTAwMg_3e1d2124-4eb5-402c-aa4c-1ea258967cad">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV80L2ZyYWc6YjA5NWRmYjQ0YWYyNGVkNzllMGM1NTY1ZDg4ZGY4M2QvdGFibGU6YTNiNjY5OGI1NjU5NDhkZmJjZjhlNjNjZjY5MWJhNzIvdGFibGVyYW5nZTphM2I2Njk4YjU2NTk0OGRmYmNmOGU2M2NmNjkxYmE3Ml8zMS0xLTEtMS0yMTAwMg_955ccd41-8b73-4589-874f-35137e031e59">2021</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV80L2ZyYWc6YjA5NWRmYjQ0YWYyNGVkNzllMGM1NTY1ZDg4ZGY4M2QvdGFibGU6YTNiNjY5OGI1NjU5NDhkZmJjZjhlNjNjZjY5MWJhNzIvdGFibGVyYW5nZTphM2I2Njk4YjU2NTk0OGRmYmNmOGU2M2NmNjkxYmE3Ml8zMi0xLTEtMS0yMTAwMg_8cfd916b-ef6d-4feb-b8b0-7dc72aa82729">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV80L2ZyYWc6YjA5NWRmYjQ0YWYyNGVkNzllMGM1NTY1ZDg4ZGY4M2QvdGFibGU6YTNiNjY5OGI1NjU5NDhkZmJjZjhlNjNjZjY5MWJhNzIvdGFibGVyYW5nZTphM2I2Njk4YjU2NTk0OGRmYmNmOGU2M2NmNjkxYmE3Ml8zMy0xLTEtMS0yMTAwMg_d83206c8-346b-4476-b650-3ce555272a94">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i9318b4034bf247a7bf81e79df11bc14e_D20210212-20210212"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMTkzL2ZyYWc6YzgxMTM0ZTkyZjE4NGZiN2ExYWZjYmQ1ZGMyZmY3MmQvdGFibGU6MTViMjViM2Y3NTQ5NDQ3Y2I5OTg2MmUzN2ZkNjFhNTIvdGFibGVyYW5nZToxNWIyNWIzZjc1NDk0NDdjYjk5ODYyZTM3ZmQ2MWE1Ml8xLTEtMS0xLTI3NjU4_38d57c4c-05bd-4fb0-bd80-03562eff751d"
      unitRef="number">0.025</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzItMi0xLTEtMjcwNjk_d0fa8a87-0583-4dbe-aa44-438729a21dce">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzItNC0xLTEtMjcxMDQ_1d91015f-66ad-42d5-87ce-9f403c36c69c">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzQtMi0xLTEtMjcwNzY_4d9aad60-57b0-43cc-9c32-3717c31c5311">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzQtNC0xLTEtMjcxMTE_878bb0e5-bbd6-48e9-9988-7643436d0dee">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzUtMi0xLTEtMjcwNzY_0cbe9984-707d-4160-b526-ea4fa4370ae5">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzUtNC0xLTEtMjcxMTE_15864d26-3ad3-4b32-a575-a615f5f41fef">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:DebtInstrumentTerm
      contextRef="if77c3753756e4eb8b7f0d6919514e0d1_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjAvZnJhZzo0NGYyNDgzZmE3NGI0MWY2OWRlOGU2ZTVhNzZlOWM2Zi90ZXh0cmVnaW9uOjQ0ZjI0ODNmYTc0YjQxZjY5ZGU4ZTZlNWE3NmU5YzZmXzU2OA_a031568f-8be9-4dd8-8877-34662d6a2613">P2Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="if6d11153da3c4046926d1df8862e08df_I20210212"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90ZXh0cmVnaW9uOmYzODY5MGU0NWM0ODQ1ZjZiMmEzOGNjMTRiZGU0NzkyXzE2NDkyNjc0NDQzMDI_d0b1e4ec-bc6a-4c22-8fd2-7d9f5a4cd028">P5Y0M0D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODcvZnJhZzowZDU0N2Q5Y2RkMjI0ZGI0YTM5YmUyNGM0Y2U4YzFlNi90ZXh0cmVnaW9uOjBkNTQ3ZDljZGQyMjRkYjRhMzliZTI0YzRjZThjMWU2XzIyNjM_78fa8817-af6f-44a3-ac14-32aa0ae3785c">SUBSEQUENT EVENTS[TBD]</us-gaap:SubsequentEventsTextBlock>
    <dei:DocumentType
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV8yOTU1_2d00d47c-8f24-4d4c-ae1e-1842c4f144d2">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6MTMwYjU4NDVjZGQ4NGY0NTg3N2ViYmQwNWM3ZDVmNjgvdGFibGVyYW5nZToxMzBiNTg0NWNkZDg0ZjQ1ODc3ZWJiZDA1YzdkNWY2OF8wLTAtMS0xLTIxMDAy_9fc7d40f-8a1e-4b04-9649-fa82afedd4eb">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV8xOTQ_89484c0f-4678-4cfb-bdf1-75b571ab7a8f">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV8xOTQ_b1099096-8dc7-4a2b-a3f9-220efcc2e693">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6MDMxZjYyZmM1MTliNDk1NzhhOTE0M2E0NmQzN2YyNmIvdGFibGVyYW5nZTowMzFmNjJmYzUxOWI0OTU3OGE5MTQzYTQ2ZDM3ZjI2Yl8wLTAtMS0xLTIxMDAy_6831a1ed-77bd-468b-bb57-4be6c1ab27f4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV8yOTU2_d0f3ace2-5e1f-4a32-a7fd-71fcc6ba30f6">001-40034</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV8yOTU4_df472f03-c43a-4cf5-a4ff-85a1de64699c">VALLON PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6ZTYwZGIwZWI5MTkwNGI5MjkzODA5ODAzN2E1NjFkOGYvdGFibGVyYW5nZTplNjBkYjBlYjkxOTA0YjkyOTM4MDk4MDM3YTU2MWQ4Zl8wLTEtMS0xLTIxMDAy_e2102b58-12e2-49b1-967a-8ee29c923791">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6ZTYwZGIwZWI5MTkwNGI5MjkzODA5ODAzN2E1NjFkOGYvdGFibGVyYW5nZTplNjBkYjBlYjkxOTA0YjkyOTM4MDk4MDM3YTU2MWQ4Zl8wLTMtMS0xLTIxMDAy_26887ad0-33f0-4367-8b2d-4b46e19c43f3">82-4369909</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6NzBkZTgxYzMzNWJmNDdjNzg2MTc0MjM0ZTNkOTFjODkvdGFibGVyYW5nZTo3MGRlODFjMzM1YmY0N2M3ODYxNzQyMzRlM2Q5MWM4OV8wLTAtMS0xLTIxMDAyL3RleHRyZWdpb246NDU3NTgwNDI5OTRiNDg0YTgwODA5ZDBhOTFhZTJkMzdfNQ_2cf877a8-f5cd-4622-b8c5-1e81f52c4bd0">100 N. 18th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6NzBkZTgxYzMzNWJmNDdjNzg2MTc0MjM0ZTNkOTFjODkvdGFibGVyYW5nZTo3MGRlODFjMzM1YmY0N2M3ODYxNzQyMzRlM2Q5MWM4OV8wLTAtMS0xLTIxMDAyL3RleHRyZWdpb246NDU3NTgwNDI5OTRiNDg0YTgwODA5ZDBhOTFhZTJkMzdfOQ_dbfbcf95-6453-498e-9d01-a32d6d90692c">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6NzBkZTgxYzMzNWJmNDdjNzg2MTc0MjM0ZTNkOTFjODkvdGFibGVyYW5nZTo3MGRlODFjMzM1YmY0N2M3ODYxNzQyMzRlM2Q5MWM4OV8wLTAtMS0xLTIxMDAyL3RleHRyZWdpb246NDU3NTgwNDI5OTRiNDg0YTgwODA5ZDBhOTFhZTJkMzdfMTM_d6ec9dec-cf50-4afd-8b6f-570091296296">Philadelphia</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6NzBkZTgxYzMzNWJmNDdjNzg2MTc0MjM0ZTNkOTFjODkvdGFibGVyYW5nZTo3MGRlODFjMzM1YmY0N2M3ODYxNzQyMzRlM2Q5MWM4OV8wLTAtMS0xLTIxMDAyL3RleHRyZWdpb246NDU3NTgwNDI5OTRiNDg0YTgwODA5ZDBhOTFhZTJkMzdfMTc_ac817c59-a8f6-4fdf-adb0-57a8d1f9f7fb">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6NzBkZTgxYzMzNWJmNDdjNzg2MTc0MjM0ZTNkOTFjODkvdGFibGVyYW5nZTo3MGRlODFjMzM1YmY0N2M3ODYxNzQyMzRlM2Q5MWM4OV8wLTAtMS0xLTIxMDAyL3RleHRyZWdpb246NDU3NTgwNDI5OTRiNDg0YTgwODA5ZDBhOTFhZTJkMzdfMjE_020da308-e644-4aff-9bca-74dfc674b69c">19103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6NzBkZTgxYzMzNWJmNDdjNzg2MTc0MjM0ZTNkOTFjODkvdGFibGVyYW5nZTo3MGRlODFjMzM1YmY0N2M3ODYxNzQyMzRlM2Q5MWM4OV8wLTEtMS0xLTIxMDAyL3RleHRyZWdpb246MTA5YjJlNGI2ZmE0NGIyN2JlYTllYjhhZWEyOTI0Y2VfNg_213a9cc6-27f0-4c4d-9eaf-cc2b5651193f">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6NzBkZTgxYzMzNWJmNDdjNzg2MTc0MjM0ZTNkOTFjODkvdGFibGVyYW5nZTo3MGRlODFjMzM1YmY0N2M3ODYxNzQyMzRlM2Q5MWM4OV8wLTEtMS0xLTIxMDAyL3RleHRyZWdpb246MTA5YjJlNGI2ZmE0NGIyN2JlYTllYjhhZWEyOTI0Y2VfMTA_e58d46c1-0d73-4add-b0b0-18b75468a75f">607-8255</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6MjQ3MmMwZTY3MDAyNDBmMmEzMmRhM2JlZjIwYzM2YzMvdGFibGVyYW5nZToyNDcyYzBlNjcwMDI0MGYyYTMyZGEzYmVmMjBjMzZjM18xLTAtMS0xLTIxMDAy_1516e01a-71f3-4c16-b33e-9ad8ac58ab2c">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6MjQ3MmMwZTY3MDAyNDBmMmEzMmRhM2JlZjIwYzM2YzMvdGFibGVyYW5nZToyNDcyYzBlNjcwMDI0MGYyYTMyZGEzYmVmMjBjMzZjM18xLTItMS0xLTIxMDAy_65949821-445f-4f26-99a2-8251abbebe26">VLON</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6MjQ3MmMwZTY3MDAyNDBmMmEzMmRhM2JlZjIwYzM2YzMvdGFibGVyYW5nZToyNDcyYzBlNjcwMDI0MGYyYTMyZGEzYmVmMjBjMzZjM18xLTQtMS0xLTIxMDAyL3RleHRyZWdpb246MWNmNTExNTFmMzMyNDE2YTkzNmZmZWE0NmQ4ZWUzMDhfNA_8ac821fc-2a2e-4983-8668-37d5a5151896">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV81NDk3NTU4MTQyNTkz_d363aeed-73e7-47cc-9dcf-1c45552cfe12">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV81NDk3NTU4MTQyNTk1_b563fb89-34e7-4534-9b86-c1c9ade72f1c">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV8yOTU5_d476e12c-7e20-4c63-9396-ce37f639287a">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV8yOTU3_a95a9c32-a515-4806-9fe1-6c6cb40f740b">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6YjllN2Y1ZmNiYjUyNGEwN2I3MjJhZTA1ZWYzMWIyMmYvdGFibGVyYW5nZTpiOWU3ZjVmY2JiNTI0YTA3YjcyMmFlMDVlZjMxYjIyZl8xLTAtMS0xLTIxMDAy_31a5c49a-732c-4e78-bdf0-a07f56a53389">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6YjllN2Y1ZmNiYjUyNGEwN2I3MjJhZTA1ZWYzMWIyMmYvdGFibGVyYW5nZTpiOWU3ZjVmY2JiNTI0YTA3YjcyMmFlMDVlZjMxYjIyZl8xLTMtMS0xLTIxMDAy_b2e0200f-73d7-43e2-9d13-fe3a58146799">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGFibGU6YjllN2Y1ZmNiYjUyNGEwN2I3MjJhZTA1ZWYzMWIyMmYvdGFibGVyYW5nZTpiOWU3ZjVmY2JiNTI0YTA3YjcyMmFlMDVlZjMxYjIyZl8yLTMtMS0xLTIxMDAy_25ce9dca-dbc4-461e-b897-fbdd9ab09e35">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV8yOTYw_b8cd682d-3714-48a4-8d18-057bc5e32f19">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV8xNjQ5MjY3NDQ1Njky_f4753500-6b4f-4372-93e1-0525db67ac16">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV8yOTYx_ab0dc4e8-6d0d-4860-bee5-70a3bb932b09">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i65072bfeaf3a4457ad6a97aa44ce8820_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV81NDk3NTU4MTQyNTk3_3bab5dec-c5fe-4680-af24-1c451a6e9205"
      unitRef="usd">22900000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="iabb727de2d49441ba5658b9b5a183b63_I20220211"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xL2ZyYWc6NjljNjEyYTRlNDkwNDU3OThjMGM1MWY4MDY1ZmI5MGEvdGV4dHJlZ2lvbjo2OWM2MTJhNGU0OTA0NTc5OGMwYzUxZjgwNjVmYjkwYV81NDk3NTU4MTQyNjEz_c64c8063-9c21-4531-aa0d-1087fb23ced9"
      unitRef="shares">6812836</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMTgvZnJhZzpkZDk2MTQ0Nzg0ODQ0OGM1OTZhNDBhYWNkNzRlMTM0ZS90ZXh0cmVnaW9uOmRkOTYxNDQ3ODQ4NDQ4YzU5NmE0MGFhY2Q3NGUxMzRlXzU0OTc1NTgxNDUzODQ_b4a9bfd0-b47b-4baa-b0b4-948186da0cce">EisnerAmper LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMTgvZnJhZzpkZDk2MTQ0Nzg0ODQ0OGM1OTZhNDBhYWNkNzRlMTM0ZS90ZXh0cmVnaW9uOmRkOTYxNDQ3ODQ4NDQ4YzU5NmE0MGFhY2Q3NGUxMzRlXzU0OTc1NTgxNDUzODk_900d7da9-79ae-4f8f-926c-05214cfe0be1">Iselin, New Jersey</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMTgvZnJhZzpkZDk2MTQ0Nzg0ODQ0OGM1OTZhNDBhYWNkNzRlMTM0ZS90ZXh0cmVnaW9uOmRkOTYxNDQ3ODQ4NDQ4YzU5NmE0MGFhY2Q3NGUxMzRlXzU0OTc1NTgxNDUzOTE_17cecf40-a600-43a9-b174-d84ea3a35261">274</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzQtMS0xLTEtMjM4NjY_ad99d1fd-06e1-4785-865d-15543323af86"
      unitRef="usd">3702000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzQtMy0xLTEtMjM3OTE_0ff625d1-bb26-4438-a2c2-852a5e65ab9d"
      unitRef="usd">109000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzUtMS0xLTEtMjM4NjY_83aa36c0-ff5d-48b8-b6d0-c3564134da34"
      unitRef="usd">3808000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzUtMy0xLTEtMjM4MDU_155fe17c-6e86-4e7e-ad63-53f3e4ff6d6d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzYtMS0xLTEtMjM4NjY_583de96d-42b3-4839-acb7-aadb3a4ae7c7"
      unitRef="usd">619000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzYtMy0xLTEtMjM3OTM_03343b6d-f5cb-42ee-a5be-24075b416e4c"
      unitRef="usd">565000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzctMS0xLTEtMjM4OTU_01b30e1b-a8ad-4706-ad41-4e03fbbc54c5"
      unitRef="usd">8129000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzctMy0xLTEtMjM3OTM_3cf5f273-0ab6-48c3-84f9-76a81b286282"
      unitRef="usd">674000</us-gaap:AssetsCurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzgtMS0xLTEtMjM4NzI_fb502b1f-10e7-4d49-9bde-4572e8427380"
      unitRef="usd">206000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzgtMy0xLTEtMjM3OTM_69b69299-9297-40fc-bbf6-92587b928c9f"
      unitRef="usd">279000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzktMS0xLTEtMjM4NzI_6bbcbc72-0bfb-4dcf-b602-2f2906724afa"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzktMy0xLTEtMjM3OTM_d2f425e4-fde3-4a81-9183-ec90e1d40bca"
      unitRef="usd">2000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzEwLTEtMS0xLTIzODk1_5a508e07-69a1-400d-921f-7c8bf3945850"
      unitRef="usd">8335000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzEwLTMtMS0xLTIzNzkz_567102ec-ae46-486c-8aeb-aaf2214c0763"
      unitRef="usd">955000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzE0LTEtMS0xLTIzODc4_a74a0485-9063-4d61-9483-9b1df93f6ab4"
      unitRef="usd">918000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzE0LTMtMS0xLTIzNzk1_da515ba5-0b8c-40ee-80c6-cea2fb7e3206"
      unitRef="usd">1226000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzE1LTEtMS0xLTIzODc4_17ab9da8-b1d6-4e12-8fe6-c4d1fed99288"
      unitRef="usd">1430000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzE1LTMtMS0xLTIzNzk1_27a04f85-1851-417e-a950-7bc404fa5f34"
      unitRef="usd">847000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzE2LTEtMS0xLTIzODc4_09ff8f85-7e7c-4840-b3b4-90df6672348b"
      unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzE2LTMtMS0xLTIzNzk1_b67a11f4-6c85-43bf-989e-2a42917fca30"
      unitRef="usd">47000</us-gaap:NotesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzE3LTEtMS0xLTIzODc4_47823c24-7bfe-4041-a6fc-7a89b2bb8762"
      unitRef="usd">97000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzE3LTMtMS0xLTIzNzk1_24d30ae7-0e17-4082-b69d-c1cc13eeb2db"
      unitRef="usd">105000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzE4LTEtMS0xLTIzODk1_5827b67d-0a50-489b-9d76-042cb2ab9aec"
      unitRef="usd">2445000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzE4LTMtMS0xLTIzNzk1_0b055212-9e2e-4ffe-9b92-2ab41b641e7d"
      unitRef="usd">2225000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzE5LTEtMS0xLTIzODg1_28d15194-4ecf-4716-a51e-62dd96b07f02"
      unitRef="usd">0</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzE5LTMtMS0xLTIzNzk1_5f7bed86-e47b-4667-b39b-c5be8bb02b4d"
      unitRef="usd">14000</us-gaap:LongTermNotesPayable>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzIwLTEtMS0xLTIzODg1_b582d57a-0c17-4e9b-9e00-be421ab393f3"
      unitRef="usd">72000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzIwLTMtMS0xLTIzNzk1_e3fdfc2a-b334-4546-a265-32d99e914995"
      unitRef="usd">170000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzIxLTEtMS0xLTIzODk1_bdfcd1cb-bf2f-468a-bcbe-c13815382ed6"
      unitRef="usd">2517000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzIxLTMtMS0xLTIzNzk1_708fa628-19df-4150-818e-ffaf03e0e469"
      unitRef="usd">2409000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzIzLTEtMS0xLTIzODk1_7c321d1e-309d-40af-aa78-451c0689179a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzIzLTMtMS0xLTIzNzk3_de994bcc-5106-4d66-a0b1-e6e63e589716"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI1LTAtMS0xLTIzNzQ5L3RleHRyZWdpb246Zjg1NjQ0Yjg5MmIwNGQ2Y2IzZGZmMjM5ZTg0MjM0NjFfMTg_09606099-9061-41fe-b0d4-b121f1c937a4"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI1LTAtMS0xLTIzNzQ5L3RleHRyZWdpb246Zjg1NjQ0Yjg5MmIwNGQ2Y2IzZGZmMjM5ZTg0MjM0NjFfMTg_187b337c-04d3-4664-8b06-e3c3e511cc2d"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI1LTAtMS0xLTIzNzQ5L3RleHRyZWdpb246Zjg1NjQ0Yjg5MmIwNGQ2Y2IzZGZmMjM5ZTg0MjM0NjFfMzI_1f742f1f-2866-47b7-aba8-5bee4f286669"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI1LTAtMS0xLTIzNzQ5L3RleHRyZWdpb246Zjg1NjQ0Yjg5MmIwNGQ2Y2IzZGZmMjM5ZTg0MjM0NjFfMzI_2447a3f2-6eaf-4c81-822c-9a4c7bcd8647"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI1LTAtMS0xLTIzNzQ5L3RleHRyZWdpb246Zjg1NjQ0Yjg5MmIwNGQ2Y2IzZGZmMjM5ZTg0MjM0NjFfMjE5OTAyMzI1NTY2OA_399844e3-7428-4b06-9b19-2e255969b59b"
      unitRef="shares">6812836</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI1LTAtMS0xLTIzNzQ5L3RleHRyZWdpb246Zjg1NjQ0Yjg5MmIwNGQ2Y2IzZGZmMjM5ZTg0MjM0NjFfMjE5OTAyMzI1NTY2OA_ee3edbd9-173c-4bc6-95c7-85d6334ceed5"
      unitRef="shares">6812836</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI1LTAtMS0xLTIzNzQ5L3RleHRyZWdpb246Zjg1NjQ0Yjg5MmIwNGQ2Y2IzZGZmMjM5ZTg0MjM0NjFfMjE5OTAyMzI1NTc4NA_afbb514c-f449-487f-9a2b-24a50aeb6723"
      unitRef="shares">4506216</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI1LTAtMS0xLTIzNzQ5L3RleHRyZWdpb246Zjg1NjQ0Yjg5MmIwNGQ2Y2IzZGZmMjM5ZTg0MjM0NjFfMjE5OTAyMzI1NTc4NA_c6ec20c8-2b7c-42eb-8d9c-89d77b7f94c6"
      unitRef="shares">4506216</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValueOutstanding
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI2LTEtMS0xLTIzODkx_01da2f2e-d3af-4066-8c02-b5d731cc9cc3"
      unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI2LTMtMS0xLTIzNzk3_9d58e650-c22d-4ec7-ac0a-61ce43842473"
      unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI3LTEtMS0xLTIzODkx_97c77fd2-41b8-49c8-b560-ce606717ae4b"
      unitRef="usd">27722000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI3LTMtMS0xLTIzNzk3_a3860075-ab2b-4610-84e1-bbc2fe4b370e"
      unitRef="usd">11145000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI4LTEtMS0xLTIzODkx_816d7cef-b337-4c6a-a38d-0d0d10d168a0"
      unitRef="usd">-2000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI4LTMtMS0xLTIzODU1_9cf67c29-d388-4a52-8c21-14693d740012"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI5LTEtMS0xLTIzODkx_ca2f5510-9817-4a81-b96a-1c98c4527eb6"
      unitRef="usd">-21902000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI4LTMtMS0xLTIzNzk3_e980274d-62fa-4d6b-8270-289286669326"
      unitRef="usd">-12599000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzMwLTEtMS0xLTIzODk5_63459bf9-3692-4677-8332-da413bdafdf9"
      unitRef="usd">5818000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzI5LTMtMS0xLTIzNzk3_8f871f36-4081-44f2-ac9d-d738f545b6af"
      unitRef="usd">-1454000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzMxLTEtMS0xLTIzODk5_157d2485-fb34-4f2d-8846-de6e97092a29"
      unitRef="usd">8335000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xMzkvZnJhZzo1YmExYTQ5OGM2NzA0ODg3OTZiZjQ2OWViODBjM2M2Zi90YWJsZTpmMDY5ZTVhMTZiYmU0NjQxOWM5N2ZmNzI3M2EwZjBkYy90YWJsZXJhbmdlOmYwNjllNWExNmJiZTQ2NDE5Yzk3ZmY3MjczYTBmMGRjXzMwLTMtMS0xLTIzNzk3_66ff9f57-4e08-4e27-972b-bd5d2b73194e"
      unitRef="usd">955000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzItMS0xLTEtMjQwMDk_31a4f353-b6ba-4178-a54e-9d2a3bd3099c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzItMy0xLTEtMjM5NjA_e4c979ee-9f1e-4401-8378-ce210a566bc9"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzQtMS0xLTEtMjQwMTU_7f6e3300-4aab-4477-8acf-18aca0319fa9"
      unitRef="usd">5187000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzQtMy0xLTEtMjM5NjY_e527c8f5-7691-4aa5-a87f-fb2f88a072d1"
      unitRef="usd">3707000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzUtMS0xLTEtMjQwMTU_8bbea440-d5a7-4925-bbe6-219e708ee614"
      unitRef="usd">4072000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzUtMy0xLTEtMjM5NjY_243a2c91-b519-4562-8b46-faaff3bf83bb"
      unitRef="usd">1181000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzYtMS0xLTEtMjQwMjE_ed26c6f9-a4f2-44c0-bb11-0240872d21fd"
      unitRef="usd">9259000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzYtMy0xLTEtMjQwMTk_ce832831-6913-4797-841a-0311d203cf12"
      unitRef="usd">4888000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzctMS0xLTEtMjQwMjU_7265a602-1e04-4cbc-8fb3-dd3e88469187"
      unitRef="usd">-9259000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzctMy0xLTEtMjQwMjM_4e43521b-51c0-4ee8-a4fc-173d93ddbd09"
      unitRef="usd">-4788000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzgtMS0xLTEtMjQwNDE_3599509c-6e87-4af4-90b6-a1938d04c421"
      unitRef="usd">61000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzgtMy0xLTEtMjM5NzI_778ed0c8-4ed9-47ed-bb53-a062c904a124"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzktMS0xLTEtMjQwNDE_6db8fcfd-f86b-414c-a27a-db1ab8f17192"
      unitRef="usd">-89000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzktMy0xLTEtMjM5NzI_e903d123-62d7-4159-a398-daa489034369"
      unitRef="usd">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzEwLTEtMS0xLTI0MDQx_d477d12a-6feb-4cf9-8a56-c9df0bf5ad7b"
      unitRef="usd">-16000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzEwLTMtMS0xLTIzOTcy_7e00ac48-ac3c-42b6-90da-71b1364810b9"
      unitRef="usd">-34000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NetIncomeLoss
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzExLTEtMS0xLTI0MDQ3_2c90ba76-338c-4d70-9922-2bff2150408c"
      unitRef="usd">-9303000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzExLTMtMS0xLTI0MDQ4_87d6691b-e747-461c-bd60-f411baacb25c"
      unitRef="usd">-4822000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzEzLTEtMS0xLTI0MDU1_de226192-e002-4428-8956-18c0be2d362c"
      unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzEzLTMtMS0xLTIzOTc4_b09943a4-3b7c-4991-8189-7ba9d16455f9"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzE0LTEtMS0xLTI0MDY0_e4e247b0-2456-441d-9c7f-f1216068dc5f"
      unitRef="usd">-9305000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzE0LTMtMS0xLTI0MDYz_187a305c-cbb1-4a22-9abd-52514a5ccfe1"
      unitRef="usd">-4822000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzE1LTEtMS0xLTI0MDcz_200fba3f-e67e-423b-8351-325c347ac0fd"
      unitRef="usdPerShare">-1.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzE1LTEtMS0xLTI0MDcz_2e66e8e5-22d5-4242-ade0-550b199b213c"
      unitRef="usdPerShare">-1.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzE1LTMtMS0xLTIzOTg0_acfb78b3-c8ae-4060-bb09-a0aacdb96c43"
      unitRef="usdPerShare">-1.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzE1LTMtMS0xLTIzOTg0_ae147274-f160-47a8-90f6-8e68d9f13ab5"
      unitRef="usdPerShare">-1.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzE2LTEtMS0xLTI0MDcz_56cd5a5a-3e5a-45c0-b6f7-696879bb3826"
      unitRef="shares">6541097</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzE2LTEtMS0xLTI0MDcz_a7042e1a-51b6-4426-86f6-bce98dd8b6ac"
      unitRef="shares">6541097</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzE2LTMtMS0xLTIzOTg0_c07bc198-8f68-4484-b32b-50cf4aeb6397"
      unitRef="shares">4506216</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDIvZnJhZzo3YTc5M2ZmOTliNDA0NGVlYmE1YThmNjgyNDU0NTA3Mi90YWJsZTo3MzExNGY4M2U0NmQ0M2Q3ODEwN2Y2ZDNiY2Y4ZDNlYi90YWJsZXJhbmdlOjczMTE0ZjgzZTQ2ZDQzZDc4MTA3ZjZkM2JjZjhkM2ViXzE2LTMtMS0xLTIzOTg0_ea33e5e5-1caa-4f81-ab94-0ec9cb07f1dd"
      unitRef="shares">4506216</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iaa705715f28d4b5eacce471c76e4867b_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzItMS0xLTEtMjQxNTY_167af536-e4c4-4875-a6f3-ef6ee77d8a43"
      unitRef="shares">4506216</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8a303ff40d68410ea858ad97833960cc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzItNS0xLTEtMjQxNjE_fc828259-4476-4cee-b1d1-7981e486b703"
      unitRef="usd">10991000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i38e2e0b664e044f1ab6f20ebf44f6f59_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzItOS0xLTEtMjQxNzc_7739fe84-d71c-4818-8429-85ceaabbcb55"
      unitRef="usd">-7777000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i23ee9c62820d4f39a904524cfe778f00_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzItMTEtMS0xLTI0MzY1_0db53ef8-3e8e-44ba-9332-a0b54d683945"
      unitRef="usd">3214000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifd9521358ab247c2b64d4cbe8a945e84_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzMtNS0xLTEtMjQxODE_34b7dee4-a7b8-4633-9117-a3e14f4e3b29"
      unitRef="usd">154000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzMtMTEtMS0xLTI0Mzcw_69049b4c-c2cf-484e-bfb3-76ae798ed123"
      unitRef="usd">154000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i60aca420575a440fa652609aad540150_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzQtOS0xLTEtMjQxODU_6cef1975-9f1d-442f-9cf8-e64258dcf4de"
      unitRef="usd">-4822000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzQtMTEtMS0xLTI0Mzcz_03238284-362a-4562-97ed-3939e81d4c4b"
      unitRef="usd">-4822000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6476323fed784d85832b674bde1f5d2b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzUtMS0xLTEtMjQzNzU_bffc1a32-ea6f-4898-a827-682097a6cd3c"
      unitRef="shares">4506216</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id5b0ac7b11494351935046ce5bf1cc8e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzUtNS0xLTEtMjQyNzA_866f8e54-2a4f-4ea6-9bc2-f2f2fa451962"
      unitRef="usd">11145000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia70712498a0f4941ab0ea3722b2be30f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzUtOS0xLTEtMjQxOTk_4a3a988a-2a4f-48b8-acec-9f4ff71e7474"
      unitRef="usd">-12599000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzUtMTEtMS0xLTI0MjAw_9ebbf65e-026b-462e-b564-3ddc4d2cb5f8"
      unitRef="usd">-1454000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="iffdd767329aa4cd59029b7fd066b141d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzYtMS0xLTEtMjY3MzI_97ba60da-e377-4bfc-a8f5-fafe9a899d69"
      unitRef="shares">54906</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i270b8e6dd74f41e4a133ae1c6754d770_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzYtNS0xLTEtMjQzNTM_326ca764-3280-4b7c-b8b4-bd47c378d7fd"
      unitRef="usd">439000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzYtMTEtMS0xLTI0MzU2_c754995a-6a67-4f78-9b59-5e8cbd4b28aa"
      unitRef="usd">439000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="iffdd767329aa4cd59029b7fd066b141d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzctMS0xLTEtMjY3MzI_2034eaf8-d80c-404d-a4d6-0e065e732c0b"
      unitRef="shares">2250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i270b8e6dd74f41e4a133ae1c6754d770_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzctNS0xLTEtMjQzNTM_4c9d86b4-d15b-4ba5-ad7f-53dbc1070558"
      unitRef="usd">15104000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzctMTEtMS0xLTI3NDMx_6cf728cc-2d6c-4a43-8ea3-6651c6d52aed"
      unitRef="usd">15104000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="iffdd767329aa4cd59029b7fd066b141d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzgtMS0xLTEtMjY3MzI_e60fd92d-567a-404a-8a63-86545f7a43d8"
      unitRef="shares">1714</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i270b8e6dd74f41e4a133ae1c6754d770_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzgtNS0xLTEtMjQzNTM_d10250cd-8e44-461d-a605-3b4d29dc0735"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzgtMTEtMS0xLTI3NDMx_cce69f44-cd53-42c7-a3db-fbadd18d2425"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i270b8e6dd74f41e4a133ae1c6754d770_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzktNS0xLTEtMjQzNTM_91997af1-3760-466e-9215-2a3d6a3e9f67"
      unitRef="usd">399000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzktMTEtMS0xLTI3NDMx_b96879d0-2161-447c-a141-3ec5ae206318"
      unitRef="usd">399000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i270b8e6dd74f41e4a133ae1c6754d770_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzYtNS0xLTEtMjQyMjU_ae4dd264-871d-43ac-bd3c-5684d0931f6a"
      unitRef="usd">626000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzEwLTExLTEtMS0yNDM1NQ_4a2c7b20-2293-452d-90b7-15d9a4130117"
      unitRef="usd">626000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia203ce9d16f8445c984d50be01b6c4af_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzctNy0xLTEtMjQyNDI_dad46fa1-a726-48c6-85f1-78c9c375a80c"
      unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzExLTExLTEtMS0yNzQzMw_d0aea2b6-1abb-40a0-b5c5-dcdf5c63657c"
      unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i2ede8e54df1449d8b82bb4b005ed5a86_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzctOS0xLTEtMjQyMzI_80a5eb2d-4172-4587-9bb5-aa229961b31a"
      unitRef="usd">-9303000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzEyLTExLTEtMS0yNDM4Ng_123358c2-f256-4b34-bd57-318e9fc180ef"
      unitRef="usd">-9303000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i92ca8836910146858994d27a6356eec0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzktMS0xLTEtMjQzMzE_3b2a6319-adb0-4798-be6a-35e49e1568bd"
      unitRef="shares">6812836</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i033d2a786a29471796dbfe50eb424da2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzktNS0xLTEtMjQzMTc_b414e1a4-13f6-4d51-b819-0d8908982815"
      unitRef="usd">27722000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic5e826ed29c14a57ab4a163d538e1c37_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzktNy0xLTEtMjQzMDk_6025c4db-a806-42ec-9e1e-70ac80eef36d"
      unitRef="usd">-2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2716e8a4ca0545f8bbce622e4d52158f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzktOS0xLTEtMjQzMDI_0fb8cfb9-2edf-4ff8-aa6c-bd5aa9ec5dea"
      unitRef="usd">-21902000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDUvZnJhZzo2ODAxY2YyOTZlMGM0NmRjOTliMzc1MTBkYTM0OGQ3NC90YWJsZTo2YWFhOWY0MzBmMzg0ODIxYjc2ZWRkMGI2YWE5Y2JjZC90YWJsZXJhbmdlOjZhYWE5ZjQzMGYzODQ4MjFiNzZlZGQwYjZhYTljYmNkXzktMTEtMS0xLTI0MzAx_685b2fbe-e705-44b3-be8b-3c682ee58858"
      unitRef="usd">5818000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzMtMS0xLTEtMjQ0ODY_36641889-9b09-450c-ac16-b70ff1ac2a7a"
      unitRef="usd">-9303000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzMtMy0xLTEtMjQ0MDA_04e6789c-c470-468b-a87a-95b98b92a3b4"
      unitRef="usd">-4822000</us-gaap:NetIncomeLoss>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzYtMS0xLTEtMjQ0OTI_4257c3c2-d5b0-441e-8c13-3d2ffb6d990b"
      unitRef="usd">73000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzYtMy0xLTEtMjQ0MDc_15fec50c-a1d3-45f2-802f-31c0998e3da1"
      unitRef="usd">74000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzctMS0xLTEtMjQ0OTg_a8a76937-28f9-4d82-a6da-54d3fa674cfd"
      unitRef="usd">-32000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzctMy0xLTEtMjQ1MDU_4d4f3f73-90f9-4b5c-b635-9b998f4a2f91"
      unitRef="usd">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzgtMS0xLTEtMjQ1MTc_3a2ff576-5940-4336-83ae-9b06f127ce06"
      unitRef="usd">-89000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzgtMy0xLTEtMjQ1MjM_f57c96ca-9df0-40de-a23a-d5e30f008052"
      unitRef="usd">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:ShareBasedCompensation
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzEwLTEtMS0xLTI0NTEx_c3b45109-d0b8-4a45-a6bb-2d9ec9537598"
      unitRef="usd">626000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzEwLTMtMS0xLTI0NDE1_7b35fa0a-618c-4c9d-8c5e-1471c3daf46c"
      unitRef="usd">154000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzExLTEtMS0xLTI0NTI5_af658aa8-3f2a-43e0-9115-ca9daad634e3"
      unitRef="usd">61000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzExLTMtMS0xLTI0NTM2_15095071-ee60-4892-88cd-fc05f3fbbf4d"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNoncashExpense
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzEyLTEtMS0xLTI0NTQy_2a0f1644-36d4-4ba8-a844-bffdb374cdaa"
      unitRef="usd">12000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzEyLTMtMS0xLTI0NDIy_f817f24c-57e4-47a9-88c1-38f457ef06f7"
      unitRef="usd">1000</us-gaap:OtherNoncashExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzE0LTEtMS0xLTI0NTcy_52be1660-888c-4407-93b7-162f841f8ba0"
      unitRef="usd">55000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzE0LTMtMS0xLTI0NDMx_0ed78c6d-87a5-41e7-9ad4-0e1b86c74674"
      unitRef="usd">464000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzE1LTEtMS0xLTI0NTcy_7cbe2e54-3910-481b-bd56-7d8c398ebce8"
      unitRef="usd">-308000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzE1LTMtMS0xLTI0NDMx_a52e7d7b-74dc-4d57-b80e-6ca19f8a7819"
      unitRef="usd">980000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzE2LTEtMS0xLTI0NTcy_a43094cf-b4d5-42d2-948f-b0b456acca50"
      unitRef="usd">583000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzE2LTMtMS0xLTI0NDMx_1c5e298f-3ab9-4444-9d36-004d3d3dc1ae"
      unitRef="usd">371000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzE3LTEtMS0xLTI0NDQ2_fec6a83c-1a22-4d3d-9b57-70afd7adfb37"
      unitRef="usd">-8312000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzE3LTMtMS0xLTI0NDQ1_89fd601b-4682-4c03-bf1a-fe8a2b0731b2"
      unitRef="usd">-3706000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzIwLTEtMS0xLTI0NTc5_1797edc1-dfc6-4190-8a83-ee0630d2bdcb"
      unitRef="usd">3842000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzIwLTMtMS0xLTI0NDM5_1b6021d1-eed1-40b0-bbc7-d3e58d84492e"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzIxLTEtMS0xLTI0NTg1_acc01bd8-50c3-4d19-9bb1-0bc1141f91b2"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzIxLTMtMS0xLTI0NDM5_5a762208-8dee-449d-a276-6323d69f4b4c"
      unitRef="usd">2000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzIyLTEtMS0xLTI0NDUw_b534e265-eb39-4bbc-a811-5b70c2cfe818"
      unitRef="usd">-3842000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzIyLTMtMS0xLTI0NDQ4_bf6d0edb-a41c-4bd8-8b4c-28a046bb601f"
      unitRef="usd">-2000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzI1LTEtMS0xLTI0NjE0_59f01675-92c4-44ff-885b-c33c1e3f01bb"
      unitRef="usd">15104000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzIzLTMtMS0xLTI0Njkz_882e3c4c-d1f1-4aad-bdc4-175383eeca3b"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzI0LTEtMS0xLTI5NTQw_127bc68d-9807-486a-a1d3-55a08b57a342"
      unitRef="usd">399000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzI0LTMtMS0xLTI5NzQ0_5eda4061-0d0c-44c6-a1e2-73bc08817054"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzI2LTEtMS0xLTI0NjI4_8e57bd1b-586a-4e59-95fa-1cd9725015e2"
      unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzI2LTMtMS0xLTI0NDU0_60bde333-6df8-4912-b830-b39991be0b8e"
      unitRef="usd">61000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzI3LTEtMS0xLTI0NjIx_3fdd6c54-7623-41e5-a5f0-ea892159ca8f"
      unitRef="usd">350000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzI1LTMtMS0xLTI0Njk5_d6d76f8d-31e8-4b13-a912-603da01b2fb7"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzI5LTEtMS0xLTI0NjM0_fd3399c6-ef8a-473a-8f8c-246989e565b7"
      unitRef="usd">106000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzI5LTMtMS0xLTI0NDYx_d54e5af0-5f2a-45b1-ae72-846a64690341"
      unitRef="usd">65000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzMwLTEtMS0xLTI0NDcw_6947db9f-83c0-4746-8b31-21bf98d88991"
      unitRef="usd">15747000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzMwLTMtMS0xLTI0NDY5_3b5c7708-2917-4ac0-9735-5b3b619c7a27"
      unitRef="usd">-4000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzMyLTEtMS0xLTI0NjAw_d21e2854-18f3-4d1b-8f80-38be3094c609"
      unitRef="usd">3593000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzMyLTMtMS0xLTI0NTk5_8a411e67-a2b6-46d6-821f-985dd6d5feb4"
      unitRef="usd">-3712000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzMzLTEtMS0xLTI0NjA3_276b412e-b313-4147-a41f-527f8168729a"
      unitRef="usd">109000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i23ee9c62820d4f39a904524cfe778f00_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzMzLTMtMS0xLTI0NDc1_9d6f1eef-0d54-4317-9dbe-a6c038de259a"
      unitRef="usd">3821000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzM0LTEtMS0xLTI0NDgy_ce5ca63e-4932-491a-bb0a-667e92a95d81"
      unitRef="usd">3702000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzM0LTMtMS0xLTI0NDgx_e314c4b4-5b64-4f38-a6ed-8d9b94c71fcf"
      unitRef="usd">109000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzM0LTEtMS0xLTI0NzMw_21bbaf93-0d71-4c3c-9634-aab210379fb9"
      unitRef="usd">29000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzM0LTMtMS0xLTI0NzMy_eb5ff639-74a3-494e-adbb-9f20d7094a9a"
      unitRef="usd">41000</us-gaap:InterestPaidNet>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzM2LTEtMS0xLTI0NjYy_9ede49d5-10e8-411f-b70a-c91aa29c57dc"
      unitRef="usd">350000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNDgvZnJhZzo2ODZiZDZiYmVhYTA0Mzg4OGE5MmFkYzczNmFiOGNjMy90YWJsZTpmYjRlYWM1MDhkYjE0NzE1YWYyZDFjNDY2YTE1YTcxMy90YWJsZXJhbmdlOmZiNGVhYzUwOGRiMTQ3MTVhZjJkMWM0NjZhMTVhNzEzXzM2LTMtMS0xLTI0NjU1_918c6745-eecf-4cbc-b6df-fb1ea514c440"
      unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:NatureOfOperations
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTQvZnJhZzo1ZmFkMjg1ZWQwYzM0N2RhOWQ5Yjc1OTE5Zjk5YmU1Ni90ZXh0cmVnaW9uOjVmYWQyODVlZDBjMzQ3ZGE5ZDliNzU5MTlmOTliZTU2XzYyMDg_cfca1a01-8765-44a0-ae2d-62c78a5de5f9">ORGANIZATION AND DESCRIPTION OF BUSINESS&#160;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vallon Pharmaceuticals, Inc. (Vallon or the Company) was incorporated in Delaware in January 2018 (inception) and is based in Philadelphia, PA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for central nervous system (CNS) disorders. The Company&#x2019;s lead investigational product candidate, ADAIR, is a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine (the main active ingredient in Adderall&#xae;) for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The Company plans to develop other abuse-deterrent products, which have potential for abuse in their current forms, beginning with the development of ADMIR, an abuse deterrent formulation of Ritalin, for which the Company has completed formulation development work.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MDUvZnJhZzoxOWE0ODJhMmNiNTU0MjBlODhhNGMxNGVjYmY2ZmRkMi90ZXh0cmVnaW9uOjE5YTQ4MmEyY2I1NTQyMGU4OGE0YzE0ZWNiZjZmZGQyXzU0OTc1NTgxNDQ3OTU_22fd94a9-2fbe-4ad7-96ba-5697dd90e37d">LIQUIDITY&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception, and does not expect to do so in the foreseeable future. The Company has incurred operating losses since inception and has incurred $21,902 in accumulated deficit through December 31, 2021. The Company has financed its working capital requirements to date through the issuance of common stock, convertible notes, short-term promissory notes, and a Paycheck Protection Program (PPP) note. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company completed a $350 convertible note financing and in February 2021, the Company closed on its initial public offering (IPO) raising net proceeds of approximately $15,500.&#160;As of December&#160;31, 2021, the Company had cash, cash equivalents and marketable securities of approximately $7,510, which management expects will provide funding for its ongoing business activities into the third quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue as a going concern is dependent on its ability to raise substantial additional capital to fund its business activities, including its research and development program. The Company intends to raise capital through additional issuances of common stock and /or short-term notes, but there can be no assurances any such financing will be available when needed or that the Company&#x2019;s research and development efforts will be successful. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. Therefore, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MDUvZnJhZzoxOWE0ODJhMmNiNTU0MjBlODhhNGMxNGVjYmY2ZmRkMi90ZXh0cmVnaW9uOjE5YTQ4MmEyY2I1NTQyMGU4OGE0YzE0ZWNiZjZmZGQyXzMyOTg1MzQ4ODkyMTQ_ca2f5510-9817-4a81-b96a-1c98c4527eb6"
      unitRef="usd">-21902000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i550459c5b5124776a49bbd935630fdc7_D20210111-20210111"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MDUvZnJhZzoxOWE0ODJhMmNiNTU0MjBlODhhNGMxNGVjYmY2ZmRkMi90ZXh0cmVnaW9uOjE5YTQ4MmEyY2I1NTQyMGU4OGE0YzE0ZWNiZjZmZGQyXzIxOTkwMjMyNTY3MTM_c6620209-3ccf-47a6-ab41-0bf1c8f4299a"
      unitRef="usd">350000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ia17353f6bf834b99aeb72bb19eed6773_D20210212-20210212"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MDUvZnJhZzoxOWE0ODJhMmNiNTU0MjBlODhhNGMxNGVjYmY2ZmRkMi90ZXh0cmVnaW9uOjE5YTQ4MmEyY2I1NTQyMGU4OGE0YzE0ZWNiZjZmZGQyXzIxOTkwMjMyNTY4MzY_e477aea9-a6c3-49bc-b692-200efe0691d5"
      unitRef="usd">15500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MDUvZnJhZzoxOWE0ODJhMmNiNTU0MjBlODhhNGMxNGVjYmY2ZmRkMi90ZXh0cmVnaW9uOjE5YTQ4MmEyY2I1NTQyMGU4OGE0YzE0ZWNiZjZmZGQyXzMyOTg1MzQ4ODkyMjc_84909b1b-2997-4ce8-83aa-8f362927bf7c"
      unitRef="usd">7510000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzE2NjYy_05ab6547-9bd5-452e-905d-470bb90e3e08">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; References in this Annual Report on Form 10-K to &#x201c;authoritative guidance&#x201d; is meant to refer to accounting principles generally accepted in the United States of America (GAAP) as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recapitalization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately prior to the closing of the  IPO (Note 10), the Company effected a one-for-40 reverse stock split of its common stock. All share and per share amounts, excluding the number of authorized shares and par value, contained in these financial statements and accompanying notes, and this Annual Report on Form 10-K give retroactive effect to the reverse split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#x2019;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#x2019;s results of operations could either benefit from, or be adversely affected by, any such change in estimate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of credit risk&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company from time to time during the period covered by these financial statements may have had bank account balances in excess of federally insured limits. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased and as of December&#160;31, 2021 and 2020 included investment in money market funds.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities consist of debt securities that are designated as available-for-sale. Marketable debt securities are recorded at fair value and unrealized holding gains or losses are reported as a component of accumulated other comprehensive income (loss). Amortization of premiums and discounts on marketable securities are included in interest expense, net on the statements of operations and comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains or losses resulting from the sale of these securities are determined based on the specific identification of the securities sold. An impairment charge is recognized when the decline in the fair value of a debt security below the amortized cost basis is determined to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the duration and severity of any decline in fair value below the amortized cost basis, any adverse changes in the financial condition of the issuers and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows ASC 820,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 820), to measure the fair value of its financial statements and disclosures about fair value of its financial instruments. ASC 820 establishes a framework for measuring fair value in GAAP, and expands disclosures about fair value measurements. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Pricing inputs that are generally unobservable inputs and not corroborated by market data.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lower priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. The Company uses this framework for measuring fair value and disclosures about fair value measurement. The Company uses fair value measurements in areas that include derivative instruments.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. The carrying amounts reported in the balance sheets for cash and cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses, and note payable approximate their fair value based on the short-term maturity of these instruments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost. The Company commences depreciation when the asset is placed in service. Computers and peripheral equipment are depreciated on a straight-line method over useful lives of three years.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to use, or control the use of, identified property, plant, or equipment for a period of time in exchange for consideration. Leases may be classified as finance leases or operating leases. Lease right-of-use (ROU) assets and lease liabilities recognized in the accompanying balance sheet represent the right to use an underlying asset for the lease term and an obligation to make lease payments arising from the lease respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At each reporting date, the finance lease liabilities are increased by interest and reduced by repayments made under the lease agreements. The ROU asset is subsequently measured at the amount of the remeasured lease liability (i.e. the present value of the remaining lease payments), any cumulative prepaid or accrued rent if the lease payments are uneven throughout the lease term, and any unamortized initial direct costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Licensing revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a license agreement (the Medice License Agreement) with  MEDICE&#160;Arzneimittel&#160;P&#xfc;tter&#160;GmbH &amp;amp; Co. KG (Medice), a related party (Note 13). The license agreement provides for an exclusive license to develop, use, manufacture, market and sell ADAIR&#160;throughout&#160;Europe, a non-refundable up-front payment, potential regulatory and sales milestones and potential royalty payments. The Company analyzed the performance obligations under the license agreements, the consideration received to date and the consideration the Company could receive in the future as part of its analysis in accordance with ASC 606&#x2013;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 606). The Company recognized  $100 as licensing revenue during the year ended December 31, 2020. No licensing revenue was recognized during the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amounts are recorded as a cumulative adjustment in the period the estimates are revised. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated its convertible notes to determine if those contracts or embedded components of those contracts qualified as derivatives to be separately accounted for in accordance with ASC 815,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The result of this accounting treatment is that the fair value of the embedded derivative is marked to market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statements of operations as other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities are classified in the balance sheets as current or non-current to correspond with its host instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on the weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of December&#160;31, 2021 and 2020, the Company concluded that a full valuation allowance was necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest or penalties in the accompanying consolidated financial statements.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net loss per common share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year. Diluted net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year, plus the dilutive effect of options considered to be outstanding during each year, in accordance with ASC 260,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers the applicability and impact of all ASUs. ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on the financial statements.&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2021, the Company adopted ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending the existing guidance.  The adoption of this standard did not have a material impact on the Company&#x2019;s financial statements.</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzE2NjYz_bfdc948a-97bb-4637-865a-c9aed2b58172">Use of estimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#x2019;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#x2019;s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzU0OTc1NTgxODMxOTM_8ab8b659-df7d-4d74-a784-3d25f04ae061">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of credit risk&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;The Company from time to time during the period covered by these financial statements may have had bank account balances in excess of federally insured limits. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzU0OTc1NTgxODMxOTI_7987ec41-f53e-4fcf-887f-f6004dbc060e">Cash equivalentsCash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased and as of December&#160;31, 2021 and 2020 included investment in money market funds.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzU0OTc1NTgxODMxOTE_e8af4bed-ec6c-47b8-83e1-36ae06771fc3">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities consist of debt securities that are designated as available-for-sale. Marketable debt securities are recorded at fair value and unrealized holding gains or losses are reported as a component of accumulated other comprehensive income (loss). Amortization of premiums and discounts on marketable securities are included in interest expense, net on the statements of operations and comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains or losses resulting from the sale of these securities are determined based on the specific identification of the securities sold. An impairment charge is recognized when the decline in the fair value of a debt security below the amortized cost basis is determined to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the duration and severity of any decline in fair value below the amortized cost basis, any adverse changes in the financial condition of the issuers and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzU0OTc1NTgxODMxOTA_031d6074-e771-4f86-a601-2361a0fe5d42">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows ASC 820,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 820), to measure the fair value of its financial statements and disclosures about fair value of its financial instruments. ASC 820 establishes a framework for measuring fair value in GAAP, and expands disclosures about fair value measurements. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Pricing inputs that are generally unobservable inputs and not corroborated by market data.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lower priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. The Company uses this framework for measuring fair value and disclosures about fair value measurement. The Company uses fair value measurements in areas that include derivative instruments.&#160;&lt;/span&gt;&lt;/div&gt;The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. The carrying amounts reported in the balance sheets for cash and cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses, and note payable approximate their fair value based on the short-term maturity of these instruments.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzU0OTc1NTgxODMxODk_c11de530-07fb-49e5-935d-c204109cb79d">Property and equipmentProperty and equipment are stated at cost. The Company commences depreciation when the asset is placed in service. Computers and peripheral equipment are depreciated on a straight-line method over useful lives of three years.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="i5daddf114f0241b4a966bccf6d899e1c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzE2NDkyNjc0NjkxNDE_c5ac46fd-86f5-4b42-b514-7a3f55ae358e">three years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="ic638fa8850574f0f85cdf96878a4008b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzE2NDkyNjc0NjkxNDE_fe3cb691-d1cf-4f4a-8fed-90602bcf4cc2">three years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzU0OTc1NTgxODc0Njg_ec54a8f0-8f4a-4bd4-8222-3cb590a190f1">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to use, or control the use of, identified property, plant, or equipment for a period of time in exchange for consideration. Leases may be classified as finance leases or operating leases. Lease right-of-use (ROU) assets and lease liabilities recognized in the accompanying balance sheet represent the right to use an underlying asset for the lease term and an obligation to make lease payments arising from the lease respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At each reporting date, the finance lease liabilities are increased by interest and reduced by repayments made under the lease agreements. The ROU asset is subsequently measured at the amount of the remeasured lease liability (i.e. the present value of the remaining lease payments), any cumulative prepaid or accrued rent if the lease payments are uneven throughout the lease term, and any unamortized initial direct costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzE2NjY2_e946a536-d39c-4861-ab51-c5c453560048">Licensing revenues&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a license agreement (the Medice License Agreement) with  MEDICE&#160;Arzneimittel&#160;P&#xfc;tter&#160;GmbH &amp;amp; Co. KG (Medice), a related party (Note 13). The license agreement provides for an exclusive license to develop, use, manufacture, market and sell ADAIR&#160;throughout&#160;Europe, a non-refundable up-front payment, potential regulatory and sales milestones and potential royalty payments. The Company analyzed the performance obligations under the license agreements, the consideration received to date and the consideration the Company could receive in the future as part of its analysis in accordance with ASC 606&#x2013;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;(ASC 606).</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzE2NDkyNjc0NzA2Mjk_da39e40b-7cc4-4e6a-9e25-612e0035b7f1"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzU0OTc1NTgxODMxOTQ_d1c1a5cb-7751-488a-837d-76e53336c0b6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzU0OTc1NTgxODMxODg_a67c794c-7a7d-4dc0-a0fa-df9c60ccd30e">Research and developmentResearch and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzE2NjY3_207e5d69-509f-4854-89a3-c8d2cf7cdc78">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amounts are recorded as a cumulative adjustment in the period the estimates are revised. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzE2Njcx_fb25203c-cd54-4ad1-8ecb-b4fa7c78d07b">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated its convertible notes to determine if those contracts or embedded components of those contracts qualified as derivatives to be separately accounted for in accordance with ASC 815,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The result of this accounting treatment is that the fair value of the embedded derivative is marked to market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statements of operations as other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.&#160;&lt;/span&gt;&lt;/div&gt;Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities are classified in the balance sheets as current or non-current to correspond with its host instrument.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzE2NjYw_c77e6a1f-3e62-49e1-a40d-a7532a85bb63">Income taxesIncome taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on the weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of December&#160;31, 2021 and 2020, the Company concluded that a full valuation allowance was necessary for all of its net deferred tax assets.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzE2Njcy_813c99e6-2a5c-40e7-8f0e-8b40b3a72b76">Net loss per common share&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year. Diluted net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year, plus the dilutive effect of options considered to be outstanding during each year, in accordance with ASC 260,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNTcvZnJhZzo1MDAyYzhkYmQ2MzI0YTVmYjMzYjQyNDQzZGJhNzI1ZC90ZXh0cmVnaW9uOjUwMDJjOGRiZDYzMjRhNWZiMzNiNDI0NDNkYmE3MjVkXzE2Njcz_ce5b7338-d6bc-4563-bf6a-fb4921b82e43">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers the applicability and impact of all ASUs. ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on the financial statements.&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2021, the Company adopted ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principals in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending the existing guidance.  The adoption of this standard did not have a material impact on the Company&#x2019;s financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90ZXh0cmVnaW9uOmE5MzllNzA3ZDFjZjQ0NDFiYjlmYmI3MTQ2YmEyYTgxXzU0OTc1NTgxNDQ5NjM_95037e7d-863e-487d-87b0-833091707680">MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s available-for-sale securities as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s investments in marketable debt securities are accounted for as available-for-sale securities and  have contractual maturity dates of one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, all of the Company&#x2019;s marketable securities were classified as Level 2 assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the embedded derivative liability identified in the 2021 Convertible Notes was a Level 3 fair value measurement. As of February 12, 2021, the embedded derivative was remeasured based upon the conversion price of $8.00 per share upon closing of the IPO. As such, an expense of $89 was recorded in the first quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the activity for the liability measured at estimated fair value using unobservable inputs for the year ended December 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Beginning balance, January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Additions during the year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Transfer out of Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90ZXh0cmVnaW9uOmE5MzllNzA3ZDFjZjQ0NDFiYjlmYmI3MTQ2YmEyYTgxXzIxOTkwMjMyNjE2MzQ_f482e5b6-8d83-4a8f-9599-868069891976">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s available-for-sale securities as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s investments in marketable debt securities are accounted for as available-for-sale securities and  have contractual maturity dates of one year or less.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie118df7159634a91976e521f2425da1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5NGRmNjFiMjk2OWE0MzllYWUyZjU1YTY0ODQxYzFkNi90YWJsZXJhbmdlOjk0ZGY2MWIyOTY5YTQzOWVhZTJmNTVhNjQ4NDFjMWQ2XzQtMS0xLTEtMjQ3NzY_06b6a5f7-d8b8-4173-b619-3ac23702f2b3"
      unitRef="usd">1153000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie118df7159634a91976e521f2425da1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5NGRmNjFiMjk2OWE0MzllYWUyZjU1YTY0ODQxYzFkNi90YWJsZXJhbmdlOjk0ZGY2MWIyOTY5YTQzOWVhZTJmNTVhNjQ4NDFjMWQ2XzQtMy0xLTEtMjQ4MDE_824a4a8d-52e2-4e13-89fb-6e223b3fe849"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie118df7159634a91976e521f2425da1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5NGRmNjFiMjk2OWE0MzllYWUyZjU1YTY0ODQxYzFkNi90YWJsZXJhbmdlOjk0ZGY2MWIyOTY5YTQzOWVhZTJmNTVhNjQ4NDFjMWQ2XzQtNS0xLTEtMjQ3ODk_6fbb64da-cad1-48d6-b31c-46115d30e829"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie118df7159634a91976e521f2425da1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5NGRmNjFiMjk2OWE0MzllYWUyZjU1YTY0ODQxYzFkNi90YWJsZXJhbmdlOjk0ZGY2MWIyOTY5YTQzOWVhZTJmNTVhNjQ4NDFjMWQ2XzQtNy0xLTEtMjc2NzU_be2586ef-6494-452e-aa59-3d348ad6096a"
      unitRef="usd">1152000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icff8b71b9c8244dcb12cc9ac5efd5b53_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5NGRmNjFiMjk2OWE0MzllYWUyZjU1YTY0ODQxYzFkNi90YWJsZXJhbmdlOjk0ZGY2MWIyOTY5YTQzOWVhZTJmNTVhNjQ4NDFjMWQ2XzUtMS0xLTEtMjQ3ODM_6976294c-6dce-4f63-b531-ac8958c1aafa"
      unitRef="usd">2657000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icff8b71b9c8244dcb12cc9ac5efd5b53_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5NGRmNjFiMjk2OWE0MzllYWUyZjU1YTY0ODQxYzFkNi90YWJsZXJhbmdlOjk0ZGY2MWIyOTY5YTQzOWVhZTJmNTVhNjQ4NDFjMWQ2XzUtMy0xLTEtMjc2ODA_1ae58ca2-52c9-4a22-824c-3a6553776472"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icff8b71b9c8244dcb12cc9ac5efd5b53_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5NGRmNjFiMjk2OWE0MzllYWUyZjU1YTY0ODQxYzFkNi90YWJsZXJhbmdlOjk0ZGY2MWIyOTY5YTQzOWVhZTJmNTVhNjQ4NDFjMWQ2XzUtNS0xLTEtMjQ3OTU_1d745a1a-83c1-4f5e-a6ff-1da2095ff4f4"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icff8b71b9c8244dcb12cc9ac5efd5b53_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5NGRmNjFiMjk2OWE0MzllYWUyZjU1YTY0ODQxYzFkNi90YWJsZXJhbmdlOjk0ZGY2MWIyOTY5YTQzOWVhZTJmNTVhNjQ4NDFjMWQ2XzUtNy0xLTEtMjc2NzU_d383c7b6-2af5-437c-8983-251895cb413e"
      unitRef="usd">2656000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5NGRmNjFiMjk2OWE0MzllYWUyZjU1YTY0ODQxYzFkNi90YWJsZXJhbmdlOjk0ZGY2MWIyOTY5YTQzOWVhZTJmNTVhNjQ4NDFjMWQ2XzYtMS0xLTEtMjc2Njk_f2701839-931a-4a41-9b9e-18c4df6fa7d8"
      unitRef="usd">3810000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5NGRmNjFiMjk2OWE0MzllYWUyZjU1YTY0ODQxYzFkNi90YWJsZXJhbmdlOjk0ZGY2MWIyOTY5YTQzOWVhZTJmNTVhNjQ4NDFjMWQ2XzYtMy0xLTEtMjc2ODA_95aa675c-c6f0-4597-b1b4-5ba57f1aadd7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5NGRmNjFiMjk2OWE0MzllYWUyZjU1YTY0ODQxYzFkNi90YWJsZXJhbmdlOjk0ZGY2MWIyOTY5YTQzOWVhZTJmNTVhNjQ4NDFjMWQ2XzYtNS0xLTEtMjc2NzI_f3246268-34b3-4aa8-8b71-da3e221c0738"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5NGRmNjFiMjk2OWE0MzllYWUyZjU1YTY0ODQxYzFkNi90YWJsZXJhbmdlOjk0ZGY2MWIyOTY5YTQzOWVhZTJmNTVhNjQ4NDFjMWQ2XzYtNy0xLTEtMjc2NzU_0f2f255c-5091-45f7-a4c7-c8ff3f29fe72"
      unitRef="usd">3808000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ia10c21fff10b48d78e5b10b6645fdc7f_I20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90ZXh0cmVnaW9uOmE5MzllNzA3ZDFjZjQ0NDFiYjlmYmI3MTQ2YmEyYTgxXzE2NDkyNjc0NDY4OTA_e774803b-4fc9-4be7-8dff-8d0822a8b5ea"
      unitRef="usdPerShare">8.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="idef5c95d6a30458ebd4eb95332917688_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90ZXh0cmVnaW9uOmE5MzllNzA3ZDFjZjQ0NDFiYjlmYmI3MTQ2YmEyYTgxXzU0OTc1NTgxNDQ5NjY_b92da458-105b-4f1a-8173-db2c02460ec8"
      unitRef="usdPerShare">89000</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90ZXh0cmVnaW9uOmE5MzllNzA3ZDFjZjQ0NDFiYjlmYmI3MTQ2YmEyYTgxXzIxOTkwMjMyNjE2MzM_7b7fb94b-f237-4c6b-882c-e28c3bad553f">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the activity for the liability measured at estimated fair value using unobservable inputs for the year ended December 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Beginning balance, January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Additions during the year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Transfer out of Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i1531f974668b4107b1b1a1654cd76006_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5M2QzMjYwZmI1MzE0OGNmYWRhYjJhMDFiNDBmMWEzMi90YWJsZXJhbmdlOjkzZDMyNjBmYjUzMTQ4Y2ZhZGFiMmEwMWI0MGYxYTMyXzAtMS0xLTEtMjYyMDk_28338377-8552-45d5-96b0-64629f7aab13"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i7f49d0df94644a32ab3d051a753eeb16_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5M2QzMjYwZmI1MzE0OGNmYWRhYjJhMDFiNDBmMWEzMi90YWJsZXJhbmdlOjkzZDMyNjBmYjUzMTQ4Y2ZhZGFiMmEwMWI0MGYxYTMyXzEtMS0xLTEtMjYyMTE_4245feb3-efcd-46d9-a0a2-50ba16a3ac9a"
      unitRef="usd">89000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="i7f49d0df94644a32ab3d051a753eeb16_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5M2QzMjYwZmI1MzE0OGNmYWRhYjJhMDFiNDBmMWEzMi90YWJsZXJhbmdlOjkzZDMyNjBmYjUzMTQ4Y2ZhZGFiMmEwMWI0MGYxYTMyXzItMS0xLTEtMjYyMTM_fcfdbaba-fa5c-4db8-9004-8f173b0e7c05"
      unitRef="usd">89000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i1531f974668b4107b1b1a1654cd76006_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjMvZnJhZzphOTM5ZTcwN2QxY2Y0NDQxYmI5ZmJiNzE0NmJhMmE4MS90YWJsZTo5M2QzMjYwZmI1MzE0OGNmYWRhYjJhMDFiNDBmMWEzMi90YWJsZXJhbmdlOjkzZDMyNjBmYjUzMTQ4Y2ZhZGFiMmEwMWI0MGYxYTMyXzMtMS0xLTEtMjYyMTM_a848d2c2-6303-4142-8f2a-416be73c1b8d"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90ZXh0cmVnaW9uOmQ0Y2RiZjUxODg1MzRkZWNiNDgwOTgyNGY3MWZlMzA4XzI5NQ_b74cdf94-7a50-46af-a03c-e6fcdc8d3cb2">LEASES&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a financing lease in relation to &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;equipment utilized in the commercial scale manufacturing of ADAIR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company evaluates renewal options at lease inception on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. Lease agreements generally do not require material variable lease payments, residual value guarantees or restrictive covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing lease ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of minimum lease payments over the lease term. The Company utilized the interest rate implicit in the lease. The lease term is based on the non-cancellable period in the lease contract. Any termination fees are included in the calculation of the ROU asset and lease liability when it is assumed that the lease will be terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the finance lease assets and liabilities recognized on the Company's balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance Sheet Line Item&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzItMi0xLTEtMjcwNjk_d0fa8a87-0583-4dbe-aa44-438729a21dce"&gt;206&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzItNC0xLTEtMjcxMDQ_1d91015f-66ad-42d5-87ce-9f403c36c69c"&gt;279&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Finance lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzQtMi0xLTEtMjcwNzY_4d9aad60-57b0-43cc-9c32-3717c31c5311"&gt;97&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzQtNC0xLTEtMjcxMTE_878bb0e5-bbd6-48e9-9988-7643436d0dee"&gt;105&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Non-current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzUtMi0xLTEtMjcwNzY_0cbe9984-707d-4160-b526-ea4fa4370ae5"&gt;72&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzUtNC0xLTEtMjcxMTE_15864d26-3ad3-4b32-a575-a615f5f41fef"&gt;170&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company&#x2019;s weighted average remaining lease term and weighted average discount rate for its financing lease as of December 31, 2021 are:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term - finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.75 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate - finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash flows related to the measurement of financing lease assets and liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating cash flows from finance lease amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Financing cash flows from finance lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maturities of the finance lease liability as of December&#160;31, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Present value of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90ZXh0cmVnaW9uOmQ0Y2RiZjUxODg1MzRkZWNiNDgwOTgyNGY3MWZlMzA4XzI5Mw_008f7186-9fab-4338-b894-b11b89070d21">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the finance lease assets and liabilities recognized on the Company's balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance Sheet Line Item&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzItMi0xLTEtMjcwNjk_d0fa8a87-0583-4dbe-aa44-438729a21dce"&gt;206&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzItNC0xLTEtMjcxMDQ_1d91015f-66ad-42d5-87ce-9f403c36c69c"&gt;279&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Finance lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzQtMi0xLTEtMjcwNzY_4d9aad60-57b0-43cc-9c32-3717c31c5311"&gt;97&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzQtNC0xLTEtMjcxMTE_878bb0e5-bbd6-48e9-9988-7643436d0dee"&gt;105&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Non-current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzUtMi0xLTEtMjcwNzY_0cbe9984-707d-4160-b526-ea4fa4370ae5"&gt;72&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzUtNC0xLTEtMjcxMTE_15864d26-3ad3-4b32-a575-a615f5f41fef"&gt;170&lt;/span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company&#x2019;s weighted average remaining lease term and weighted average discount rate for its financing lease as of December 31, 2021 are:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term - finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.75 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate - finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash flows related to the measurement of financing lease assets and liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating cash flows from finance lease amortization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Financing cash flows from finance lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzItMi0xLTEtMjcwNjk_2c425270-8104-498b-805f-1d8b9b6480d9"
      unitRef="usd">206000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzItNC0xLTEtMjcxMDQ_f71167f1-7745-4a7e-bfac-610fe126fdc9"
      unitRef="usd">279000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzQtMi0xLTEtMjcwNzY_4ac8978a-daa8-46b4-b967-73a0f0e6b340"
      unitRef="usd">97000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzQtNC0xLTEtMjcxMTE_41a828e8-3881-48ae-ab6f-7aeb938bb996"
      unitRef="usd">105000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzUtMi0xLTEtMjcwNzY_b3916301-7f29-4e94-b045-ef1204bba8ad"
      unitRef="usd">72000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzUtNC0xLTEtMjcxMTE_8498fe20-b37a-4de5-b58a-0594a9e839c6"
      unitRef="usd">170000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzYtMi0xLTEtMjcxMjI_f37595fc-4f27-4bf7-a2e7-927fd85031f9"
      unitRef="usd">169000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTpkZjg5OTM5Zjk2OGE0NWE3OWI3NzA5NjNmODk3NmY4MC90YWJsZXJhbmdlOmRmODk5MzlmOTY4YTQ1YTc5Yjc3MDk2M2Y4OTc2ZjgwXzYtNC0xLTEtMjcxMjM_cd968853-db64-43d8-82c4-8c01c80c799a"
      unitRef="usd">275000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTo2NmFlYzAwMWY2NTA0NDViYTA2YmE4MWI0ZmFjNDI1OC90YWJsZXJhbmdlOjY2YWVjMDAxZjY1MDQ0NWJhMDZiYTgxYjRmYWM0MjU4XzQtMS0xLTEtMjU4NjA_d76b84fa-121e-46cd-87e9-957f8dcb3661">P1Y9M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTo2NmFlYzAwMWY2NTA0NDViYTA2YmE4MWI0ZmFjNDI1OC90YWJsZXJhbmdlOjY2YWVjMDAxZjY1MDQ0NWJhMDZiYTgxYjRmYWM0MjU4XzUtMS0xLTEtMjU4NjA_90fce56f-7b16-4ab5-8a03-ba51ff648c34"
      unitRef="number">0.1350</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZToyODc2NGMwYzBlMzc0NDMzYjFjYWIzYmQ1ZjU1NzEwOC90YWJsZXJhbmdlOjI4NzY0YzBjMGUzNzQ0MzNiMWNhYjNiZDVmNTU3MTA4XzItMS0xLTEtMjU5MDI_c434bc4f-41d2-4d29-a2ca-6c50d3eff930"
      unitRef="usd">73000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZToyODc2NGMwYzBlMzc0NDMzYjFjYWIzYmQ1ZjU1NzEwOC90YWJsZXJhbmdlOjI4NzY0YzBjMGUzNzQ0MzNiMWNhYjNiZDVmNTU3MTA4XzItMy0xLTEtMjU5MDg_7b58ef28-761d-476a-8889-a640f8b8df01"
      unitRef="usd">74000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZToyODc2NGMwYzBlMzc0NDMzYjFjYWIzYmQ1ZjU1NzEwOC90YWJsZXJhbmdlOjI4NzY0YzBjMGUzNzQ0MzNiMWNhYjNiZDVmNTU3MTA4XzMtMS0xLTEtMjU5MDI_2d98aced-5007-4398-a296-ae2ea48afd2b"
      unitRef="usd">106000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZToyODc2NGMwYzBlMzc0NDMzYjFjYWIzYmQ1ZjU1NzEwOC90YWJsZXJhbmdlOjI4NzY0YzBjMGUzNzQ0MzNiMWNhYjNiZDVmNTU3MTA4XzMtMy0xLTEtMjU5MDg_d793bbd8-8d7f-4abf-8a6c-3bb77ba69694"
      unitRef="usd">65000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90ZXh0cmVnaW9uOmQ0Y2RiZjUxODg1MzRkZWNiNDgwOTgyNGY3MWZlMzA4XzI5NA_6282946d-0a57-4144-8e30-e94515e7be9d">&lt;div style="margin-top:8pt"&gt;&lt;span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maturities of the finance lease liability as of December&#160;31, 2021 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Present value of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTozYmU0MTAyOWJhMGI0ZjczYjc2ZDliZGU0NjUzYWE1OC90YWJsZXJhbmdlOjNiZTQxMDI5YmEwYjRmNzNiNzZkOWJkZTQ2NTNhYTU4XzAtMS0xLTEtMjU5NTI_2ae4a818-8f27-4828-82ed-a34b7aa4da8c"
      unitRef="usd">114000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTozYmU0MTAyOWJhMGI0ZjczYjc2ZDliZGU0NjUzYWE1OC90YWJsZXJhbmdlOjNiZTQxMDI5YmEwYjRmNzNiNzZkOWJkZTQ2NTNhYTU4XzEtMS0xLTEtMjU5NTI_73c0b065-fdde-4a1f-8381-c9f7eb5936b3"
      unitRef="usd">76000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTozYmU0MTAyOWJhMGI0ZjczYjc2ZDliZGU0NjUzYWE1OC90YWJsZXJhbmdlOjNiZTQxMDI5YmEwYjRmNzNiNzZkOWJkZTQ2NTNhYTU4XzItMS0xLTEtMjU5NzI_9e83ff52-ffd9-4040-a504-2deb2f9f0461"
      unitRef="usd">190000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTozYmU0MTAyOWJhMGI0ZjczYjc2ZDliZGU0NjUzYWE1OC90YWJsZXJhbmdlOjNiZTQxMDI5YmEwYjRmNzNiNzZkOWJkZTQ2NTNhYTU4XzQtMS0xLTEtMjU5NjA_8709b49c-455e-4cc8-b928-2905e3929f38"
      unitRef="usd">21000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzgvZnJhZzpkNGNkYmY1MTg4NTM0ZGVjYjQ4MDk4MjRmNzFmZTMwOC90YWJsZTozYmU0MTAyOWJhMGI0ZjczYjc2ZDliZGU0NjUzYWE1OC90YWJsZXJhbmdlOjNiZTQxMDI5YmEwYjRmNzNiNzZkOWJkZTQ2NTNhYTU4XzUtMS0xLTEtMjU5NjA_a1034a01-f361-46e4-8cf3-318601996b73"
      unitRef="usd">169000</us-gaap:FinanceLeaseLiability>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90ZXh0cmVnaW9uOjM5ODlhZjUxNTcxYTQ2Zjg5YzU4ZjczNmRlZmZhMTFmXzMx_9e202638-f7ba-4590-8e45-54214f41434f">ACCRUED EXPENSES&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accrued expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;894&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;183&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Payroll and related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;291&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Licensing related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90ZXh0cmVnaW9uOjM5ODlhZjUxNTcxYTQ2Zjg5YzU4ZjczNmRlZmZhMTFmXzMy_6f330044-7012-4828-9d4e-265fd529522e">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accrued expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;894&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;183&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Payroll and related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;291&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Licensing related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <ck0001824293:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90YWJsZTo0YTQ5YTdmMzQyNTU0ZGU2YWY0ZTNiYTdlODgxZjRjYS90YWJsZXJhbmdlOjRhNDlhN2YzNDI1NTRkZTZhZjRlM2JhN2U4ODFmNGNhXzItMS0xLTEtMjYwMjM_cabbad77-5466-41de-b369-3e6ffeac60ee"
      unitRef="usd">894000</ck0001824293:AccruedResearchAndDevelopmentCostsCurrent>
    <ck0001824293:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90YWJsZTo0YTQ5YTdmMzQyNTU0ZGU2YWY0ZTNiYTdlODgxZjRjYS90YWJsZXJhbmdlOjRhNDlhN2YzNDI1NTRkZTZhZjRlM2JhN2U4ODFmNGNhXzItMy0xLTEtMjYwMDk_8758752d-b072-4208-8fad-c568e431134c"
      unitRef="usd">259000</ck0001824293:AccruedResearchAndDevelopmentCostsCurrent>
    <ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90YWJsZTo0YTQ5YTdmMzQyNTU0ZGU2YWY0ZTNiYTdlODgxZjRjYS90YWJsZXJhbmdlOjRhNDlhN2YzNDI1NTRkZTZhZjRlM2JhN2U4ODFmNGNhXzMtMS0xLTEtMjYwMjM_0db1c9cd-c417-4200-95b5-68c4a7bbc52a"
      unitRef="usd">183000</ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent>
    <ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90YWJsZTo0YTQ5YTdmMzQyNTU0ZGU2YWY0ZTNiYTdlODgxZjRjYS90YWJsZXJhbmdlOjRhNDlhN2YzNDI1NTRkZTZhZjRlM2JhN2U4ODFmNGNhXzMtMy0xLTEtMjYwMjA_17df80a9-d02c-4cde-881f-9faeee7a1916"
      unitRef="usd">156000</ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90YWJsZTo0YTQ5YTdmMzQyNTU0ZGU2YWY0ZTNiYTdlODgxZjRjYS90YWJsZXJhbmdlOjRhNDlhN2YzNDI1NTRkZTZhZjRlM2JhN2U4ODFmNGNhXzQtMS0xLTEtMjYwMjM_12ecaee7-424a-4c0d-a2d0-3d1b66108a4b"
      unitRef="usd">291000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90YWJsZTo0YTQ5YTdmMzQyNTU0ZGU2YWY0ZTNiYTdlODgxZjRjYS90YWJsZXJhbmdlOjRhNDlhN2YzNDI1NTRkZTZhZjRlM2JhN2U4ODFmNGNhXzQtMy0xLTEtMjYwMjA_2173cc59-ae49-4ab1-bae9-e0b4c0dcf346"
      unitRef="usd">342000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <ck0001824293:AccruedLicensingFeesCurrent
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90YWJsZTo0YTQ5YTdmMzQyNTU0ZGU2YWY0ZTNiYTdlODgxZjRjYS90YWJsZXJhbmdlOjRhNDlhN2YzNDI1NTRkZTZhZjRlM2JhN2U4ODFmNGNhXzUtMS0xLTEtMjYwMjM_da76b58a-11f7-48f7-8792-0ae096274b70"
      unitRef="usd">62000</ck0001824293:AccruedLicensingFeesCurrent>
    <ck0001824293:AccruedLicensingFeesCurrent
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90YWJsZTo0YTQ5YTdmMzQyNTU0ZGU2YWY0ZTNiYTdlODgxZjRjYS90YWJsZXJhbmdlOjRhNDlhN2YzNDI1NTRkZTZhZjRlM2JhN2U4ODFmNGNhXzUtMy0xLTEtMjYwMjA_529004d3-922a-4d2c-ac46-67133ab25281"
      unitRef="usd">81000</ck0001824293:AccruedLicensingFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90YWJsZTo0YTQ5YTdmMzQyNTU0ZGU2YWY0ZTNiYTdlODgxZjRjYS90YWJsZXJhbmdlOjRhNDlhN2YzNDI1NTRkZTZhZjRlM2JhN2U4ODFmNGNhXzYtMS0xLTEtMjYwMjM_406c1acf-a3c3-4910-9ff5-047185b44551"
      unitRef="usd">0</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90YWJsZTo0YTQ5YTdmMzQyNTU0ZGU2YWY0ZTNiYTdlODgxZjRjYS90YWJsZXJhbmdlOjRhNDlhN2YzNDI1NTRkZTZhZjRlM2JhN2U4ODFmNGNhXzYtMy0xLTEtMjYwMjA_0c573a73-d9e8-4667-a697-6f3b88827efd"
      unitRef="usd">9000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90YWJsZTo0YTQ5YTdmMzQyNTU0ZGU2YWY0ZTNiYTdlODgxZjRjYS90YWJsZXJhbmdlOjRhNDlhN2YzNDI1NTRkZTZhZjRlM2JhN2U4ODFmNGNhXzctMS0xLTEtMjYwNDA_89c41c33-8dec-4450-a41d-b573627392c7"
      unitRef="usd">1430000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODEvZnJhZzozOTg5YWY1MTU3MWE0NmY4OWM1OGY3MzZkZWZmYTExZi90YWJsZTo0YTQ5YTdmMzQyNTU0ZGU2YWY0ZTNiYTdlODgxZjRjYS90YWJsZXJhbmdlOjRhNDlhN2YzNDI1NTRkZTZhZjRlM2JhN2U4ODFmNGNhXzctMy0xLTEtMjYwNDE_1f41c3c2-36df-406a-86fb-b440be482790"
      unitRef="usd">847000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjAvZnJhZzo0NGYyNDgzZmE3NGI0MWY2OWRlOGU2ZTVhNzZlOWM2Zi90ZXh0cmVnaW9uOjQ0ZjI0ODNmYTc0YjQxZjY5ZGU4ZTZlNWE3NmU5YzZmXzM2Nzg_8f0953fe-5d32-4583-8de1-4993418fad1d">PPP NOTE AND CONVERTIBLE NOTESIn May 2020, the Company issued a promissory note under the PPP (the PPP Note) totaling $61. The note had a stated interest rate of 1% and had a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjAvZnJhZzo0NGYyNDgzZmE3NGI0MWY2OWRlOGU2ZTVhNzZlOWM2Zi90ZXh0cmVnaW9uOjQ0ZjI0ODNmYTc0YjQxZjY5ZGU4ZTZlNWE3NmU5YzZmXzU2OA_a031568f-8be9-4dd8-8877-34662d6a2613"&gt;two&lt;/span&gt;-year maturity. Payments were required to be made over a 1.5 years period beginning in November 2020 unless forgiven. In January 2021, the Company was notified that the loan along with accumulated interest had been forgiven. As a result, the Company recorded income from the extinguishment of its obligation in the amount of $61 as other income on the accompanying statements of operations and comprehensive loss.In January 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#x2019;s Chief Executive Officer, pursuant to which the Company issued the 2021 Convertible Notes, for cash proceeds of $350. The 2021 Convertible Notes bore an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September&#160;30, 2021. The 2021 Convertible Notes converted into 54,906 shares of the Company&#x2019;s common stock upon completion of the IPO. The Company identified the mandatory conversion into shares of the Company&#x2019;s common stock as a redemption feature, which requires bifurcation from the 2021 Convertible Notes and treated it as a derivative liability under ASC 815 as the redemption feature was not clearly and closely related to the debt. The Company evaluated the fair value of the derivative liability. Upon the conversion of the 2021 Convertible Notes to common stock at the closing of the IPO, the embedded derivative liability was remeasured and removed from the balance sheet.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1944122310504f56b217249a0d49b19a_I20200531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjAvZnJhZzo0NGYyNDgzZmE3NGI0MWY2OWRlOGU2ZTVhNzZlOWM2Zi90ZXh0cmVnaW9uOjQ0ZjI0ODNmYTc0YjQxZjY5ZGU4ZTZlNWE3NmU5YzZmXzE1NQ_4696ab27-74f7-41b3-9955-6594dafec0cb"
      unitRef="usd">61000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1944122310504f56b217249a0d49b19a_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjAvZnJhZzo0NGYyNDgzZmE3NGI0MWY2OWRlOGU2ZTVhNzZlOWM2Zi90ZXh0cmVnaW9uOjQ0ZjI0ODNmYTc0YjQxZjY5ZGU4ZTZlNWE3NmU5YzZmXzU1NQ_83bea831-ad21-42f3-b7a1-b938c02597b7"
      unitRef="number">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ck0001824293:DebtInstrumentPaymentTerm
      contextRef="if77c3753756e4eb8b7f0d6919514e0d1_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjAvZnJhZzo0NGYyNDgzZmE3NGI0MWY2OWRlOGU2ZTVhNzZlOWM2Zi90ZXh0cmVnaW9uOjQ0ZjI0ODNmYTc0YjQxZjY5ZGU4ZTZlNWE3NmU5YzZmXzYyMQ_bc9b6aba-5901-4406-9ff5-ebe71bbfcb08">P1Y6M</ck0001824293:DebtInstrumentPaymentTerm>
    <ck0001824293:ForgivenessOfDebtInstrument
      contextRef="i4ff8206d11c1434cb0abe54052617449_D20210101-20210131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjAvZnJhZzo0NGYyNDgzZmE3NGI0MWY2OWRlOGU2ZTVhNzZlOWM2Zi90ZXh0cmVnaW9uOjQ0ZjI0ODNmYTc0YjQxZjY5ZGU4ZTZlNWE3NmU5YzZmXzE2NDkyNjc0NTI3NjE_ff546cd3-e42c-4dd6-ab1c-194597bb1e1c"
      unitRef="usd">61000</ck0001824293:ForgivenessOfDebtInstrument>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ib9d5b9a898334b7cb7f34285a2ddd313_D20210111-20210111"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjAvZnJhZzo0NGYyNDgzZmE3NGI0MWY2OWRlOGU2ZTVhNzZlOWM2Zi90ZXh0cmVnaW9uOjQ0ZjI0ODNmYTc0YjQxZjY5ZGU4ZTZlNWE3NmU5YzZmXzE2NDkyNjc0NTI3Njc_6dc19c23-f1b5-405f-9667-a17be7b506fa"
      unitRef="usd">350000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icfa130da617a43abb627558cf21129fe_I20210111"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjAvZnJhZzo0NGYyNDgzZmE3NGI0MWY2OWRlOGU2ZTVhNzZlOWM2Zi90ZXh0cmVnaW9uOjQ0ZjI0ODNmYTc0YjQxZjY5ZGU4ZTZlNWE3NmU5YzZmXzE2NDkyNjc0NTI3NzU_e28bf6b9-6d18-4cd2-94ca-668dbb9508ae"
      unitRef="number">0.070</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i3844e69fe7884e4db36fb500c88c1e90_D20210201-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjAvZnJhZzo0NGYyNDgzZmE3NGI0MWY2OWRlOGU2ZTVhNzZlOWM2Zi90ZXh0cmVnaW9uOjQ0ZjI0ODNmYTc0YjQxZjY5ZGU4ZTZlNWE3NmU5YzZmXzE2NDkyNjc0NTI3ODM_e5ed3e8e-8e36-4ae9-b156-f94f96fc5c4f"
      unitRef="shares">54906</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85NTQvZnJhZzphY2EwZjhjNTVkNGY0MjkxODZiMDU3MzU2ZjRiYTg2ZC90ZXh0cmVnaW9uOmFjYTBmOGM1NWQ0ZjQyOTE4NmIwNTczNTZmNGJhODZkXzU0OTc1NTgxNDA3MzE_e176c425-4133-4e81-8c62-8433395b8625">EMPLOYEE BENEFIT PLANSThe Company maintains a tax-qualified SIMPLE IRA retirement plan which covers all employees. Pursuant to the SIMPLE IRA program, employees are eligible to contribute to an individual SIMPLE IRA account on a tax-deferred basis. The Company makes matching contributions to the employee&#x2019;s SIMPLE IRA account in an amount up to 3% of the employee&#x2019;s base salary (subject to applicable IRS compensation limits). Expenses related to Company contributions were $24 and $17 for the years ended December&#160;31, 2021 and 2020, respectively.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i3f45c53a2fd14b19a55e65c0b6f087be_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85NTQvZnJhZzphY2EwZjhjNTVkNGY0MjkxODZiMDU3MzU2ZjRiYTg2ZC90ZXh0cmVnaW9uOmFjYTBmOGM1NWQ0ZjQyOTE4NmIwNTczNTZmNGJhODZkXzU0OTc1NTgxNDA3MzM_3bfc4431-952c-4a08-a408-f49ed2122f71"
      unitRef="number">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85NTQvZnJhZzphY2EwZjhjNTVkNGY0MjkxODZiMDU3MzU2ZjRiYTg2ZC90ZXh0cmVnaW9uOmFjYTBmOGM1NWQ0ZjQyOTE4NmIwNTczNTZmNGJhODZkXzIxOTkwMjMyNTc1OTc_99f56d50-b075-4732-a07a-c80fd282f2bb"
      unitRef="usd">24000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85NTQvZnJhZzphY2EwZjhjNTVkNGY0MjkxODZiMDU3MzU2ZjRiYTg2ZC90ZXh0cmVnaW9uOmFjYTBmOGM1NWQ0ZjQyOTE4NmIwNTczNTZmNGJhODZkXzIxOTkwMjMyNTc2MDQ_11eb2344-f5b6-40da-a460-75b53d021acb"
      unitRef="usd">17000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjYvZnJhZzpmYzg2MDcyMjQzNmE0YTU4YjMzY2IwYmE2OGYwZTExZi90ZXh0cmVnaW9uOmZjODYwNzIyNDM2YTRhNThiMzNjYjBiYTY4ZjBlMTFmXzY2MDY_6bf85a98-dcda-4771-a630-0e1516d3bc48">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employment agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the Company was named as a defendant in a putative class action lawsuit filed in the California Superior Court, County of Los Angeles, styled &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rendon v. Vallon, Inc., et al&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The complaint brought one claim for violation of California&#x2019;s Unruh Civil Rights Act (Unruh Act), alleging that the Company&#x2019;s website is not compatible with software used by vision-impaired individuals.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company settled the lawsuit for an immaterial amount&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;COVID-19 Impact&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The global COVID-19 pandemic continues to present uncertainty and unforeseeable new risks to the Company&#x2019;s operations and business plan. The Company has closely monitored recent COVID-19 developments, including states&#x2019; lifting COVID-19 safety measures, drops in vaccination rates, and the spread of various coronavirus strains such as the Delta and Omicron variants. In light of these developments, the full impact of the COVID-19 pandemic on the Company&#x2019;s business, operations and clinical development plans remains uncertain and will vary depending on the pandemic&#x2019;s future impact on its clinical trial enrollment, clinical trial sites, clinical research organizations (CROs), third-party manufacturers, and other third parties with whom the Company does business, as well as any legal or regulatory consequences resulting therefrom. To the extent possible, the Company is conducting business as usual, with necessary or advisable modifications to employee travel and with most of its employees and consultants working remotely. The Company will continue to actively monitor the COVID-19 situation and may take further actions that alter its operations, including those that may be required by federal, state or local authorities, or that it determines is in the best interests of its employees and other third parties with whom the Company does business.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ic698111b087341fab1ee0949330016d5_I20211106"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjYvZnJhZzpmYzg2MDcyMjQzNmE0YTU4YjMzY2IwYmE2OGYwZTExZi90ZXh0cmVnaW9uOmZjODYwNzIyNDM2YTRhNThiMzNjYjBiYTY4ZjBlMTFmXzU0OTc1NTgxNTgyNTU_641c6a11-9a49-4eba-bb94-a8b4b8f6e1a9"
      unitRef="claim">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90ZXh0cmVnaW9uOmYzODY5MGU0NWM0ODQ1ZjZiMmEzOGNjMTRiZGU0NzkyXzcxNDY4MjU1ODMwOTI_dedc3bd2-1d24-4c1d-9395-18cf8444a44e">STOCKHOLDERS EQUITY (DEFICIT)&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the Company completed its IPO of 2,250,000 shares of common stock at a public offering price of  $8.00 per share. As a result of the IPO, the Company received approximately $15,500 in net proceeds, after deducting discounts and commissions of $1,600 and offering expenses of approximately $905.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the IPO, the Company granted the underwriters warrants (the Underwriters' Warrants) to purchase an aggregate of 112,500 shares of common stock at an exercise price of $10.00 per share. The Underwriters&#x2019; Warrants have a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90ZXh0cmVnaW9uOmYzODY5MGU0NWM0ODQ1ZjZiMmEzOGNjMTRiZGU0NzkyXzE2NDkyNjc0NDQzMDI_d0b1e4ec-bc6a-4c22-8fd2-7d9f5a4cd028"&gt;five&lt;/span&gt;-year term and became exercisable after August 12, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;85.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.155&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, all of the Underwriters&#x2019; Warrants were outstanding.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ia17353f6bf834b99aeb72bb19eed6773_D20210212-20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90ZXh0cmVnaW9uOmYzODY5MGU0NWM0ODQ1ZjZiMmEzOGNjMTRiZGU0NzkyXzE2NDkyNjc0NDQyNTc_98e19324-4b40-4e6a-861e-3a38bfc62c4e"
      unitRef="shares">2250000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i9f824c725f73426d90c2105cddf2d5ca_I20210212"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90ZXh0cmVnaW9uOmYzODY5MGU0NWM0ODQ1ZjZiMmEzOGNjMTRiZGU0NzkyXzE2NDkyNjc0NDQyNzQ_18e5693e-480a-429a-8b87-84f9b4736083"
      unitRef="usdPerShare">8.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ia17353f6bf834b99aeb72bb19eed6773_D20210212-20210212"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90ZXh0cmVnaW9uOmYzODY5MGU0NWM0ODQ1ZjZiMmEzOGNjMTRiZGU0NzkyXzE2NDkyNjc0NDQyODU_0c2fd096-6e8a-4ce0-a7ae-fc822d9d9b9e"
      unitRef="usd">15500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:StockIssuanceCostsDiscountsAndCommissions
      contextRef="ia17353f6bf834b99aeb72bb19eed6773_D20210212-20210212"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90ZXh0cmVnaW9uOmYzODY5MGU0NWM0ODQ1ZjZiMmEzOGNjMTRiZGU0NzkyXzcxNDY4MjU1ODMwOTU_d115aa79-b1ae-4465-8664-0842ae8e502b"
      unitRef="usd">1600000</ck0001824293:StockIssuanceCostsDiscountsAndCommissions>
    <ck0001824293:StockIssuanceCostsOfferingExpenses
      contextRef="i9318b4034bf247a7bf81e79df11bc14e_D20210212-20210212"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90ZXh0cmVnaW9uOmYzODY5MGU0NWM0ODQ1ZjZiMmEzOGNjMTRiZGU0NzkyXzcxNDY4MjU1ODMxMDc_5d8dd4f7-bc3a-4e57-abb6-1d1f05893a75"
      unitRef="usd">905000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="if6d11153da3c4046926d1df8862e08df_I20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90ZXh0cmVnaW9uOmYzODY5MGU0NWM0ODQ1ZjZiMmEzOGNjMTRiZGU0NzkyXzE2NDkyNjc0NDQyOTA_3ce643c6-de3b-4530-8df0-7bbd6d1838b4"
      unitRef="shares">112500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="if6d11153da3c4046926d1df8862e08df_I20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90ZXh0cmVnaW9uOmYzODY5MGU0NWM0ODQ1ZjZiMmEzOGNjMTRiZGU0NzkyXzE2NDkyNjc0NDQyOTc_63aa6772-42f7-45d8-98c8-bab993c499ee"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90ZXh0cmVnaW9uOmYzODY5MGU0NWM0ODQ1ZjZiMmEzOGNjMTRiZGU0NzkyXzIxOTkwMjMyNTgwOTE_34e36fed-8325-4120-9e55-4a43823eb2d8">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;85.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.155&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i5f7f365dc72f44f98ddaa19c2a6fe7c2_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90YWJsZTplMzk0NTRhYjRiNWI0NmI1OGZlMDYxMTY5ODk4MWNhMC90YWJsZXJhbmdlOmUzOTQ1NGFiNGI1YjQ2YjU4ZmUwNjExNjk4OTgxY2EwXzAtMS0xLTEtMjM2Mjg_88c1924d-fcf7-4e0c-928d-ae9cecb6338e"
      unitRef="number">0.850</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i233cc24405d641289d6ab6f271edbce0_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90YWJsZTplMzk0NTRhYjRiNWI0NmI1OGZlMDYxMTY5ODk4MWNhMC90YWJsZXJhbmdlOmUzOTQ1NGFiNGI1YjQ2YjU4ZmUwNjExNjk4OTgxY2EwXzEtMS0xLTEtMjM2Mjg_b25a5687-f418-41af-bf47-3b727422ea2d"
      unitRef="number">2.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i0508ecc21bf1424db461226872bd262c_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90YWJsZTplMzk0NTRhYjRiNWI0NmI1OGZlMDYxMTY5ODk4MWNhMC90YWJsZXJhbmdlOmUzOTQ1NGFiNGI1YjQ2YjU4ZmUwNjExNjk4OTgxY2EwXzItMS0xLTEtMjM2Mjg_4ad2327d-38c6-4ff2-9fda-51fb3d14b569"
      unitRef="number">0.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i6dc2bc5f633b4fe997a55197c7618e72_I20211231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV85MzMvZnJhZzpmMzg2OTBlNDVjNDg0NWY2YjJhMzhjYzE0YmRlNDc5Mi90YWJsZTplMzk0NTRhYjRiNWI0NmI1OGZlMDYxMTY5ODk4MWNhMC90YWJsZXJhbmdlOmUzOTQ1NGFiNGI1YjQ2YjU4ZmUwNjExNjk4OTgxY2EwXzMtMS0xLTEtMjM2Mjg_8ae68fa5-fdf7-4156-9c22-8626911f369a"
      unitRef="number">0.00155</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90ZXh0cmVnaW9uOjNkN2QyMGZlMGUyYjRkOTJiOTFjY2Y2OTIyNzY5M2VjXzQ1MjU_65649de2-4ff3-4d06-b2aa-1bf360f0f325">STOCK-BASED COMPENSATION&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company issues stock-based awards pursuant to its 2018 Equity Incentive Plan (the 2018 Plan). The 2018 Plan provides for the granting of stock options, restricted stock, or restricted stock units. The Company's employees, officers, directors and other persons are eligible to receive awards under the Plan.  The number of shares of the Company's common stock authorized under the 2018 Plan will automatically increase on January 1st of each year until the expiration of the 2018 Plan, in an amount equal to four percent of the total number of shares of the Company's common stock outstanding on December 31st of the preceding calendar year, subject to the discretion of the Company's board of directors or compensation committee to determine a lesser number of shares shall be added for such year. The total number of shares authorized for issuance under the 2018 Plan was 621,022 as of December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount, terms of grants, and exercisability provisions are determined and set by the Company's board of directors or compensation committee. The Company measures employee stock-based awards at grant-date fair value and records compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;expense on a straight-line basis over the vesting period of the award. Stock-based awards issued to non-employees are revalued until the award vests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded  stock-based compensation related to stock options issued under the 2018 Plan in the following expense categories of its accompanying statements of operations for the years ended December&#160;31, 2021 and 2020  :&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;103&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;543&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;51&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;626&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;154&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has granted stock options to purchase its common stock to employees and consultants under the 2018 Plan that generally have a contractual life of up to 10 years. The Company has also granted certain stock options outside of the 2018  Plan. As of December&#160;31, 2021, all equity awards granted from the 2018 Plan were in the form of stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures equity-based awards granted to employees, and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for equity awards is the date of grant, and equity-based compensation costs are recognized as expense over the requisite service period, which is the vesting period or for certain performance-based awards. The Company records the expense for these awards if it concludes that it is probable that the performance condition will be achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below represents the activity of stock options granted to employees and non-employees for the year ended December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term&#160;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;266,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.22&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;442,240&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;708,490&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.64&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;205,888&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Vested and expected to vest at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;708,490&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.64&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;83.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;85.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.85&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fair value of common stock on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.72&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The aggregate intrinsic value of stock options outstanding and stock options exercisable as of December&#160;31, 2021 was $1,716 and $640, respectively. At December&#160;31, 2021, the unrecognized compensation cost related to unvested stock options expected to vest was $885. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of 2.49 years.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <ck0001824293:ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90ZXh0cmVnaW9uOjNkN2QyMGZlMGUyYjRkOTJiOTFjY2Y2OTIyNzY5M2VjXzU0OTc1NTgxNTIyNTM_4b01660e-6c2d-4432-97b6-34737ae8ba90"
      unitRef="number">0.04</ck0001824293:ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i01c972ebfcea4e9f9fb0d25b4590b552_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90ZXh0cmVnaW9uOjNkN2QyMGZlMGUyYjRkOTJiOTFjY2Y2OTIyNzY5M2VjXzIxOTkwMjMyNjg5MDM_09c6945f-0d7c-4df4-8779-db5fc0a797b0"
      unitRef="shares">621022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90ZXh0cmVnaW9uOjNkN2QyMGZlMGUyYjRkOTJiOTFjY2Y2OTIyNzY5M2VjXzIxOTkwMjMyNjg3Mzk_6eecf8f5-8aad-4246-8055-a907abaacb05">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded  stock-based compensation related to stock options issued under the 2018 Plan in the following expense categories of its accompanying statements of operations for the years ended December&#160;31, 2021 and 2020  :&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;103&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;543&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;51&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;626&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;154&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i414ab16442df41e0a789424f9dcdbb64_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpjM2UzNmE3OTlhNTg0NmE2YThhNGFiY2YzMDdhYzFjYi90YWJsZXJhbmdlOmMzZTM2YTc5OWE1ODQ2YTZhOGE0YWJjZjMwN2FjMWNiXzItNS0xLTEtMjM2NDE_d9cc12be-29a9-4e1f-9fc2-5f4bee6e1720"
      unitRef="usd">83000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic219cdbb38f64f029ff62ec56ce54f18_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpjM2UzNmE3OTlhNTg0NmE2YThhNGFiY2YzMDdhYzFjYi90YWJsZXJhbmdlOmMzZTM2YTc5OWE1ODQ2YTZhOGE0YWJjZjMwN2FjMWNiXzItNy0xLTEtMjM2NDE_72da2c47-90d2-42b3-ab75-b5dcc3960c3d"
      unitRef="usd">103000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic19d630a0cfb4614bc03d9687c1b1adf_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpjM2UzNmE3OTlhNTg0NmE2YThhNGFiY2YzMDdhYzFjYi90YWJsZXJhbmdlOmMzZTM2YTc5OWE1ODQ2YTZhOGE0YWJjZjMwN2FjMWNiXzMtNS0xLTEtMjM2NDE_a345ebfd-4443-4033-887b-dfa108a2d347"
      unitRef="usd">543000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i25bc9e21732d46a495fab6ec37e81bd6_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpjM2UzNmE3OTlhNTg0NmE2YThhNGFiY2YzMDdhYzFjYi90YWJsZXJhbmdlOmMzZTM2YTc5OWE1ODQ2YTZhOGE0YWJjZjMwN2FjMWNiXzMtNy0xLTEtMjM2NDE_f55633c1-cd04-4e8a-a1d7-645dff85ecbc"
      unitRef="usd">51000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia48dc025b4ca46bfbb1119e73f604f09_D20211001-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpjM2UzNmE3OTlhNTg0NmE2YThhNGFiY2YzMDdhYzFjYi90YWJsZXJhbmdlOmMzZTM2YTc5OWE1ODQ2YTZhOGE0YWJjZjMwN2FjMWNiXzQtMS0xLTEtMjYxMjU_f2789815-3f58-45fa-946e-24d3617517a8"
      unitRef="usd">626000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iefc0efe048504719968099425a5fc1f0_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpjM2UzNmE3OTlhNTg0NmE2YThhNGFiY2YzMDdhYzFjYi90YWJsZXJhbmdlOmMzZTM2YTc5OWE1ODQ2YTZhOGE0YWJjZjMwN2FjMWNiXzQtMy0xLTEtMjYxMjg_aff236cb-8f35-4e24-9adc-75205f2825a1"
      unitRef="usd">154000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i2042fe817e6b415d99dcd18a2761b5b7_D20181001-20181001"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90ZXh0cmVnaW9uOjNkN2QyMGZlMGUyYjRkOTJiOTFjY2Y2OTIyNzY5M2VjXzI3NDg3NzkwODIzNjU_320cfbee-f62c-42d8-99b6-612099c3b1a7">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90ZXh0cmVnaW9uOjNkN2QyMGZlMGUyYjRkOTJiOTFjY2Y2OTIyNzY5M2VjXzIxOTkwMjMyNjg3NDA_f94fa49b-e770-4785-aac1-f66ddd58bfda">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below represents the activity of stock options granted to employees and non-employees for the year ended December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term&#160;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;266,250&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.22&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;442,240&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;708,490&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.64&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;205,888&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Vested and expected to vest at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;708,490&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.64&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzEtMS0xLTEtMjM2NDE_41a372bb-00e1-41f3-96b4-76bcd8785fb1"
      unitRef="shares">266250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzEtMy0xLTEtMjM2NDE_ffa9a5bf-5979-4c12-b700-f61abd355fa1"
      unitRef="usdPerShare">2.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i7543349bff1e4b3d8106535d9eae2358_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzEtNS0xLTEtMjM2NDE_835812b2-3c7d-468a-84dd-7b706ac1624a">P8Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzItMS0xLTEtMjM2NDE_6aeb7d29-2170-47bf-8cab-f02dadfd28df"
      unitRef="shares">442240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzItMy0xLTEtMjM2NDE_f9fc0dc3-21d5-4da9-b453-4c18386fa6b9"
      unitRef="usdPerShare">4.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzUtMS0xLTEtMjYxMzQ_beb021b7-c87c-4276-a365-9f732a167c47"
      unitRef="shares">708490</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzUtMy0xLTEtMjM2NDE_4a58427c-9b6f-45ef-a96f-13747ba2ffbd"
      unitRef="usdPerShare">3.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzUtNS0xLTEtMjM2NDE_7680d65e-ed90-487a-8a1a-55464a2fcb2e">P8Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzYtMS0xLTEtMjM2NDE_cedfdb6a-8ef3-4a0d-a204-1f45501df0b0"
      unitRef="shares">205888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzYtMy0xLTEtMjM2NDE_bc7d39b5-650b-42b6-8cc3-4b0b442471b9"
      unitRef="usdPerShare">2.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzYtNS0xLTEtMjM2NDE_1ffc48c4-baac-463c-b995-5410abb4c741">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzctMS0xLTEtMjkxMDg_d751353d-c240-49e6-a274-ae2f9878de48"
      unitRef="shares">708490</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzctMy0xLTEtMjkxMTY_05b97b78-02c4-4de1-a5fb-a82cf92ae6a7"
      unitRef="usdPerShare">3.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTpkYzhiMTljZmUwZmM0MTY2OTM1NDM0ZmY1YWU1NDk5YS90YWJsZXJhbmdlOmRjOGIxOWNmZTBmYzQxNjY5MzU0MzRmZjVhZTU0OTlhXzctNS0xLTEtMjkxNjU_1e91c925-558a-4856-ab2e-d882abf5ebdc">P8Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90ZXh0cmVnaW9uOjNkN2QyMGZlMGUyYjRkOTJiOTFjY2Y2OTIyNzY5M2VjXzIxOTkwMjMyNjg3NDE_d8d62c3e-f986-4a68-bcd3-272d068401ff">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;83.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;85.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.85&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fair value of common stock on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.72&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTo4ZmI2MGU2OTIwODI0YmZjYjA2YWQ5MzgzYWU0YzczZC90YWJsZXJhbmdlOjhmYjYwZTY5MjA4MjRiZmNiMDZhZDkzODNhZTRjNzNkXzItMS0xLTEtMjM2NDE_258c57f7-41d2-484e-9e1d-c7c9bcd9e105"
      unitRef="number">0.8378</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTo4ZmI2MGU2OTIwODI0YmZjYjA2YWQ5MzgzYWU0YzczZC90YWJsZXJhbmdlOjhmYjYwZTY5MjA4MjRiZmNiMDZhZDkzODNhZTRjNzNkXzItMy0xLTEtMjM2NDE_f10e67ea-33eb-4ab0-a5cc-aa7a3495fc04"
      unitRef="number">0.8500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTo4ZmI2MGU2OTIwODI0YmZjYjA2YWQ5MzgzYWU0YzczZC90YWJsZXJhbmdlOjhmYjYwZTY5MjA4MjRiZmNiMDZhZDkzODNhZTRjNzNkXzMtMS0xLTEtMjM2NDE_43e25e1f-512a-4360-82b2-7ae7b48aee19">P5Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTo4ZmI2MGU2OTIwODI0YmZjYjA2YWQ5MzgzYWU0YzczZC90YWJsZXJhbmdlOjhmYjYwZTY5MjA4MjRiZmNiMDZhZDkzODNhZTRjNzNkXzMtMy0xLTEtMjM2NDE_8bd8d676-5465-4b78-82a5-cd75890a8504">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTo4ZmI2MGU2OTIwODI0YmZjYjA2YWQ5MzgzYWU0YzczZC90YWJsZXJhbmdlOjhmYjYwZTY5MjA4MjRiZmNiMDZhZDkzODNhZTRjNzNkXzQtMS0xLTEtMjM2NDE_a97ce02b-2a17-4cd5-a867-075d3410f686"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTo4ZmI2MGU2OTIwODI0YmZjYjA2YWQ5MzgzYWU0YzczZC90YWJsZXJhbmdlOjhmYjYwZTY5MjA4MjRiZmNiMDZhZDkzODNhZTRjNzNkXzQtMy0xLTEtMjM2NDE_42873156-053d-486c-8b30-568b26389938"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTo4ZmI2MGU2OTIwODI0YmZjYjA2YWQ5MzgzYWU0YzczZC90YWJsZXJhbmdlOjhmYjYwZTY5MjA4MjRiZmNiMDZhZDkzODNhZTRjNzNkXzUtMS0xLTEtMjM2NDE_05505e71-e020-4447-8a37-62f6865e7614"
      unitRef="number">0.0101</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTo4ZmI2MGU2OTIwODI0YmZjYjA2YWQ5MzgzYWU0YzczZC90YWJsZXJhbmdlOjhmYjYwZTY5MjA4MjRiZmNiMDZhZDkzODNhZTRjNzNkXzUtMy0xLTEtMjM2NDE_78420572-d451-4e11-ae5b-b49f779e81c7"
      unitRef="number">0.0064</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharePrice
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTo4ZmI2MGU2OTIwODI0YmZjYjA2YWQ5MzgzYWU0YzczZC90YWJsZXJhbmdlOjhmYjYwZTY5MjA4MjRiZmNiMDZhZDkzODNhZTRjNzNkXzYtMS0xLTEtMjM2NDE_400ebfb6-3932-4b0f-94ab-652d9e670439"
      unitRef="usdPerShare">4.00</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90YWJsZTo4ZmI2MGU2OTIwODI0YmZjYjA2YWQ5MzgzYWU0YzczZC90YWJsZXJhbmdlOjhmYjYwZTY5MjA4MjRiZmNiMDZhZDkzODNhZTRjNzNkXzYtMy0xLTEtMjM2NDE_89ac8d83-7a33-4fae-b8bc-09f98a918446"
      unitRef="usdPerShare">4.72</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90ZXh0cmVnaW9uOjNkN2QyMGZlMGUyYjRkOTJiOTFjY2Y2OTIyNzY5M2VjXzE2NDkyNjc0NTU3NDg_3860f3f1-6c2d-4797-a35d-b51d50e36cc8"
      unitRef="usd">1716000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90ZXh0cmVnaW9uOjNkN2QyMGZlMGUyYjRkOTJiOTFjY2Y2OTIyNzY5M2VjXzE2NDkyNjc0NTU3NTU_1797c476-7b01-4e9b-97ea-0a065d610ad2"
      unitRef="usd">640000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90ZXh0cmVnaW9uOjNkN2QyMGZlMGUyYjRkOTJiOTFjY2Y2OTIyNzY5M2VjXzI3NDg3NzkwODA1MjQ_1f9ee6a1-5a68-4813-a770-0f520346c1a1"
      unitRef="usd">885000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNjkvZnJhZzozZDdkMjBmZTBlMmI0ZDkyYjkxY2NmNjkyMjc2OTNlYy90ZXh0cmVnaW9uOjNkN2QyMGZlMGUyYjRkOTJiOTFjY2Y2OTIyNzY5M2VjXzI3NDg3NzkwODA1Mjg_8001a681-f21f-41b3-b42c-17095e646ba0">P2Y5M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90ZXh0cmVnaW9uOjkyMmVhMDE4OGZjZTRkZGQ4NWRmMTFiMzkxOWEzNWE4XzI1Mzk_b52ad8a7-2de7-4900-9fbd-50b2d46b1122">INCOME TAX&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax expense (benefit) at the US federal statutory income tax rate and the income tax provision in the financial statements is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected income tax benefit at the federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;State and local taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-deductible items and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prior year provision to return adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(31.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(40.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal components of the Company&#x2019;s deferred tax assets  and liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Federal and state net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Share based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accruals and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Company&#x2019;s history of losses, the Company recorded a full valuation allowance against its deferred tax assets as of December&#160;31, 2021 and 2020. The Company increased its valuation allowance by approximately $2,864 for the&#160;year ended December&#160;31, 2021. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support a reversal of the allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company had federal, state and local net operating loss carryforwards of $20,125, $20,362, and $15,866, respectively. The federal net operating loss carryforwards do not expire. The state and local losses begin to expire in the&#160;year ending December&#160;31, 2038.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the provisions of Sections&#160;382 and 383 of the Internal Revenue Code (IRC), certain substantial changes in the Company&#x2019;s ownership may have limited, or may limit in the future, the amount of net operating loss and credit carryforwards that can be used to reduce future income taxes if there has been a significant change in ownership of the Company, as defined by the IRC. Future owner or equity shifts could result in limitations on net operating loss and credit carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of December&#160;31, 2021 and 2020, the Company had no unrecognized income tax benefits that would affect the Company&#x2019;s effective tax rate if recognized. The Company would recognize both accrued interest and penalties related to unrecognized benefits in income tax expense. The Company&#x2019;s uncertain tax positions yet to be determined would be related to years that remain subject to examination by relevant tax authorities. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90ZXh0cmVnaW9uOjkyMmVhMDE4OGZjZTRkZGQ4NWRmMTFiMzkxOWEzNWE4XzcxNDY4MjU1ODM1NTQ_12ddbd4c-16c8-4a46-9060-0400e9ad9d12">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax expense (benefit) at the US federal statutory income tax rate and the income tax provision in the financial statements is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected income tax benefit at the federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;State and local taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-deductible items and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prior year provision to return adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(31.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(40.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZTo4MGQxNmYxNGQ5NzM0OTUzYmFkYmI3ZTJiZDc1Zjk4Yy90YWJsZXJhbmdlOjgwZDE2ZjE0ZDk3MzQ5NTNiYWRiYjdlMmJkNzVmOThjXzItMS0xLTEtMjU0MTY_1df9cfb1-0111-45b3-949b-cb0db63615e3"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZTo4MGQxNmYxNGQ5NzM0OTUzYmFkYmI3ZTJiZDc1Zjk4Yy90YWJsZXJhbmdlOjgwZDE2ZjE0ZDk3MzQ5NTNiYWRiYjdlMmJkNzVmOThjXzItMy0xLTEtMjU0NDk_0ab7de08-2a96-44d5-9c59-2dbccd9bef18"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZTo4MGQxNmYxNGQ5NzM0OTUzYmFkYmI3ZTJiZDc1Zjk4Yy90YWJsZXJhbmdlOjgwZDE2ZjE0ZDk3MzQ5NTNiYWRiYjdlMmJkNzVmOThjXzMtMS0xLTEtMjU0MTY_347afd1c-70d0-408c-8c16-cc59ceba87fd"
      unitRef="number">0.106</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZTo4MGQxNmYxNGQ5NzM0OTUzYmFkYmI3ZTJiZDc1Zjk4Yy90YWJsZXJhbmdlOjgwZDE2ZjE0ZDk3MzQ5NTNiYWRiYjdlMmJkNzVmOThjXzMtMy0xLTEtMjU0NDk_555a18cb-7e3d-4416-8f20-bb1da079cbac"
      unitRef="number">0.128</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZTo4MGQxNmYxNGQ5NzM0OTUzYmFkYmI3ZTJiZDc1Zjk4Yy90YWJsZXJhbmdlOjgwZDE2ZjE0ZDk3MzQ5NTNiYWRiYjdlMmJkNzVmOThjXzUtMS0xLTEtMjU0MjM_d1b5bbac-d3a0-4799-9dd9-dabec3d8bd24"
      unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZTo4MGQxNmYxNGQ5NzM0OTUzYmFkYmI3ZTJiZDc1Zjk4Yy90YWJsZXJhbmdlOjgwZDE2ZjE0ZDk3MzQ5NTNiYWRiYjdlMmJkNzVmOThjXzQtMy0xLTEtMjU0NTY_f44c6434-6a2b-4e65-b81d-bcb10d8cb285"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZTo4MGQxNmYxNGQ5NzM0OTUzYmFkYmI3ZTJiZDc1Zjk4Yy90YWJsZXJhbmdlOjgwZDE2ZjE0ZDk3MzQ5NTNiYWRiYjdlMmJkNzVmOThjXzYtMS0xLTEtMjU0MjM_90db3553-7fbe-4ad7-85eb-8db1acfc6168"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZTo4MGQxNmYxNGQ5NzM0OTUzYmFkYmI3ZTJiZDc1Zjk4Yy90YWJsZXJhbmdlOjgwZDE2ZjE0ZDk3MzQ5NTNiYWRiYjdlMmJkNzVmOThjXzUtMy0xLTEtMjU0NTY_2dfacc8f-50e8-41b9-902a-0fe5e75c8b28"
      unitRef="number">0.064</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZTo4MGQxNmYxNGQ5NzM0OTUzYmFkYmI3ZTJiZDc1Zjk4Yy90YWJsZXJhbmdlOjgwZDE2ZjE0ZDk3MzQ5NTNiYWRiYjdlMmJkNzVmOThjXzgtMS0xLTEtMjU0MzA_e4269391-b851-449e-9e37-002ab61b26dd"
      unitRef="number">-0.311</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZTo4MGQxNmYxNGQ5NzM0OTUzYmFkYmI3ZTJiZDc1Zjk4Yy90YWJsZXJhbmdlOjgwZDE2ZjE0ZDk3MzQ5NTNiYWRiYjdlMmJkNzVmOThjXzYtMy0xLTEtMjU0NjM_afe1e45b-312c-47ef-ab7c-d5cedbeb4232"
      unitRef="number">-0.402</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZTo4MGQxNmYxNGQ5NzM0OTUzYmFkYmI3ZTJiZDc1Zjk4Yy90YWJsZXJhbmdlOjgwZDE2ZjE0ZDk3MzQ5NTNiYWRiYjdlMmJkNzVmOThjXzktMS0xLTEtMjU0MzA_503ddab9-2b81-420a-9da8-fe9f35a9b085"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ia3582a43ec9a4545860582fcc58b5e5a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZTo4MGQxNmYxNGQ5NzM0OTUzYmFkYmI3ZTJiZDc1Zjk4Yy90YWJsZXJhbmdlOjgwZDE2ZjE0ZDk3MzQ5NTNiYWRiYjdlMmJkNzVmOThjXzctMy0xLTEtMjU0NjM_20d37d0e-500c-4f79-9a32-b528fc6f6e8a"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90ZXh0cmVnaW9uOjkyMmVhMDE4OGZjZTRkZGQ4NWRmMTFiMzkxOWEzNWE4XzI1NDE_7c2c0517-960a-44af-bb9b-b98f0353b0bd">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal components of the Company&#x2019;s deferred tax assets  and liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Federal and state net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Share based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accruals and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzMtMS0xLTEtMjU1MDg_ec225afd-5283-42ad-a1c5-d44473b9066d"
      unitRef="usd">6617000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzMtMy0xLTEtMjU1NDA_501d0362-6a1b-4ce9-b915-0ef9d0cf4826"
      unitRef="usd">3939000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzQtMS0xLTEtMjU1MDg_4be9be90-d975-4b42-80a6-cfbd95761d7a"
      unitRef="usd">308000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzQtMy0xLTEtMjU1NDA_c017d2b0-21f9-4b45-a449-e2da91f8fe62"
      unitRef="usd">97000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <ck0001824293:DeferredTaxAssetsLeaseOligations
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzUtMS0xLTEtMjU1MDg_6c661e15-dae2-4178-80ee-4c37aa74ec48"
      unitRef="usd">57000</ck0001824293:DeferredTaxAssetsLeaseOligations>
    <ck0001824293:DeferredTaxAssetsLeaseOligations
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzUtMy0xLTEtMjU1NDA_daa0d696-29e1-4d66-a58c-52f94ae449a1"
      unitRef="usd">96000</ck0001824293:DeferredTaxAssetsLeaseOligations>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzctMS0xLTEtMjU1MTU_7d0a0878-77e7-4e3c-9582-ee76cd53a33a"
      unitRef="usd">98000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzctMy0xLTEtMjU1NDY_c19f1d35-dcb4-4954-829e-7f51555c3a47"
      unitRef="usd">108000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzgtMS0xLTEtMjU1MTU_61eec97c-8524-48f5-9183-c961a247594a"
      unitRef="usd">7080000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzgtMy0xLTEtMjU1NTk_c4bd215e-9765-47da-a212-c5d973a608bf"
      unitRef="usd">4240000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzktMS0xLTEtMjU1MjE_10afd87f-bb22-47bb-8855-91f643ca2066"
      unitRef="usd">70000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzktMy0xLTEtMjU1NjU_90829de2-8c90-4653-813a-0f41a44a09ef"
      unitRef="usd">94000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzEwLTEtMS0xLTI1NTI3_28a4c29d-28d0-4979-8e13-aeb30257f5a9"
      unitRef="usd">7010000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzEwLTMtMS0xLTI1NTcx_925c6840-d505-408b-978d-b3068a3d9945"
      unitRef="usd">4146000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="id84cb895052844b483a1ef69b0f12655_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzExLTEtMS0xLTI1NTMz_dff85afd-02c9-41d8-85e2-11de54cf94c0"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ib7361a85c9d0470a8ca351dad193b452_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90YWJsZToxZjZkNmI2NWE4ZWY0Mjg0OGI4NzhlZDg1MDFiNzdlZi90YWJsZXJhbmdlOjFmNmQ2YjY1YThlZjQyODQ4Yjg3OGVkODUwMWI3N2VmXzExLTMtMS0xLTI1NTc3_ccf71a15-47c2-4b65-9fb5-3ea468911e3e"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90ZXh0cmVnaW9uOjkyMmVhMDE4OGZjZTRkZGQ4NWRmMTFiMzkxOWEzNWE4XzI3NDg3NzkwNzIzNzg_69bf7880-816f-4746-883d-7706571a4372"
      unitRef="usd">2864000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i1d5a202b2ddb4a648aebf40b599e2cf3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90ZXh0cmVnaW9uOjkyMmVhMDE4OGZjZTRkZGQ4NWRmMTFiMzkxOWEzNWE4XzI3NDg3NzkwNzIzODY_7133128e-1261-4444-9c76-83e31a8eb02b"
      unitRef="usd">20125000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i7f9b7fb9cf6a4e3a91f85fc43dab1e80_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90ZXh0cmVnaW9uOjkyMmVhMDE4OGZjZTRkZGQ4NWRmMTFiMzkxOWEzNWE4XzI3NDg3NzkwNzIzOTE_147cea5f-873d-414a-bb85-6ac52b046467"
      unitRef="usd">20362000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i2ffe46279ad1467fbb2755ef0532a308_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xODQvZnJhZzo5MjJlYTAxODhmY2U0ZGRkODVkZjExYjM5MTlhMzVhOC90ZXh0cmVnaW9uOjkyMmVhMDE4OGZjZTRkZGQ4NWRmMTFiMzkxOWEzNWE4XzI3NDg3NzkwNzIzOTc_3a95978a-c4f7-4e39-a1c8-ce003efd6cab"
      unitRef="usd">15866000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzUvZnJhZzo0Zjc5YWJlOWZjOTU0OTE3OWZjMWNkNTdmZWNmZDZmZS90ZXh0cmVnaW9uOjRmNzlhYmU5ZmM5NTQ5MTc5ZmMxY2Q1N2ZlY2ZkNmZlXzE0MTI_7008e21e-8905-4d1f-a3b3-41492ad0956e">RELATED PARTY TRANSACTIONS&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 2020, the Company&#160;entered into a license agreement with Medice which grants&#160;Medice&#160;an exclusive license, with the right to grant sublicenses, to develop, use, manufacture, market and sell ADAIR&#160;throughout&#160;Europe.&#160;&#160;Medice&#160;is responsible for obtaining regulatory approval of ADAIR in the licensed territory.&#160; Under the license agreement,&#160;Medice&#160;paid&#160;Vallon&#160;a $100 upfront payment&#160;and is required to pay milestone payments upon first obtaining regulatory approval to market and sell ADAIR in any country, territory or region in the licensed territory and upon achieving certain annual net sales thresholds.&#160;&#160;Medice&#160;will also pay tiered royalties on annual net sales of ADAIR at rates in the low double-digits. The initial term of the license agreement will expire five years after the date on which&#160;Medice&#160;first obtains regulatory approval in any country, territory or region in the licensed territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#x2019;s Chief Executive Officer, pursuant to which the Company issued the 2021 Convertible Notes for cash proceeds of $350. The 2021 Convertible Notes bore an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September 30, 2021. The 2021 Convertible Notes converted into 54,906 shares of the Company&#x2019;s common stock upon completion of the IPO.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1b89a713dfe46188f25b2cff340c80d_D20200101-20200131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzUvZnJhZzo0Zjc5YWJlOWZjOTU0OTE3OWZjMWNkNTdmZWNmZDZmZS90ZXh0cmVnaW9uOjRmNzlhYmU5ZmM5NTQ5MTc5ZmMxY2Q1N2ZlY2ZkNmZlXzU0OTc1NTgxNDI2MTg_9d1997bc-8e0b-4dc4-bd2a-348c449df715"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ck0001824293:RelatedPartyTransactionLicenseAgreementTerm
      contextRef="ib1b89a713dfe46188f25b2cff340c80d_D20200101-20200131"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzUvZnJhZzo0Zjc5YWJlOWZjOTU0OTE3OWZjMWNkNTdmZWNmZDZmZS90ZXh0cmVnaW9uOjRmNzlhYmU5ZmM5NTQ5MTc5ZmMxY2Q1N2ZlY2ZkNmZlXzU0OTc1NTgxNDI2Mjc_6436d258-ba3b-408a-b00f-ea5b6f8a68e0">P5Y</ck0001824293:RelatedPartyTransactionLicenseAgreementTerm>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i3b1123c092e44fef8394165e79c1a211_D20210101-20210131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzUvZnJhZzo0Zjc5YWJlOWZjOTU0OTE3OWZjMWNkNTdmZWNmZDZmZS90ZXh0cmVnaW9uOjRmNzlhYmU5ZmM5NTQ5MTc5ZmMxY2Q1N2ZlY2ZkNmZlXzIxOTkwMjMyNTg0Mzc_a7892222-2cc8-4700-bd3f-b11e42952644"
      unitRef="usd">350000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i55442e45b4004aa1ab3f8d35b70ac615_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzUvZnJhZzo0Zjc5YWJlOWZjOTU0OTE3OWZjMWNkNTdmZWNmZDZmZS90ZXh0cmVnaW9uOjRmNzlhYmU5ZmM5NTQ5MTc5ZmMxY2Q1N2ZlY2ZkNmZlXzIxOTkwMjMyNTg0OTQ_1149d0fb-95fb-446a-a4e9-6252792ad5fe"
      unitRef="number">0.070</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i3b1123c092e44fef8394165e79c1a211_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjhjNzcyYjE1NjgyMTRhNzI5NDU1ODE3MTQ3MWRmZGE1L3NlYzo4Yzc3MmIxNTY4MjE0YTcyOTQ1NTgxNzE0NzFkZmRhNV8xNzUvZnJhZzo0Zjc5YWJlOWZjOTU0OTE3OWZjMWNkNTdmZWNmZDZmZS90ZXh0cmVnaW9uOjRmNzlhYmU5ZmM5NTQ5MTc5ZmMxY2Q1N2ZlY2ZkNmZlXzIxOTkwMjMyNTg2MTU_e9abbe06-9b58-44b6-9504-3d21127a86d6"
      unitRef="shares">54906</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>63
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M, K8C0"\7PI@A=V-^893?K.;_@-02P,$%     @ XH%.5&X-JB9V @  NP8
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M7 UFV1JRUFW[C^RB%$NYQ<C(;U%6.&[SCN7*R5H\7RZ7+]+UB;@QXA=I(D9
M<FM\CX\ TFA*.1;/CDYF!UAZWL-3-HL@7E/F'M.&G+0EP!%2!NQ#9)J8:97#
M[9(<ZWE^LWSW0CBI/.\,)B%<S(D*GRC=8'>G, !(;\6S^<GX9#:;B(OT\2!)
M]^U7LD ^?#5.OX(SLI8Z983!8PS>4D@\\P1VM,5Q://E^&0^Z^NRE@;3DM/:
M\1>I5UHSYK4JF+&F8#_ XN0UZC:5=U];[2#LZQ#$8, H:5>(SP@C4LP(X,OB
M'N&^_>;58O[R1XBG*MXRI;A%*-0=RO[++L*-I2 \'0H&VB5@3Y2C#:\C>BL*
MF+,BBT(Q9[@A=!3&/?8FR3X ?\PUI6/REJ]PU4J'$*4B1TO0MDEQ:EH6WB\@
M^ YT?@=FL-K5R!Z@OE3\E[623$T1Z;WZZ(HBBZG3.E9LT)-QSNTQNE91:F$1
M8'=\3FG$1;F62B=6;"IT<@,F,HG=0?<><O*HYU2"!CU#,@YX#N.^C!IU6'XY
M";@G)KN(B<V"Y ZU"\(.:'I-<7]K+\-IWQ<C:\2LB$QQ0VR+*S,E4H/*0SK;
MOKK7/??;%1(;P/,M(P9^[G"<)2HB=RLG"N4'ZB6*[QH^Q*%%;U.N\<!#*Q]W
M:8"#^WPK;,S871L?CNG7\7SRU#3&5.&0MBREE')9_(-'7?L9.%O?NR)TE%OT
MNMXP1S37H$R:<OT8Y4N.^9!&[1!K1*5?/BRW/WX3CVI^KS)S\'YMYR::@!>1
MW>+4A^WDH0?/=.^M69-;I1>UYQEN0OOL'$Z'1_M%^U;=76]?_&^E6RGD3%,)
MT=GDY<E(N/85W6Z";=++-;,![^"TK/"/!SF^@.^E1:EU&S8P_"MS_A]02P,$
M%     @ XH%.5(K\$KG]$P  _3<  !D   !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&ULQ5MK<]NXDOTK*-^M6;M*EA_)S&3SJE*<QWCO)/&-X[NUM;4?(!*2
M,"$)#4#:47[]/=T-D* >R:VMW=H/,[%$$.AN=)\^W8">/SC_):R,:=77NFK"
MBZ-5VZZ?GIV%8F5J':9N;1H\63A?ZQ8?_?(LK+W1);]45V>7Y^>_G-7:-D<O
MG_-W-_[E<]>UE6W,C5>AJVOM-Z],Y1Y>'%T<I2\^V>6JI2_.7CY?ZZ6Y->W=
M^L;CTUD_2VEKTP3K&N7-XL71[.+IJ\<TG@?\W9J'D/VM2).Y<U_HPW7YXNB<
M!#*5*5J:0>.?>W-EJHHF@AA_QCF/^B7IQ?SO-/M;UAVZS'4P5Z[Z#UNVJQ='
M3XY4:1:ZJ]I/[N$W$_7YF>8K7!7X_^I!QCY^=*2*+K2NCB]#@MHV\J_^&NV0
MO?#D_, +E_&%2Y9;%F(I7^M6OWSNW8/R-!JST1^L*K\-X6Q#FW+;>CRU>*]]
M>7OW_OWLTW^JCV_5[?6[#]=OKZ]F'SZKV=75Q[L/GZ\_O%,W'W^_OKI^<_O\
MK,5Z]-99$>=^)7-?'IC[XE*]=TV["NI-4YIR/,$9!.VEO4S2OKK\[HRO33%5
MCRXFZO+\\N([\SWJM7_$\STZ,-^L*%S7M+99JAM7V<*:H/YK-@^MA[?\]W<6
M>-PO\)@7>/Q_8M[_K;G5)[,PWC0%U+.-:E<VJ%G3=+K"D[7SK4)\D).KB_/3
MOZK6J9_^\N3R\OR9[MJ5\[;5%#IJV=E28Q)^>/%,89;:Z*:E%SRM0'_HP:1K
M;YO"KBNLNC2-\;JJ-O3<K%M3BB!&W366/MUB#8QS"S6KC;>%5L?O9K.;$Z6#
M6F#"?GRV97BG*;4O@[IRI5W@)0[TX]GM%=[#*WO'WJU+7@K#[DYH09KUK6V@
MF85!]K[SRN$?=?QV=OOJ9 J;%7H-HU3VFZQX7=>FM)@5^D%IQX:@:8O*!9HI
MKG)]\U$=?W"M@9U/)OS5E:O7NMDHLU@ IV (C;TPIT#;T\?GL.J]\<$HP$#Q
M185U95N:R[9!%:ZNL30_F:I95:FPTMZPWFML1?Q4DS)AHLS7HNI*DH56;;IZ
MCC&8*N[P-ZS,;P290'MUKZO.3+!.TP+;^PV#-(O>6(%V#1#=RFNT]ZP.K=-
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MUDU'[0-L[R11/JGZ07MFKV?7GW(3O^D(5TBRQC6GWE OCM--MSY%*) (LD?
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M]*6# !Z$+I$RUUP?#7=&]MMIF"1O@_?Y<FBF.#X"'8JIY'[<FS=>8&UTW%V
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MGX_D "M]:-V:?^"%<JMU-?^Y,AJ;2@/P?.%0'<4/M$#_B[^7_P!02P,$%
M  @ XH%.5$3S)(TJ!0  T L  !D   !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&ULM5;;<MLV$/V5'373:68476@[417;,Y(MIV[MU&/9Z4.G#R"Q$M&   .
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MESF-W.A8@+XO+-5WLV$#NR'^_!]02P,$%     @ XH%.5(8N\28#!0  ; P
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MP8?S $Q[\UJ%=.5/^U83WQTOYOQ8H7$![-]IGJE37('^^9O^ E!+ P04
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MU]9;;*"40H%VPFAB83^GB\EU/@OQ,>!!0.M.UB14LC/F*1A?RSD=!T$@H<!
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MT5 J#<#[A4.5$[_0 MT/UU[]'U!+ P04    " #B@4Y4\;4*+=P#  #-"
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M\T%P'4"*&:N$G:OZ'G?U]!Q?HH3Q7ZB;V%XO@*0R5A4[,"DHN&S^[&UW#D>
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M,B[P7H$N\YRIPR5F<K_P0J]9>.#;G;$+_G)>L"VNT7PI[A7-_!8EX3D*S:4
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M+F\H95U-H<JP:NUO_D)9FB-^F=/@1NT<Z'RIE-T;CJ#^%?1^ U!+ P04
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M!*X#U/R:,7GHZ$NW>6/C_U!+ P04    " #B@4Y43^LO3] #   X#0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6RU5UMOXC@4_BM':%9J)99<N'8$
M2-S:[6K:(NC,/JSVP22'8C6)6=N!0=H?O\<A#90)+BOMO$#L^#O?=WPN=KI;
M(5_5"E'#]SA*5*^RTGK]V7%4L,*8J9I88T)OED+&3--0OCAJ+9&%&2B.'-]U
M6T[,>%+I=[.YJ>QW1:HCGN!4@DKCF,G=$".Q[56\RMO$C+^LM)EP^MTU>\$Y
MZJ_KJ:214U@)>8R)XB(!B<M>9>!]OO.:!I"M^,9QJXZ>P;BR$.+5#.[#7L4U
MBC#"0!L3C/XV.,(H,I9(Q]^YT4K!:8#'SV_6;S/GR9D%4S@2T1\\U*M>I5.!
M$)<LC?1,;'_#W*%,8" BE?W"-E_K5B!(E19Q#B8%,4_V_^Q[OA%' *]Q!N#G
M /]20#T'U"\%-') XQ30.@-HYH#FI0RM'-"Z%-#. >TL6/O=S4(S9IKUNU)L
M09K59,T\9/'-T!01GIA4G&M);SGA='\ZG<+CT_,$!H]C&#T]?IO,GN^'7R;9
MY!RNQJ@9C]0U_ I?YV.X^G0-GX G\+P2J6))J+J.)AG&F!/DE,,]I7^&\G>6
MU,#SJN"[OE<"']GAM[BH@=\Y"Q]?P%X_SSZQPQ_8[@WMEJ!O[>@Q!E;RN\OA
M)^P.Q;T(OE\$W\_LU<_8FV'$-(8P95+OX%FR1+%]A_CS"RV%>XVQ^LM"5"^(
MZAE1XUS,J%=2QTE0*1!+,$F7"(UET=L;:F>&3!_=]%NT4YL2\D9!WK"23Z4(
M$$,%2REB"$2R0:GY(L),0VD"-WX046^ZA8I]I"]8<_?C&K?<EV;A2]/JRYQ%
M,85GNF+4AJLP6"YYQ"F&9E<?,.0! A4EC-F&AS!DKRBK,)H\P3\P.O*;=B3F
M2@FY@T?: IBF,EA1/X?!BT2D@T9;8MXJI+9^;G*U"Z*V=4\R%WBB4:+2(%EI
M7@WM-MHUU_VE+!W_,^R="YW"A<[_G:*=C]-O;%_S3NE-H?3&JG1TJJWZ)A?#
M*BC*2U1 N952Y*_HG-C/7)>U^3U1ZTA=LW'CMDY\^&C5.R\\]W#LN?8=9SNZ
MU06OIA9T?BVBQQ?)8JJ8P8S.OD%@*P/OZ(3U?FXA>(=^[OE6K\:XT%0*2LO4
M5'$5ELQTA%BDIR6=GW7^Q=W6._1ZS][L+ZK'R0=&O \JRSMT?\_>_C,Y=&=-
M)=>[4B5VO \[9%+9M!RZMV=OWT9+%=9L9Z(#:Y1<A*62[&:\3!*T@,X"O2J5
MYAQ="<TWQ0.C$SA1$.&23+JU-C'(_35]/]!BG=T2%T+3G3-[7-&G#4JS@-XO
M!6G/!^;B67PL]?\%4$L#!!0    ( .*!3E0@IQHJF@(  )P&   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;+U5;6_:,!#^*Z>HTUJI(R%0F"I *B_5
M*I4.E7;3-.V#20YBU2^9[93R[VL[(:,=H'W:%V)?[GFY,[[TUE(]Z0S1P MG
M0O>#S)C\,@QUDB$GNB%S%/;-4BI.C-VJ5:ASA23U(,[".(HZ(2=4!(.>C\W4
MH"<+PZC F0)=<$[49HA,KOM!,]@&[NDJ,RX0#GHY6>$<S6,^4W87UBPIY2@T
ME0(4+OO!5?-RU'7Y/N$;Q;7>68.K9"'ED]O<I/T@<H:086(< [&/9QPA8X[(
MVOA=<0:UI /NKK?LU[YV6\N":!Q)]IVF)NL'GP-(<4D*9N[E^@M6]5PXOD0R
M[7]A7>9VXP"20AO)*[!UP*DHG^2EZL,.H-DY (@K0/P>T#X :%6 EB^T=.;+
M&A-#!CTEUZ!<MF5S"]\;C[;54.%.<6Z4?4LMS@PFT]GMUQ^3"0PG=Y/KFP>8
MW5[=S>%TC(90IL_@$SS.QW!Z<@8G0 4\9++01*2Z%QHK[TC"I)(:EE+Q :EF
M#%,I3*9A(E),WQ*$UG=M/MZ:'\9'&<>8-*#5/(<XBIM[#(W^'1X=L=.J>]GR
M?*V#?$L;26%DJU1T4?C_Z8P1 6.J$R9UH1!^WMH<N#'(]:\CFNU:L^TUVP<T
M1Y+G1&P@V='<>S8E3=?3N*O]/(C;O?!YMUM_IS2[=<H;=Q>UNXNC[J;DA?*"
M'ZFS4S-U_EMON[5F]ZC["<^9W*"R]\TD&16K-UT^AQQ5@L* 7 *6J:@_PDI)
MK2$G&S@M<C#R;-]I'!=N-:+HP[X"PIV+SE&M_/S3UE8A3'EMZF@]8J_\9'D7
M']K16T[*/S3EW)X2M:)" \.EI8P:77O"JIR%Y<;(W(^3A31V./EE9C\?J%R"
M?;^4TFPW3J#^( U> 5!+ P04    " #B@4Y41>H?O1<"   _!   &0   'AL
M+W=O<FMS:&5E=',O<VAE970T,"YX;6Q]5$N/FS 0_BL6IU9* R&/;5<$:4/2
M%BEAHR3='JH>')B M<:FMA.V4G]\;4,0E9I<P&//]YAA3%!S\2H+ (7>2LKD
MW"F4JAY=5Z8%E%@.>05,GYRX*+'2H<A=60G F065U/4];^:6F# G#.S>5H0!
M/RM*&&P%DN>RQ.+W BBOY\[(N6[L2%XHL^&&085SV(/Z5FV%CMR.)2,E,$DX
M0P).<^=I]+B8F'R;\$*@EKTU,I4<.7\U09S-'<\8 @JI,@Q8ORX0 :6&2-OX
MU7(ZG:0!]M=7]L^V=EW+$4N(./U.,E7,G8\.RN"$SU3M>/T5VGJFAB_E5-HG
MJIO<Z=A!Z5DJ7K9@[: DK'GCM[8//<#HTPV WP)\Z[L1LBZ76.$P$+Q&PF1K
M-K.PI5JT-D>8^2A[)?0IT3@51L^;37S8K)+#'CTE2Q0])X<X^;)*HGBU1Q_0
MFBB28]O =TM0F%#Y/G"55C9X-VU5%HV*?T,EX9<A\F8#Y'O^**68E/]RN-IU
M9]WOK/N6='*#= <LT[8T\PNFE+,!BEDZ'" ]R9BB/T@/E**0]4JX(SKN1,=6
M='Q#=,VE1!%GBK <6$I HA]KG8-B!:7\>4=ATBE,[I:UU65I<O2?-C6M;N S
M"S=W[A*. O?25W1[\V"NU@:+G#")*)PTQAL^3!TDFG%M L4K.R)'KO3 V66A
M;S@(DZ#/3YRK:V"FKOMGA'\!4$L#!!0    ( .*!3E0N?IID1 ,  (4)   9
M    >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;+66;6_;-A#'O\I!*+ $R")1
MB1]2V 82)T&-=4T6QRN&82\8Z6P3H42-1\<IL ^_HZ3('B(+Q8#ZA452O#]_
M=^0=-=H:^TQK1 >OF<YI'*R=*SZ&(25KS"2=F@)S?K,T-I..NW854F%1IJ51
MIL,XBOIA)E4>3$;EV+V=C,S&:97CO07:9)FTWZY0F^TX$,';P(-:K9T?"">C
M0JYPCFY1W%ONA8U*JC+,29D<+"['P:7X>"7.O4$YXW>%6]IK@W?ER9AGWYFE
MXR#R1*@Q<5Y"\N,%IZBU5V*.OVO1H%G3&^ZWW]1O2^?9F2=).#7ZJTK=>AP,
M TAQ*3?:/9CM)ZP=ZGF]Q&@J_V%;SXT"2#;D3%8;,T&F\NHI7^M [!F<#0X8
MQ+5!7')7"Y64U]+)R<B:+5@_F]5\HW2UM&8XE?M=F3O+;Q7;N<G\\6[ZRZ>[
MS]<W#W.X^6TQ>_P#CJYO;F?3V>,Q_ Q?I+72!XY'T4FEZ1@^0 BTEA8)5 Z+
M7#DZX4%N/Z[-AF2>TBAT#.>7"),:Y*H"B0^ W.+3*8CX!.(H%HOY-1Q].-XM
M5/W_5S5D5QM_X\;?N%SF[, R4RV)P"QA[DSR#']^YO<P<YC17QWJ9XWZ6:E^
M?D#],DV5/VQ2\Q)+M"I? ;YR!A&V1:02&Y1B/GU>)A=1;Q2^M!"<-P3GG02S
M^[L./WJ-2N\'1*G?J/<[&>=2HQ>G4OR(STVUO<?P#[1M=!6L2K._%ZPX[D7\
M:P_8H($9?#_,"116)0@%VHJDI-M0NAOQD+MSV08Z>+>KPW;$88,X[$3\PL6Y
ML"9!3 F6UF1 ^]!M#,-W#*+7.Q2JBX;CHCM4Y7XIHHW,.4B)(9_XJ:+$;')'
MP(G/@UG&,S@'6F-S\9ZK?PA+1+L:%G6"+?(4[=8JAY9^@DNMC>.+PW4<5;%7
M'\4/2 6QJT<B[F3_Z@NLC][*/S#][GRH=?<30HCXX":+70T3W46L)N+"A391
MA'5._(],$.\+G#B$MRMPHKO"-0'C;PQR?.:XR)X ;WW6BM MUH-O*&WKQ1+N
M7:K^ ^57:5<J)]"X9*GH=, EU%9W?M5QIBCOV2?C^-8NFVO^3D+K)_#[I3'N
MK>.O[N;+:_(O4$L#!!0    ( .*!3E2%)"_5LP(  #((   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0R+GAM;+56VV[B,!#]%2M/6ZDE<;B45H#4 E71MFH7
M>M%JM0\N&<#"B;/V .W?[SA)TW15LD^\)+[-\3DG'D]Z.VW6=@6 [#56B>U[
M*\3TW/?M? 6QL V=0D(S"VUB@=0U2]^F!D24!<7*#X.@X\=")MZ@EXW=FT%/
M;U#)!.X-LYLX%N;M$I3>]3WNO0],Y7*%;L ?]%*QA!G@8WIOJ.>7*)&,(;%2
M)\S HN]=\/-+WG0!V8HG"3M;:3,GY47KM>M,HKX7.$:@8(X.0M!K"T-0RB$1
MCS\%J%?NZ0*K[7?TJTP\B7D1%H9:/<L(5WVOZ[$(%F*C<*IWUU (:CN\N58V
M>[)=L3;PV'QC4<=%,#&(99*_Q6MA1"6 M_8$A$5 F/'.-\I8C@2*0<_H'3-N
M-:&Y1B8UBR9R,G%?98:&9B7%X6#V<#?\?GUW,QI/9VS\XW'R\)-]&XVO)L/)
MPQ$[86.+DK0#TPN&*V!70AKV)-2F''D6QH@$+1-)Q"XL?=[4^6T)!E!(98]Z
M/A)3MY\_+UA=YJS"/:Q&,&^P)C]F81#RS^$^"2Q5AJ7*,,-K[<%[TDJ@5!+?
M:L":)5@S VON 1LJ8:U3/T,]7[-?-S3/)@BQ_5V#WBK16[542SLIA2R2IS)9
M'K,8A-T8H'1 )I-T@U]YF@/S($-VZ;@=!(UNN^=OO^#3+OFT:_F,7U-*((@8
M@HEI;_8&PM@:H9T2N', &T]+]--#V9@#<UZQ,6SL<;%;TNG6TAG)K8R $L10
M+M7(.ROQS@Y@'@\^;H7@4/85R)WJ*?S:/%ZYI'@MG:FTZY.% :!MZ1R"Q?\9
MR3^N!AX>PLJ/VX(W#V9ECLS#3QD=!+S][W'T*Q7 5=-;89:2[F %"XH,&J>4
MY"8O4'D'=9H5A1>-5&*RYHJ*.ABW@.876N-[Q]69\C=A\!=02P,$%     @
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M')3"'"^INN7KKU YU#9\":?2/M&ZLO4<E"REXGD%U@IRPLHW?JH"T0!HGMV
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MB2)85<P;=@?C2))@"-2BOT;C&)F=&#[^]<'NDBA*$C\"F-]!%&$(W(TX@CD
M#Q@21?5[<.=]%*[>4^'ZE\SA7U!+ P04    " #B@4Y4EXJ[',     3 @
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M;$Q(0(%C 5EU1!=EK!1UJ4W>'F=66VQ,R$+!V<J=KED]VXKZL!XT8:NC%=P
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MTT]02P$"% ,4    " #B@4Y4!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .*!3E1PJ0HV[@   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( .*!3E297)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ XH%.5%4Q%I+Q!0  8!D  !@
M         ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( .*!3E0,>7RO& (  &@%   8              " @30.  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #B@4Y4F0 ^L2@%  "_$P
M&               @(&"$   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ XH%.5&X-JB9V @  NP8  !@              ("!X!4  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( .*!3E3,J4!I> 0
M -L/   8              " @8P8  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    " #B@4Y4R3QB29T$  "A$@  &               @($Z
M'0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ XH%.5.K.
MDS<N!@  81@  !@              ("!#2(  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( .*!3E3@2.'IS@,  #$(   8
M  " @7$H  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #B
M@4Y4Q6Z"WY<%  #6#   &               @(%U+   >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ XH%.5(K\$KG]$P  _3<  !D
M         ("!0C(  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    " #B@4Y41/,DC2H%  #0"P  &0              @(%V1@  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( .*!3E2&+O$F P4  &P,
M   9              " @==+  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ XH%.5-<KDG2# @  804  !D              ("!$5$
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #B@4Y4OHB/
M)D4"   *!0  &0              @('+4P  >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( .*!3E3\J/KK! ,  ($&   9
M  " @4=6  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
MXH%.5,DB3F40!@  :PT  !D              ("!@ED  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    " #B@4Y4!'ZQVK4#  #^!P  &0
M            @(')7P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( .*!3E2LZ+R_3 <  *<2   9              " @;5C  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ XH%.5)0XC^4?!P
M51$  !D              ("!.&L  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    " #B@4Y4J'0OFH($  !&"@  &0              @(&.
M<@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( .*!3E1^
MXAK#Z@$  %8$   9              " @4=W  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ XH%.5)+$ _!@$@  Q#8  !D
M     ("!:'D  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .*!3E24'Q;EBP0  +H*   9              "
M@:69  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ XH%.
M5)[NIK_M P  X0@  !D              ("!9YX  'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    " #B@4Y4P.LQ\[P"  #*!P  &0
M        @(&+H@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( .*!3E3<\;:/8 (  ((%   9              " @7ZE  !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ XH%.5#S9KG!6 @  (08
M !D              ("!%:@  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    " #B@4Y46_,4"#4#  #="@  &0              @(&BJ@
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( .*!3E3\;YT4
M60(  -4$   9              " @0ZN  !X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ XH%.5$998TC) @  %@8  !D
M ("!GK   'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #B
M@4Y4AHLJ?-P#   W#@  &0              @(&>LP  >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( .*!3E0AB2>R:P(  #4&   9
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M970T,"YX;6Q02P$"% ,4    " #B@4Y4+GZ:9$0#  "%"0  &0
M    @(%:Q@  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M .*!3E2%)"_5LP(  #((   9              " @=7)  !X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L! A0#%     @ XH%.5$*.CEAP P  >@D  !D
M             ("!O\P  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M% ,4    " #B@4Y4]#I:1^<"  "2"   &0              @(%FT   >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( .*!3E12:E@9R@,
M -@.   9              " @833  !X;"]W;W)K<VAE971S+W-H965T-#4N
M>&UL4$L! A0#%     @ XH%.5("":MT/ P  E@@  !D              ("!
MA=<  'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " #B@4Y4
M_ENM"2P#  "B"0  &0              @('+V@  >&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;%!+ 0(4 Q0    ( .*!3E25DP.N_P(   4)   9
M      " @2[>  !X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%
M  @ XH%.5%@IH^3" @  #P@  !D              ("!9.$  'AL+W=O<FMS
M:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " #B@4Y46C?51V\#   1#
M&0              @(%=Y   >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+
M 0(4 Q0    ( .*!3E2L/B9X1 ,  -84   -              "  0/H  !X
M;"]S='EL97,N>&UL4$L! A0#%     @ XH%.5)>*NQS     $P(   L
M         ( !<NL  %]R96QS+RYR96QS4$L! A0#%     @ XH%.5)O,BO:7
M!   -"$   \              ( !6^P  'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( .*!3E0X@V\FQ $   T>   :              "  1_Q  !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( .*!3E2 A/B=P $
M   >   3              "  1OS  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@     Z #H S0\   SU      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>63</ContextCount>
  <ElementCount>320</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>28</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - Statement of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss</Role>
      <ShortName>Statement of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - Statements of Changes in Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit</Role>
      <ShortName>Statements of Changes in Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/StatementsofCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS</Role>
      <ShortName>ORGANIZATION AND DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LIQUIDITY</Role>
      <ShortName>LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104103 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2108104 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS</Role>
      <ShortName>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2113105 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2117106 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSES</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2120107 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES</Role>
      <ShortName>PPP NOTE AND CONVERTIBLE NOTES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2122108 - Disclosure - EMPLOYEE BENEFIT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/EMPLOYEEBENEFITPLANS</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2124109 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2126110 - Disclosure - STOCKHOLDERS EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICIT</Role>
      <ShortName>STOCKHOLDERS EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2130111 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2136112 - Disclosure - INCOME TAX</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/INCOMETAX</Role>
      <ShortName>INCOME TAX</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2141113 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2143114 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2205201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2314302 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/LEASES</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2318303 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ACCRUEDEXPENSES</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2327304 - Disclosure - STOCKHOLDERS EQUITY (DEFICIT) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables</Role>
      <ShortName>STOCKHOLDERS EQUITY (DEFICIT) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICIT</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2331305 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2337306 - Disclosure - INCOME TAX (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/INCOMETAXTables</Role>
      <ShortName>INCOME TAX (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/INCOMETAX</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - LIQUIDITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LIQUIDITYDetails</Role>
      <ShortName>LIQUIDITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/LIQUIDITY</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recapitalization and License Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRecapitalizationandLicenseRevenueDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recapitalization and License Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of the Company???s Available for Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails</Role>
      <ShortName>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of the Company???s Available for Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails</Role>
      <ShortName>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails</Role>
      <ShortName>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - LEASES - Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LEASESAssetsandLiabilitiesDetails</Role>
      <ShortName>LEASES - Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - LEASES - Maturity Schedule (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LEASESMaturityScheduleDetails</Role>
      <ShortName>LEASES - Maturity Schedule (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails</Role>
      <ShortName>ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails</Role>
      <ShortName>PPP NOTE AND CONVERTIBLE NOTES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/EMPLOYEEBENEFITPLANSDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/EMPLOYEEBENEFITPLANS</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - COMMITMENTS AND CONTINGENCIES - Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESLitigationDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2428413 - Disclosure - STOCKHOLDERS EQUITY (DEFICIT) - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails</Role>
      <ShortName>STOCKHOLDERS EQUITY (DEFICIT) - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - STOCKHOLDERS EQUITY (DEFICIT) - Estimate of the Fair Value of the Warrants and Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails</Role>
      <ShortName>STOCKHOLDERS EQUITY (DEFICIT) - Estimate of the Fair Value of the Warrants and Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2432415 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - STOCK-BASED COMPENSATION - Activity of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Activity of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2438419 - Disclosure - INCOME TAX - Reconciliation of Federal Statutory Income Tax Rate to the Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails</Role>
      <ShortName>INCOME TAX - Reconciliation of Federal Statutory Income Tax Rate to the Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2439420 - Disclosure - INCOME TAX- Components of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxAssetsDetails</Role>
      <ShortName>INCOME TAX- Components of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2440421 - Disclosure - INCOME TAX - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails</Role>
      <ShortName>INCOME TAX - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ck0001824293-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2442422 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS</ParentRole>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="ck0001824293-20211231.htm">ck0001824293-20211231.htm</File>
    <File>ck0001824293-20211231.xsd</File>
    <File>ck0001824293-20211231_cal.xml</File>
    <File>ck0001824293-20211231_def.xml</File>
    <File>ck0001824293-20211231_lab.xml</File>
    <File>ck0001824293-20211231_pre.xml</File>
    <File>vlon-202110k_ex231.htm</File>
    <File>vlon-202110k_ex311.htm</File>
    <File>vlon-202110k_ex312.htm</File>
    <File>vlon-202110k_ex321.htm</File>
    <File>vlon-202110k_ex322.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="353">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>69
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ck0001824293-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 15,
   "contextCount": 63,
   "dts": {
    "calculationLink": {
     "local": [
      "ck0001824293-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ck0001824293-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ck0001824293-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ck0001824293-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ck0001824293-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ck0001824293-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 356,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 10,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 15
   },
   "keyCustom": 10,
   "keyStandard": 310,
   "memberCustom": 8,
   "memberStandard": 20,
   "nsprefix": "ck0001824293",
   "nsuri": "http://www.vallon-pharma.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.vallon-pharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104103 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108104 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS",
     "role": "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS",
     "shortName": "MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113105 - Disclosure - LEASES",
     "role": "http://www.vallon-pharma.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117106 - Disclosure - ACCRUED EXPENSES",
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSES",
     "shortName": "ACCRUED EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120107 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES",
     "role": "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES",
     "shortName": "PPP NOTE AND CONVERTIBLE NOTES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122108 - Disclosure - EMPLOYEE BENEFIT PLANS",
     "role": "http://www.vallon-pharma.com/role/EMPLOYEEBENEFITPLANS",
     "shortName": "EMPLOYEE BENEFIT PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124109 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126110 - Disclosure - STOCKHOLDERS EQUITY (DEFICIT)",
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICIT",
     "shortName": "STOCKHOLDERS EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130111 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136112 - Disclosure - INCOME TAX",
     "role": "http://www.vallon-pharma.com/role/INCOMETAX",
     "shortName": "INCOME TAX",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.vallon-pharma.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141113 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143114 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2205201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309301 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)",
     "role": "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables",
     "shortName": "MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314302 - Disclosure - LEASES (Tables)",
     "role": "http://www.vallon-pharma.com/role/LEASESTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318303 - Disclosure - ACCRUED EXPENSES (Tables)",
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327304 - Disclosure - STOCKHOLDERS EQUITY (DEFICIT) (Tables)",
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables",
     "shortName": "STOCKHOLDERS EQUITY (DEFICIT) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331305 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337306 - Disclosure - INCOME TAX (Tables)",
     "role": "http://www.vallon-pharma.com/role/INCOMETAXTables",
     "shortName": "INCOME TAX (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "id84cb895052844b483a1ef69b0f12655_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - LIQUIDITY (Details)",
     "role": "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
     "shortName": "LIQUIDITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "id84cb895052844b483a1ef69b0f12655_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "id84cb895052844b483a1ef69b0f12655_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - Balance Sheets",
     "role": "http://www.vallon-pharma.com/role/BalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "id84cb895052844b483a1ef69b0f12655_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recapitalization and License Revenue (Details)",
     "role": "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRecapitalizationandLicenseRevenueDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recapitalization and License Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives",
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic638fa8850574f0f85cdf96878a4008b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)",
     "role": "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives",
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic638fa8850574f0f85cdf96878a4008b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "id84cb895052844b483a1ef69b0f12655_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of the Company\u2019s Available for Sale Securities (Details)",
     "role": "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails",
     "shortName": "MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of the Company\u2019s Available for Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "id84cb895052844b483a1ef69b0f12655_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "idef5c95d6a30458ebd4eb95332917688_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Narrative (Details)",
     "role": "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails",
     "shortName": "MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "idef5c95d6a30458ebd4eb95332917688_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "i7f49d0df94644a32ab3d051a753eeb16_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)",
     "role": "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails",
     "shortName": "MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "i7f49d0df94644a32ab3d051a753eeb16_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "id84cb895052844b483a1ef69b0f12655_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - LEASES - Assets and Liabilities (Details)",
     "role": "http://www.vallon-pharma.com/role/LEASESAssetsandLiabilitiesDetails",
     "shortName": "LEASES - Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "id84cb895052844b483a1ef69b0f12655_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "id84cb895052844b483a1ef69b0f12655_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - LEASES - Maturity Schedule (Details)",
     "role": "http://www.vallon-pharma.com/role/LEASESMaturityScheduleDetails",
     "shortName": "LEASES - Maturity Schedule (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "id84cb895052844b483a1ef69b0f12655_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "id84cb895052844b483a1ef69b0f12655_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:AccruedResearchAndDevelopmentCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - ACCRUED EXPENSES (Details)",
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails",
     "shortName": "ACCRUED EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "id84cb895052844b483a1ef69b0f12655_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:AccruedResearchAndDevelopmentCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "i4ff8206d11c1434cb0abe54052617449_D20210101-20210131",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:ForgivenessOfDebtInstrument",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES (Details)",
     "role": "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
     "shortName": "PPP NOTE AND CONVERTIBLE NOTES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "i4ff8206d11c1434cb0abe54052617449_D20210101-20210131",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:ForgivenessOfDebtInstrument",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)",
     "role": "http://www.vallon-pharma.com/role/EMPLOYEEBENEFITPLANSDetails",
     "shortName": "EMPLOYEE BENEFIT PLANS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "id84cb895052844b483a1ef69b0f12655_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - Balance Sheets (Parenthetical)",
     "role": "http://www.vallon-pharma.com/role/BalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "id84cb895052844b483a1ef69b0f12655_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic698111b087341fab1ee0949330016d5_I20211106",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claim",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - COMMITMENTS AND CONTINGENCIES - Litigation (Details)",
     "role": "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESLitigationDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Litigation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic698111b087341fab1ee0949330016d5_I20211106",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claim",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "i9318b4034bf247a7bf81e79df11bc14e_D20210212-20210212",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:StockIssuanceCostsOfferingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428413 - Disclosure - STOCKHOLDERS EQUITY (DEFICIT) - Narrative (Details)",
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails",
     "shortName": "STOCKHOLDERS EQUITY (DEFICIT) - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "i9318b4034bf247a7bf81e79df11bc14e_D20210212-20210212",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:StockIssuanceCostsOfferingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "i5f7f365dc72f44f98ddaa19c2a6fe7c2_I20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - STOCKHOLDERS EQUITY (DEFICIT) - Estimate of the Fair Value of the Warrants and Assumptions (Details)",
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
     "shortName": "STOCKHOLDERS EQUITY (DEFICIT) - Estimate of the Fair Value of the Warrants and Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "i5f7f365dc72f44f98ddaa19c2a6fe7c2_I20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "id84cb895052844b483a1ef69b0f12655_I20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432415 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "id84cb895052844b483a1ef69b0f12655_I20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ia48dc025b4ca46bfbb1119e73f604f09_D20211001-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ia48dc025b4ca46bfbb1119e73f604f09_D20211001-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ib7361a85c9d0470a8ca351dad193b452_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - STOCK-BASED COMPENSATION - Activity of Stock Options (Details)",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Activity of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438419 - Disclosure - INCOME TAX - Reconciliation of Federal Statutory Income Tax Rate to the Effective Income Tax Rate (Details)",
     "role": "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails",
     "shortName": "INCOME TAX - Reconciliation of Federal Statutory Income Tax Rate to the Effective Income Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "id84cb895052844b483a1ef69b0f12655_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439420 - Disclosure - INCOME TAX- Components of Deferred Tax Assets (Details)",
     "role": "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxAssetsDetails",
     "shortName": "INCOME TAX- Components of Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "id84cb895052844b483a1ef69b0f12655_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440421 - Disclosure - INCOME TAX - Narrative (Details)",
     "role": "http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails",
     "shortName": "INCOME TAX - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - Statement of Operations and Comprehensive Loss",
     "role": "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss",
     "shortName": "Statement of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442422 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "role": "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ib1b89a713dfe46188f25b2cff340c80d_D20200101-20200131",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "iaa705715f28d4b5eacce471c76e4867b_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - Statements of Changes in Stockholders\u2019 Equity (Deficit)",
     "role": "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit",
     "shortName": "Statements of Changes in Stockholders\u2019 Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "iaa705715f28d4b5eacce471c76e4867b_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - Statements of Cash Flows",
     "role": "http://www.vallon-pharma.com/role/StatementsofCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "role": "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS",
     "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - LIQUIDITY",
     "role": "http://www.vallon-pharma.com/role/LIQUIDITY",
     "shortName": "LIQUIDITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20211231.htm",
      "contextRef": "ic6464e0336a74a28aabe9f5d02ff9749_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 28,
   "tag": {
    "ck0001824293_A2018EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Equity Incentive Plan",
        "label": "2018 Equity Incentive Plan [Member]",
        "terseLabel": "2018 Equity Incentive Plan"
       }
      }
     },
     "localname": "A2018EquityIncentivePlanMember",
     "nsuri": "http://www.vallon-pharma.com/20211231",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued General and Administrative Expenses, Current",
        "label": "Accrued General and Administrative Expenses, Current",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "AccruedGeneralAndAdministrativeExpensesCurrent",
     "nsuri": "http://www.vallon-pharma.com/20211231",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_AccruedLicensingFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Licensing Fees, Current",
        "label": "Accrued Licensing Fees, Current",
        "terseLabel": "Licensing related"
       }
      }
     },
     "localname": "AccruedLicensingFeesCurrent",
     "nsuri": "http://www.vallon-pharma.com/20211231",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_AccruedResearchAndDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research and Development Costs, Current",
        "label": "Accrued Research and Development Costs, Current",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "nsuri": "http://www.vallon-pharma.com/20211231",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliate of Medice and David Baker, CEO",
        "label": "Affiliate of Medice and David Baker, CEO [Member]",
        "terseLabel": "Salmon Pharma, Affiliate of Medice and David Baker, CEO"
       }
      }
     },
     "localname": "AffiliateOfMediceAndDavidBakerCEOMember",
     "nsuri": "http://www.vallon-pharma.com/20211231",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]",
        "terseLabel": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.vallon-pharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Promissory Note Purchase Agreement",
        "label": "Convertible Promissory Note Purchase Agreement [Member]",
        "terseLabel": "Convertible Promissory Note Purchase Agreement"
       }
      }
     },
     "localname": "ConvertiblePromissoryNotePurchaseAgreementMember",
     "nsuri": "http://www.vallon-pharma.com/20211231",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_DebtInstrumentPaymentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Payment Term",
        "label": "Debt Instrument, Payment Term",
        "terseLabel": "Note, payment period"
       }
      }
     },
     "localname": "DebtInstrumentPaymentTerm",
     "nsuri": "http://www.vallon-pharma.com/20211231",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ck0001824293_DeferredTaxAssetsLeaseOligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Lease Oligations",
        "label": "Deferred Tax Assets, Lease Oligations",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseOligations",
     "nsuri": "http://www.vallon-pharma.com/20211231",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_ForgivenessOfDebtInstrument": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forgiveness Of Debt Instrument",
        "label": "Forgiveness Of Debt Instrument",
        "terseLabel": "Forgiveness of PPP note"
       }
      }
     },
     "localname": "ForgivenessOfDebtInstrument",
     "nsuri": "http://www.vallon-pharma.com/20211231",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_LeaseCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Cash Flow Information",
        "label": "Lease, Cash Flow Information [Abstract]",
        "terseLabel": "Other Information"
       }
      }
     },
     "localname": "LeaseCashFlowInformationAbstract",
     "nsuri": "http://www.vallon-pharma.com/20211231",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ck0001824293_LocalTaxAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local Tax Authority",
        "label": "Local Tax Authority [Member]",
        "terseLabel": "Local"
       }
      }
     },
     "localname": "LocalTaxAuthorityMember",
     "nsuri": "http://www.vallon-pharma.com/20211231",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_MediceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medice",
        "label": "Medice [Member]",
        "terseLabel": "Medice"
       }
      }
     },
     "localname": "MediceMember",
     "nsuri": "http://www.vallon-pharma.com/20211231",
     "presentation": [
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_PaycheckProtectionProgramCARESActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck Protection Program, CARES Act",
        "label": "Paycheck Protection Program, CARES Act [Member]",
        "terseLabel": "Paycheck Protection Program, CARES Act"
       }
      }
     },
     "localname": "PaycheckProtectionProgramCARESActMember",
     "nsuri": "http://www.vallon-pharma.com/20211231",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_RelatedPartyTransactionLicenseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, License Agreement, Term",
        "label": "Related Party Transaction, License Agreement, Term",
        "terseLabel": "License agreement, term"
       }
      }
     },
     "localname": "RelatedPartyTransactionLicenseAgreementTerm",
     "nsuri": "http://www.vallon-pharma.com/20211231",
     "presentation": [
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ck0001824293_RendonVVallonIncEtAlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rendon v. Vallon, Inc., et al",
        "label": "Rendon v. Vallon, Inc., et al [Member]",
        "terseLabel": "Rendon v. Vallon, Inc., et al"
       }
      }
     },
     "localname": "RendonVVallonIncEtAlMember",
     "nsuri": "http://www.vallon-pharma.com/20211231",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Payment Award, Number of Additional Shares Authorized, Based on Percent of Total Shares Outstanding End of Prior Year, Percent",
        "label": "Share-based Payment Award, Automatic Increase in Number of Shares Authorized, Based on Percent of Total Shares Outstanding End of Prior Year",
        "terseLabel": "Automatic increase in shares authorized based on percent of total shares outstanding on December 31st of the preceding calendar year."
       }
      }
     },
     "localname": "ShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedBasedOnPercentOfTotalSharesOutstandingEndOfPriorYear",
     "nsuri": "http://www.vallon-pharma.com/20211231",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ck0001824293_StateTaxAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State Tax Authority",
        "label": "State Tax Authority [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateTaxAuthorityMember",
     "nsuri": "http://www.vallon-pharma.com/20211231",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_StockIssuanceCostsDiscountsAndCommissions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issuance Costs, Discounts And Commissions",
        "label": "Stock Issuance Costs, Discounts And Commissions",
        "terseLabel": "Stock issuance costs, discounts and commissions"
       }
      }
     },
     "localname": "StockIssuanceCostsDiscountsAndCommissions",
     "nsuri": "http://www.vallon-pharma.com/20211231",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_StockIssuanceCostsOfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issuance Costs, Offering Expenses",
        "label": "Stock Issuance Costs, Offering Expenses",
        "verboseLabel": "Additional offering expense"
       }
      }
     },
     "localname": "StockIssuanceCostsOfferingExpenses",
     "nsuri": "http://www.vallon-pharma.com/20211231",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r207",
      "r245",
      "r294",
      "r295",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r446",
      "r485",
      "r486",
      "r497",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r207",
      "r245",
      "r280",
      "r294",
      "r295",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r446",
      "r485",
      "r486",
      "r497",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r207",
      "r245",
      "r280",
      "r294",
      "r295",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r446",
      "r485",
      "r486",
      "r497",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32",
      "r413"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of marketable securities premiums"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued Liabilities, Current, Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails",
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Abstract]",
        "terseLabel": "Accrued expenses:"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r48",
      "r49",
      "r50",
      "r477",
      "r491",
      "r492"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r47",
      "r50",
      "r57",
      "r58",
      "r59",
      "r94",
      "r95",
      "r96",
      "r356",
      "r487",
      "r488",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r316",
      "r317",
      "r318",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r297",
      "r298",
      "r322",
      "r323"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r203",
      "r259",
      "r266"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of Underwriters Warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r298",
      "r313",
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r89",
      "r133",
      "r136",
      "r142",
      "r161",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r354",
      "r357",
      "r378",
      "r411",
      "r413",
      "r461",
      "r476"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets [Abstract]"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r45",
      "r89",
      "r161",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r354",
      "r357",
      "r378",
      "r411",
      "r413"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Assets, Current [Abstract]"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r154"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r151",
      "r168"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Adjusted Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r148",
      "r152",
      "r168",
      "r466"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r150",
      "r168"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities, available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r28",
      "r78"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r28"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents, and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r72",
      "r78",
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r72",
      "r379"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant exercise price (in usd per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants granted (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r41",
      "r181",
      "r467",
      "r481"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r189",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common Stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending Balance, shares (in shares)",
        "periodStartLabel": "Beginning Balance, shares (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheetsParenthetical",
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, $0.0001 par value; 250,000,000 shares authorized; 6,812,836 and 4,506,216 shares issued and outstanding as of December\u00a031, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r52",
      "r54",
      "r55",
      "r61",
      "r469",
      "r483"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computers"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r124",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r81",
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Conversion of convertible notes to common stock"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r81",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Convertible notes, converted, shares issued (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r85",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r221",
      "r228",
      "r229",
      "r231",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "PPP NOTE AND CONVERTIBLE NOTES"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r88",
      "r92",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r233",
      "r234",
      "r235",
      "r236",
      "r387",
      "r462",
      "r464",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r206",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in usd per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r204",
      "r233",
      "r234",
      "r386",
      "r387",
      "r388"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r38",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Note interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r39",
      "r88",
      "r92",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r233",
      "r234",
      "r235",
      "r236",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Note maturity"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Debt Securities, Available-for-sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r16",
      "r17",
      "r335",
      "r463",
      "r474"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTerseLabel": "Less: deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r338"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r342",
      "r343"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "Federal and state net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r342",
      "r343"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Share based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r342",
      "r343"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accruals and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Less: valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "terseLabel": "Defined Contribution Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Company contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer matching contribution, percent of employees' gross pay (up to)"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]",
        "terseLabel": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "terseLabel": "Embedded Derivative Liability"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails",
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivatives Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r299",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Activity of Stock Options Granted"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r62",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r107",
      "r109",
      "r111",
      "r112",
      "r113",
      "r116",
      "r117",
      "r367",
      "r368",
      "r470",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share of common stock, basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r62",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r109",
      "r111",
      "r112",
      "r113",
      "r116",
      "r117",
      "r367",
      "r368",
      "r470",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share of common stock, diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r114",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r90",
      "r328",
      "r349"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Expected income tax benefit at the federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r328",
      "r349"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r328",
      "r349"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Non-deductible items and other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "auth_ref": [
      "r328",
      "r349"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent",
        "terseLabel": "Prior year provision to return adjustments"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r328",
      "r349"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State and local taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation, weighted average amortization period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r57",
      "r58",
      "r59",
      "r94",
      "r95",
      "r96",
      "r98",
      "r104",
      "r106",
      "r118",
      "r162",
      "r259",
      "r266",
      "r316",
      "r317",
      "r318",
      "r346",
      "r347",
      "r366",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r487",
      "r488",
      "r489",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails",
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails",
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails",
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r371",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails",
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r371",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Activity for the Liability Measured at Estimated Fair Value Using Unobservable Inputs"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "auth_ref": [
      "r373"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3",
        "terseLabel": "Transfer out of Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Additions during the year ended December 31, 2021"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance, ending",
        "periodStartLabel": "Balance, beginning"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r390",
      "r400"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/LEASESAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vallon-pharma.com/role/LEASESMaturityScheduleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Present value of lease liability",
        "totalLabel": "Total finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESAssetsandLiabilitiesDetails",
      "http://www.vallon-pharma.com/role/LEASESMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease Liability [Abstract]",
        "terseLabel": "Finance Lease Liability [Abstract]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r390"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/LEASESAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturity of Finance Lease Liability"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r390"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/LEASESAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Non-current finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r400"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/LEASESMaturityScheduleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vallon-pharma.com/role/LEASESMaturityScheduleDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r400"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/LEASESMaturityScheduleDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r400"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/LEASESMaturityScheduleDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r400"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/LEASESMaturityScheduleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESMaturityScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r393",
      "r396"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Payment of finance lease liability",
        "terseLabel": "Financing cash flows from finance lease payments"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESAssetsandLiabilitiesDetails",
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r389"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Non-current finance lease assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r392",
      "r395",
      "r401"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Operating cash flows from finance lease amortization"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESAssetsandLiabilitiesDetails",
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r398",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate - finance lease"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r397",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term - finance lease"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r169",
      "r170",
      "r171",
      "r172",
      "r230",
      "r257",
      "r365",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "negatedTerseLabel": "Revaluation of derivative liability",
        "terseLabel": "Revaluation of derivative liability"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss",
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r76",
      "r237",
      "r238"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Forgiveness of PPP note"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r176",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r331",
      "r332",
      "r334",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r329",
      "r333",
      "r340",
      "r348",
      "r350",
      "r351",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAX"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAX"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r56",
      "r326",
      "r327",
      "r333",
      "r334",
      "r339",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r71",
      "r73",
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Finance Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r35",
      "r89",
      "r137",
      "r161",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r355",
      "r357",
      "r358",
      "r378",
      "r411",
      "r412"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r89",
      "r161",
      "r378",
      "r413",
      "r465",
      "r479"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r37",
      "r89",
      "r161",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r355",
      "r357",
      "r358",
      "r378",
      "r411",
      "r412",
      "r413"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Liabilities, Current [Abstract]"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes Payable, Noncurrent",
        "terseLabel": "Note payable, non-current"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Pending claim"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Dividend rate"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected term in years"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal bonds"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r121",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r72",
      "r74",
      "r77"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r51",
      "r53",
      "r59",
      "r60",
      "r77",
      "r89",
      "r97",
      "r99",
      "r100",
      "r101",
      "r102",
      "r105",
      "r106",
      "r110",
      "r133",
      "r135",
      "r138",
      "r141",
      "r143",
      "r161",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r368",
      "r378",
      "r468",
      "r482"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss",
      "http://www.vallon-pharma.com/role/StatementsofCashFlows",
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Note payable, current"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r133",
      "r135",
      "r138",
      "r141",
      "r143"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r36"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r46",
      "r48"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on marketable securities, available-for-sale"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss",
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r36",
      "r413"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashExpense": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.",
        "label": "Other Noncash Expense",
        "terseLabel": "Non-cash interest, depreciation and other expense"
       }
      }
     },
     "localname": "OtherNoncashExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriters' Allotment"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r66",
      "r67",
      "r149"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "EMPLOYEE BENEFIT PLANS"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/EMPLOYEEBENEFITPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r299",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r26",
      "r27"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from convertible notes"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from common stock issuance, net of offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from issuance of warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Proceeds from PPP loan"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r30",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r175",
      "r413",
      "r472",
      "r480"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r29",
      "r175",
      "r495",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r284",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r284",
      "r405",
      "r406",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r284",
      "r405",
      "r408",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r403",
      "r404",
      "r406",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r325",
      "r447",
      "r499"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r266",
      "r319",
      "r413",
      "r478",
      "r490",
      "r492"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r94",
      "r95",
      "r96",
      "r98",
      "r104",
      "r106",
      "r162",
      "r316",
      "r317",
      "r318",
      "r346",
      "r347",
      "r366",
      "r487",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r131",
      "r132",
      "r134",
      "r139",
      "r140",
      "r144",
      "r145",
      "r146",
      "r277",
      "r278",
      "r448"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue recognized",
        "verboseLabel": "Licensing revenue \u2013 related party"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRecapitalizationandLicenseRevenueDetails",
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r84",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Licensing Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Federal Statutory Income Tax Rate to the Effective Income tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r298",
      "r312",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r298",
      "r312",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Investments [Line Items]",
        "terseLabel": "Schedule of Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.",
        "label": "Schedule of Investments [Table]",
        "terseLabel": "Schedule of Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r30",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r299",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r42",
      "r86",
      "r119",
      "r120",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r252",
      "r257",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted average remaining contractual term\u00a0(years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Exercisable, Ending Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Exercisable, Ending Balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r304",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, Ending Balance (in shares)",
        "periodStartLabel": "Outstanding, Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, Ending Balance (in usd per share)",
        "periodStartLabel": "Outstanding, Beginning Balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r299",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Fair value of option on grant date (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Stock awards, contractual life (up to)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r308",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, Balance Ending (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, Beginning Balance (years)",
        "verboseLabel": "Outstanding, Ending Balance (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r44",
      "r57",
      "r58",
      "r59",
      "r94",
      "r95",
      "r96",
      "r98",
      "r104",
      "r106",
      "r118",
      "r162",
      "r259",
      "r266",
      "r316",
      "r317",
      "r318",
      "r346",
      "r347",
      "r366",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r487",
      "r488",
      "r489",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r118",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r43",
      "r222",
      "r259",
      "r260",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock for convertible notes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common stock for services (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r259",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock for IPO, net of issuance expenses (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r44",
      "r259",
      "r266"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock for convertible notes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of common stock for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r259",
      "r266"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock for IPO, net of issuance expenses"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r23",
      "r24",
      "r89",
      "r147",
      "r161",
      "r378",
      "r413"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets",
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r87",
      "r244",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r258",
      "r266",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRecapitalizationandLicenseRevenueDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.",
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "terseLabel": "LIQUIDITY"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r155",
      "r156",
      "r158",
      "r159",
      "r160",
      "r230",
      "r257",
      "r365",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r122",
      "r123",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedTerseLabel": "Valuation allowance, increase"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrants outstanding, measurement input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants outstanding, term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDEFICITNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r108",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r107",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=51888271"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r500": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r501": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r502": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r503": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r504": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r505": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r506": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r507": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r508": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r509": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r510": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r511": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r512": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r513": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r514": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r515": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r516": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>70
<FILENAME>0001824293-22-000004-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001824293-22-000004-xbrl.zip
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M.U63]:>$_SR%?X+UTV!#X_<$\FP!R(&C:XKE@_)K *0-P[9DSS(56?>I:9H
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M:)LJB'ME1]',$E5*W+B3&P2.X7N.:RJFYAB&9S@Z48'?N)X2JIIEFM\Z-YE
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MG8DW!^!?H$4#]%E-P6)J,/)TP_<4XE'34$S-4FUCH51245="??AY'L9Z!#S
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M,7Q;,T/ ,LT*7'0/*Z8?!*$6F#YY.G_PSXJHYTH>>!3G] ^TZUI?</1!#+>
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M#VURA0I($Z]C&BZ>33JY/ZI\A85Q\?S74/P)^&0K2:8D/J23-"NVI##-QJ2
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MCF.30)%U/51D0[=LV?&T0#8\PZ*J"XI6J&^]<S3\"1W%#X7GRQ/DK#L2Y'Z
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M#\8_M;50]3?,Z &9T>6(LIH(9!1U&$MZI0H>,@(%"'E1()$XKAA2DU-Y5%P
M"R]A3HO\J*$OE780\BA4I[#;AQ3 K\DINW2249\RGZZJ\358IZU<>@4KA_!/
M/O5'4CY*L3JY;*E1C$AQ\WTN2;[(7MG-XI5>;[.BCU=:X[T]2@%,4^\,W@IO
M8M?C5 ;8CU@,N^SD;"=LNR0O)%?A*P1DEL_SW4=G)J)C&6_V@PZ7@A33WXRG
M8(&_^2TP; OT%E^VJ89Y()8NN[H+?(3J=FCIKN;89.L="+\59B2K) =[Z?,?
MS+R6L+YLMJ'X(9<!!C..B@+X$HV!T61I@DZR>";1"YK-I YZPG DRP65]DA!
M>.>9&PRX7J.I*BY8J\ 0IS&OVQK(0^D5_FC_H>G:3F7.1JS9PP2;/3P<(\YN
M9\1\YQ5KI?GK'4EZ(G;9.%H\6<$]?S]VJ7\CKDE<'QOKF*HI&XYBR2[8?;+E
M6[YG**%M*-ZJLDOI.?EE+_W1QV^8X6W,D/GB8M@XE8CO S/,<"X5XPKHB$N6
M?@N&<R(O_2$? Q>%IV2E-@0<9 R',$.M%%8#W0W/Z%0ZS=++8E3^N@/Z*65;
M8WX_UJR-Y;AA:I<&;WG+!MG/ZA_E9=^]X-;ME=>A.BJNO66KY95SCDE5\V2M
M=$TV]>N='T"6M:FK59T=W7CX]C>:NV.8#Y^GI!D[QB,TZ]'T'5U][/2G7TSW
M/YOF113.GHD1?5Q.M ]1!B%>[&D[RMY+)CQ'5<?S@KGU^P'X-R7H)VFYF>T"
M)IVFV6RQ+18?5<EPS!<7K75SK..S..YI^'TO.CX[FO4.VI<]K:-WSSZ,3H8M
M]>3K\77W:V?6'2^T#8KZ7X_T$[0HM ]1#TLNABW]^,R':_?C[MZ7^.2L>W5\
MUIF=Q$M2O725F+[A$MG6-5\VJ.U@EW]%)HH=FA8Q==UQ4<U>HN3=7:2Q]L1^
M]1LS\L%MRO$+@_&CLS%VD.^G.3PYSU_@J*&GXULWVIUY&L49]R'PK<"6#9UJ
MLANHNAQ2G9B.:EBVZWYOU-##]^/ZM2SVM689[>4V\H9A_!C#*(_Q@)WB+C_$
M#>/X6<8Q6^R3:/K4#7PB!YYOR(:E4MES7%L.O2!PB:>X5#?OQ3A6/,6P$][A
M9,-JR'OFQF"(A 5&0.W#))DBE:8Y=] !YO.I74O&*J09>U8\PX=?1O!H]/PE
M\&XIJA474<[4R(0D?D1B= U@%UR\&*?)!R0+<@G;WD;!G=6,^BLR']R>\[@]
MIU_\\3G%53U>AL\T>UGC97XEI')\^<US_,!RM$#6;17HW"&&[ 2J(RNF[?DF
MU;50=;\['F9%2?N'8YPB@T3H\Y+HL$F*@F)_::1;H"QL- ][(Z<LJZ*JI"9Y
M#KHK?E5ZM6D84A:U2T3Y.=X983 O 5)&3,_26$I!7#<HO#8EV)3[*L'94(Q7
M7I7A/""91V!9N7\5TQE+2WFEFM+1S@ G6MN:A>7+K_'%Z[<4N=->#&36X"-A
ME(UY"'0"SR9X$; >EE<<L!V3:1 58E^"53Q3,.D1>47'#[,6OFB:M6IP[\?D
M=,,M^/"\WMEGLWMVK/?V8#]GY[-OH6&;NJDHLN49(9@6-I@6.E6!<VAFX%DV
M\57K-LXAW2LQ?VUX!PL)YB,:QU7P[M5M&?FW!KY>EUE8*Y'K^O@F/Q[7'8K[
M;TAC*)&OOH%R'?@&=60K4 *0R)8B>Y2:LJT0W?-<70/E^WL2>75SLE8B96U%
MF4Z+:0D?I@FV\^1S1J57R"9B3-CTA'M,"LBLY!_98D>7<9JCM,;2Q'C&C0N*
M1DE.@88#,5!8^L^43\K99LN0TU-8"=G=F)6+B0KEVQ_B\YKF'&N:)2!DEE7+
M4AQ"3#R%E7*60D4F8)Q<14#:%#;S3\%4]EDV$]P_32+.4J8Y:.5S/,8R%5OS
M0DI"G1B&:9/ (JY-X&^?.HZF?.LP'F/IRA;P61\>$>?_VI+-14;SB:D\^W%*
M;@R63*9C.4@+6=R^)>')P*W6[\5U;F:WZ]]TCW@FZRAJAA1'1BH 5\U@I38J
ML:BK*6#[:]I.-1VAA*A@ D ;,<+7(VB^HMI<(C%7(Q$=X:BQ'Y-_;S03R_1(
M'I#_W*AOQ!_GZ.9'LDB>C]3WJ9<!(<XD567;UJI.K(LDPEH$Y#>HA'B>K=D!
MU0+#-0S5(Z9E.I[KF41U=,_2&94P&=RDDDYO?TE2-CMKUJ5@P![5GQ;,QP!\
M]WYTH_S.='/6OOX&>I'O*)C#[6,-O*FK,B$@PU7%L4-/TWT:@.2VMAU5VW9T
M:X%X>!N(O"2()>VZFKTDI$NPZ*2TAM+]JEU7I#_5K\P]^^%I N4%@@3U.Z:N
MB!<7KP)72D$ZQ8.Y?;3)W6Y.\4P#3V62<C_4VXQB?O,%K0_CO^?#%^+Y2GT+
M\?(TGA:WW[*THGEI@[_&O_%^1K2.;X.\54T+,,T@MN8:INFHMFK8:A &Q/QF
M;Y7WC+(Z&'%*92^CY!P$!&#16Q)?DEF^]69^8["KYBG\T LL8<QA^&B,F1,&
M,#8Q8>4M<\+@5; =LC)[D489LO]_W MJ0_+G&[*VN_?6>?.\Z]DN2NRDR-F;
M_% _@MNI=Y5&FMPR;[OU_F,;1V/O]GO#=F\X6-W1H\M?X.ZQJO<%X]I(5579
M,=V'SR6V[1U#<1Y\66?'<A\TE?C)LA=6<'[A)Q#CI:]FYT=2/SSBGY]F*7!'
M6>S5]RD%QOPCO9J^M\8],T"J$_RY5DT/)$V6'?!S*14_N)?[2S95V7K7ZP_;
MTF'[H'6XU^D=2/O]PZ_PI_RQW_\;/P^&K6&[R]G^3:GW,\AP:T>O.U3R'\';
MD/W?K^'MC34V>+MJ>.O8^M:[P\[@;VF_M3OL'TJ#HVZW=7C\BRAZ%^YL&.@&
M$9<@HN5LO0/,^[L]1'UR[V@P/#R66KT]J3_\JWTH[;6&K8?AFX_*'7_*?-EP
MU!>$R*J.LZ(.AUQ[[)3!O8=DIP\#] S?>^-2>BB8J[? ^%?%W2\ >^,]?!Q0
M=];6 8>[!R-DK?<O<H9V'E8;>+ED]OYHT.FU!X.5.*N-_'D4LK >4/X\G+*Q
MXH2QGJ!VUUK^N&LN?]Q*_K1^50#]-G36<"_]BA#:&$&K3QOZQ@CZ'4"M:>LL
MA'#W((2DM7X!]?W& +HGB1WU#MN#_L<O[3V,P>UC^D6WNYA^L;&(7AB'PG32
MC4GT&\#:7&MI9*ZW283[YR:1MK&([DEFGP[[G]J'PTY[8P^];+;T<"+HM]'6
MUA/6SEJ+(&?-19!3BB!]8Q3=D\P^M@]:'R401+OM-J8K;HRAE\V=-L;0[P%K
M75UG282[7V=)A/L7<ULVQM ]R:S;Z;6E06N_/3R6]CJ#W8_]P='AQC)ZX3SJ
M>_*H?"WQ;/>N^N2GR!A_\#4V]1B;[.$EI&'P[&&ITUD9^;%A@H\%:=U^7O?0
M=UI$KQR@.Z@;KB6P[5(O-#<>BA=-U0#H-39?8/>LR@K+L+" %<M9.X/A8:LW
M% UW!BQZWN])[<]'G>'Q-ESQL35DH?7^[M]_]3_NM0^E;FLX;!\.6/E69S X
M:DN?C@YW_VH-V@-L?\!OE0;MW:/#SB]&03:^I]5'J8<3<[^-4;R6L#:4=?8]
MX>[7V?>$^^<ZAK7Q/=V3S/[O87O0/OS2WOM_*W%:&Q'T6(3QW);6&M+&>L)Z
MK<LSC34OSS2J\DQ[8^:^=#);;S1E9FZO=< Z,E6V+<:?C@:##MBW:+NV>JV/
MQX,.,UKW.[U6;[?3^HC=^_; ;!77@ 9Q]''(+L&DOA;^L#%H7S;J;PS:WP/6
MSEJG]3EKGM;G5&E]]J;8]L73V>>UQM,CW'VK-^P,00'XTF::P>>CUL?R<YW8
M(K7>]X^&$F]U)F%M]$J@]499>"S4,(R-Z^%W@+6[UIF7[IIG7N+^G8W3X:43
MV/Y:(VB'.QVX&Z'N!\VTA<'1IT\?V>?6X;%H=[H"B+S1"QX+&1Y.+]@8-RL-
M:V.M]0)CS?4"HW0BN!L?PDLGL]VU1M._N _AH#V0.CRVL-<9M X.VT)+^-H9
M_B6U=G?[1Z CX!<8@> ?<;X$WE '*6J'PTI@_$:->"RLV;@7?I\T<K=*(W=_
MV2/^VT![;2&]QM(,=M]GMN[PL/^1V[>LU<#>+U9V;NS:U0?\QJ[]/6"M*FN=
M[LVVO\Z6+7L!H0W\<C/0#:FM/*C[ZXVI0]P^3O+J]/;[AUV6)[<2"+O1!!X-
MYL8*M;_;0/4AH*HQH8_=L]W=Y[= -S!],)@V$I3F1MBV.P<]Z</186>PU]EE
MN<W2\*_6$,RY]I=V;PC<?/"IO2N2GE?$(;'AZ(^')]]CZ>6+_53?GD=H<?/@
M:VS&UV[Z]BQ3=_2J<<^O=N[9,,(59X0(:V-3 O+;A%U4Q:K&?BD;3\L]P;W7
M.6RSF5_;4OO?[=TCE@??W]_O[):M87;[AY_ZAZUA6SKH?VD?8NAZ$ZU^R7S3
M>DB^^=L$,->8;];C$C?S>E\X;0.HVVOLH8;M_QNW7PJJW7[W4[LW^%4W]4:7
M7P/ FP\VMO+G5)!-&\ZG@K:J50)I,ZWJ91,V@GJPO@()M\_D*>N1>2SUO_;
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M>*=@(L@-&FNQU_T!Q>:!E+YET190 CZUF3>JUQ_>:,'Q%?Z4/_;[?^/G>FK
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M O=\S7,H4A2H'#2.!J[DNVU@^_8<UT*G2</TXVX;! *<8;[1^Y^09=$KU.D
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MY/%SD89Y.EX@XW1:,+8A3/*CG<$.,'_I@F01Y>J&B"CE>>HWJ@"Q1"=+B$C
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MCB3KW)3K\>(50DTO;X_$0K1BA@[*IJ-3QE/M8KCV[?YSSM@V1OXZ%%86]7D
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M,@?/JN^.S9[>8FK!AS"AB6WV7I9WT#@].#V)31L_KYU^#N/A&^<"G4]M!Q-
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M_,%-N4I 9.X0!)VJ=A I\#3>1^01\ P#-N!\0$5QE.S$>CH\+2?<Q6@6%&"
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M%%X0I0#7@;#.K!M4G 5QOZCVU)Y#CZ5J/O<YC:$PI?3WDVU73N STSJA<X6
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MTI1I.YO+.$;[V8SXNGD*82J<F9FNZ/N*W\\C$FIS^!,:(5JRM^7M )AP!H[
MD(8;P32HV^'*G*YNJM>)12]Y#=0X?6&.7:<QRWN,6<N+Q>J/W_^P.,LTGGF
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MUIZ[;]*K']!4%Y8&+A=*T LI03E/DEP!X(<;ZKB%:,A,D'?%#<D;@0<RE0L
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M /7?!99K6-RO%E]\__V++_5F9;!QW,7V<&Q?Y0D_/>A!,![1VU@#\^:/H]-
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M,S/*J(B0A<8\U/XA@C-WEHZBRPOF"*U! KHLJO!S.$*J05C.Q26E3JSSD@5
M^.V=I:%E3^[Q<+1C/4>.LNP%@CD&=UFH.JM'!AJIV-/D;I:2=3?\@/MXQC((
M:UEZ"@[>C:0WO2&?T]ZU-2:!,AFGU92BS3Q-:)??.X,;<\-<$=F/BU0\>NH\
M2[FJG< +>-DF#0!B<BP^D9U5!(<N^>H,##/%IETWB5%:8;IGH_4%O:D!8JE6
M87("_ )1KC]D*#?;EG(&N;\>Z-#!7?(-/VHLF1S6?7EE]+=LR!@UUC*[CL7D
M25"GS-C!4>*-%M%?&5MC.;"KXMRKQX4LDZ5@,V9_WW'Q]2!B6_5SIU#FG)D>
M!E&RK/;HS#N8)9N=TD0)"L^:W$*KI9QH:J(E9]V*KJ@[IX692Z'343\S;?%^
M .3=S_4=SC57][E9RF,QR-OH*S^)$,6E?-E,-,CGSF"C>F/6 8;@Z/N7Y)&^
MK(DX 7\Y_G[?9W6'T\P3ZP_(H.L<LT"PTVE+ R%,\LD1NR;VD_FU)O/21R@V
M7V"09)=9[( 1IX*@ALFE36_ W\NP>K; N%;,YN$E3_8'\A\SX3Y:<9N5,<U#
M+1D42\4!ITR%VX5H8J$O[T%7VT!7W^Y!5WO0U0X\_1YT=0O0U?X0^8)#A,5[
MUKW@@SGFIIKGKJ>S(I004CZ:N5%(M9+',*@;/#&-[RQB3B7N5IG-BG6G4*HI
MKU9(9^CB,4C;<QV-:5%8M$D)O<$I(S'3#+\(':CW+A_[+H#%6H/WUC@>92/N
M'.,4*O=A+'66- 4^),!CWBG#"L]YO4@\6; F[B^7P?4)O,&J]&0;E!1'N-S<
M/[GC]S'622(J0)YFQ*<3>+U\NOJ"6PB%PBMY</+RPT.&@&I1L5B&PI?M+J',
M=DLWIP^D)"BPQFP-6G^OON8^8:$0KBNC,\>M?\JJ2JC(524E-V>FK&*YYN9/
MQ18,"O*AB4!S ]<\11HKR@2!'6K?61$]X'E3]VLJA0&7&=HZA" XL/-0L2DC
M8?A3HEGRB6EZH:8@HY'TU:>JOJQ2=W'&QIT5MB!PN2#,@ VN-.F=)<N,^GM,
M/KJHUW2ODVHP;Q22591)-PI2J"XUI>JU4&9=%3N&[&E=$ K,&$W$+9FCD:-L
M.>K]5&%:%(PO8%5X+JD96F93YS1#-O'P;" AN++/E7^UH(_F&1B9*DJH>7;,
M?;S]M8:>NZ#<BL^I_*_;Q@C+@ML-E2::D?U$?-6) %!I/\9?=8Q#C\#5^:+]
M8/^VP19!X&4V YZ2#GRX,7S,4Q<L^:K<]KSC'NM++LX;#M54.G(4%T3<U](\
M3-!=,'.25-3&MCE;KW?@(IEV6Q")0"3,P'1P0@HG]KU4HG[G^X2&'1\FU'%N
MO0<T:_&5PZIQ&"5QEW'D3+N/,.-VY4K$%]$0[MSS<S_&<L6@9D$WCRA_6ZH/
MG)\738!YY(2E0GL_R6$FSH@T(;Z.9I1JP85;#])4HNPH\X":\AS5&@;*$T77
M:8-XS_"VM"1*;9GWBO($Y)HW&36>R.4AJ!+N,:O/*T)-Z<@*C4C\/ID\#&*A
MZ('2!+I@DBF8F_X)_@5/10_@939TIID:I9208/ A [)=A%%Y4X'"S KM0/2F
MA%$;:H?'D_YZO@V&)BDA"2##4FA#+PN[^M#55::94/<;-*.E$ZUHDVPUQ)<_
MT1#&A/*M!Q5P]YBG>8Q(>"_J641*FSL3@XZ8(FN8;-OHM%*<693_(XO-CH[T
M_BRAQAU^;7],/XG!9W^"/([L$7FO.+<24V91>Y'\ZWCP!(=U42_=S&>->Q6,
MG%8,F\)W6GD<9N/[-P(1$B'0I2J]295<2"-N) QH)*B_1U((J%D;,%EXHDC_
MTB+ =%^1E#E+8/9WYQS\[?_=^;/IH\G,J9"P2DY,SASA"3#NL/LZG6Q?;4N;
MKJ0(KVJ.OPA$2SVG*F*:%ZQ/,!/^5_??1?A!27^@"8_Q@Y1[,<][0)(#F9A1
M7;8;?2J3U[#-SR(PW5>2/P:+,W7$>-2+B(J018L@$C&.L6@::(743<!+Z4MX
M#?OH+1G?36O],/G VU&1S(.]*"E0AE33?;/SPK=V3,G@HH2,;5(ET_*PH5B0
MVM:>D,X>7-NK)<9ZE[3ARF:(5N;G+N)WH#96I-,/O#_,*4$6<75O53'%F=><
M@*8$*VV)_HKXEJ(NT<8G_E R4A](>V4'D(HS0BJI%&0KIP7.0NE LSEH3S^6
M!3!-,#;TC&)M*?O8>GT9,R;GSOMO!)A.O35W?\Q<:2%>!):X+9SF>,G V-,,
MTYWLS G >DHU!&WUK.O,2XIQ:4$R6;GWE;&.')SH&C267>V&I(U79;B(5G9R
M*>3 4TM5HH!="T\SA)5(+0GPPK""8\X_H3;2EBO11#&.RI>H=-[A,?#'3O+
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MM4,,^<F#)S=Y1,ZJA T.;@+PM<WG+N)W/G\]<VZH"Y8>^(?]$0OAO;S,5T[
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M>)P#PP>SA;-;8X!1I(*9-8UHMV25<!Y>>BD>8M)R<[?KNX.F4=>6P1">E?6
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M>N1O=&2QL!ZT#Q46I7/XO?OV\.OR**S_9D3U9"'JU?!3]]M0<F#X@*\.,_D
M?>WB(0Z<F>*51E_R;#HWO36M[ <7#R>&!,OT 1UL[4.[@%0(MN6C<>(V\"\@
M!+[EJB78#DA0"VZLUERD>+1<:I9ZL)(-?Q1T-;>OW8F5*W=1(6,:N'G1"*42
M;B8SN>-+_&,M-)$LVLC9>2YN@_F :PX=5[VRA( )RPDP%&-:M^&V9'G+QP_0
MW7+\^"$Q\%%/[\<K?AK"D-\+YL7W#%@O_F\&?!&ZDGBZG %T6YBS3NN#",>5
M7@>WXEXE(*@V'MVUXZL@N2L/8PLA)3$1''#09,DF=]]/#!9*(F58$%\:1UN%
M6U_^#ZUYTXCZ<<*Y#,?)MP3-WBVG,.($/6!MZ,FYNQM_,!J[4.IDB#;Y:1%Z
MZLP[_(*E[UL&H(?@4N:,X'MUSCD7S0_F@[ ;O#>2P*4N(1^+HLF%/@6^GO*2
M" W3.%VP_6+:=04Y5H+$JA2MN\LL6\XD9<0/3]_\89FYU78Z6]2 <^(R!W30
MTQ=6=5XL&51H@AWWOWFAVL&!WV?7DSBO>"[TQ>,QK*6UATE0E _-5Q?BS>F)
M4QAC:)8.18!K%@H5-#Q$N4.Z?IC"V+9 QDR"41O-LIP/ICY-K.;614WE8TH\
M2"FD;#^Y,ZLH!IR46G''1=V$D7.9"\K?%ADTNTV/=?V*"01[1O'M_VD9W!+C
M![0)-S,<S,";G4%L-^K(Y7R*>2J%"-AV$V[4#??4?'TJ^+:-H&T6A;15A'F"
MA!MR+.8>[/095;,IRZR&/4B7A2;:4+6)Q(-V_/3_B.SE;U@"<)_]XLY:B93:
MO]_PO6-.FL?/AIPT=RA1A@;K9]_OTF$;C];QD\.G-#JO=&=_=%'?W1ZVR<O>
M1XZT>-A"^C2GM!$?^#RXP>.XLRP;F#^*8J%WKF;9G*4F/QU.N;^U:%4G"M>_
MR0$-@R!]G5)B/'WUPH-$3[ML/K=YN1_Z)1J2D@>G)S\\!.?@\=&WU'[B=K=T
ML\7VF?3'EGPJ.(O6+=Q]W9NY,*JA7FJQWGK.XY74H+DW/R^]W*)TZ^M+!YLO
M/L9P5)PW.34P>!P?B@XN?,7A_9?')WVWQR?M\4D[\/1[?-(M\$E[%^+W=2'^
MZ2.*.W8DHB,OQ#ETPOD8V7@/_ANET%R6[K&R(,2B=1LNV^9]VS4;GP1&-\3*
MA0]4I>D*6PRR9VYPDT=DKLY74%?AQO'Q?MW^]G5+I$H'/U+ ^UH#W@]9=Y=+
MMY"UNRT4M^N7$PGVTW6V0>K9?0@RB8\-VL BW00J4C#^7NIQ !.X-8]$4 PU
M8 :L=LORQH(N\GB9[]?O7=C=EYJ4V26SJYFB9%-"YJI-COXC.2MF&?7"7DHC
M)(%A@R$&"T0IR<B\QJ?"Y: %-=M\*3UZU*R9@>#"WU+[]:S"V=T7 6Y9S7B#
M^O_=/_9M,"Z,69BL0DRA5WY9<_/ZR>DO#XDYYMG!T:.4"VN[M/UT+I('7 MX
M_N31P[O<:CQ"8#(__06,.P?'1SLY;A$\Z?4*O#[2"E8G?C#3)%[K=S&F;'3"
M>![OY'B.U^'?DX\$>R2+:\?W;H?RK":V9VVI(/$, J.@D% M8!.07]+>;/?$
M.:\*T,X3.1W/ ]D#3F"Y/P32,JZZH75"V*B0&VP41\E:1-Y[/PL($(!PR,=9
M+M56,7V>[=K 'VSOAGA;9]D2S]XN"D$'2-\A7?53L8D82[E'1"[>-%0@"/V%
M$7,-L;GP][C9Q'(%4=5H[4&@0I&EZ!.3Q01MEF##Y&I?W-7[["8J\7?4U1N
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M5MA?';;ZY&@/6]W#5G?@Z?>PU9VAU;METOXG)I?EZKG1*[HH[DG:WKY %K^
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M ULHY1O""A5O8#$2+H"$A&9X)W-F4P9X>@1\ C9-SOH.X[ L5R4?[ 3ARGL
M5XSFGZ&6)LGS1M*W4FX9,:1"TA@<!^[&_,SJ_=:?-XG5!AJ^*0>;YMW<V*@\
M"SB STHVFU \I: :41U]A40N*/< +L#)1X/=K3;).7V[HM1E-EOTG1%[I\%8
MT\IRH[W4U"S1=_KGG'Q,G AN3"D13"69MO-C(50.SN?2+ZHX1>/)Q8@+GCA'
M@[D.$\WLD-'-N2,LW-R*H:K'(EO^/4_^"UZ*U@5XA^C9&251/PCS&O(5>"7J
M?EHE3:W@7"*P0-^*W)QWIKR]IV[C%Y"^%)XO+25,M''Z*WA$RJ04Y@,=8_%L
MPYQFRXT[J!\Z7X( %*PX!5<A,T,I&]*D*5\IGSA,9L"^K%C2>-N6%G.GF)VR
M8!FC!^5#);&F9%GN\YHE16#)QGV75@0G<3@S%/1")M-.RA""L/-L Q1T-B<T
M++IQR-LIG+7[QAV'?&=MAV/_8X_+V8;+.=[C<O:XG!UX^CTN9V=P.5<:C(%%
M;PMJ=E##+HW!*;1!;GX": VVJSM4F"OB 3T' -DW,+O??W-\>/0M7_5,K#O5
MB:'$R+D\N-WF%BDKC80G02]X70W*+GP-T@QS]XAOX)X1#3<FF0Z),CH5W2^:
MHCC NZAF5@/1DFM?/0BU\"=S %6KDEP1"-G/ W&Z_SFU7JN>V^B M$6E3*FW
MR.]S[HS 2?!=<2&HD23B%(^CIB^G='BRNT'QAZ# &C@=[CY"OF59 AYLXSQ^
M7^[Y;[>BVN151;6:E\6,ZC8-K\#'DL*#;TBM^G?_MM?Q?-NM(04!;L4@GA<&
MQ>LD&B%'!<)C<Q712"1^$)BZ)13CKOCRD=O&%+&XX,<-7?OP1BV\,G#RV.HI
M-FZ''9#(3[9NB[_KOWSO'/?U,MO\O:PP#/C1]W(Q<2_)AX+5<69#?$6<5_QQ
M<*\.C]C%ZAKWOUSO+!\?XJ/_[/+Q9]\^.GS^[;.M'Q\='F_][*K+'A\?/CO^
M[HLN>_5GCY\_^2H/^^AF#_2?&%\>8S>-M![^U]\>_RWXR&@D^OM1<HQEH-?S
M7_UN]-5'Z\_TY7$P,)QVGO'?>U-^=R.K2=9E8%QHE_@-\7L,3?BJ[!=LIS40
M666>T#M^?Z\&C>Q--$)?^K9_J2$[NLVB.LMFGYR/Z#R8 WG"V:QP;L]5;TU-
M?G_,.]_PP%-F'V4.0M;H^'O.;BEV!,#"X6JZ;A1NMBJ.DOLP2M]\I9>W+PV8
MYTZ]-=;"H^\'1:K?=03HHUN.Q%6&Z+H=.31F^S7\9U_#QYJ.W:WU>^NC98[_
M=Z^.%@EQ37?!WV_BD5SWZC=Q2/[P:_Q.K@(;DJ,=G]AM[%1;9_?1[09BTI[N
MGFEYFAX___;+C,L.'8%_\DEZG'Y[=(>3]#O9^?MA%[:WEWZ199@8BGNRZ)ZD
M1]\^NN6BNV+BOY9EN.FA^.><I&-GOH_O;I+^4A[#1]35ZI%#^%L\AM\0F^W>
M8OPN??3TNUT,5.[ R_A33>R3]/GSY[LXL7^%"/0-%?"1R:S'Y=8O..7^5"OS
M 6S.P]N>?;MA;GY'U^7/-:E/TF^?/]^Q2?TKU%%L@_]?+ _R[+9>]#X)<I\*
M.7MGXV:#_(+AZV4U:*:?:E[_B^5#'CR_O9]Q3[V)>S@[7V8==B\5LM/689(8
MX2_F*#PX?G9S,[!W$O[HV7G\Y$YFYZ_@&[PMNF19MZ/DPPWC,H'C/G8CG-<]
M@7L1F_TUT2F_Y]#L^([\+GU\]/A+@_G?-#)W[''M]\5^7UR9Y'K^Z-&]VA<X
MY/X3/18[V>ES-3CXPP <_".EU#\(./A]! [>25:R-V,Y4A P1;*E5W3P1+U,
M1U-\F?UZWM3$K,CL!4$:M;^=KNIA\K:>4D_%XQJ24&DWO,GS'M^8\,FNZ7_U
M;5?.-SNS%/_T@JF\()\>/O(+DK[ZS>/#;R=7:'OEE/MV.\A K;D1<\D\VM3%
M^M2(]09"[^OE7HAS,1##B_Y*8.7F%EE[\4EB:6;L,$VA4PJ;D2K,4%_8$+4S
MUWL]G[?.QS[;@$I37JF>\Z@,?[WMF8Q\%E0]C2+GW;<MWG*__"6T"GC//#&S
MB\5R;#;1[[5G'AU^-]XS\78PJVE(R#X'4<K53.>R>Q[K;5(C.N631H&Q'4WA
MQ):IK+B1[B?WJH=+@?$G8G\/HTA?/@J[=H=I4J\JO=T'%O#75?)SMI%%%BB7
MLQ&5MV'O?O^>60EHSK]Y=DS4S(?)2<MDUH.>8=&MSP,#*3, ="0?!9%DHJ@!
M( )$!;@7K4WGMC3U4D7,'IR#G+AA0H)OG_['0]5--DM\461+HN$AKBO5LA42
MWN ',??^B+T:^];=7(F9A0<8CY.!V(N%LV:S'@:Y,#2L]'IG15%YBG*,AOIC
MJDM/SGRN'(6>)FJ:1SU0:H%4848_#H(&Q+[\Y.CIP:.C@R='!S=SIG9I=VPG
M0'\SJD;MY*9Y>0M7-XU8*(0X6]8$"G+Y#8BEARH.VPFM4UEU]'S,4O7-\^]
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M6A,8%/!4F1QT[1-T4VM!K(($AD=(/N 8 Y!N,64X=C'E#),JD>6@,,*!TV;
M@4-UKEEM\RCA602[:.UQ+J*?4'XL-00E4YJ<)12:!3D5TOL40"_405/,N1&?
M2Z<@+$FTN^^%:(_F$NW)+YW+GX%MG5\2J0(GZ_Q\<Z:)]Q_G=[^(SLG)U>]
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M.E^#,Y%NS*F^R"[\^%,,U!@%VQ<38*SB]E^9W^UBGA([;[)KN.TSB7KX]13
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M.(ERA*W+8G+K!H%A.;PC>\*&N';\).0$<B*<G,'OY8^3N\GUW-NX*OTE\22
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M%4!1*RF4047&GJ U$)&@? ZC(+=08?,/6'56:& QF2XQ,"J**25!#H0M(^0
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M_XVUX'>[QG>CQ,@'OR\^R:]Y"'6CM)@G.VZO7W5Y1@X"2;)U.98.O=W]PS>
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MA7'):VF>)[+_3S^W4:22!V9XM7PR;P@(R@+R7';!VW^;6U.\]ULBBE7JHE-
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MG$5=R(/<_W][4(H%55V];.Q4QXY/%2G<Y+0_*%3J3D4CJB 0,:B^:K4JS<*
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MLQ.8NI!8WE:<OQ7<SAL!OF=>&2TO9= 3/'BQVW=P%-2E^D[YI<I!45\;=Z0
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MI7'>5-13RJ8(#D)X(RXLT0$R1S;H&Y3K?E !NC8+1:[G5!5NI[2T\A?*"$H
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M#^/_?CLY;.X=?MO]:NSN[1W_:)[M-L^,SP<'I\9N<]\X/3CYZW#OX+3>F.+
M.M7R_GR\F0H/WJA1XM6>VBA.V^#/_"N^_]!).LU>6WXI5\/2Y<V=@*<<<X<Z
M5)B6Y3"7,N(Q%@@_LD.31)'O4O]B'\#&3?D_!#]@8N$MHR/5Z_]LA2+^H#J
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ML9HY;Y_6)'I2MSM=T1NU1XW"%99--K0Q D"1@N5:[8V<=A/^ZRII ?0PS/'
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M'[>.V TAB2BQ!451*"Q$F8>1CST+">Z; H?4#+CDUA=7AM>T H+8JY*^F!Q
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M;!EN 5L/V34/RL@"[)8I<"-]*38 :-5R;'%RC(^8,#\N7.+8S#$)PL*DB/*
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MD2>7E=_\"6A4QR+FD^MXV);ECQ=2#T<!LR(D'%<@2JP >9:-D45L;E&7<1,
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M?.%\::T>W]@U&2K^^D$NN#1K?-]FR&&.]$TBUT-^8/O(%AZ7.C* &ZZ;?MP
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M3:Z/,T%M?MR9OD:[BU.&<0AH'[[\A %!,>C+[MD)# ,@V0:_X:)T)1P![__
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ME-A:SG=T\R/T^@MW^KP,AT45YFBN6IJ^V$5Y[GO.Y.GQ." 6Z"D:8B*]S9A
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M?]5"T4[2,# 2%(WDH50J8K$0B7;HZDF=+4^X9JEA9:$\#GE<[A]9EB@7J92
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MBEH;I#S%EH%@CXQRDVD0W>*5A8TLKFR^B\_61Q!\P%<6C<HQ/!L<VQMVS_N
MM&QOB8[/?[==..&8;1UCZMY1Q*F.)*4DE5B\T2I)E$HYD8GB*G&1I3)=V^SW
M[+PWQ&^Q!]$_LGYG#(RO6''LJ]WOY<-V[4/V(^O4]I"J@ _UH/9G^3U\_&L=
M3SDP]/;X*E9V]D3\W"J J8"MJV-F_+D\VO7&1M%W@W.4_8#V#6+]'QD>$)(,
M+LM*8V5TTE%L+.*E:PM?_"XFFSI4*>Q@T*F.P\<BKY_[(YLN4#:\ JM*>/?>
MLTJ&9=$_B_7DA^:WW6U"T]HN+*L>+,M@KS>SCSM]!1L['C<,P]ANY4)#OX>'
M;V>Y+=#T'/8J<W)0QEL,>T C\)/UT+H'P\JSXG1\"C?+4C/!O6I89!A\[0\A
MI\_XT.H?!7-T^R#E^\A2N44\>#78B39L4Q&K/J2XJ%Y; _G@C>'Q;85T%B90
M!5+ G2;OGWG+_P<8Q".C&ZWBH@P3P[D4L 826P/#1:#OAQ@RD_=[\D>6PV<L
MU(^'KL40.\25,2O;MC.0_OXF+&B.BA;N!+A1>-._@SM1G3<5=F8N/BIEV.G4
M,D]'XZB=N6VJ E)F5WJTM.MS =5 !FA!3+[/K[\/+?%S&&^RO^$\@U'\P&,O
M8\]*S3=ZZ6@0X[>ZH8_,&8VYYSTRXS<.O BQ/2SKCJ]=G_T)Q6TQ\6T^:KG7
MSX]E+[NLIO'GA[UF\1>N498;<B9SW$O9&SIX*;P^KS:M##SW%]7PHLQ6;J+S
M=A4K,R(VT[>3*R91]F/E>5RQBQKH"1@+B,+<'F/J1!5;5=C_&P(:\(=ZF"=1
MZA(+]FC>[P(Q]T=I$7Z! 4&@ZIC-J\0'F:'V-X^Y =X[+$!MK)?#[0'1%P5N
M (IC VK&,UNW;S*7:3D^]A[[F8 486NKS8,'=/O%."%CXJ2^=(+AT*5//NKG
MIV7%WBX8;9V+:7[T5# 2"?[<LSIB&''G-'G"3E8&#[X&G4T#>8H4G?M-*55Z
MY:.3G0$F" PFQ<,D,X,%!NSA+ZV\5N,4*="ZSAKLF+%>\CPN4:>/M".'<%_N
MRR&LU_SPX'[0:<:6CC58@6SL[%,8'CR*$RX6K]4#R>E.;K4[1F"%X=(>P=#@
MR<]@ODZD)^QX9R9Z%Y;N^$74+^MCF%T'F-ULO>\TMK^=-+:/@\;W W9P\G>[
M?MD^.8#[#KI[\)L6]3F8?7 ),%O4/^W#/?6@N?V%'IX<9O7NSF7S4^,$QIP=
MXF^7IQ?_N=0_&]LX+AQ__;S9VCTRUNA0&4:H89QP30U)PU00FFB7<,XEYW;V
M:(,9F0(@%VDH(A[8$&X(0QE'-J Z<,'<4<S75O/#__?_FO]L[^Q]K>U\V=]M
M'=3^W-[YN/MAM_77 XYB;GW_LU#]M1;U-?BO#/;TM+K<X \0R$>K\FORBZK
M8Q^K6V!\ZHV)$PMCVB6-0Q$Z/!4,N4I3:17(-T53:TT4QZ-\&D89&7VXQ0[_
M"F9TT_FU+<UN^&,BBGVWU\IA0<K!O8B(]F>0%1,1[=M834<?I8FE:8AB0O$
M3')?Y89:$LHP44Y'3(.LV&3K3 3K0)(W!;7/ACJC3TUU$*4Z!U0*ROP,A('W
MP=\<WO+9YGYG9T@J=0GC.F;"Q2%GD4D##80CM#&.&:%EE8LS0TGL!CKZC..Y
M>MN*+$JRN/QR1!,KHC2TA">!))RE0!8JB4G"7:IX'$9!$F+D]2**&#O&IS*)
MYZ+=)Y**;891[/+L+.__S-#= ,CR7@%0OR9LY@.@)FCD P#2S%30=*\::_/^
MPN:Y@Z&>FZJ:V_M'P+#.!&E$(IM@]R,;$!E+2YQ.&#.I255JL?':NEA$5P#7
M>W8PSO $4PU/56$?1S:4 32('JIQ\C!FPGI3XY[)H(]&3U,)YYZ<4%EA&(+O
MV[L]&K /*QH/=T50=T.Z^T>&4B%EC%E80$:<1P*T5\1)D' F+<BP@&%TW7JT
MB)Z\73=23:-*N4@J#Q=$:4@3T*- -([Q6,9 0-3&J7&4*DVY?2S":5;#'H46
MKXBB)(J?]6U])$QB#!8X4CH$*6-%3#!Q%ZPAZ@*1I'CXNK:9!F)!1O&"!*F7
M8W+4OLL\ETL?W[7KPY5ZMN0F[T59" R.<2[5H80/^CC/LP$&=YU7TRQKCNU/
M_/0_XR7XRSNN1\4/,-/C^#BWQ[<E@2^T91R6'J$B-#+4/.!1"N"3&I<D$;-!
M8MQBX+G A/F 1\M-5XVQF?OCJ;$Q8_6P=%E]P.,I\_YB-)?JPCOJA;<.7YNM
MK:-0VXB'.H+%"17A(@P([%- 8J4,)I*#;<-!+U"V&&G<8--@Q0R;ZPR(:FS-
M/,28>5J:VJG&Z V<\8]C0J(K8AD3BSZ*0BD!U3$LAA8#L9B$I(E.B)( _6!W
M4H!]WL=YB['3FA%&HQ.HT>K7VO*'7=+J:<^]$9?U[=TC$RAJ.:R'TA&:!XR1
MQ!E&8I,Z(;DV 4O6-AT88%.UU-"E7YXH6@VL,6)0?TY2F@A;P^-A,:@!NU>5
M'.8<DD_HN?XHL_P;9I=O%87U4'^B6'.]2N=NHFDYS!'3P06-?B\?_?D>4R"_
M^7QU(+B6U>U>]G]#6_AXQK?K]9[,M#D&6V#G*.0VC)PU) E]MC$+2&H%?)(\
M3%AH%3-SA6*7#ANA#'G?D?J4?-7M?@>5D*][0%#9H)W2[1O;\:%L/O($3_Z*
M@3=5KJEE, 9+8Z!U%4%>#@663&)P_#&P"Q@99:&%XMW=0:2O&WT5Y^T+5<."
M=>198=^-/OP;K/.SCKQXE_7\M/U-_ZZ>506'B[.Y.M4^&K3\^2HT&B2Q#X^N
M>KM4;ZY^WO _S53=+G]+XHTX2:[].=B@U_YVTV-1-5!VI\>^@5:PWWQX%I:L
M6/5]O2E_7+C8A9$P.F:.<Y>"T2HEEL*2(,5BS18W3YES58[0!:B-$MPUAX-B
M('VH1J5=RHI39\,E2A-_J,(HFP*<=>J7IT$#QG1PLI<UON\&C>XN;7XZ[-2W
M#W[66P>BN7W*Z]\;[?J'F:8 W?U+/Z9/'[/&IUUZ</(%WK7/#[O[YXV3G9^-
MDU/>A/%BNNA_+K<F6J;46?WD^ @K,J6,&^(T8D4;:)*R! 2H3;75*@K#!-1*
M(A;4HRIS-O^88HI;Q,$+XGKT1&EOK2,:RWIEVNH=),#4',-7R>DL#+5FG ?"
M1(!+DM1$4D6.Q=0:I6VPF-/G#JX>Q.DOU<#[O8R^,\?HB@DIHB0FCF/=.2H=
M48[')%0QBSEC5C*SMLDVYIV(]V'PUZ#OMS'.V6(U*@"A*Y5_DR (1)!8$ 54
M.<I!BR@>4<: RI@R+&)ZI?*?71+LSDD"+@T+66Q(F.B(<.<829V11%"G0BS]
M(Z)T;3-X<QI_+RM.B<NMG:ZQ>D^5_SH9/3*:*2T<X$'%G4W36 I!TUC'$4UL
M? VV%RM&_WV,7I_']M)&B9."...[HXB(I-X'&;$HI12,M50BHU,QK_2O9?5Q
M4ZUQ /!D7.2RN9^V_*''XBHS/FMJY%6ZT<_MRUCUKTCU$:.@*<K:9S_7O"8*
MFCY]*[%QO'/3?9@H-K975A;SL0'^M.F]+*P9M199$B\Q,N"X$^#AMCFMG[SO
M'H)P@/N#P^U3>.\I,&>C"]==U$\T" YXQ\5L!=_&:8-]N:BC0/BT#_?LG39;
M?V?-UL<3$"UPS^Y%X_) U-FWD_]<?J'UD_VC2$0\-9:A\@X)-T%$%).2  P+
MH\ %+IPO0<E#,,PHLSK&N V,)K&&,9E*;<,X9&QA/#1YO_5U!\O2U#_O-+YN
MM7:;C0>$0M_^ZNFAII)QFH8\YLIPED0P-ZU3$86IL_"8975S3U7W+\HC5H*%
M]LRH3,ED5P ,1&8!36IE\#^F*F/EXQ^VAI7)RD@ _SO^^=>H5G?U]Z@23#$N
MJN5C"ZH:*>7A;NEG+WP)K0'L%/HR_"_K9?;/])=>_T]7IOR?B9R1]7$EFO6:
MR7*K!_U\,I'D#'[Q.5DS!3.K6,C1 DQT6/,Y<F47+@\X_, 7U73^G]EJSF4J
MS*4U$X^[6AF?V@/7P)YZJ-6YP.0;K%'C^W6,>E#0,HG(2MWVGAUXUB#K5$E.
M9UD^3LB=>OKZ=)5-B^5([U]H\V%=IMGB4*I9X;B%*[TUFO]N-?7=WG2(^=9X
M$?V]S5'=S:;S_=;+BR; V4[/--UG+ QPX'LDW2$__+EAVS-(Y\D$<?B^53_B
M*J!1%%@2:68(YR'86K&*" BW,)8V41)[KKK^,%]X$J]'U9/:MFQ >%]FF0 M
M2/TC(%0+*_KW>8_(I/X*W+B> 69 CEBO3=0%]47$QU42YU^J^D!U^/65<, &
M)I/E0WWXZF!@O5P8YZW59 W[0L&0YF8&_P%6QK).OH:X+WHUK-BU%%37+,F$
MA,";LBK0<+&XD,4]@Z<"JM.86>6TE1SP3NI48)A07*2!$N(:4VA1_L>8=2>1
MSQ9BSN.R#O?%8NZ^CI5?1#C5,[#EQ-'ZR;&H;]>/@E1' ,4="4R,+: <)TD<
MI\0HX70@8^!18,L(;(2 L<5]H*ZS*F9C,981J93J:]T?;?BI>/10)1J/HTW*
M*OT>:91!Y[XTT(AQRX+]A9TM''=/83!3"[O*8;_*_EV HN2@'"_Q_4TF @3*
M#@+8T:V8?MNJ%MQ]:L&%JUIP2S"652VXY1[\JA;<(E/_5M-]QM17-I4VX+&(
MX/I$F#02&@A=)(I1%41\"4W]*K&F;.[@"Z7 ;P2O*[L[E.UM)\N65LU1*]#L
MM=A&F> PK=A&;0'[OKO7=!>*W+?X\3;OR$[U=_F7S)9E>.+*!;IMS1#S":OZ
MZ?:KS7]DVEX#:#M8P@(_-=T>2+KC'F+5SWY-O'_O[7KSIH!I6+\\/8JLU2YQ
M@L#&@+W(>$220 @"9F(LE91:!>)%Q'S.==B=0G)3Z&RBB\24YVK$#XO,MJK2
MR57DYX@K@=+L,9A#=ESWY&[=61]0G+Y6>XTAI3'?"&GT^"&E=(-%U]]ZTV-O
M_BT4XBGB7P%N/4;\Z^AD.,#SX(GGC2]-[W)27D*%WW-ZG-P)/WRLV 6]@;6=
M*6ZI :,\)$+@VB6:B+0I^<;WM4*XTN]DIH9SO2F\:/'BP3.>9^50A-PEJ.C6
MJ;Z=]0K>6@3:WJA2'*J:B<IVLW1SVY3OMO_!HGB514OR!#1PM_7X[VL9AMV^
M[W=;A%'83G!KT,ZSK<(]TO8YY5+1B'-F'*<VD'&2 IATJ=%&J8B7*!]0PEW;
M:%4@WIK%&+]*VU^6K/T'0_DJ8N>DSO:QCG#8;'7:\/P /K.#5KN-D3@ XR_K
MVZ9]< F0/IN-V*E?'K:PCK 6S>\[,)<O\/FPW?RT@]>=')[4SQOLXTG]>R/#
MT+S&1,1.8WOGR*1:4Z8L8:G$>L+4D=1I1H3CRMK(TI@%:YO)?*>WQPA3G54H
M*^FRDBZ+F_0QFJ(<"1,7<1>PU+F(62TB;05W-"G;LXVDRQW:LZVDR]-(EXMI
MZ1(S(YGF,4D#@\GA*B12Q8(H8;0.TRC0H<&\\%O$R^N)^/UD>UAMU<,L:;I9
M+T-_WN J'_LI@GY?!(?3U$1A( /M,*2?*QV$)HV26%-%I7$K_+ ,'%Z?PP\R
MY,(JAY$F/"0\"$.2)+$BQDD:))*9D,=KFX(_"$#<P_!\S;S!A-*I930.F>&1
MY*EP4D56A[%-J#+12OLM"6_,:#\G1!2&FA)M HY]VR61U,0DXL(XEPBKE0;>
MH+\E_ZTVR@Y=9O7H0P$?Z'.HO-68_VKZ0_1]>U"\LAD>:8E>ET4A>6)T@$%T
M6O)(.:4HI:F-0Q<%8&&D*[RQ##+URT2&T<%/3$1P+$[2A H2.I$0#IJ0I#RR
MA'$31C06-)8)QM%%R^2P6(FFE6BZNVBR3@?6V8 G(N Q3<$*"M*48S:]T]0%
M*[BW)*+I8E(T'1])YU@8:442%PJ >XR35!I-8L$"X5@"&TBQ-#._ ]Y[63F/
MLXVG1F5'IX,K)JN)^KY&DVD#$_UWYEOK+(K'\/UHCDMW2N=B5!APU- :LV0Z
MF?,1BL.SB829A2%*+.#,@2T5VTAQ*DR*IQ84K-<XHDJH&#F.)A7'E1\6AM:K
MVT/KU6QH_<XX]Z<,4)K/=#'#_,*GP+Q(KOR%6*6PL7T<-BY/SYO;NY<-4/XA
M0_>0M<1%3!/.L,QDJB(2 1FFJ0X5E3&Z$V<9IHRQF6^0!O*R/R;64<^N::+%
M=!9L@#Z9EU6EDMV>Z3O=,GST(NQO-9L3@NF^XPBCO#N74[<T7?MN%P!7$?5^
M]M,!A^."Q/W)3#_D]^D Q/*FLDU:ED_5Y"M7R51EB,>9B.-8?!_M-Q../XK5
M*F.NL!U6-9YQY*1OB>7;519E:.$XAM*G&GJ>[&E;S:;\;;UVWLYT&_M@70FB
MZ\,P84VPP-,X.;&DQ^Y5$8)R4CC&:<+)BJDI^^E6F1.32SR3[H"-N,HXSE$$
M)&:1C&-);YOXQ.0632GWXQSQS/P*E4.?9KE1ID25\CBQ(_9J1S*,H4/QC.W+
M;#'N.P;C.,O[R@>UC5N.3KS7=X++JGK851:7;F?VAS6_-59U,K_\UGRKXKJ$
MJU6$:AFAVMC>.G(I=Y*GBM@X#@B/$T&DU!240&2,$8ER1KZ("-4R(E/93O\<
M>*%J"5JR@^\&F)5MKZ<5T"*)N4!@3D:3WAA,^AHC2$6\P<+P*2)(DP<&ICY#
M!.F+&FRX$;&[/?;Q8CE?5+AK8YQB7 F"ISLN6_JU^%[56*Z-:BQ/]P_X;2MS
MXVG),R9:/G 5RW;%/@M_PFK&9-M28_SIK:;93*PW$A [48D"TW\G0\UK<P'"
M]UR&^SDU7VQ9MX6U#%0<1E0F0J<FX'$@$RU#08TT- T5KVH9S/DT'[.60;.4
MIQ,;W*A*IKSF6@:5<_3TX+*=U5N=$ZSH=MBM!_46 O Z;6S7@\/N 3WXO@^?
M3\7!UUGGZ-Y)\Q. \^\-?%_WX/(+C 5 ^^5^4+^$^9Q\:Q^VL!Q)ISU;#!;/
MPCF5(3: (T%@*>'4A22-%"=QI+1) -,[1=<V611AF\QE.KMYK-.9YV31I8HW
M74I9=7V7H6446"-5OE5J\JE612M)=5])-1NUXV0JA7)$I'&*K;\948"HB ,R
M4 :L(8?'.&PCO>4<YY'$U)L'%@L==;'@8<A3Y1RU7(4FH4$D0F%2*RT+13+C
MJ O"!4GE#SVQN94?]T; ^L,5KFX!K&:O[6SG=[/J;/!I CM-F6(DU+$A/$HD
M2;@Q) :&C:2F$>,26RQ?552:JR'YRL++2V?A6RL@O=#2>) O_TDUN-^=8K<Z
MZ/V4]XN7T8_RA<B'W3FC(\*NTX:EA%%_<@!*'>";(BY@ ."<88EQ:YN<LW7&
M'V1TW&);O$I#X4V@_F<0'M>>!2Z4'BL3X#'EQJP)D#H=&!V"W#""<"-3 J9>
MB,9 $B:1DY%*06XLZF;Z-,[HJ4O?@/=U1,YW03*OJAF.;P3 _OW<AN1JZ7YY
MZ>[#LB^(,S_V<V>SUVMCW)V*?D-RXJM=B+>FSVXY3;Q3>:8WY?2[HXW_L+X&
MJ]/$EP70]Z>SP"Z_'"FK8%]53'2"U=19'!$91H*D+@Z9I%&L,>L\#I)UGB['
M:>*K= 7<"S^^.A_!,@J?E5O@,:7.C%N 2Y& K-$D59$C7%A'9 J?:!CS6$GF
MG#)KF^%&]'M$SFLWZ)ZZJ/3J_.^E,>3L^5\<)8&)A"76I 'A22Q)(JDD0@!U
M #]JQ;"5_$;$W\CYW\ZHDTK'/MC.N#(G9I.Q7[ 0>6GVQ,1&KNR)QQ8D!W,'
MA=H:9U0$XL-B>TL9&")9P EU7(B &A=@=R86B/4D258'A:N#PJ66&"LCX#%%
MQ8P1H'1LPE0)$HE 84G+B"1:@]!0@>*<\9CBV>!#PP-?N5-YR2']]3QT':2G
M*TC_:^PU"^FI<YHGFA-L/4-X%&JBTE00P6D@E>(ZYG1M,]Y(YHH\O%)(_\T6
M@ZKU(>;,ZRH7&//Q?Q'BWUYR:64 /)LZ+[=]JX?U8?RFM_KXU>J<X0FED9ZP
M"TY_UK>/CTPL:"A"0S3C >&IC< NB#F1EKDTB1-C>?)+YPPKNV!E%SRW(%F9
M"X\I02XF)$CKX"@0*HU5G)"  :CAQE(BA5-$)DR[E$D;8<FJAYX9K,R%YS07
M[LU:*ROBB;BN,:&WL5 <M2G5*0.S0222\$2 WE;,$I,D3"HGK#+ZK@<#-Y=B
M_%V-3Q?+>-_2=42-LE/VQ=TJBF&W_,YW:5[5DAK5DMHY,HF)F XM ?@6$2ZC
MA"AM0L)B9H(HX0'8GR^BEM3[CM2G!.BCW\'&HWZ["99#P1"S;M_83NU<%K5A
M496.*@8 ,09VHE[>;"_[OJM9J=M3Y:=&I?7*:FOPB*L"=/!H?-5T3]3S2MZ1
M48T1>46+K['P5,PW1,J?HAMH'#RLZM+-O_&G&FR\:EUZ?>6=%]^Z]#D7[X5V
M+WWF)7MS#4R_]3L ?CK9X.+I:YTL],0LJ_$T[[3H58[#QTQXY(_FMO@(B 2A
MK)V L2/[ZFJ3]P"\C'T3A+U09%N:27U^V-UE@&81O6*MZ^  #)R#DRUV\/T+
MF#S'EV F!3">R\,/,V;22;M[<')P?M@"Q'NR!>/<RPZ[C:R^?=B&]UXVMQM@
M)NW!W!NGB_*CF4BTB%U,.,7V? FW)+44F"+6*<!B^!P(;/ZY$<\'/90UXIZF
M/S!]$5[!/YXTJ',EK6Z05C(48,CST.I4<L%%$@7PA=-:)$I8(<L6&2-I-5>=
M:26M7H2TFLW*IH&-8BM)&%H%MKL*B!1:$REC&6)3/!UPD%9B45KV2EK]\6N(
MT/G_O21$N#,^+;=Y%YLK^'*F#Y+9BR8?KGSHO^1#OTEROF*?^.\2G_7Y"IRA
M90+[NPO*).%A%) $:V?%TL:*)]):FJYMBHU$W.@3?R#//"AYY;7RW8/@RXKO
M7@C?S<"61.&A0QP1P2-!.)X%P^8+HDTLDC20V.7-\]TO1;2]!A_.=O8C,Q;;
M^ !>?JSTT]=H_KP(9\UH-U?&S_VER)<Y[2W36-N *<(DC0G71A"91#$)8F%"
M3@,7)=':9O!XML]+MW">P1_SVL7.B_"ZK,3.+XF=V91WEL0A%1$), J6)Y$F
MB0H#(J)$L2A,TC1,5F+G;3E6]K+BE+C<8L?*@<TQ$>'!@&W![%^CY%QJP(;[
M^1&V<[?:S97DO+_DW)\#;($0@; Q)8#: L(YCTDBPYA$#*$:_!)1,/OH1D!_
M57(NEB O3G(^MF-I)7:6&["MQ,ZCB)T9P!8GG 4B9L1P00FWE!)IA2**IRZ.
M4YM0'2-@B^;3D]^FV'D#?K6/4T&^NM_M]L=MSGL3T<"_@M5?37;:W38\?!&4
M_NQY:Z\IA^QWR?3YZC2PN58Y%9$P#1D6FG DY5*12#"3VB@.>/@+Y>A7I2Y7
M8N$W=\%;B84'B879@\54ZL0D(8EE&!+NI"4J49H$J4L3F5*0WQ&*A9C=+!;N
MD.6&?R,]9+TRQ6SY<J+^=V:$)4DIFTH+!"LB97@B3!H)'24,S!]&51#Q,I=*
M'A_G]AC3H;+>(,]Z1::OX-)D.E11ZT\6\NZ9F5_M9/F] N\>Y7F4V'I4H\.G
M9OWW36SX*%J9A$]8:79WM%3>KKM;&8KPA7+ZPS,0=X!33R\:)SIHM/;#QO;Q
M40A&N L=)9%FAO XC0F(4D,4B%,1V##2.EG;I.LQC>;8UI/<L]'-XQ16FJ8;
MNJ*-$6VT]H\H4(/F<41B%:#QGBJ28L!K((-(F(@&TK"US6A!K[+U6FX+/ #+
M?MC.Q49M:W"-Z%GWF6C#7FYU_[@' A;1SM66PA_HSK<=6=49&O9^E 6(9B7=
M3"FBYY)H.]VS3O_"VJ\V_P&@8K& :_2K67B:+%K]@>Q,_OX!)MWH#PXL#&ZT
M+).IU6^82'=1:(6-RU. -ENT?O+EB+K4VDA2(C![FB<T)#*. Q(XP8*01YIB
M?]SD*HQP3*0;M58[*VX@OFR:L)2M35S9!P1=DPM2C+M]0-:7Y1/.?',TU+Q/
M'/?Z9'17MG?[V,^KK_"Z5Q>3]WCT>'R4! $%2J3$,>H(IRHDBC--:!RDPL).
M*XFU6S=X.@MKRXCPC7ET6[LV5;W"G#$#4'K6+_SNO//B$@3O53[Y']-5 ZIL
M].#J%JF*?F<XN/Z6:5 ]GV_Z3##[(Z%\>G$F_XWC]_28Z#AFB@K VI3+F*5<
MB(3&E,?4."/%$1@G:Z.[VOE5=O,QV#"YE:=$.ICD.]DYEQ?%VK^FEP;697(?
M9I?PVI5Q[LE6IMP@4%3]W)/0NV'/V!RO@C')I1E+K9VC /ROVS<H!M/(VS$@
M2K%:#3:H_-]_R<UK.>/W4^CBY&> E1U0!)]!('>EMD/O="G6:[L]O;'T@P=E
M  \#U?<QZ\F>SF2G]G4 4*Q;+O^2C_[/K ?HLC^$9QA8<?M36\R:0M7H+1=0
MSM5?1@[D7XODR/.Y%19/B;*-IT820)C]KFW)G]M9H3O]8I@O3<6>YO:7D7H7
M]9._.P>M+?BNW3U@^\'A)U#3V]].#T]V?AZ<U$6]U6G7+[^UFQ]FU3NH_NZW
M=GU[AS<_'9X<MO9.#S]]X0T85[WU,:M?GOYL?M^Y;'S?X:#>*?Q]I 23)I$Q
M8<;&A*=!0%*G#!&!8@84.JPC*^T)4-F KA 744YY$L&OJ8@Y"T.5<F82DT:&
M6@M/FZWJL]OXT*SOU%I;_[DV[-Y3Y$*_TJTO^WV%H7:<*\V^,1WA03J"1Y ?
MG<P/>JG*0/U^HM(_&]LX+AQ_'<8$-@PS1AD.(#'28,-('I$TB,"&P:.65)K4
M4+;T9:"VO'5TM<NHJC-/!+6!_.DMJ5YA:W\JV[,N&_PU*N.T_[7F+" "4"X%
M*)?AH)]?3-Z(P7Q>7N/%$]^?Y?T?6>%YH%?6?1HKJ6*LI-"&DT55$NJUUGRB
M\=WJ'=VSC%*:A$]0\RD4#ZLD=>M@[_;8*KYBQH"BK-STZ1/)'$CFFF*QKZTF
MU&T%H.ZT7J^N;-&JTM.JTM.=\_HG5%.EXD8:;EZ]_6I&X=LMM?*+H>OS#OL[
MX-6MP<=R![^.-G#JXN6)$GTHEAV%#M0_??G9Z![\;'SZ(AJ7]:#9VK\\Z'X\
M/>CNAH>MO[/#;4T/3T[Y.-Q@'#IP?'ZXO</@V>AG#>N7<'^KD1U\W\L.3DRG
MWOW[M''YK=MLM4^F"S_M8PW>(VI<JIVB)*"4$BY42%*>*J)58%041E38$*0+
M0(!5)97ERS-\N\+H%P/:5\)H*831Q94P:FR?'@52Q<8&"6$RC0CG1I!4BY0P
MH[0VJ;*.)BMAM,H^+"?L_>'>/='IPX@0_MEBO=:S _1_C)!?!0A7.8G+!>S\
MYFWUS#^X=>/K;+$2HO<3HO4Y1!?R6#I#-8D#$Q >))HDFD8$5&.JK9))[,S:
M)@TVYJ/*GB7O9Y7R]WH0THJK'XVK9Z"1$$+21"L26RR_P(&A$\<"HA0U,HA3
M#73N#RE_N3[O(W+U&_!!-?H]8JP9PE+CJ44VL-W"8Y+^H&WSMU6ZZL_?#3L*
MF#'(E(=(*MBWJVW;*0_(5E+J?E)J?QI[G-2/#%5" 443$\H 0]I3DAJ3$@-;
MJT.3*,,XYAS/1X3^]9O+PZPJ0[T>U+&8ER?34%SVTQIR:?/^BL?OQ^-?II$(
MV!>.<Y#<(2>19(IP&PFB$FJ(THH&!B *2\0:@(Z$4?;OY:@%]58\(I_SK)_[
M6.:)$(U!OY;;P3#OU:0Y&1:#Z0C"E>&T%.X0OW/8%6K*:%J)L,<080=S,"4-
MC J%"$GLE"5<FI@DPBJ2&$6E=CJB4?)H(FSE)5EF9G\.O+*8V5=,?4_;8P:7
M,..DUHDC(K )9O^ [1$P20)GA8V%3@"8K&U&&TM2[NBM.$@^M#$S& -%?XS:
MTM8P,>-<]O0;*^W]DOPCY;;M]K:MLWEN#5RT511V,-%<>+2)*]%U/]%U/(U'
M+K>.+&=1&J84#"DLU<93[+X6QB0 ^:4BJEADS-IF2#?F*T2N_":OA-M_'8BL
MN'T9N?U@&JB ]2&=I98+14+*-.&Q=42J6!,CM#7**LY"MK;)@XWY:CW/PNV/
MY#CQ[XXWPGBY\8I/S?\5]T@54U3EH& =,-,?XMF0CRMZNQ%[O\>M\J',T(.%
M;)[9,NMYY4AY)%%V.@=<1! :(\'28BH!X,("25(C$^)@9T,A4Q4\HB_X$?GK
M)4;T/8/S9R7*GM-IM!)E3R?*]!PJ8X$)8Q-8(H( 4)F+4Y+*D!$E6.)TY"*;
MR)4H>\3@Y)OK3"Y;BO7(,IK(-8.'Y]9U@'-]JAG&'5O/R+[>X\!VS_JYS"]J
M)H-O<PNV4U%3=G!N;9DTK66>7_CRD5V@C?(NZ:VN,J@YDPI[1F<6DZCSB1SK
MW)YAH2NX\VR8G_4+6XR3M$>/&A8P5+QK,FN[NGACKJS!;RE/,&=;8IS@U1S?
M>&6"7>IK]FNF T%CDD8 I3B7CBB5*J+2Q 6A"%6@S-)7(\!"JF<Y$%YV!L2*
M9=WZ/5O1-](HUCV3O0LO2N-_%Z 8*]9"(JT88(X#?.68536!536!536!536!
M536!536!Q^\Y/*^&WOU*?N_CT-.#SU0>?X1ORP]<I?I6M=TQT] G%I:6.$#O
M3K\H2@@/,-L7=?V5 (*7V1WC7C-<:OOT&>I5S]E#S1%M_0.D]6&2LJ;2JEY&
M@?U?= /]!'OIM-'=96@='7X_".HGQT'STRYO7+8[A]O'M+[],6M<FLYA-NL&
M^MAM=+^P@Y,#>M"":T^^7,!8^,')<=C\] W>NW]>_[X;-MBW[DSV)#SS^,AJ
MQH1TAL#NAH0S:8BD6A"#?1M#E0919-8VH_6(QDL41_1(ON&5Q'J5$NMA+7M6
M$FM))=:5XYHVMO$,CIH@C!B))%6$:YL2E5)! NM@O[7C"8O6-L/U-$R72&(]
MDD'Q0L"D;PI0\SU1IOH<O*WXQV4 65A=N?JNRA2;ZF/3,^_+>B'%XCX.V*=A
M);'N);&^S&$LKFP*_P3$I+$@L+N,)(&,B';*I"*.J(DE2*S@EU/95R&/2\O@
M3X9)5@S^# P^ TET0&/#5$ 8=2DRN""2\Y189F1*7>)LQ-8VTU^VH%9!C@]D
MU'\LT/WD^=HJ'_2)@(@^A9G0A'&6AO/"RN]#$]9C%-VS$CSW$#S[<\@BTE%$
M+1@_1EI&.(T30!;6@E44QE+&W&J>K&V*5^BZ63'L(P&+%<,^*</.( 4C96"B
M-"(LM91P$T5$BD03P5S*I070@"T$TV4J5?>V/!=;6N=#8)&W6M-J.7T6>Q9F
M\\-B"-UH@_Q_[61$W4HXW4LXZ6DTT=H_BDT@@P0P1!QC\RD;:I**A!%KXT@;
M$<HPE""<5FZ*U\O3O]%-L>+I)^'I*<!Q<*1IZJ@)P4+0BA.>"DX2P!XD=H(*
M(70H>8S5<9>)J1_3-T&CI8<<GW(,K5D0%?P(69FO.UGI-V(2OTFK@]W'$U7'
M<_ CHM;J--8D$0Q$5>($26D2$IV"2F(\%F AK6W&ZT'RR^T0[L4D+\C3\4:Y
M_LE0RXKK'Y_K)P%*Z_1(<V48%9:D<20(CXTDDE%&M#!I',HH2)1;V^3KC+\,
MKG\#D>/_V*)X-PU8?O5HY<7:5M=7O7EZ<#+.GEX93 ^51Z?3*.1DYX@&TIDD
MQD1$QD >*4621" 4<1$/M61!% $*F1=&J\I4KX%''QM*K'CT,7AT$C.<[!^E
M0<)28QE)=!H0'HF0)#3$TI><2LYED%K #.E\Y<N77$]J^1'!8Q6\?+''ML\)
M!FXL8;<R8!Y+&.V<>T'D0<,NS&,W/&*)Y!KD$6$)-B!+XY0DEH9$6A4&3,1.
MR-3[+>BO@(95",;R\O*3^1]6O/S4O%R?X&7]\RAE0D<)#X@!P8S-!!5)X\00
MX.0HD:%)4R[0&T'Y?(C&L_#RVXK.:-C!70Y*[I@(_OAUWI9MO>Z>#_B8*[/4
M<GT9(-J$+0@4?6N-NY4TOY,T_SF-S.J71\:YQ"<W!TRGA%.38-\31B@U5G#M
M4JZ#QV[=]$PU[A[3&[02GROQN<RG<BOQ^43B<PH,AT=:NYA*BJ=RFA&N(D%2
MIP0)K>11DE)J0_N:Q.<++-/I\_EJ_=["0H/MK!CT\PNL0XC5>VRQ/GE9+;<:
ME]/49,T-.YU%[KN:/)99KQC4LL'BNH725SD<%6$KMSRDZS4$1CZ$&EE\H]::
M>&W6T[GUP\:'+GJINJC)L[.\_Q-$PL!V+FK_?0^I\XMEU^?%S[P-/BN01MTD
MMGPQTM=MH?]"Q<^PL7T<-BY/SV$>EXW+XR- TBY.DH D-'(@9'A$DB0T)(Z#
M2(#DX6',UC;9>A+->_)]L5>@YI+D? M(BUU1KZ'%61(<P,4%MHKL GT/X/_
M!(M($?8SZ]2*H7.9SFQO4#OK%QE6KJ[9'YG!&K<U^Q/8S#^K&)YAH5IX5&Y!
MT!2R,RH!.G[@3"W:91,G6S>P\[3P:$M3<V7)L/6J7I@O88KU3VZM'(8ON0]/
M4R,D#$$Q8Q27$4^D58X'2J2I9=J%=S7$KJ_?LF+:NS!M<_O@**9A2%EB"9C
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M>2*S1IV*WV(>&GSVN2]3UHHQ=W)&V_3S;IK/CJ>I6V83SFM50-^->,[1>I&
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M$ _!W/Q*VC*''@@\5E)2C:XVU[[*7-@3QX5'"\[Y2*@TMCC!FE@.C# O;$A
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MZ7U5< +#K]T(#\OYH-P_V8P@C<?4C%V-V[\O1Z,/!J/?870,<?"Y7ZRQ<1W
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M97U'LEAHGUS/_W>OFX\T,;V7?Y %O_[^7-0%@>HRDA/*(<MC?4T:2P2@<O
MY80#%(5I)AD+66Y7HL>59F.CWD_+.?L](%I5-9?5^%;52%YTK8Q"BN#'EV=%
MQ'V.NIP,H\5)V="#,\1!&Z@T#K:M"K;,"NAKL/VYQK2@LNTBV%@7U.8Y/K%S
MB;C[ S\GV@U_7N@2U-;C1J<"[$\K;XME\:5ZU962\JA>T%0DS7!$)4XSP/(D
M5(S-&, Q"P'*\U3D<9IDTBC.I4O(V,AWHZ<N\&5;Z+43SM.'F2Y \DR"UOA8
MG6B> N#LX\VC @8[ZSQEXO;!Y\G/]O3I5B$O][+R-;[.I^KA\OJ?+\7RU;:(
MG\F[1O3]W<1@S66PK?&_!;7.?BKXV:#D=N$UDCSLHFH#QL&":?6PW?S@HIA<
MSY;J11^*J5A<*4E?YHO728JYX!13D*=$[5SB- (YC&*0YXQG,8LQ,0LG/_+^
ML2V!M8I!I6.P4M)L_3N&8#>7.,#%]YF,%23&]'#"\!8B* 7[RY?YMY_5DQ4'
M_!/J'T']8S7QC[USD"E^PJ#59#[U,8?E#"9)ACD3D((4YQ) F:<@CP@!"<MB
MFLE((A2?7673:@H/5EI3-JGU=8G-Z29$WD'-@HD@ B5)RH ,H;[!BQ4]9I2!
MG.1,A)1%.<K/K@4Q-FI\4"_3OL,Z-FD76D.6[ ;6S.\Z&R[/C'FLK(/G @Y>
M?*AV26]?BN&8C]3]X;Z%I*18+ 1?GRQO9=Q,H,Q81J@BU21* ,PSHKA _10F
M(2(AX@1&X>2@%Y)!B:3C,GM<YA]K]N1T>RS*\J_Z+K]2O*H6VIMW.R$W8XFS
M$1PJ.[C!2U]U[63=_6W159RA1ZVITW@XKC?5(7#@FE.G33^L.V7PC/T>JTD(
M?KW^SK[J<T[=?F:2()311&" 89541Q$@N=IS099QSCBFT"RZ^9B L;D2*QV#
ME9)5=R3S;58KB*?W6>="X_MXQ@X5JYU6E^F]MUJM+QULK]5ETO9FJ_-S?0])
M-"LLGN?U+41U+G.EB](M7J_F7$Q"75])B$QMM'2$'\<Y("P3 ,>($D*B%,G8
M[M"D4][8IG=S8K"C\T6= :I@#AK- ZVZ[=%*-^ZF1RW.T!SFZ.4L('L<R!C!
M<^8!3;>,@0]LC P^/, Q>^R,V)-WIR]'W^U?CNK\H;_K+?IE6;X\5>E#I6Y&
M]6$AQ,U,37]1+JN2^2@6><AD"'+!,NUT$$!AF.KHOS!F3.18&)'48!J/C>:T
MCD J)8.BT;)'\P/_XVQXES6FT?/M:)T?S%)EZ55F!UMV7U0]^@)M>K"RO0I?
M=!SJ,L0XN0^!\:KU\*$Q0PQ":\C,(()=E%R_FL^^B<6RH%-1_UC6<9I,1),\
M8U$<YA&(11H!M;_%@&:2 \DEDY"H)0A;]58VECRV562C7_"L%:RR>U]*WCNS
MUWP,3,_1/"#K_5!MKWK[EMJKOU20.TX=ML;*8X'W+NEO6/'= )3N$O F+W!2
M]\HR&NC(TR.:%0>EF'R$^YR P6<%IK<)Z3EA\(G*2XX:;EYR7NA%G4QUS?B;
MV15Y+G2'S_G3D]Z:ZF8_F:!AR'@"6 (A@%F6@QSF.<AB'E$4I@G.K'J0GQ8Y
MMJ5VHW'PK%0&Q0RP6FG+ K>GP3:C#+<0>F:/+?2TMFK3&S3ZZA55:US'%#HL
M86L,C]NJM:?%#ENHUAB&@]JTYD_V/0C_*+X4FL%FR^H2!@H.%;U$@,H0 4@3
M"0@2"<AX)! GN4B$463,,0%CHY3FA':CI.5-5BN(IL?8_:$9YMS:%)4>1]3M
MII]Y)KWWTH$/H=M-.CQU/O*YGG&#JW.!K=OMIF@+OY]]U%=GBV+VY1TIB_+7
MV9R68O%-%[N^F3V_+'<3,#=M!9%@ B+*0$Q$"&!"0T!@G(,0JG_A""&86G71
M\*'DV(CD$_LJ^,NT"JR[U+FN>@+)^:+JLKL.9%H5U.&ZI>MUN2R>JJH/6Z>1
MOY8*B6 ;A:""P3;NT<?WPLPI>NO1]LR-F[&ZV [WV8RL\J/61@:5E1<MX[F7
M$!]\?JS^S4M[2Y\CXC98T8>BP\8Z>H3Z(%32IZQ^R]&]8KO%95F*97FG7M^4
MV\<XX2Q6"PAB3  H$@3RG$= L(03AF1.F%6_SE8I8UL0*B4#4FEIQ]WM()J1
M[]G0>&;/&I5:P8M@HZ([LNM$P"E;M4L:E&XZC=WGB^X/]PQS:-R>>WGR:JL\
M=K=5K7P3)L,4Q9GR-PG" &8ZFC*' I!,9(0G41QG5A=*SC0;&[%L>YHF-^%E
MYU5XXWA8-C]P-^R&T0UO,9B^HQB&'4?[2 77F+N-2'"FW;"1!ZY!/8@P<"Z@
M;R3!HOA&=,VG<J\K_"2*49(B"173ZZZF)-$IR2D!&(LHRA,2LC"S"QTX)FIL
MU+VEZ=;MMG5JS5%D30,"7.#E/0)@K>1%4*L9?&[^]+))/HV*X[O^H^(&OMP_
M9?;A;?[))T80,GO]_5DP7:*S^%9P,>-5*&7,,<G", 4R$2F 4 T+SGD.J.*=
M6/> #[E5\ROO&H^.P!K=WCI0MG5T#5W),8V9;Q?37Z#LRO)@_948<9QLUS"-
M-TZV5>L_;YQLUR!XC9/M%-QOJ=K12KU1+(NZ2\+[HF33N3Z"M8P^LWCCB AF
MHV;P3LR$+-0NU4=06@]TG,YK&_F#SM >P.S/M3ZOZ#=KJIN(>]D4(ED)_%1\
MF16R8$1-8<9T E8Q^U)YEH4H-WN;4.0\PC0%*6,)@%3WDDHA 1Q'.2<AI%0B
M&]_M'&7&YI9]^O677RX__B.X_Q!\NOG;W<V'FZO+N\?@\NKJ_M>[QYN[OP4/
M][<W5S?7G^Q\MK,&S(SWAAH&ST18F:%/\K8-J5I8;YD2;&P)5L8$G[WL9EW
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M'SW^,9^D,H^@X!1$'&8 (AF!/ QS0"6.,)0XB;!=]+V9W+&1BOIN)0Y*TK8
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M_@HTK/!^:]C#8OXL%LM7?26Z5$NE+N=3+92/ZGU-%#2!G$1(1"#.]5%E+A)
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M] )M^-+O;U.ZHA<XO0J_GUG:0L_4)I;]-8KI8[&<B@D1F">4$;6OBB" "'*
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M4]XX1 Q01&- .<4H@J%>J?L6JNR'^."%*C7C,E)^#>1T_D=3(VT7^>=&?Y?
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M@(@P!W&<LC#+*(QCN^JG/149VVJ@= 0;)8-"!VE6 33SY=>.HBUN!\>,]X>
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M>J/>L/VA.]X]]HQWGI];N(YM_$41R$)WB-F=L[J? (68 ;6#)  JOP_DB"+
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MJ\.@#-<3H'VBZ_N:GJT2%G,F!"\_*'-6ON#-3+V?3!]>Z+1@*Y]PDJ8A8:F
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MI2PHE8D7P787C=8!NPAH99L^@7'8^,$EUFZ;0CC1;-B&$2[!/&@FX?3E??W
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ME!:<<!;%J;2RO\[(&1N3U:J"C:Z@5A8TVMIG,71!V\U5'@$+S$D]L7+*9[!
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MH?AA/OO2)&?PK,@9)Q3F14$@(03#G'(%"T[UDIFF"BFKF" GJ6/;"%3JZ7T
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M2&.2L2ABR*G7EKL*8Z/5,P=5.\MD-Q0;'X^O";OHB-#3-%SWJ+#O#/@Z-;0
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M(B.18 4%EAR2.&>P*#B'3&2B2 G/\LB*31QDCHU4C+*@UA9LU:T^CA[5XL_
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M6#@L[RHKP1N0EGN+BZ )O2EX]>DV?79OUG4#L2HB9+W4NP"_IZ^G$?%<2^A
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MA#VDV00:3J9A-D=3U@G^(\H_O9Y=3I?S[Z]G$2,FZ6G*)H)77((PA1.#/G)
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MI9(&;-%S$HJ<1>L(4*O*I09MP$F5@2OA B.&,U+'-.UY5M)[?[.#8JLGA30
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MK9O_'RT6);T>T7<>B:"XH!HQ$ZT&X90%W#$24.ZIR)$ZP^LD7G8@MMG*IGU
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M.W;RO!JP;Q\SW);"R+/D7) !HL.P3E#%P6CJ(-'L5>9.4E^I\<"&% [;]?R
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MW&IPB6>0AB8K/+.I4HC9"_E-;8V5<%E)F8TA^-H?N!8G#9X:*PE$;<HX"2'
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MD[7,,D3A*F'JA[0-#*Y^0' ?6OUJI &,G9Q=#Y:0(3 5,3)70@-Z>!K]49/
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M;%1'?[AYO&%?AA!4\!HR425O03W@#H7[9D@N<E22D77RFCTS,O <O.%6QI"
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M'/C^=KOUMEV/B[6_7/@&*O9SSB5X1!%G-#0K>@1,1M\-7[DNFO"L*H IE G
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M7:GISCOGIT)?!;ABA^+/%[;P&F70T? %K3T)SJ) A2Z ,*@CRS[_&TC^)D\
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M.+6*^#V4>80Z$3@K&2PCZ(26<Y9AW@FR!&4IEY@LX&#N+8VPCUP/6B:)7*(
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M[>:4S_S:L?CT/[QT/P$]^3]02P,$%     @ XH%.5(&L7TV_!   \Q0  !8
M  !V;&]N+3(P,C$Q,&M?97@S,C$N:'1M[5A;;]I(%'[?7W%*M6TBX1LV(1@:
MB8"CHLT" J>7I]78'L,HML<['D+87[]GQK!)FG8W56])M3Q8ML]MSG<^GSE,
M_]EH.@S?SP)8R3R#V<7I^7@(#<.RWKI#RQJ%(W@=_GX.GFD[$ I25$PR7I#,
MLH)) QHK*4O?LC:;C;EQ32Z65CBWE"O/RCBOJ)G(I''25V_P2DER\DO_F6'
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MDGUC0B+L*FMYW^0_SN!VU_HX4!],GOP-4$L#!!0    ( .*!3E0V*' @P 0
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M+3(P,C$Q,C,Q+FAT;5!+ 0(4 Q0    ( .*!3E1H..XVO@P  ')V   9
M          "  0BV @!C:S P,#$X,C0R.3,M,C R,3$R,S$N>'-D4$L! A0#
M%     @ XH%.5+E=B!FI%@  9=(  !T              ( !_<(" &-K,# P
M,3@R-#(Y,RTR,#(Q,3(S,5]C86PN>&UL4$L! A0#%     @ XH%.5#%:ZFS$
M*0  ?ZD! !T              ( !X=D" &-K,# P,3@R-#(Y,RTR,#(Q,3(S
M,5]D968N>&UL4$L! A0#%     @ XH%.5)NO+0K=G   XJP& !T
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:+FAT;5!+!08     "P +  X#  #]'@0    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
